Patents in Blood Anticlot Technology, Medications and Medical
Devices

Thank you for visiting FormulaScan . Please click on the WO Patent No to study the full patent document

US GRANTED PATENTS IN BLOOD ANTICLOT DRUGS AND DEVICES PUBLISHED FROM 1997 TO 2009



Patent No.: US5591403A  Issued: 07/Jan/1997

Title: Portable prothrombin time test apparatus and associated method of performing a prothrombin time test

Applicant/Assignee: INTERNATIONAL TECHNIDYNE CORPORATION

Application No.: 617296   Filing Date: 18/Mar/1996

Abstract:

A portable device for performing coagulation tests on a patient's blood. Blood is first drawn from a patient using a lancet. The blood is then supplied to a disposable cuvette placed within the testing device. The blood is drawn into multiple conduits within the cuvette. Each of the conduits contains a dried or lyophilized activation reagent that is rehydrated by the blood. The blood in each of the conduits is then reciprocally moved across a restricted region until a predetermined degree of coagulation occurs. Since the coagulation time is being monitored in multiple conduits, a representation coagulation time for a given sample can be determined. In at least one of the conduits a normalizing control agent is present. The normalizing control agent counteracts any effects of anticoagulants present in the blood sample, thereby allowing the blood sample to have generally normal coagulation characteristics. The normalized blood is tested simultaneously with the untreated blood to provide a reference value against which the functionality of the test system and the quality of the sample can be judged.

Priority: US1995-424063 Applic. Date: 1995-04-19; US1994-327320 Applic. Date: 1994-10-21

Inventor: GAVIN MICHAEL [US]; CIMINI CATHERINE M [US]; HUANG MING [US]; KUKLO JR ANTHONY [US]; MAWHIRT JAMES A [US]; MARCELINO EDUARDO [US]; SIMONE ALBERT [US]


Patent No.: US5593419A  Issued: 14/Jan/1997

Title: Fixed wire dilatation catheter with distal twistable segment

Applicant/Assignee: C.R. BARD, INC

Application No.: 189293   Filing Date: 31/Jan/1994

Abstract:

A fixed-wire type of balloon dilatation catheter has a small diameter and can be steered to and passed to and through narrow stenoses. The catheter has a balloon at its distal end which is collapsible to a low profile to enable it to be passed through the stenosis. The catheter includes a connection between the distal end of the balloon and the supporting core wire which displays the least resistance to twisting about the core wire when the core wire is rotated with respect to the balloon and the balloon is subsequently inflated. Consequently, any twisting of the catheter about the wire will occur distally of the balloon so as not to obstruct fluid flow through the balloon.

Priority: US1990-539707 Applic. Date: 1990-06-18

Inventor: SEGAR LORI K [US]


Patent No.: US5599682A  Issued: 04/Feb/1997

Title: Method for the protection of leucocytes and method of blood analysis

Applicant/Assignee: IMMUNOTECH

Application No.: 246239   Filing Date: 19/May/1994

Abstract:

A method for protecting leukocytes in a blood sample, comprising contacting the blood sample with a preparation comprising an aliphatic aldehyde, a salt of an alkali metal or an alkaline earth metal, and optionally an agent to adjust isotonicity and hypotonically lysing erythrocytes in the blood sample.

Priority: FR19930006332 Applic. Date: 1993-05-19

Inventor: VAN AGTHOVEN ANDRE [FR]


Patent No.: US5599718A  Issued: 04/Feb/1997

Title: Measurement of the thrombolytic activity of blood

Applicant/Assignee:

Application No.: 107672   Filing Date: 18/Aug/1993

Abstract:

PCT No. PCT/GB92/02328 Sec. 371 Date Aug. 18, 1993 Sec. 102(e) Date Aug. 18, 1993 PCT Filed Dec. 16, 1992 PCT Pub. No. WO93/12423 PCT Pub. Date Jun. 24, 1993An in vitro method of monitoring thrombolysis of an occlusive thrombus formed under conditions which simulate in vivo is described. Thrombus is formed in a capillary tube by causing blood to flow under pressure from a non-anticoagulated supply thereof through the capillary lumen and into a reservoir in such a way that the thrombus forms solely by shear-stress. Formation of the thrombus is detected and the pressure on the tube is reduced, the reduced pressure being maintained for a predetermined period of time during which the thrombus stabilises. The pressure is then applied on the thrombus across anticoagulated blood from the same sample and lysis of the thrombus is detected. Preferably the supply of anticoagulated blood is produced by mixing the blood exiting the capillary tube with anticoagulant in the reservoir, the blood flow direction being reversed once thrombus stabilisation has taken place. The reservoir may be connected to a second reservoir by a connecting line. A photo-sensor monitoring blood in the line is then capable of detecting both formation of the thrombus and lysis of the thrombus.

Priority: GB19910026987 Applic. Date: 1991-12-19; WO1992GB02328 Applic. Date: 1992-12-16

Inventor: GOROG DIANA [GB]


Patent No.: US5601418A  Issued: 11/Feb/1997

Title: Blood pump

Applicant/Assignee: KYOCERA CORPORATION BAYLOR COLLEGE OF MEDICINE

Application No.: 488719   Filing Date: 08/Jun/1995

Abstract:

A centrifugal blood pump for heart-lung machines or the like. An impeller is provided with pump vanes and a magnet. The impeller is rotatably accommodated in a casing having an inlet and an outlet. A magnet drive means is disposed outside the casing. The impeller is supported by at least three balls above a bottom plate of the casing, held at the center of the bottom plate and rotated around the center axis of the impeller by the magnet means and the magnet drive means. When the upper and lower ends of the rotation shaft of the impeller are supported by the casing, the upper end of the rotation shaft is supported by a bearing embeddedly disposed at the top section of the conical section of the casing, and the inlet of the casing is disposed adjacent to and eccentric from the top section.

Priority: US1993-055233 Applic. Date: 1993-04-28

Inventor: OHARA YASUHISA [US]; MAKINOUCHI KENZO [US]; NOSE YUKIHIKO [US]


Patent No.: US5607579A  Issued: 04/Mar/1997

Title: Apheresis apparatus for separating an intermediate density component from whole blood

Applicant/Assignee: HAEMONETICS CORPORATION

Application No.: 536499   Filing Date: 28/Sep/1995

Abstract:

An apheresis apparatus for increasing the purity and yield of platelets separated from donated whole blood by centrifugation incorporates a centrifuge for separating whole blood into lower, intermediate, and higher density components. The centrifuge has inlet and outlet ports in selective fluid communication with a container for receiving lower density blood component from the outlet port. A pump is coupled to the container and the inlet port for recirculating lower density blood component from the first container through the inlet port into the centrifuge at a first, substantially constant, rate so as to widen the region of the centrifuge occupied by the intermediate density component without causing the intermediate density component to exit the centrifuge, and subsequently at a second rate, so as to displace intermediate density component from the centrifuge.

Priority: US1993-053734 Applic. Date: 1993-04-27

Inventor: LATHAM JR ALLEN [US]; JORGENSEN GLEN E [US]; SIBINGA THEODOOR H S [US]; PLANTE JOSEPH R [US]; KNAPP TRACEY E [US]


Patent No.: US5607937A  Issued: 04/Mar/1997

Title: Piperazides of substituted phenylalanine derivatives as thrombin inhibitors

Applicant/Assignee: PENTAPHARM AG

Application No.: 318649   Filing Date: 05/Jan/1995

Abstract:

PCT No. PCT/CH94/00026 Sec. 371 Date Jan. 5, 1995 Sec. 102(e) Date Jan. 5, 1995 PCT Filed Feb. 9, 1994 PCT Pub. No. WO94/18185 PCT Pub. Date Aug. 18, 1994The present invention relates to D,L-, L- and D-phenylalanine piperazides of formula (I) defined in claim 1 that inhibit blood coagulation, and thrombin and/or trypsin, respectively. The compounds are extraordinarily absorbable after oral, intraduodenal and in particular rectal administration and show only a low toxicity.

Priority: CH19930000405 Applic. Date: 1993-02-10; CH19930002827 Applic. Date: 1993-09-20; WO1994CH00026 Applic. Date: 1994-02-09

Inventor: STUERZEBECHER JOERG [DE]; VIEWEG HELMUT [DE]; WIKSTROEM PETER [CH]; ADLER CHRISTOPH [CH]


Patent No.: US5610024A  Issued: 11/Mar/1997

Title: Method for the determination of lupus anticoagulant antibodies that cause thrombosis

Applicant/Assignee: MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG D ER WISSENSCHAFTEN E.V

Application No.: 412854   Filing Date: 29/Mar/1995

Abstract:

In order to determine lupus anticoagulant (LA) antibodies in blood, plasma or tissue samples by means of the inhibitory effect of these antibodies on the neutralizing effect of protein C on the blood coagulation system, a defined amount of activated protein C is added to the sample, after incubation the remaining amount of a physiological substrate of protein C or protein S activity in the sample is determined according to known methods and the amount of LA antibodies present is calculated by comparison with a standard containing no LA antibodies. The method according to the present invention can be used to diagnose a predisposition to thrombotic events or disease-dependent risk of thrombosis as well as to monitor a therapy.

Priority: DE19924229933 Applic. Date: 1992-09-08; US1993-116685 Applic. Date: 1993-09-07

Inventor: MUELLER-BERGHAUS GER [DE]; POETZSCH BERND [DE]; SEELIG CHRISTOPH [DE]


Patent No.: US5612473A  Issued: 18/Mar/1997

Title: Methods, kits and solutions for preparing sample material for nucleic acid amplification

Applicant/Assignee: GULL LABORATORIES

Application No.: 587209   Filing Date: 16/Jan/1996

Abstract:

The present invention provides methods and apparatus for detecting and discriminating multiple analytes within a test sample which are simple, user-friendly, cost-effective and fast. In particular, it is preferred that the overall time for sample preparation, nucleic acid sequence amplification, and nucleic acid sequence differentiation be about 5 hours or less. The methods of the present invention comprise (i) rapid sample processing means for rapidly preparing sample material of various types for amplification of nucleic acid sequences using unique nucleic acid extraction buffer formulations, (ii) multianalyte non-preferential amplifying process means for simultaneously and non-preferentially amplifying multiple target nucleic acid sequences, if present within the sample, using appropriate primer oligonucleotides optimized to achieve substantially similar amplification efficiencies, and (iii) multianalyte recognition process means for detecting and discriminating amplified nucleic acid sequences which incorporate nucleic acid sequence mismatch detection means for differentiating minor mismatches between multiple amplified nucleic acid sequences, including only single base mismatches, using appropriate probe oligonucleotides modified with neutral base substitution molecules. The processing kit products in accord with the present invention may incorporate all, or only some, of the above-described means.

Priority:

Inventor: WU LINXIAN [US]; COOMBS JANA [US]; MALMSTROM SHARON L [US]; GLASS MICHAEL J [US]


Patent No.: US5614106A  Issued: 25/Mar/1997

Title: Method and apparatus for collection of platelets

Applicant/Assignee: BAXTER INTERNATIONAL INC

Application No.: 459529   Filing Date: 02/Jun/1995

Abstract:

Methods and apparatus are disclosed for separating and collecting blood fractions or components such as platelets. A first anticoagulant solution is added to whole blood, which is then separated into platelet-rich plasma and red cells. A second anticoagulant is added to the platelet rich plasma, which is then separated into platelet-poor plasma and platelet concentrate. The rate of red cell sedimentation is increased and the time of the separation/collection procedure may be reduced when the pH of the first anticoagulant is greater than approximately 6.0.

Priority: US1993-030710 Applic. Date: 1993-03-12

Inventor: PAYRAT JEAN M [BE]; SCHOENDORFER DONALD W [US]


Patent No.: US5614499A  Issued: 25/Mar/1997

Title: Peptide derivatives as thrombin inhibitors

Applicant/Assignee: ASTRA AKTIEBOLAG

Application No.: 984884   Filing Date: 02/Dec/1992

Abstract:

The invention relates to new competitive inhibitors of thrombin, pharmaceutical compositions containing the compounds as active ingredients, and the use of the compounds as anticoagulants for prophylaxis and treatment of thromboembolic diseases, according to the formula Formula I wherein A represents a methylene group, an ethylene group or a propylene group, which may be substituted or A represents -CH2-O-CH2-, -CH2-S-CH2-, -CH2-SO-CH2-, or A represents -CH2-O-, -CH2-S-, -CH2-SO-, with the heteroatom functionality in position 4

n is an integer 2 to 6

and B represents -N(R6)-C(NH)-NH2, wherein R6 is H or a methyl group, or B represents -S-C(NH)-NH2, or -C(NH)-NH2.

Priority: SE19910003612 Applic. Date: 1991-12-04

Inventor: BYLUND RUTH E [SE]; TEGER-NILSSON ANN-CATRINE E [SE]


Patent No.: US5624794A  Issued: 29/Apr/1997

Title: Method for extending the useful shelf-life of refrigerated red blood cells by flushing with inert gas

Applicant/Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Application No.: 473675   Filing Date: 05/Jun/1995

Abstract:

Method using oxygen removal for extending the useful shelf-life of refrigerated red blood cells. A cost-effective, 4 DEG C. storage procedure that preserves red cell quality and prolongs post-transfusion in vivo survival is described. Preservation of adenosine triphosphate levels and reduction in hemolysis and in membrane vesicle production of red blood cells stored at 4 DEG C. for prolonged periods of time is achieved by removing oxygen therefrom at the time of storage

in particular, by flushing with an inert gas. Adenosine triphosphate levels of the stored red blood cells are boosted in some samples by addition of ammonium phosphate.

Priority:

Inventor: BITENSKY MARK W [US]; YOSHIDA TATSURO [US]


Patent No.: US5627036A  Issued: 06/May/1997

Title: Use of an anticoagulant as a diagnostic agent

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: 183788   Filing Date: 21/Jan/1994

Abstract:

Detectably labelled annexines and compositions thereof are disclosed. Also disclosed are methods for diagnosing a disruption or activation of the hemostatic system or a prothrombotic state in an individual suspected of having a hemostatic disorder, by contacting the blood of said individual with an annexine, and detecting whether an annexine-platelet complex is formed.

Priority: DE19893942988 Applic. Date: 1989-12-27; WO1990EP02257 Applic. Date: 1990-12-19; US1992-904366 Applic. Date: 1992-06-26; US1992-862572 Applic. Date: 1992-06-26

Inventor: REUTELINGSPERGER CHRISTIAAN [NL]


Patent No.: US5628727A  Issued: 13/May/1997

Title: Extracorporeal virioncidal apparatus

Applicant/Assignee:

Application No.: 515135   Filing Date: 15/Aug/1995

Abstract:

An extracorporeal radiation-therapy apparatus for use in treating the blood of a donor for diseased cells or organisms. The apparatus separates the blood by a density gradient device and treats the different blood fractions with drugs and/or high energy radiation.

Priority:

Inventor: HAKKY SAID I [US]; HAKKI A-HAMID [US]; HUDSON PERRY B [US]


Patent No.: US5629209A  Issued: 13/May/1997

Title: Method and apparatus for detecting viscosity changes in fluids

Applicant/Assignee:

Application No.: 545523   Filing Date: 19/Oct/1995

Abstract:

An apparatus for detecting changes in the viscosity of a fluid comprises a cartridge having a fluid receiving/dispensing reservoir, one or more fluid-receiving chambers, and a conduit that permits fluid communication between the fluid receiving/dispensing reservoir and the fluid-receiving chamber. Fluid is introduced into the cartridge through an injection port and fills the reservoir, moving from the reservoir through the conduit into the chamber. An air vent/fluid plug device in fluid communication with the chamber permits air to exit while the fluid enters the system but prevents the fluid from leaving after the chamber is filled. A freely movable ferromagnetic material is placed within the fluid-receiving chamber and is caused to move by an electromagnet. Changes in the viscosity of the fluid are detected by determining the position of the ferromagnetic material in the fluid-receiving chamber.

Priority:

Inventor: BRAUN SR WALTER J [US]; BOIARSKI ANTHONY A [US]; BRAUN JR WALTER J [US]; BRAUN STEVEN P [US]


Patent No.: US5632779A  Issued: 27/May/1997

Title: Zirconium oxide and zirconium nitride coated vascular grafts

Applicant/Assignee: SMITH & NEPHEW, INC

Application No.: 467457   Filing Date: 06/Jun/1995

Abstract:

Vascular grafts fabricated from a substrate of a low modulus metal coated with blue to black zirconium oxide or zirconium nitride. The coating provides enhanced thrombogenicity, biocompatibility, blood compatibility, corrosion-resistance, friction and microfretting resistance, durability, and electrical insulation, where applicable. The coatings may be applied to low modulus metallic substrates by physical or chemical vapor deposition as well as other ion-beam assisted methods. Preferably, however, for optimizing attachment strength, the vascular grafts are fabricated from zirconium or zirconium-containing alloys and the coatings are formed by oxidizing or nitriding through an in situ method that develops a coating from and on the metal surface of the vascular graft, without need for depositing a coating on the metal surface.

Priority: US1993-112587 Applic. Date: 1993-08-26; US1992-919932 Applic. Date: 1992-07-27; US1992-830720 Applic. Date: 1992-02-04; US1990-557173 Applic. Date: 1990-07-23; US1989-385285 Applic. Date: 1989-07-25

Inventor: DAVIDSON JAMES A [US]


Patent No.: US5632897A  Issued: 27/May/1997

Title: Method for removing aluminum ions from blood

Applicant/Assignee: FRESENIUS AG

Application No.: 464568   Filing Date: 05/Jun/1995

Abstract:

A method for removing aluminum from blood includes the step of adding to the blood an anticoagulant and a complexing agent for aluminum or one compound effective in both preventing coagulation of blood and capable of complexing aluminum. The complexing agent or compound capable of complexing aluminum is allowed to intermingle with the blood and complex with aluminum present in the blood. The complex of complexing agent and aluminum formed during the intermingle step is then separated using a semi-permeable membrane, and the blood is recovered. The method is particularly useful in treating patient's having aluminum intoxication.

Priority: DE19924230513 Applic. Date: 1992-09-11; US1993-119908 Applic. Date: 1993-09-10

Inventor: MATHIEU BERND [DE]


Patent No.: US5635359A  Issued: 03/Jun/1997

Title: Method for measuring the activity of angiotensin converting enzyme in biological samples

Applicant/Assignee: B.M.R.A. CORPORATION B.V

Application No.: 270364   Filing Date: 05/Jul/1994

Abstract:

The activity of angiotensin converting enzyme (ACE) is measured in biological samples as body fluids. ACE-activity is estimated in minimally diluted specimens, using the natural substrate angiotensin I at close to physiological concentration. Femtomoles of generated angiotensin II are trapped by specific high affinity monoclonal antibodies and thus protected from degradation by angiotensinases during the incubation step. The same antibodies are subsequently used for quantitation by radioimmunoassay.

Priority: EP19910810074 Applic. Date: 1991-02-01; US1992-830341 Applic. Date: 1992-01-31

Inventor: BRUNNER HANS R [CH]; NUSSBERGER JURG [CH]


Patent No.: US5637081A  Issued: 10/Jun/1997

Title: Anticoagulant composition for use in blood dialysis circuit

Applicant/Assignee: NOF CORPORATION

Application No.: 460983   Filing Date: 05/Jun/1995

Abstract:

An anticoagulant composition for a blood dialysis circuit contains a fatty acid derivative in liquid form at ambient temperature, and an antioxidant. The antioxidant is contained in an amount of 0.0001 to 5.0 parts by weight relative to 100 parts by weight of the fatty acid derivative. An air trap chamber device for a blood dialysis circuit contains a vessel for storing blood dialysed by a dialysis unit, an inlet tube for introducing the blood treated with dialysis into a liquid in the vessel selected from the group consisting of a layer of the aforementioned anticoagulant composition, and the blood, a measurement unit for measuring the pressure of air in the vessel lying above the layer of the anticoagulant composition, an adjustment unit for adjusting the pressure of the air and an outlet tube for conducting the blood treated with dialysis out of the vessel. A method for blood dialysis involves passing blood taken out of a mammal through the aforementioned vessel in which the blood and air are not in contact with each other, and returning the blood into the mammal.

Priority: US1993-167221 Applic. Date: 1993-12-14

Inventor: NOGUCHI YASUHISA [JP]; KASAMA TOSHIO [JP]


Patent No.: US5639599A  Issued: 17/Jun/1997

Title: Amplification of nucleic acids from mononuclear cells using iron complexing and other agents

Applicant/Assignee: GEN-PROBE INCORPORATED

Application No.: 254310   Filing Date: 06/Jun/1994

Abstract:

Method and kit for the preparation of nucleic acid, such as for amplification. The nucleic acid may be prepared by centrifuging a sample of whole cells, particularly mononuclear cells, with an appropriate centrifugation medium so as to separate desired cells from non-desired cells, then removing and lysing said desired cells. A complexing agent able to complex ferric ion may be added to the lysed cells. The nucleic acid associated with the lysed cells can be amplified, and the nucleic acid can also be screened for a certain nucleic acid sequence, such as a vital nucleic acid sequence.

Priority: US1992-895587 Applic. Date: 1992-06-08

Inventor: RYDER THOMAS B [US]; KACIAN DANIEL L [US]


Patent No.: US5639623A  Issued: 17/Jun/1997

Title: Method of measuring immunokinetics

Applicant/Assignee:

Application No.: 181867   Filing Date: 13/Jan/1994

Abstract:

A method of measuring and assessing T and B cell immunokinetics in human, particularly cancer immunokinetics by applying the multiple regression analysis, one of multivariate data analyses, to the counts in blood samples of CD3, CD4, CD8 and OKIa1 positive lymphocytes, helper, suppression inducer, cytotoxic and suppressor T lymphocytes, activated suppression inducer/helper and activated suppressor/cytotoxic T lymphocytes and natural killer cell, monocyte, basophil, eosinophil and neutrophil.

Priority: JP19890234484 Applic. Date: 1989-09-08; US1991-689054 Applic. Date: 1991-05-06

Inventor: YAMAUCHI TAMIO [JP]


Patent No.: US5643193A  Issued: 01/Jul/1997

Title: Apparatus for collection washing and reinfusion of shed blood

Applicant/Assignee: HAEMONETICS CORPORATION

Application No.: 571496   Filing Date: 13/Dec/1995

Abstract:

An integrated, vacuum-driven shed blood processing system that collects, dilutes, filters and washes postoperatively shed blood and concentrates red blood cells for reinfusion to the patient. The location of the centrifuge bowl between the surgical site and the vacuum source used to clean the site allows the immediate collection of shed blood in the bowl without an intermediate reservoir or an additional pump. In conjunction with a modified centrifuge bowl having a sealed aperture in its floor that permits reinfusion directly from the bowl without an additional reinfusion bag or reverse pump, this configuration processes blood for reinfusion using fewer steps and components yet without loss of functionality. Dilution of the blood upon its introduction into the system reduces the tendency to coagulate and allows the use of lower bowl rotation speeds. Slower rotation reduces red blood cell damage and lowers power requirements, which improves portability.

Priority:

Inventor: PAPILLON JEAN [FR]; PAGES ETIENNE [FR]


Patent No.: US5648265A  Issued: 15/Jul/1997

Title: Apparatus for preparing fibrinogen adhesive from whole blood

Applicant/Assignee:

Application No.: 370793   Filing Date: 10/Jan/1995

Abstract:

A process and apparatus for one-step preparation of fibrinogen adhesive by polyethylene glycol-mediated precipitation from plasma are disclosed. The methods and apparatus of the invention permit preparation of autologous fibrinogen adhesive composition from the patient during surgery, and can be applied generally to provide such compositions. Also disclosed are an apparatus and method for application of sealant comprising this fibrinogen adhesive composition.

Priority: US1993-090587 Applic. Date: 1993-07-12; US1989-372443 Applic. Date: 1989-06-23

Inventor: EPSTEIN GORDON H [US]


Patent No.: US5651766A  Issued: 29/Jul/1997

Title: Blood collection and separation system

Applicant/Assignee: TRANSFUSION TECHNOLOGIES CORPORATION

Application No.: 482617   Filing Date: 07/Jun/1995

Abstract:

A system compact enough to be located entirely beside the donor's chair, and able to process the blood while the donor is still resting in the chair after having donated the blood. The separated blood components (plasma and red blood cells) may be stored in their individual optimum environments immediately after the whole blood is drawn, and the blood does not need to be transported back to a separation laboratory for processing. The system includes a needle (72) (or other cannula-like device) for insertion into a vein of the donor and drawing whole blood therethrough, a rotor (2a) for holding the blood after it is drawn, and a motor (50) for spinning the rotor so as to cause the blood to separate into components, for example, plasma and red blood cells. The system also provides for a container for collecting a separated component. In a preferred embodiment two containers are used: the first container (92) for containing an anticoagulant, which is preferably added to the whole blood as it is drawn from the donor, and then for storing the plasma after it has been separated from the red blood cells, and the second container (91) for storing the separated red blood cells. The system further includes tubing (73), which may have valving (81) built into it and which may be acted on externally, so as to direct the blood components in the desired manner. The tubing connects the needle (72), the rotor (2a), and the first and second containers (92, 91). With the valving, the tubing is able to permit (i) the flow of whole blood from the needle (72) to the rotor (2a), (ii) the flow of anticoagulant from the first container (92) to the whole blood flowing from the needle to the rotor, (iii) the flow of plasma from the rotor to the first container, and (iv) the flow of red blood cells from the rotor to the second container (91).

Priority:

Inventor: KINGSLEY GORDON F [US]; HEADLEY THOMAS D [US]; HALPERN LISE N [US]


Patent No.: US5656027A  Issued: 12/Aug/1997

Title: Surgical fluid suction accumulator and volume measurement device

Applicant/Assignee: COBE LABORATORIES, INC

Application No.: 472990   Filing Date: 06/Jun/1995

Abstract:

An apparatus for minimizing trauma to a medical fluid while transporting the medical fluid from a surgical wound by reducing the air to fluid interface during transport. The apparatus includes a suction wand for collecting medical fluid and tubing for transporting the medical fluid to a reservoir. The reservoir repeatedly accumulates the medical fluid and discharges it in a bolus when a predetermined volume is achieved. The reservoir comprises a fluid inlet, a fluid outlet, and a gas outlet. A siphon is disposed inside the reservoir for removing the bolus of medical fluid once the predetermined fluid volume is accumulated. The siphon includes a first end for suctioning the medical fluid and a second end exiting the reservoir through the fluid outlet, thereby defining an external siphon length. A pump is attached to the second siphon end to provide suction to the system. A bypass line connects the reservoir, from its gas outlet, to the external siphon length thereby removing air from the reservoir and, thus, increasing the reduction of the air to fluid interface during transport of the medical fluid.

Priority:

Inventor: ELLINGBOE BRUCE S [US]


Patent No.: US5658271A  Issued: 19/Aug/1997

Title: Closed circuit autologous sequestration reservoir system

Applicant/Assignee:

Application No.: 598688   Filing Date: 08/Feb/1996

Abstract:

An apparatus is provided for autologous sequestration of blood from a patient prior to, during and after surgery. Sequestered blood contained in an assembly of blood collection bags is kept in fluid contact with the patient throughout surgery, thereby assuring continuity with the patient's circulatory system. The plurality of blood collection bags is interconnected with a corresponding plurality of valves which is interconnected with a plurality of flexible tubes which is attached to a patient's right atrium or a peripheral artery. Following induction of anesthesia in the operating room, a patient's blood is sequestered into a collection bag assembly which forms a closed circuit blood reservoir system. Collected blood during surgery trickles back into the patient's blood system, thereby emulating venous blood flow.

Priority:

Inventor: LOUBSER PAUL G [US]


Patent No.: US5665061A  Issued: 09/Sep/1997

Title: Biological/pharmaceutical method and apparatus for collecting and mixing fluids

Applicant/Assignee: COBE LABORATORIES, INC

Application No.: 364471   Filing Date: 27/Dec/1994

Abstract:

A blood circulation apparatus includes a suction wand for receiving blood from a patient, a reservoir for collecting received blood, a flow path between the suction wand and the reservoir, and an anticoagulant pump and line for introducing anticoagulant into the flow path upstream of the reservoir. Sensors detect pressure in the flow path and in the anticoagulant line, and transmit corresponding pressure signals to a controller that regulates anticoagulant introduction as a function of the pressure signals.

Priority: US1992-928040 Applic. Date: 1992-08-11

Inventor: ANTWILER GLEN DELBERT [US]


Patent No.: US5665723A  Issued: 09/Sep/1997

Title: Fibrinogen receptor antagonists

Applicant/Assignee: MERCK & CO., INC

Application No.: 460372   Filing Date: 02/Jun/1995

Abstract:

Fibrinogen receptor antagonists having the formula

Fibrinogen receptor antagonists having the formula for example

Priority: US1995-391851 Applic. Date: 1995-02-22

Inventor: HARTMAN GEORGE D [US]; HUTCHINSON JOHN H [US]; HALCZENKO WASYL [US]


Patent No.: US5667963A  Issued: 16/Sep/1997

Title: Anticoagulant solution for use in blood chemistry-related techniques and apparatus

Applicant/Assignee: BECTON DICKINSON AND COMPANY

Application No.: 603610   Filing Date: 21/Feb/1996

Abstract:

An anticoagulant solution of sodium citrate for use in blood chemistry-related techniques and apparatus is disclosed. The anticoagulant solution should include an effective concentration of sodium citrate sufficient for preventing the coagulation of a sample of blood employed in the technique or added to the apparatus. The sodium citrate-based anticoagulant solution should have a pH ranging from above 6.0 to about 8.5 and a sodium citrate concentration preferably ranging from about 0.05M to about 0.2M.

Priority: US1992-897305 Applic. Date: 1992-06-11

Inventor: SMITH WARD C [US]; CARROLL RICHARD L [US]


Patent No.: US5670329A  Issued: 23/Sep/1997

Title: Method and analytical system for performing fibrinogen assays accurately, rapidly and simply using a rotating magnetic field

Applicant/Assignee: CARDIOVASCULAR DIAGNOSTICS, INC

Application No.: 68855   Filing Date: 28/May/1993

Abstract:

A method of performing a quantitative fibrinogen assay is provided which uses a dry reagent chemistry in combination with a rotational magnetic field and which has excellent correlation with the Fibrometer, the gold standard in the industry. Additionally, an apparatus for conducting the assay, a qualitative fibrinogen assay and a method for preparing a calibration curve for use with the quantitative fibrinogen assay are provided.

Priority:

Inventor: OBERHARDT BRUCE J [US]


Patent No.: US5674489A  Issued: 07/Oct/1997

Title: Method to enhance thrombomodulin APC generation using cationic proteins

Applicant/Assignee: REGENTS OF THE UNIVERSITY OF MINNESOTA

Application No.: 698329   Filing Date: 15/Aug/1996

Abstract:

A method of inhibiting blood coagulation in a patient is provided. This method involves administering to the patient an effective anticoagulant amount of a cationic protein

wherein the cationic protein has an isoelectric point of at least about 7.4, and is capable of enhancing the production of activated protein C by a thrombomodulin-thrombin complex by a factor of at least about two. A particularly preferred cationic protein is purified Platelet Factor 4.

Priority: US1993-121226 Applic. Date: 1993-09-14

Inventor: SLUNGAARD ARNE [US]


Patent No.: US5676645A  Issued: 14/Oct/1997

Title: Method and apparatus for controlling concentrations in vivos and in tubing systems

Applicant/Assignee: COBE LABORATORIES, INC

Application No.: 472931   Filing Date: 06/Jun/1995

Abstract:

A method and apparatus for maximizing the total amount of blood processed during an apheresis procedure by optimizing the concentration of anticoagulant in a donor/patient and the associated extracorporeal tubing set is provided. A simplified model of an anticoagulant accumulation in a donor/patient's body is used to calculate an optimal anticoagulant infusion rate profile to the donor/patient during a blood processing procedure. A maximum acceptable anticoagulant concentration in the donor/patient acts as an upper limit on the rate at which anticoagulant may be infused to the donor/patient using the optimized infusion rate profile. A minimum acceptable anticoagulant level acts as a lower limit in optimally controlling the anticoagulant concentration in the extracorporeal tubing set. Both the maximum acceptable anticoagulant level in the donor/patient and the minimum acceptable anticoagulant level in the extracorporeal tubing set may be customized for a specific donor/patient thereby allowing the optimized infusion rate profile and the extracorporeal tubing set anticoagulant concentration to be customized for the specific patient.

Priority: US1992-845677 Applic. Date: 1992-03-04

Inventor: VAN WAEG GEERT [BE]; LANGLEY ROBERT W [US]; DUMONT LARRY JOE [US]


Patent No.: US5676841A  Issued: 14/Oct/1997

Title: Blood processing systems and methods which monitor citrate return to the donor

Applicant/Assignee: BAXTER INTERNATIONAL INC

Application No.: 472439   Filing Date: 07/Jun/1995

Abstract:

Blood collection systems and methods minimize citrate toxicity in donors. The systems and methods convey whole blood at a prescribed rate Qb into a separation device for separation into red blood cells and a plasma constituent. The systems and methods add anticoagulant including citrate to the whole blood. The systems and methods control Qb (in ml/min or equivalent) based upon a citrate equivalent blood flow rate EqQBCIR, where: where: CIR is a selected nominal a-symptomatic citrate infusion rate (in mg/kg/min or equivalent), AC is a selected anticoagulant ratio, Wgt is the donor's weight (in kg or equivalent), and CitrateConc is the citrate concentration in the anticoagulant (in mg/ml or equivalent).

Priority: US1993-097967 Applic. Date: 1993-07-26; US1992-965088 Applic. Date: 1992-10-22; US1991-814403 Applic. Date: 1991-12-23

Inventor: BROWN RICHARD I [US]


Patent No.: US5678570A  Issued: 21/Oct/1997

Title: Method of treating cardiac arrest

Applicant/Assignee: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL

Application No.: 422337   Filing Date: 14/Apr/1995

Abstract:

A method of treating a subject under cardiac arrest comprises the steps of: blocking the descending aorta of the subject

then withdrawing blood from the subject

oxygenating the blood withdrawn from the subject

and perfusing the aortic arch of the subject with oxygenated blood in an amount effective to deliver oxygen to the heart of the subject. This method enables the subject to continue to receive oxygenating material (i.e., blood in this instance) without the danger of volume overload that would be present if another oxygenated solution were continuously infused.

Priority:

Inventor: MANNING JAMES E [US]


Patent No.: US5681273A  Issued: 28/Oct/1997

Title: Systems and methods for predicting blood processing parameters

Applicant/Assignee: BAXTER INTERNATIONAL INC

Application No.: 483483   Filing Date: 07/Jun/1995

Abstract:

Systems and methods predict a whole blood processing volume required to achieve a desired platelet yield based upon inputs of selected processing parameters.

Priority: US1993-097967 Applic. Date: 1993-07-26; US1992-965088 Applic. Date: 1992-10-22; US1991-814403 Applic. Date: 1991-12-23

Inventor: BROWN RICHARD I [US]


Patent No.: US5683347A  Issued: 04/Nov/1997

Title: Balloon catheter

Applicant/Assignee: NIPPON ZEON CO., LTD

Application No.: 508885   Filing Date: 28/Jul/1995

Abstract:

A balloon catheter used for intra-aortic balloon pumping (IABP). In the balloon catheter, an outer diameter of a catheter tube is not made constant in the axial direction. Rather, the outer diameter of the catheter tube from a hemostatic valve to a bifurcation, the portion which is positioned outside the patient's blood vessel, is made 3 to 30 percent larger than the outer diameter of the catheter tube from the balloon portion to the hemostatic valve, which is positioned inside the patient's blood vessel. The bifurcation has a first passage and a second passage. The first passage is communicating with a shuttle gas port and is disposed straight along the direction of the axial center of the catheter tube. In the balloon catheter, improvements in a channel resistance of a shuttle gas and in the response can be expected compared with the conventional balloon catheter, where the blood pressure measurement port (the second passage) was disposed straight along the direction of the axial center of the catheter tube and the outer diameter of the catheter tube was made constant in the axial direction.

Priority: JP19920285093 Applic. Date: 1992-09-30; JP19920285094 Applic. Date: 1992-09-30; JP19920343355 Applic. Date: 1992-11-30; JP19920343356 Applic. Date: 1992-11-30; US1993-125843 Applic. Date: 1993-09-24

Inventor: MIYATA SHINICHI [JP]; KAWABATA TAKASHI [JP]; TOYOKAWA TETSUO [JP]; SAKAI KOUICHI [JP]


Patent No.: US5687718A  Issued: 18/Nov/1997

Title: Device for continuously detecting blood parameters

Applicant/Assignee: HEWLETT-PACKARD COMPANY

Application No.: 490320   Filing Date: 14/Jun/1995

Abstract:

Disclosed is a device for continuing detecting blood parameters. The device includes a catheter adapted to be introduced into the artery of a patient. A sensor is arranged in the catheter. A tube us adapted to be coupled to a vein of a patient and is also connected to the first catheter. A device controllably maintains blood flow across the sensor, the device being controlled such that initially the flow of blood to the first catheter via the tube is prevented so long as the detective blood parameters indicated a sufficient amount of fresh arterial blood is flowing around the sensor. In the event that a detective blood parameters indicate that an insufficient amount of blood flows around the sensor, then blood flow through the first catheter to the vein of the patient via the tube is then established.

Priority: DE19944424267 Applic. Date: 1994-07-09

Inventor: FISCHER BERNHARD [DE]; ZOLL MARTIN [DE]; WENDER JOACHIM [DE]; ROCHLITZER FRANK [DE]


Patent No.: US5690670A  Issued: 25/Nov/1997

Title: Stents of enhanced biocompatibility and hemocompatibility

Applicant/Assignee:

Application No.: 468258   Filing Date: 06/Jun/1995

Abstract:

Cardiovascular and other medical implants fabricated from low-modulus Ti-Nb-Zr alloys to provide enhanced biocompatibility and hemocompatibility. The cardiovascular implants may be surface hardened by oxygen or nitrogen diffusion or by coating with a tightly adherent, hard, wear-resistant, hemocompatible ceramic coating. The cardiovascular implants include heart valves, total artificial heart implants, ventricular assist devices, vascular grafts, stents, electrical signal carrying devices such as pacemaker and neurological leads, defibrillator leads, and the like. It is contemplated that the Ti-Nb-Zr alloy can be substituted as a fabrication material for any cardiovascular implant that either comes into contact with blood thereby demanding high levels of hemocompatibility, or that is subject to microfretting, corrosion, or other wear and so that a low modulus metal with a corrosion-resistant, hardened surface would be desirable.

Priority: US1993-112599 Applic. Date: 1993-08-26; US1993-036414 Applic. Date: 1993-03-24; US1992-986280 Applic. Date: 1992-12-07; US1991-647453 Applic. Date: 1991-01-28; US1989-454181 Applic. Date: 1989-12-21

Inventor: DAVIDSON JAMES A [US]


Patent No.: US5690835A  Issued: 25/Nov/1997

Title: Systems and methods for on line collection of cellular blood components that assure donor comfort

Applicant/Assignee: BAXTER INTERNATIONAL INC

Application No.: 719312   Filing Date: 24/Sep/1996

Abstract:

Systems and methods convey anticoagulated blood suspension from a donor into a separation device for component separation. One or more components are retained for therapeutic use, while one or more are returned to the donor. The systems and methods monitor the rate at which anticoagulant carried in the returned components is being returned. The rate, expressed in terms of milligram (mg) of anticoagulant per kilogram (kg) of donor body weight per unit of time of blood processing, is compared to a nominal rate that is correlated with donor comfort.

Priority: US1995-551579 Applic. Date: 1995-11-01; US1993-097967 Applic. Date: 1993-07-26; US1992-965088 Applic. Date: 1992-10-22; US1991-814403 Applic. Date: 1991-12-23

Inventor: BROWN RICHARD I [US]


Patent No.: US5691329A  Issued: 25/Nov/1997

Title: Compounds containing basic and acidic termini useful as fibrinogen receptor antagonists

Applicant/Assignee: THE DUPONT MERCK PHARMACEUTICAL COMPANY

Application No.: 694043   Filing Date: 08/Aug/1996

Abstract:

This invention relates to novel compounds containing basic and acidic termini, pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of platelet aggregation, as thrombolytics, and/or for the treatment of thromboembolic disorders.

Priority: US1994-343159 Applic. Date: 1994-11-22; US1993-174552 Applic. Date: 1993-12-28

Inventor: DEGRADO WILLIAM FRANK [US]; XUE CHU-BIAO [US]


Patent No.: US5691453A  Issued: 25/Nov/1997

Title: Separation of polymerized hemoglobin from unpolymerized hemoglobin on hydroxyapatite using HPLC

Applicant/Assignee: BIOPURE CORPORATION

Application No.: 475899   Filing Date: 07/Jun/1995

Abstract:

A method for producing a stable polymerized hemoglobin blood-substitute from blood. The method of this invention includes contacting a polymerized hemoglobin solution with a hydroxyapatite HPLC column and recovering the substantially pure polymerized hemoglobin.

Priority:

Inventor: WERTZ CURTIS E [US]; GAWRYL MARIA S [US]


Patent No.: US5698220A  Issued: 16/Dec/1997

Title: Asymmetric membranes in delivery devices

Applicant/Assignee: PFIZER INC

Application No.: 462473   Filing Date: 05/Jun/1995

Abstract:

A device for controlled release of an active substance through one or more asymmetric membranes by diffusion and/or osmotic pumping.

Priority: US1992-951931 Applic. Date: 1992-09-25; US1989-391741 Applic. Date: 1989-08-09; US1988-238371 Applic. Date: 1988-08-30

Inventor: CARDINAL JOHN R [US]; HERBIG SCOTT M [US]; KORSMEYER RICHARD W [US]; LO JEELIN [US]; SMITH KELLY L [US]; THOMBRE AVINASH G [US]


Patent No.: US5702365A  Issued: 30/Dec/1997

Title: Dual-lumen catheter

Applicant/Assignee:

Application No.: 674964   Filing Date: 03/Jul/1996

Abstract:

A dual-lumen blood-treatment catheter has inner and outer lumina open towards the patient end. The catheter has expandable portions in the outer lumen located near the patient end for atraumatically preventing collapse of the blood vessel to ensure free flow of blood into and out of the catheter, In one embodiment, the outer lumen has a plurality of slits around its circumference which form slats therebetween. Withdrawal of the inner lumen relative to the outer lumen causes the slits to open, thereby bowing the slats to expand the outer lumen.

Priority: GB19920018994 Applic. Date: 1992-09-08; US1995-387810 Applic. Date: 1995-02-27

Inventor: KING TOBY ST JOHN [GB]


Patent No.: US5709874A  Issued: 20/Jan/1998

Title: Device for local drug delivery and methods for using the same

Applicant/Assignee: EMORY UNIVERSITY

Application No.: 660203   Filing Date: 03/Jun/1996

Abstract:

A device for the local delivery of a substance into a natural tissue conduit in the mammalian body. The device has a substance delivery segment which provides a means for locally delivering a substance into the boundary layer of fluid flowing through the conduit without disrupting the fluid flow therethrough. For example, an indwelling catheter is provided for endovascular delivery of a substance locally to a targeted treatment area. Also provided are methods of locally delivering a substance into a natural tissue conduit in the mammalian body utilizing the device of the present invention.

Priority: US1994-188248 Applic. Date: 1994-01-28; US1993-046622 Applic. Date: 1993-04-14

Inventor: HANSON STEPHEN R [US]; SCOTT NEAL A [US]; KING III SPENCER B [US]; HARKER LAURENCE A [US]


Patent No.: US5712798A  Issued: 27/Jan/1998

Title: Blood component collection system with optimizer

Applicant/Assignee: COBE LABORATORIES, INC

Application No.: 439649   Filing Date: 12/May/1995

Abstract:

A blood component collection system with optimization capabilities. In one embodiment, process parameters are derived from an input/configured predetermined blood component yield and which is based upon the maximization of at least one process parameter. Thereafter, the blood component collection procedure is performed with these derived process control parameters. In another embodiment, process parameters are derived from an input total procedure time from a maximized value for at least one of the other process control parameters so as to maximize blood component yield in this fixed time. Thereafter, the blood component collection procedure is performed with these derived parameters.

Priority: US1993-140254 Applic. Date: 1993-10-21; US1992-912973 Applic. Date: 1992-07-10; US1992-845677 Applic. Date: 1992-03-04; US1993-110432 Applic. Date: 1993-08-23

Inventor: LANGLEY ROBERT W [US]; KELLER JOHN J [US]; URDAHL STEVEN GAGE [US]


Patent No.: US5713947A  Issued: 03/Feb/1998

Title: Cardiovascular implants of enhanced biocompatibility

Applicant/Assignee: SMITH & NEPHEW, INC

Application No.: 470251   Filing Date: 06/Jun/1995

Abstract:

Cardiovascular and other medical implants fabricated from low-modulus Ti-Nb-Zr alloys to provide enhanced biocompatibility and hemocompatibility. The cardiovascular implants may be surface hardened by oxygen or nitrogen diffusion or by coating with a tightly adherent, hard, wear-resistant, hemocompatible ceramic coating. The cardiovascular implants include heart valves, total artificial heart implants, ventricular assist devices, vascular grafts, stents, electrical signal carrying devices such as pacemaker and neurological leads, defibrillator leads, and the like. It is contemplated that the Ti-Nb-Zr alloy can be substituted as a fabrication material for any cardiovascular implant that either comes into contact with blood thereby demanding high levels of hemocompatibility, or that is subject to microfretting, corrosion, or other wear and so that a low modulus metal with a corrosion-resistant, hardened surface would be desirable.

Priority: US1993-112599 Applic. Date: 1993-08-26; US1993-036414 Applic. Date: 1993-03-24; US1992-986280 Applic. Date: 1992-12-07; US1991-647453 Applic. Date: 1991-01-28; US1989-454181 Applic. Date: 1989-12-21

Inventor: DAVIDSON JAMES A [US]


Patent No.: US5716400A  Issued: 10/Feb/1998

Title: Cardiovascular implants of enhanced biocompatibility

Applicant/Assignee: SMITH & NEPHEW, INC

Application No.: 468537   Filing Date: 06/Jun/1995

Abstract:

Cardiovascular and other medical implants fabricated from low-modulus Ti-Nb-Zr alloys to provide enhanced biocompatibility and hemocompatibility. The cardiovascular implants may be surface hardened by oxygen or nitrogen diffusion or by coating with a tightly adherent, hard, wear-resistant, hemocompatible ceramic coating. The cardiovascular implants include heart valves, total artificial heart implants, ventricular assist devices, vascular grafts, stents, electrical signal carrying devices such as pacemaker and neurological leads, defibrillator leads, and the like. It is contemplated that the Ti-Nb-Zr alloy can be substituted as a fabrication material for any cardiovascular implant that either comes into contact with blood thereby demanding high levels of hemocompatibility, or that is subject to microfretting, corrosion, or other wear and so that a low modulus metal with a corrosion-resistant, hardened surface would be desirable.

Priority: US1993-112599 Applic. Date: 1993-08-26; US1993-036414 Applic. Date: 1993-03-24; US1992-986280 Applic. Date: 1992-12-07; US1991-647453 Applic. Date: 1991-01-28; US1989-454181 Applic. Date: 1989-12-21

Inventor: DAVIDSON JAMES A [US]


Patent No.: US5716795A  Issued: 10/Feb/1998

Title: Thrombomodulin-based coagulometric assay of the protein C system

Applicant/Assignee:

Application No.: 582384   Filing Date: 03/Jan/1996

Abstract:

The present invention provides a one-stage assay which uses soluble thrombomodulin for directly determining the functional status in plasma of the protein C system. The activity of the protein C system is used to determine the risk of thrombosis in the host individual. Alternatively, the activity of the protein C system is used to determine the presence of a malignant cancer and other pathologies. In another embodiment of the invention, a heparin adsorbent step is added to the assay process which reveals the existence of an additional component in protein C activation, and thus the existence of an additional component in the regulation of blood coagulation.

Priority: US1995-481185 Applic. Date: 1995-06-07; US1991-771644 Applic. Date: 1991-10-04

Inventor: MATSCHINER JOHN T [US]


Patent No.: US5719144A  Issued: 17/Feb/1998

Title: Fibrinogen receptor antagonists

Applicant/Assignee: MERCK & CO., INC

Application No.: 391851   Filing Date: 22/Feb/1995

Abstract:

Fibrinogen receptor antagonists having the formulaor 2

and Z is -CR1=CR2-

which are useful for inhibiting platelet aggregation for example

Fibrinogen receptor antagonists having the formula where L is L is (CH2)p, where p is 1 or 2

and Z is -CR1=CR2-

which are useful for inhibiting platelet aggregation for example

Priority:

Inventor: HARTMAN GEORGE D [US]; HUTCHINSON JOHN H [US]; HALCZENKO WASYL [US]


Patent No.: US5719162A  Issued: 17/Feb/1998

Title: Fibrinogen receptor antagonists

Applicant/Assignee: MERCK & CO., INC

Application No.: 459882   Filing Date: 02/Jun/1995

Abstract:

Fibrinogen receptor antagonists having the formula

Fibrinogen receptor antagonists having the formula for example

Priority: US1995-391851 Applic. Date: 1995-02-22

Inventor: HARTMAN GEORGE D [US]; HUTCHINSON JOHN H [US]; HALCZENKO WASYL [US]


Patent No.: US5725548A  Issued: 10/Mar/1998

Title: Self-locking stent and method for its production

Applicant/Assignee: IOWA INDIA INVESTMENTS COMPANY LIMITED

Application No.: 629318   Filing Date: 08/Apr/1996

Abstract:

A tubular member is formed from a flat sheet having opposed longitudinal edges. Rows of parallel longitudinal slots are cut in the flat sheet and at least three holes are cut along the opposed longitudinal edges. The holes are aligned with the holes on the opposed edge and sutured together to form the tubular member. The tubular member is compressed over a balloon catheter and thereafter permanently positioned within a desired portion of a blood vessel.

Priority:

Inventor: JAYARAMAN SWAMINATHAN [IN]


Patent No.: US5728060A  Issued: 17/Mar/1998

Title: Blood collection and separation system

Applicant/Assignee: TRANSFUSION TECHNOLOGIES CORPORATION

Application No.: 662617   Filing Date: 13/Jun/1996

Abstract:

A system for collecting and processing blood from a donor (70), wherein the system may be compact enough to be located entirely beside the donor's chair, and be able to process the blood while the donor is still resting in the chair after having donated the blood. Thus, the separated blood components (plasma and red blood cells) may be stored in their individual optimum environments immediately alter the whole blood is drawn, and the blood does not need to be transported back to a separation laboratory for processing. The system includes a needle (72) (or other cannula-like device) for insertion into a vein of the donor and drawing whole blood therethrough, a variable-volume rotor (2a) for holding the blood after it is drawn, and a motor (50) for spinning the rotor so as to cause the blood to separate into components, for example, plasma and red blood cells. The system also provides for a container for collecting a separated component. In a preferred embodiment two containers are used: the first container (92) for containing an anticoagulant, which is preferably added to the whole blood as it is drawn from the donor, and then for storing the plasma after it has been separated from the red blood cells, and the second container (91) for storing the separated red blood cells. The system further includes tubing (73), which may have valving (81) built into it and which may be acted on externally, so as to direct the blood components in the desired manner. The tubing connects the needle (72), the rotor (2a), and the first and second containers (92, 91). With the valving, the tubing is able to permit (i) the flow of whole blood from the needle (72) to the rotor (2a), (ii) the flow of anticoagulant from the first container (92) to the whole blood flowing from the needle to the rotor, (iii) the flow of plasma from the rotor to the first container, and (iv) the flow of red blood cells from the rotor to the second container (91). The motor (50) and the valving are preferably controlled by an electronic controller. Preferably, the system also includes a pump (61), which is also controlled by the controller, and which forces the blood components out of the rotor (2a) to the tubing. The pump is preferably able to draw the whole blood into the rotor.

Priority: US1995-482617 Applic. Date: 1995-06-07

Inventor: KINGSLEY GORDON F [US]; HEADLEY THOMAS D [US]; HALPERN LISE N [US]


Patent No.: US5728420A  Issued: 17/Mar/1998

Title: Oxidative method for attachment of glycoproteins to surfaces of medical devices

Applicant/Assignee: MEDTRONIC, INC

Application No.: 694535   Filing Date: 09/Aug/1996

Abstract:

A method for making a medical device having a glycoprotein immobilized on a substrate surface is provided. The method includes oxidizing 1,2 dihydroxy moieties with a periodate to form an aldehyde-functional material

combining the aldehyde-functional material with an amino-functional material to bond the two materials together through an imine moiety

and reacting the imine moiety with a reducing agent to form a secondary amine.

Priority:

Inventor: KEOGH JAMES R [US]


Patent No.: US5731512A  Issued: 24/Mar/1998

Title: Method for quick estimation of erythrocyte sedimentation rate with capillary tubes lined with preformed anticoagulant, mounted in an oblique position, and supported on a specially designed stand

Applicant/Assignee:

Application No.: 714467   Filing Date: 16/Sep/1996

Abstract:

An improved method for the estimation of Erythrocyte Sedimentation Rate (ESR), with capillary tubes lined with preformed anticoagulant, in an oblique position, on a specially designed stand. The method utilizes the property of whole blood to sediment faster in an oblique position but avoids cumbersome mixing of blood and requirements for special equipment. Standard anticoagulant coated capillary tubes are allowed to fill with blood to a predetermined length by capillary action and the tubes are then placed on a specially designed stand for standardized readings of the final blood plasma/erythrocyte cell interface level after 10 minutes. The method enables the physician to obtain information with regards to the ESR within a short time as during consultation or a house call.

Priority:

Inventor: LEWY HENRY [IL]; LEWY HEIRESS BY ELSA [IL]


Patent No.: US5750330A  Issued: 12/May/1998

Title: Method and composition for lyophilizing red blood cells

Applicant/Assignee: LITRON LABORATORIES

Application No.: 666134   Filing Date: 19/Jun/1996

Abstract:

Disclosed are a composition for the lyophilization of mammalian red blood cells comprising a hydrophilic polymer, a carbohydrate, and an organic solvent

and a method of using the composition to lyophilize red blood cells comprising mixing red blood cells with the composition, freezing the mixture, and drying the mixture by removing water by sublimation. Also disclosed are red blood cells lyophilized according to this method for lyophilization, and a method for reconstituting the lyophilized red blood cells. In particular, the composition used to lyophilize the red blood cells comprises a mixture of a hydrophilic polymer ranging from 1,450-20,000 Daltons at 5-50% w/v, a mono- or disaccharide or a mixture thereof from 0.01-0.2M and an organic solvent such as a primary alcohol, a secondary alcohol, dimethyl sulfoxide or combinations thereof at 0.5-20% v/v.

Priority:

Inventor: TOMETSKO ANDREW M [US]; DERTINGER STEPHEN [US]; TOROUS DOROTHEA [US]; TOMETSKO KENNETH [US]


Patent No.: US5750360A  Issued: 12/May/1998

Title: Method for quantitatively measuring apoptosis

Applicant/Assignee: LXR BIOTECHNOLOGY INC

Application No.: 484339   Filing Date: 07/Jun/1995

Abstract:

The invention encompasses methods of detecting and/or quantifying epsilon ( gamma -glutamyl)lysine isodipeptide by catalytically releasing lysine, then measuring free lysine.The invention encompasses methods of detecting and/or quantifying epsilon ( gamma -glutamyl)lysine isodipeptide by catalytically releasing lysine, then measuring free lysine.

Priority:

Inventor: FESUS LASZLO [HU]; PIACENTINI MAURO [IT]


Patent No.: US5753497A  Issued: 19/May/1998

Title: Diagnostic assay providing blood separation

Applicant/Assignee: UNIVERSAL HEALTH WATCH INC

Application No.: 577105   Filing Date: 22/Dec/1995

Abstract:

This invention provides a device and method for preparing a plasma enriched sample for use in an immunoassay strip. All parts that contact blood or a blood fraction remain in a container and prevent contamination from used blood. In one embodiment a sampling device collects blood and enters the container. A plasma enriched sample fills a plasma receptor which in turn is transferred to an immunoassay strip. Plasma is washed out of the strip by an aqueous solution. In another embodiment the sampling device doubles as a plasma separator. The invention allows sensitive and safe immunoassays to be performed on whole blood samples outside of the normal clinical laboratory setting.\!

Priority:

Inventor: BERNSTEIN DAVID [US]; CHILDS MARY ANN [US]; TRAINOR WILLIAM [US]


Patent No.: US5759564A  Issued: 02/Jun/1998

Title: Iontophoretic material

Applicant/Assignee: IMPLEMED, INC

Application No.: 633222   Filing Date: 16/Apr/1996

Abstract:

An iontophoretic material is provided that uses controlled electrical current derived from two dissimilar galvanic materials to drive oligodynamic metal ions into solution to kill microorganisms on and near the material. Iontophoretic structures or material associated with a medical device are partially or completely covered with one or more covering layers that alter physical, mechanical, chemical, or biological properties of the device and/or the iontophoretic material. In addition to being partially coated or completely enveloped by iontophoretic material or structures, all or a portion of a medical device can be integrated with, impregnated by, or fabricated from an iontophoretic material.

Priority:

Inventor: MILDER FREDRIC L [US]; ANDERSON DONALD [US]; WEITZNER BARRY D [US]


Patent No.: US5762791A  Issued: 09/Jun/1998

Title: Systems for separating high hematocrit red blood cell concentrations

Applicant/Assignee: BAXTER INTERNATIONAL INC

Application No.: 512807   Filing Date: 09/Aug/1995

Abstract:

Blood separation systems and methods utilize a membrane separation device comprising a gap between a microporous membrane and a surface facing the microporous membrane, one of the microporous membrane and the surface being rotatable relative to the other to cause separation of whole blood in the gap into plasma and concentrated red blood cells. The systems and methods include an inlet pump element coupled to the membrane separation device to convey whole blood having a known beginning hematocrit value into the gap for separation. The systems and methods also include a drive element coupled to the membrane separation device to cause rotation of the rotatable one of the microporous membrane and the facing surface. The systems and methods command the inlet pump element and the drive element as a function of the known beginning hematocrit value. This command technique obtains concentrated red blood cells having a high end hematocrit value that remains substantially constant despite variances in the known beginning hematocrit value, and, in particular, when the known beginning hematocrit value is low.

Priority:

Inventor: DENIEGA JOSE C [US]; DUFF DANIEL H [US]


Patent No.: US5763199A  Issued: 09/Jun/1998

Title: Platelet blockade assay

Applicant/Assignee: MOUNT SINAI SCHOOL OF MEDICINE OF THE CITY UNIVERSITY OF NEW YORK

Application No.: 315026   Filing Date: 29/Sep/1994

Abstract:

The present invention is an assay for determining glycoprotein IIb/IIIa receptor blockade in whole blood. Agglutinization of small polymeric beads coated with a glycoprotein IIb/IIIa ligand such as fibrinogen results when the beads are contacted with whole blood containing platelets with glycoprotein IIb/IIIa receptors that are not blocked. Failure to agglutinate indicates that blockade of the GPIIb/IIIa receptors has been achieved. In a preferred embodiment, the addition of a thrombin receptor activator results in an assay that is rapid and convenient enough to be performed at bedside and that results in agglutination of the small polymeric beads within a convenient, known period of time if the glycoprotein IIb/IIIa receptors are not blocked.

Priority:

Inventor: COLLER BARRY [US]


Patent No.: US5776345A  Issued: 07/Jul/1998

Title: Automatic priming technique

Applicant/Assignee: COBE LABORATORIES, INC

Application No.: 472676   Filing Date: 07/Jun/1995

Abstract:

Blood from a patient is treated extracorporeally by any selected one of a plurality of predetermined treatments. Each of the treatments involves the flow of blood from the patient into a primary chamber of a filtration unit, past a semipermeable membrane located in the filtration unit which separates the primary chamber from a secondary chamber of the filtration unit, out the filtration unit and back to the patient. A replacement fluid is selectively and controllably added to the blood, as required for the selected treatment. A secondary fluid is controllably and selectively introduced into the secondary chamber of the filtration unit for controllably collecting material passing across the semipermeable membrane from the blood or for supplying material to pass across the semipermeable membrane into the blood as required for the selected treatment. Materials are removed from the secondary chamber and collected in accordance with the selected treatment. Upon selection of one of the plurality of extracorporeal blood treatments available, the primary and secondary circuits are automatically primed with a priming fluid, in accordance with the selected treatment. An apparatus which automatically performs and monitors the selected treatment is also described.

Priority: US1993-017571 Applic. Date: 1993-02-12

Inventor: TRUITT LORI A [US]; MILLER DOUGLAS P [US]; MANICA KEITH [US]


Patent No.: US5779660A  Issued: 14/Jul/1998

Title: Blood collection and separation process

Applicant/Assignee: TRANSFUSION TECHNOLOGIES CORPORATION

Application No.: 662615   Filing Date: 13/Jun/1996

Abstract:

A system compact enough to be located entirely beside the donor's chair, and able to process the blood while the donor is still resting in the chair after having donated the blood. The separated blood components (plasma and red blood cells) may be stored in their individual optimum environments immediately after the whole blood is drawn, and the blood does not need to be transported back to a separation laboratory for processing. The system includes a needle (72) (or other cannula-like device) for insertion into a vein of the donor and drawing whole blood therethrough, a rotor (2a) for holding the blood after it is drawn, and a motor (50) for spinning the rotor so as to cause the blood to separate into components, for example, plasma and red blood cells. The system also provides for a container for collecting a separated component. In a preferred embodiment two containers are used: the first container (92) for containing an anticoagulant, which is preferably added to the whole blood as it is drawn from the donor, and then for storing the plasma after it has been separated from the red blood cells, and the second container (91) for storing the separated red blood cells. The system further includes tubing (73), which may have valving (81) built into it and which may be acted on externally, so as to direct the blood components in the desired manner.

Priority: US1995-482617 Applic. Date: 1995-06-07

Inventor: KINGSLEY GORDON F [US]; HEADLEY THOMAS D [US]; HALPERN LISE N [US]


Patent No.: US5779983A  Issued: 14/Jul/1998

Title: Test tube for determining the erythrocyte sedimentation rate and a surfactant for use therein

Applicant/Assignee: BECTON, DICKINSON & COMPANY

Application No.: 666112   Filing Date: 19/Jun/1996

Abstract:

In an improved method for measuring the erythrocyte sedimentation rate (ESR) a pre-evacuated test tube (T) is used to collect a blood specimen. The tube (T) is made of a material such as glass or plastics and contains an anticoagulant agent. In order to facilitate mixing of the blood sample a surfactant such as an organo-silicone fluid is provided in the tube (T) as an additive.

Priority: EP19950111546 Applic. Date: 1995-07-21

Inventor: DUFRESNE CHRISTOPHER [FR]; BONNEVIAL GEORGES [FR]; EMIN JEAN [FR]; GOLABEK JR ROBERT S [US]


Patent No.: US5780480A  Issued: 14/Jul/1998

Title: Fibrinogen receptor antagonists

Applicant/Assignee: MERCK & CO., INC

Application No.: 807843   Filing Date: 26/Feb/1997

Abstract:

Fibrinogen receptor antagonists of the general formula: X-A-Y-Z-BIand which includes, for example, the compounds of formula IV are useful for inhibiting the binding of fibrinogen to blood platelets, inhibiting the aggregation of blood platelets, treating thrombus formation or embolus formation, and preventing thrombus or embolus formation.

Priority: US19960012380P Applic. Date: 1996-02-28

Inventor: WAI JOHN [US]; FISHER THORSTEN E [US]; DUGGAN MARK E [US]; HARTMAN GEORGE D [US]; PERKINS JAMES J [US]


Patent No.: US5782759A  Issued: 21/Jul/1998

Title: Cardiovascular testing device

Applicant/Assignee: WARNER-LAMBERT COMPANY

Application No.: 774671   Filing Date: 30/Dec/1996

Abstract:

The present invention relates to a method and device for creating and testing arterial and venous thrombotic conditions. The invention includes a tube which is inserted into a blood vessel of an animal. The tube contains one or more strands upon which various materials, such as procoagulants and anticoagulants may be placed. Blood flows through the tube and clots form on the threads. After the completion of the test, the tube is removed from the animal, the strands are removed from the tube and the clots may be measured and weighed. In a preferred embodiment, a flowmeter may be connected to the blood vessel to measure the blood flow so that the clot measurements may be correlated with the blood flow.

Priority:

Inventor: CHI LIGUO [US]; SAGANEK LORI [US]; GALLAGHER KIM P [US]; UPRICHARD ANDREW [US]


Patent No.: US5782910A  Issued: 21/Jul/1998

Title: Cardiovascular implants of enhanced biocompatibility

Applicant/Assignee: SMITH & NEPHEW, INC

Application No.: 468536   Filing Date: 06/Jun/1996

Abstract:

Cardiovascular and other medical implants fabricated from low-modulus Ti-Nb-Zr alloys to provide enhanced biocompatibility and hemocompatibility. The cardiovascular implants may be surface hardened by oxygen or nitrogen diffusion or by coating with a tightly adherent, hard, wear-resistant, hemocompatible ceramic coating. The cardiovascular implants include heart valves, total artificial heart implants, ventricular assist devices, vascular grafts, stents, electrical signal carrying devices such as pacemaker and neurological leads, defibrillator leads, and the like. It is contemplated that the Ti-Nb-Zr alloy can be substituted as a fabrication material for any cardiovascular implant that either comes into contact with blood thereby demanding high levels of hemocompatibility, or that is subject to microfretting, corrosion, or other wear and so that a low modulus metal with a corrosion-resistant, hardened surface would be desirable.

Priority: US1993-112599 Applic. Date: 1993-08-26; US1993-036414 Applic. Date: 1993-03-24; US1992-986280 Applic. Date: 1992-12-07; US1991-647453 Applic. Date: 1991-01-28; US1989-454181 Applic. Date: 1989-12-21

Inventor: DAVIDSON JAMES A [US]


Patent No.: US5783447A  Issued: 21/Jul/1998

Title: Hypercoagulability comparative determinants obtained using detection systems with variable force-induced energy inputs

Applicant/Assignee: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY

Application No.: 731177   Filing Date: 02/Oct/1996

Abstract:

A method of analyzing samples of whole blood from a patient is disclosed which involves determining whether or not there is a significant difference or change in the comparative determinants of hypercoagulability in the sample. The comparative determinants are derived using two or more different detection systems, or two or more components of a single detection system, especially two or more probes, which provide variable force-induced energy inputs to the samples being measured in order to identify the presence of incipiency of a symptomatic or asymptomatic pathology caused by, or leading to, differences or changes in hypercoagulability.

Priority:

Inventor: SPILLERT CHARLES R [US]; LAZARO ERIC J [US]


Patent No.: US5789147A  Issued: 04/Aug/1998

Title: Method for concentrating white cells from whole blood by adding a red cell sedimentation reagent to whole anticoagulated blood

Applicant/Assignee: NEW YORK BLOOD CENTER, INC

Application No.: 349747   Filing Date: 05/Dec/1994

Abstract:

A therapeutic product formed from a high concentration of white blood cells having a high degree of cell viability. The white blood cells are sequestered from their normal population presence in whole blood by placing the blood into a container and preventing coagulation of the blood, separating the blood into two components, one of which is extremely rich in white blood cells through the use of a reagent and centrifugation, sequestering the white cell concentration, and freezing the white cells.

Priority:

Inventor: RUBINSTEIN PABLO [US]; COELHO PHILIP HENRY [US]; STEVENS CLADD E [US]


Patent No.: US5789151A  Issued: 04/Aug/1998

Title: Prolonged cold storage of red blood cells by oxygen removal and additive usage

Applicant/Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Application No.: 857474   Filing Date: 15/May/1997

Abstract:

Prolonged cold storage of red blood cells by oxygen removal and additive usage. A cost-effective, 4 DEG C. storage procedure that preserves red cell quality and prolongs post-transfusion in vivo survival is described. The improved in vivo survival and the preservation of adenosine triphosphate levels, along with reduction in hemolysis and membrane vesicle production of red blood cells stored at 4 DEG C. for prolonged periods of time, is achieved by reducing the oxygen level therein at the time of storage

in particular, by flushing the cells with an inert gas, and storing them in an aqueous solution which includes adenine, dextrose, mannitol, citrate ion, and dihydrogen phosphate ion, but no sodium chloride, in an oxygen-permeable container which is located in an oxygen-free environment containing oxygen-scavenging materials.

Priority:

Inventor: BITENSKY MARK W [US]; YOSHIDA TATSURO [US]


Patent No.: US5792660A  Issued: 11/Aug/1998

Title: Comparative determinants of viscosity in body fluids obtained with probes providing increased sensitivity

Applicant/Assignee: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY

Application No.: 720675   Filing Date: 02/Oct/1996

Abstract:

This invention involves a method of analyzing a body fluid such as blood from a patient to determine whether or not there is a significant difference or change in the comparative determinants of viscosity in the body fluid sample, the comparative determinants being derived using a probe which provides increased sensitivity and corresponding improved relative viscosity values when used together with a suitable viscosity device, in order to identify the presence or incipiency of a symptomatic or asymptomatic pathology caused by or leading to said differences or changes in viscosity.

Priority:

Inventor: SPILLERT CHARLES R [US]; LAZARO ERIC J [US]


Patent No.: US5801057A  Issued: 01/Sep/1998

Title: Microsampling device and method of construction

Applicant/Assignee:

Application No.: 620994   Filing Date: 22/Mar/1996

Abstract:

A minimally intrusive and less painful, self-use microsampling device and method for the measurement of glucose and other analytes in blood are provided. The device of the invention may have one or two optical windows for measuring the concentration of an absorbent reaction product or no windows if methods other than optical absorbance is used. The sampling chamber of the device can contain analytical reagents and other additives to facilitate the sampling and analytical steps. Also provided is a fabrication method for the microsampling device.

Priority:

Inventor: SMART WILSON H [US]; SUBRAMANIAN KUMAR [US]


Patent No.: US5804442A  Issued: 08/Sep/1998

Title: Process for preparing macrophages, kits, and composition for the use of this process

Applicant/Assignee: I.D.M. IMMUNO-DESIGNED MOLECULES

Application No.: 654383   Filing Date: 28/May/1996

Abstract:

The invention relates to a process for preparing a composition comprising macrophages, optionally activated, and/or cells derived from monocytes with a strong potential for antigen presentation, said process comprising a stage of culture of monocytes present in the starting composition, this stage being preceding and/or followed by a stage of elimination of all or part of the constituents other than the monocytes present in the starting composition, with the aid of antibodies directed against said constituents, and/or followed by a stage of elutriation. The invention also concerns the compositions of kits for reducing this process to practice.

Priority: FR19950000785 Applic. Date: 1995-01-24

Inventor: ROMET-LEMONNE JEAN-LOUP [FR]; CHOKRI MOHAMED [FR]


Patent No.: US5807344A  Issued: 15/Sep/1998

Title: Arterial blood gas syringe including filter member

Applicant/Assignee: IN-X CORPORATION

Application No.: 797134   Filing Date: 10/Feb/1997

Abstract:

A syringe device for obtaining an arterial blood sample is provided. The syringe device includes a syringe barrel, a plunger assembly having a sealing plug and a filter member. The syringe device preferably includes a carrying device including an anticoagulant and a carrying device body. The carrying device body is made of a hard, non-porous material. The filter member permits the passage of air while preventing the passage of blood. The filter member has a periphery that is in contact with the inner wall of the syringe barrel so that the air does not pass along the inner wall past the filter member. Preferably, the filter member is detached from the sealing plug. During operation, a blood sample from a patient is received in a blood receiving area defined in the syringe barrel, while displaced air passes through the filter member and is substantially contained between the filter member and the sealing plug.

Priority:

Inventor: IWASAKI DEAN H [US]


Patent No.: US5811390A  Issued: 22/Sep/1998

Title: Use of beta HCG for the control of retroviral infection

Applicant/Assignee: METATRON, INC

Application No.: 517755   Filing Date: 22/Aug/1995

Abstract:

Described is a method for inhibiting the growth and/or replication of human immunodeficiency virus (HIV) in human patients. The invention relates to the unexpected activity of human chorionic gonadotropin (hCG) and in particular, to the beta chain of hCG (beta hCG) in controlling a human immunodeficiency virus (HIV) infection and other virus-related immunodeficiency disorders. The invention comprises administering an anti-HIV effective amount of beta hCG to an asymptomatic individual with an HIV infection, including an individual presenting the symptoms of AIDS.

Priority:

Inventor: BOURINBAIAR ALDAR S [US]


Patent No.: US5817042A  Issued: 06/Oct/1998

Title: Method and apparatus for controlling concentrations in vivos and in tubing systems

Applicant/Assignee: COBE LABORATORIES, INC

Application No.: 622642   Filing Date: 27/Mar/1996

Abstract:

A method and apparatus for maximizing the total amount of blood processed during an apheresis procedure by optimizing the concentration of anticoagulant in a donor/patient and the associated extracorporeal tubing set is provided. A simplified model of anticoagulant accumulation in a donor/patient's body is used to calculate an optimal anticoagulant infusion rate profile to the donor/patient during a blood processing procedure. A maximum acceptable anticoagulant concentration in the donor/patient acts as an upper limit on the rate at which anticoagulant may be infused to the donor/patient using the optimized infusion rate profile. A minimum acceptable anticoagulant level acts as a lower limit in optimally controlling the anticoagulant concentration in the extracorporeal tubing set. Both the maximum acceptable anticoagulant level in the donor/patient and the minimum acceptable anticoagulant level in the extracorporeal tubing set may be customized for a specific donor/patient thereby allowing the optimized infusion rate profile and the extracorporeal tubing set anticoagulant concentration to be customized for the specific patient.

Priority: US1995-472931 Applic. Date: 1995-06-06; US1992-845677 Applic. Date: 1992-03-04

Inventor: LANGLEY ROBERT W [US]; WAEG GEERT VAN [BE]; DUMONT LARRY JOE [US]


Patent No.: US5817144A  Issued: 06/Oct/1998

Title: Method for contemporaneous application OF laser energy and localized pharmacologic therapy

Applicant/Assignee: LATIS, INC

Application No.: 728618   Filing Date: 10/Oct/1996

Abstract:

A method for contemporaneously applying laser energy and locally delivering pharmacologic therapy to a selected site in a body lumen using a liquid core or fiber optic laser catheter or angioscope. The method comprises preparing a solution of a pharmacologic agent, inserting the catheter into the lumen, directing the catheter to the site, transmitting visible light to the site, flowing the light transmissive liquid through the catheter to the site to be treated, positioning an emission end of the fiber near (+/-2 mm) the distal end of the catheter, transmitting laser energy through the fiber to be emitted at the emission end of the fiber into the liquid to treat the site, and introducing a flow of the pharmacologic agent in solution into the catheter for contemporaneous discharge at the distal end into the lumen adjacent the site.

Priority: US1994-328857 Applic. Date: 1994-10-25; US1996-644533 Applic. Date: 1996-05-10

Inventor: GREGORY KENTON W [US]


Patent No.: US5821241A  Issued: 13/Oct/1998

Title: Fibrinogen receptor antagonists

Applicant/Assignee: MERCK & CO., INC

Application No.: 495560   Filing Date: 01/Aug/1995

Abstract:

PCT No. PCT/US94/01881 Sec. 371 Date Aug. 1, 1995 Sec. 102(e) Date Aug. 1, 1995 PCT Filed Feb. 22, 1994 PCT Pub. No. WO94/18981 PCT Pub. Date Sep. 1, 1994Compounds of the invention have the formula or for example The compounds have fibrinogen receptor antagonist activity.

Priority: WO1994US01881 Applic. Date: 1994-02-22

Inventor: CLAREMON DAVID ALAN [US]; BALDWIN JOHN J [US]; LIVERTON NIGEL [US]; ASKEW BEN [US]


Patent No.: US5824230A  Issued: 20/Oct/1998

Title: Method and device for separating a component such as fibrin I from blood plasma

Applicant/Assignee: E.R. SQUIBB & SONS, INC

Application No.: 745119   Filing Date: 07/Nov/1996

Abstract:

A method and a device for separating a component, such as fibrin monomer from blood, by centrifugation, involve feeding of blood admixed an anticoagulant to a first annular chamber in a device, where the annular chamber is defined by a cylindrical outer wall and a cylindrical inner wall, both walls extending coaxially about a common axis, as well as by a top wall and a bottom wall. The top wall or the bottom wall is formed by a piston body displaceable within the first chamber. This method involves furthermore a centrifugation of the device about the said common axis to substantially separate blood into a cell fraction and a plasma fraction followed by the resulting plasma fraction being transferred while influenced by the piston body to a second chamber defined by an outer cylindrical wall. The outer cylindrical wall extends coaxially with the said common axis, whereby a fraction with fibrin I is caused to be separated in the second chamber while a suitable enzyme is being added. The separation of fibrin monomer from the plasma fraction in the second chamber is carried out during continued centrifugation whereby a fibrin polymer is deposited on the cylindrical outer wall of said second chamber, whereafter the fluid fraction collected at the bottom of the second chamber is transferred while influenced by the piston body to the first chamber. The fraction with fibrin polymer remaining in the second chamber is substantially deposited on the cylindrical wall and is caused to be dissolved by addition of a solvent and by centrifugation, whereafter it is transferred to a receiving container by passing after addition of a binder to the enzyme through a filter removing said enzyme, whereby a fibrin monomer containing solution is provided.

Priority: US1995-566348 Applic. Date: 1995-12-01; US1994-348668 Applic. Date: 1994-12-02

Inventor: HOLM NIELS ERIK [DK]; EDWARDSON PETER A D [GB]


Patent No.: US5827746A  Issued: 27/Oct/1998

Title: Method to determine the sedimentation of blood and relative device

Applicant/Assignee: SIRE ANALYTICAL SYSTEMS SRL

Application No.: 613233   Filing Date: 08/Mar/1996

Abstract:

Method and apparatus to determine the sedimentation of blood. A blood sample is taken, and an anti-coagulant substance is added. The sample is homogenized. The method includes a step of measuring an optical density, or absorbance, of the sample as a function of time and without waiting for the formation of a plasma/corpuscle interface to obtain an optical density measurement. The measurements are carried out at any fixed point of a reading container which contains a micro-volume of blood. The inner diameter of the containing chamber ensures a linear relationship between the optical density and the number of corpuscles present. Finally, the optical density measurement is processsed to obtain a speed of sedimentation.

Priority: IT1995UD00042 Applic. Date: 1995-03-15

Inventor: DUIC GIOVANNI BATTISTA [IT]


Patent No.: US5833866A  Issued: 10/Nov/1998

Title: Blood collection systems and methods which derive instantaneous blood component yield information during blood processing

Applicant/Assignee: BAXTER INTERNATIONAL INC

Application No.: 807820   Filing Date: 26/Feb/1997

Abstract:

Systems and methods for separating platelets from blood derive the yield of platelets in real time as processing is accomplished. The systems and method determine an incremental blood volume processed during a succession of incremental time periods during the separation step. The systems and methods also estimate a separation efficiency for the separation device during each incremental time period, while also estimating a current count of platelets available from the donor during each incremental time period. The systems and methods multiply the determined incremental blood volume for each incremental time period by the estimated current count of platelets for each incremental time period by the estimated separation efficiency for each incremental time period, to derive an incremental platelet yield for each incremental time period. The systems and methods sum the incremental platelet yields over the succession of incremental time periods to obtain the derived yield of platelets. In this way, the systems and methods take into account the dynamic systemic and physiological changes that occur virtually continuously throughout the blood collection and separation process.

Priority: US1995-472748 Applic. Date: 1995-06-07; US1993-097967 Applic. Date: 1993-07-26; US1992-965088 Applic. Date: 1992-10-22; US1991-814403 Applic. Date: 1991-12-23

Inventor: BROWN RICHARD I [US]


Patent No.: US5837729A  Issued: 17/Nov/1998

Title: Methods for treating and preventing HIV infection using acetaminophen and derivatives thereof

Applicant/Assignee: METATRON, INC

Application No.: 638098   Filing Date: 26/Apr/1996

Abstract:

The present invention relates to the use of acetaminophen (Tylenol) and derivatives thereof which can be used to inhibit the growth, replication and elaboration of the human immunodeficiency virus (HIV). The present invention comprises in vitro as well as in vivo methods for the prevention and/or treatment of HIV infections and acquired immune deficiency syndrome (AIDS), at doses of acetaminophen or its derivatives which are effective to inhibit the replication, growth and/or elaboration of HIV.

Priority:

Inventor: BOURINBAIAR ALDAR S [US]


Patent No.: US5839443A  Issued: 24/Nov/1998

Title: Method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal circulation

Applicant/Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK

Application No.: 648561   Filing Date: 16/May/1996

Abstract:

This invention provides an assay to monitor antithrombic activity of a Factor IXa compound infused into circulation of a patient which includes: (a) obtaining Factor IXa-deficient plasma

(b) mixing the plasma from step (a) with diatomaceous and with plasma from the patient

(c) incubating the mixture with a source of lipid and calcium chloride under conditions suitable for clot formation

and (d) measuring time necessary for clot formation in the incubate, thereby monitoring the antithrombic activity of the Factor IXa compound infused into the circulation of the patient.

Priority:

Inventor: ROSE ERIC [US]; STERN DAVID [US]; SCHMIDT ANN MARIE [US]; SPANIER TALIA [US]


Patent No.: US5843172A  Issued: 01/Dec/1998

Title: Porous medicated stent

Applicant/Assignee: ADVANCED CARDIOVASCULAR SYSTEMS, INC

Application No.: 842660   Filing Date: 15/Apr/1997

Abstract:

A medicated prosthesis, such as a stent, is deployed in a human vessel. A metallic stent has a plurality of pores in the metal which are loaded with medication. When the stent is implanted into the vasculature of a patient, the medication in the stent dissipates into the tissue of the vasculature proximate the stent. The stent may be formed from a porous metal in the form of a wire, tube, or metal sheet. The present invention also includes a method of treating vasculature disease by delivering medication to the site of the vascular disease including the step of deploying a metal stent having a plurality of pores in the stent and further having medication in the pores and delivering the stent to the site of vasculature disease.

Priority:

Inventor: YAN JOHN Y [US]


Patent No.: US5851835A  Issued: 22/Dec/1998

Title: Multiparameter hematology apparatus and method

Applicant/Assignee: CENTER FOR LABORATORY TECHNOLOGY, INC

Application No.: 764322   Filing Date: 12/Dec/1996

Abstract:

A multi-parameter hematology analyzer and method are provided for in vitro determination of blood parameters. The analyzer apparatus includes a laser for transmitting light through a specimen container containing a minimally diluted blood sample. The light scattered by the constituents of the blood sample are scattered into a pattern which is recorded on a camera image. This image is then processed by image processing software and is used to establish specific blood parameters.

Priority: US19950008818P Applic. Date: 1995-12-18

Inventor: GRONER WARREN [US]


Patent No.: US5853382A  Issued: 29/Dec/1998

Title: Blood collection and separation process

Applicant/Assignee: TRANSFUSION TECHNOLOGIES CORPORATION

Application No.: 662613   Filing Date: 13/Jun/1996

Abstract:

A system compact enough to be located entirely beside the donor's chair, and able to process the blood while the donor is still resting in the chair after having donated the blood. The separated blood components (plasma and red blood cells) may be stored in their individual optimum environments immediately after the whole blood is drawn, and the blood does not need to be transported back to a separation laboratory for processing. The system includes a needle (72) (or other cannula-like device) for insertion into a vein of the donor and drawing whole blood therethrough, a rotor (2a) for holding the blood after it is drawn, and a motor (50) for spinning the rotor so as to cause the blood to separate into components, for example, plasma and red blood cells. The system also provides for a container for collecting a separated component. In a preferred embodiment two containers are used: the first container (92) for containing an anticoagulant, which is preferably added to the whole blood as it is drawn from the donor, and then for storing the plasma after it has been separated from the red blood cells, and the second container (91) for storing the separated red blood cells. The system further includes tubing (73), which may have valving (81) built into it and which may be acted on externally, so as to direct the blood components in the desired manner. The tubing connects the needle (72), the rotor (2a), and the first and second containers (92, 91). With the valving, the tubing is able to permit (i) the flow of whole blood from the needle (72) to the rotor (2a), (ii) the flow of anticoagulant from the first container (92) to the whole blood flowing from the needle to the rotor, (iii) the flow of plasma from the rotor to the first container, and (iv) the flow of red blood cells from the rotor to the second container (91).

Priority: US1995-482617 Applic. Date: 1995-06-07

Inventor: KINGSLEY GORDON F [US]; HEADLEY THOMAS D [US]; HALPERN LISE N [US]


Patent No.: US5854005A  Issued: 29/Dec/1998

Title: Platelet blockade assay

Applicant/Assignee: MOUNT SINAI SCHOOL OF MEDICINE

Application No.: 754773   Filing Date: 20/Nov/1996

Abstract:

The present invention is an assay for determining glycoprotein IIb/IIIa receptor blockade in whole blood. Agglutinization of small polymeric beads coated with a glycoprotein IIb/IIIa ligand such as fibrinogen results when the beads are contacted with whole blood containing platelets with glycoprotein IIb/IIIa receptors that are not blocked. Failure to agglutinate indicates that blockade of the GPIIb/IIIa receptors has been achieved. In a preferred embodiment, the addition of a thrombin receptor activator results in an assay that is rapid and convenient enough to be performed at the bedside and that results in agglutination of the small polymeric beads within a convenient, known period of time if the glycoprotein IIb/IIIa receptors are not blocked.

Priority: US1994-315026 Applic. Date: 1994-09-29

Inventor: COLLER BARRY S [US]


Patent No.: US5863289A  Issued: 26/Jan/1999

Title: Cross-spike prevention system

Applicant/Assignee:

Application No.: 421217   Filing Date: 13/Apr/1995

Abstract:

An improved device and process of assuring separation of an anticoagulant type fluid from a saline type fluid each of which is utilized in the process and operation of a plasma-pheresis apparatus or the process of collecting donor blood, is disclosed. The improvement includes a cross-spike prevention receptacle which is dimensioned, and installed positionally in reference to a plasmapheresis or blood donor apparatus, to receive an anticoagulant fluid container to which a proper respective supply communication line will connect, and to exclude and not receive a saline fluid container or container holding a similar type of fluid, whose fluid line will not reach and connect to the installed cross-spike prevention receptacle. As a part of the process and concepts of the invention the supply containers or bags of fluids which are supplied for use with the invention are provided so that the respective anticoagulant bags are smaller in volume capacity and size than the respective saline solution container bags used in the plasmapheresis or blood collection process, and the bags are dimensioned so that the saline container or bag will not fit into the cross-spike prevention receptacle even upon substantial forcing or where such force would cause rupture of the container or-would otherwise result in a container in a condition which could not be reasonably used with respect to the plasmapheresis or blood collection process.

Priority: US1993-117729 Applic. Date: 1993-09-07

Inventor: HOOVER BRYAN JAY [US]


Patent No.: US5866542A  Issued: 02/Feb/1999

Title: Nematode-extracted anticoagulant protein

Applicant/Assignee: CORVAS INTERNATIONAL, INC

Application No.: 486397   Filing Date: 05/Jun/1995

Abstract:

Proteins which are potent anticoagulants and have at least one NAP domain and are described. These proteins having anticoagulant activity can be isolated from natural sources such as nematodes, chemically synthesized or made by recombinant methods using various DNA expression systems.

Priority: US1994-326110 Applic. Date: 1994-10-18

Inventor: VLASUK GEORGE PHILLIP [US]; STANSSENS PATRICK ERIC HUGO [BE]; MESSENS JORIS HILDA LIEVEN [BE]; LAUWEREYS MARC JOZEF [BE]; LAROCHE YVES RENEN [BE]; JESPERS LAURENT STEPHANE [BE]; GANSEMANS YANNICK GEORGE JOZEF [BE]; MOYLE MATTHEW [US]; BERGUM PETER W [US]


Patent No.: US5866907A  Issued: 02/Feb/1999

Title: Ultralow background multiple photon detector

Applicant/Assignee: BIOTRACES, INC

Application No.: 669970   Filing Date: 25/Jun/1996

Abstract:

An ultralow background multiphoton detectors device for radioisotopes has a background of about one count per day. Two opposed gamma and X-ray photon detectors each preferably include a scintillation crystal and a photomultiplier tube. Sandwiched between the detectors are a separator and a sample holder for a sample labelled with a radioisotope such as I125. The detectors convert emissions from the radioisotope into electric output pulses which are then subjected to signal processing for pulse shape analysis, discrimination of coincident from non-coincident events, and quantification of the radioisotope. Detector materials and components are selected to minimize background, and are shielded from external radiation. The device may further be constructed to resolve and provide images of two dimensional sample arrays.

Priority: US1993-133919 Applic. Date: 1993-10-12

Inventor: DRUKIER ANDRZEJ J [US]; SAGDEJEV IGOR R [US]


Patent No.: US5869024A  Issued: 09/Feb/1999

Title: Methods and compositions for using non-ionic contrast agents to reduce the risk of clot formation in diagnostic procedures

Applicant/Assignee: BRACCO INTERNATIONAL B.V

Application No.: 893865   Filing Date: 05/Jun/1992

Abstract:

In accordance with the present invention a novel method and composition for using nonionic contrast media to reduce the risk of clot formation in a diagnostic procedure is disclosed. Novel compositions for such method are also disclosed. The present method comprises employing a triiodinated phenyl contrast agent having a heterocyclic group or a dimeric triiodinated phenyl contrast agent having one or more heterocyclic groups.

Priority: US1991-708656 Applic. Date: 1991-05-31; US1990-617716 Applic. Date: 1990-11-26; US1989-442869 Applic. Date: 1989-11-29

Inventor: RANGANATHAN RAMACHANDRAN S [US]; TWEEDLE MICHAEL F [US]; WEDEKING PAUL W [US]


Patent No.: US5871692A  Issued: 16/Feb/1999

Title: Method and apparatus for cleaning, decontaminating, and sterilizing catheters

Applicant/Assignee: STERIS CORPORATION THE CLEVELAND CLINIC FOUNDATION

Application No.: 782647   Filing Date: 14/Jan/1997

Abstract:

A method for cleaning, decontaminating, and sterilizing catheters (10) using a combination of liquid and gaseous/plasma sterilization techniques to ensure the complete and efficient sterilization of a catheter (10). Angiographic dye and saline are removed from the interior (36) of the balloon (14) and its lumen (16). The outer surfaces of the catheter (10) and a guide wire lumen (18) of the catheter (10) are cleaned, decontaminated, and sterilized (42) with a liquid sterilant. The liquid sterilant fills a balloon (14) and a balloon lumen (16) of the catheter (10). The liquid sterilant is retained in the balloon (14) and the lumen (16) for a select amount of time. Thereafter, the liquid sterilant is drained from the balloon (14) and the balloon lumen (16). The filling, retaining, and draining steps are repeated until an interior (36) of the balloon (14) and the balloon lumen (16) are sterilized. Residual liquid sterilant is rinsed from the interior (36) of the balloon (14) and the balloon lumen (16). The catheter (10) is dried and then a plasma or gaseous sterilant is used to sterilize at least the outer surfaces and the guide wire lumen (18) of the catheter (10).

Priority:

Inventor: HAIRE DONNA M [US]; WOLF-BLOOM DAVID F [US]; MALCHESKY PAUL S [US]


Patent No.: US5872098A  Issued: 16/Feb/1999

Title: Nematode-extracted anticoagulant protein

Applicant/Assignee: CORVAS INTERNATIONAL, INC

Application No.: 461965   Filing Date: 05/Jun/1995

Abstract:

Proteins which are potent anticoagulants and have at least one NAP domain and are described. These proteins having anticoagulant activity can be isolated from natural sources such as nematodes, chemically synthesized or made by recombinant methods using various DNA expression systems.

Priority:

Inventor: VLASUK GEORGE PHILLIP [US]; STANSSENS PATRICK ERIC HUGO [BE]; MESSENS JORIS HILDA LIEVEN [BE]; LAUWEREYS MARC JOZEF [BE]; LAROCHE YVES RENE [BE]; JESPERS LAURENT STEPHANE [BE]; GANSEMANS YANNICK GEORGES JOZE [BE]; MOYLE MATTHEW [US]; BERGUM PETER W [US]


Patent No.: US5879318A  Issued: 09/Mar/1999

Title: Method of and closed system for collecting and processing umbilical cord blood

Applicant/Assignee: NPBI INTERNATIONAL B.V

Application No.: 912501   Filing Date: 18/Aug/1997

Abstract:

A closed sterile bag system contains at least two separate compartments with communication between them temporarily blocked and with one of the compartments containing an erythrocyte sedimentation solution. The umbilical cord blood is collected and contacted with an anticoagulant whereupon the blockage is removed and the erythrocyte sedimentation solution is caused to contact the blood all within the closed sterile system.

Priority:

Inventor: VAN DER HEIDEN JOHANNES [NL]; MEIJER ELSE JOHANNA [NL]


Patent No.: US5885239A  Issued: 23/Mar/1999

Title: Method for collecting red blood cells

Applicant/Assignee: TRANSFUSION TECHNOLOGIES CORPORATION

Application No.: 800086   Filing Date: 12/Feb/1997

Abstract:

A rotor for collecting and centrifuging biological fluids in a range of volumes. The rotor includes an elastic impermeable diaphragm which defines at least a portion of a variable-volume processing chamber, where the fluid is centrifuged. The rotor includes a rigid mounting member, to which the diaphragm is mounted and which is held and spun by a chuck. Preferably, this rigid mounting member includes a boundary wall which together with the elastic diaphragm defines the chamber. The boundary wall may be a substantially imperforate circular wall which extends to the periphery of the processing chamber but defining one opening, preferably near the axis of rotation, permitting a conduit or conduits to pass therethrough so as to be in fluid communication with the processing chamber. The rotor may include a separate structure for controlling the flow of liquid out of the chamber into the conduit. In a preferred embodiment, this outlet-control structure is a perforate, substantially rigid wall or plate, located within the processing chamber and mounted adjacent the rigid boundary wall. In an alternative embodiment, the outlet-control structure for controlling flow from the processing chamber to the conduit may include at least one tube or preferably a set of tubes, wherein each tube provides fluid communication between the chamber and the conduit. In one preferred embodiment, grooves in the boundary wall may be used as the outlet-control structure.

Priority: US1994-322601 Applic. Date: 1994-10-13

Inventor: HEADLEY THOMAS D [US]; POWERS EDWARD T [US]


Patent No.: US5888824A  Issued: 30/Mar/1999

Title: Blood test ware and matrixes

Applicant/Assignee: SEKISUI KAGAKU KOGYO KABUSHIKI KAISHA

Application No.: 648132   Filing Date: 05/Jul/1996

Abstract:

PCT No. PCT/JP95/00461 Sec. 371 Date Jul. 5, 1996 Sec. 102(e) Date Jul. 5, 1996 PCT Filed Mar. 17, 1995 PCT Pub. No. WO96/09541 PCT Pub. Date Mar. 28, 1996This invention has for its object to provide a blood component deposition-preventing agent and a blood coagulation accelerator, which are substantially indifferent to blood coagulation activity and serum chemistry parameters and a plastic blood test ware and a blood test matrix which do not confound measured values. The invention relates to a blood component deposition-preventing agent comprising a random copolymer of a monomer component (a) giving a water-soluble homopolymer and a monomer component (b) giving a water-insoluble homopolymer, a blood coagulation accelerator comprising a substantially blood-insoluble antimicrobial composition comprising a carrier and, as supported thereon, an antimicrobial metal, and a blood test ware or matrix carrying them on its inside wall or surface.

Priority: JP19940223093 Applic. Date: 1994-09-19; WO1995JP00461 Applic. Date: 1995-03-17

Inventor: ISOGAWA HIRONOBU [JP]; ANRAKU HIDEO [JP]


Patent No.: US5891506A  Issued: 06/Apr/1999

Title: Oxidative method for attachment of glycoproteins or glycopeptides to surfaces of medical devices

Applicant/Assignee: MEDTRONIC, INC

Application No.: 984922   Filing Date: 04/Dec/1997

Abstract:

A method for making a medical device having at least one glycoprotein and/or glycopeptide immobilized on a substrate surface is provided. The method may include oxidizing 1,2 dihydroxy moieties with a periodate to form an aldehyde-functional material

combining the aldehyde-functional material with an amino-functional material to bond the two materials together through an imine moiety

and reacting the imine moiety with a reducing agent to form a secondary amine. Another method of the present invention may be employed to crosslink glycoproteins and/or glycopeptides immobilized on medical device surfaces. Additionally, one method of the present invention may be employed to crosslink glycoproteins and/or glycopeptides, thereby forming a crosslinked biomaterial or a crosslinked medical device coating.

Priority: US1996-694535 Applic. Date: 1996-08-09

Inventor: KEOGH JAMES R [US]


Patent No.: US5891736A  Issued: 06/Apr/1999

Title: Reagents and methods for releasing and measuring lead ions from biological matrices

Applicant/Assignee: BAYER CORPORATION

Application No.: 752869   Filing Date: 20/Nov/1996

Abstract:

The present invention provides a reagent for extracting lead ions from a variety of biological matrices such as human whole blood that has been anticoagulated with either heparin or EDTA, and lyophilized human blood and bovine EDTA whole blood. The released lead is measured in situ with a colorimetric porphyrin reagent without further manipulation of the supernatant. The lead ion releasing reagent can be used in conjunction with a variety of assay formats for the determination of lead in various biological fluids.

Priority: US19960020036P Applic. Date: 1996-06-21

Inventor: CHAPOTEAU EDDY [US]; CZECH BRONISLAW P [US]; CRAINE JONATHAN [US]


Patent No.: US5899874A  Issued: 04/May/1999

Title: Preparation and method for production of platelet concentrates with significantly prolonged viabilty during storage

Applicant/Assignee: STIFTELSEN FOR MEDICINSK-TEKNISK UTVECKLING

Application No.: 884358   Filing Date: 27/Jun/1997

Abstract:

PCT No. PCT/SE93/00383 Sec. 371 Date Jan. 13, 1995 Sec. 102(e) Date Jan. 13, 1995 PCT Filed Apr. 30, 1993 PCT Pub. No. WO93/21935 PCT Pub. Date Nov. 11, 1993The invention relates to a water-based preparation to be mixed with blood, containing citrate ions which inhibit coagulation, as well as a method applied at collection of blood from a living organism while adding an anticoagulant substance including citrate ions. The new features of the invention are that acetate, being a physiologic energy source, inter alia for platelets, is included in the preparation and is added to the blood during collection in addition to the anticoagulant substance in order to obtain prolonged shelf-life of the platelet concentrate without increased risk for the donor or patient.

Priority: SE19920001413 Applic. Date: 1992-04-30; WO1993SE00383 Applic. Date: 1993-04-30

Inventor: JONSSON SVANTE [SE]


Patent No.: US5900091A  Issued: 04/May/1999

Title: Process for making a safety pipet tube

Applicant/Assignee: DRUMMOND SCIENTIFIC COMPANY

Application No.: 937522   Filing Date: 27/Aug/1992

Abstract:

A disposable one-time use, inexpensive, capillary-action safety micro-pipet for obtaining a sample of blood or other liquid comprises a transparent glass tube which is capable of drawing blood or other liquid into the tube by capillary action, and a resilient sheet, with an adhesive layer adhering the resilient sheet in one or more layers around the outside surface of the tube for covering the outside surface of the tube and protecting a user against being cut by any jagged edges of a broken tube. The method of the invention comprises making a safety pipet by taking an elongated glass tube, taking a resilient sheet having an inner surface coated with a layer of adhesive, wrapping the resilient sheet around the outer surface of the tube and around inner layers of the resilient sheet, adhering the resilient sheet to the outer surface of the tube and to the inner layers of the sheet, to provide a wrapped safety glass tube in which the wrapping strengthens the tube against breaking and also protects the user against being cut by any jagged edges of a broken tube and from being infected by the contents of the tube which may be contaminated.

Priority: US1989-382547 Applic. Date: 1989-07-19

Inventor: KENNEY JAMES W [US]


Patent No.: US5902251A  Issued: 11/May/1999

Title: Transcervical intrauterine applicator for intrauterine hyperthermia

Applicant/Assignee:

Application No.: 851099   Filing Date: 05/May/1997

Abstract:

A transcervical intrauterine catheter applicator for the hyperthermia/thermal therapy treatment of the uterus. The applicator includes one or more EMR antennas and one or more temperature sensors for measuring the temperature of the endometrial tissue. Each EMR antenna has an elongated helical coil connected to the center conductor of a coaxial cable to thereby generate a light bulb shaped radiation pattern and thus generate a similar-shaped pattern of thermal energy in the endometrium tissue. The catheter can be of the balloon type that can be inflated, thereby radially moving the antenna and temperature sensor against the walls of the uterus.

Priority: US19960016898P Applic. Date: 1996-05-06

Inventor: VANHOOYDONK NEIL C [US]


Patent No.: US5906589A  Issued: 25/May/1999

Title: Method and apparatus for occlusion monitoring using pressure waveform analysis

Applicant/Assignee: COBE LABORATORIES, INC

Application No.: 747852   Filing Date: 13/Nov/1996

Abstract:

A method and apparatus for occlusion monitoring in a flow circuit using pressure waveform analysis. The flow circuit includes a first conduit and a second conduit which fluidly interconnects a fluid supply with the first conduit. A pump is disposed in an intermediate portion of the second conduit. Monitoring of the pressure in the first conduit is used to identify any occlusions in that portion of the second conduit which is disposed between the pump and the fluid supply.

Priority:

Inventor: GORDON TIMOTHY M [US]; SCOVILL STEPHEN K [US]; FLETCHER-HAYNES PETER [US]; MARTIN SCOTT [US]


Patent No.: US5906915A  Issued: 25/May/1999

Title: Method for storing red cells using reduced citrate anticoagulant and a solution containing sodium, citrate, phosphate, adenine and mannitol

Applicant/Assignee: BAXTER INTERNATIONAL INC

Application No.: 742279   Filing Date: 31/Oct/1996

Abstract:

The present invention provides an improved aqueous solution for suspending and storing red blood cells. The solution includes sodium citrate, a combination of sodium biphosphate and sodium phosphate dibasic, adenine, and mannitol. The solution is formulated at a low osmolarity and has a physiological pH of approximately 7.4. The solution simultaneously maintains stored red cells ATP and 2,3-BPG. Also disclosed is a method for storing red blood cells comprising adding an anticoagulant with a reduced citrate concentration compared to a CPD solution comprising 26.3 g/l, sodium citrate and 3.28 g/l citric acid hydrous to whole blood, separating the red cells and adding a storage solution comprising sodium citrate, sodium diphosphate, sodium phosphate dibasic, adenine and mannitol.

Priority: US1995-491099 Applic. Date: 1995-06-16; US1994-216734 Applic. Date: 1994-03-22; US1990-610478 Applic. Date: 1990-11-07

Inventor: PAYRAT JEAN-MARC [BE]; HOGMAN CLAES F [SE]; DEBRAUWERE JACK [BE]; MATHIAS JEAN MARIE [BE]


Patent No.: US5908637A  Issued: 01/Jun/1999

Title: Transmucosal delivery system

Applicant/Assignee: MINNESOTA MINING AND MANUFACTURING CO

Application No.: 877397   Filing Date: 17/Jun/1997

Abstract:

A device for delivering a heparinic anticoagulant across a mucosal surface in order to achieve or maintain a therapeutically effective blood level of the heparinic anticoagulant. The device involves a matrix containing a therapeutically effective amount of a heparinic anticoagulant, and a mucoadhesive or other mechanism for maintaining the matrix in contact with the mucosal surface for a time sufficient to allow release of the heparinic anticoagulant to the mucosal surface.

Priority: US1994-259873 Applic. Date: 1994-06-15

Inventor: BENES LUCE R M [FR]; HORRIERE FRANCOISE L R B [FR]


Patent No.: US5910252A  Issued: 08/Jun/1999

Title: Technique for extracorporeal treatment of blood

Applicant/Assignee: COBE LABORATORIES, INC

Application No.: 17571   Filing Date: 12/Feb/1993

Abstract:

Blood from a patient is treated extracorporeally by any selected one of a plurality of predetermined treatments. Each of the treatments involves the flow of blood from the patient into a primary chamber of a filtration unit, past a semipermeable membrane located in the filtration unit which separates the primary chamber from a secondary chamber of the filtration unit, out the filtration unit and back to the patient. A replacement fluid is selectively and controllably added to the blood, as required for the selected treatment. A secondary fluid is controllably and selectively introduced into the secondary chamber of the filtration unit for controllably collecting material passing across the semipermeable membrane from the blood or for supplying material to pass across the semipermeable membrane into the blood as required for the selected treatment. Materials are removed from the secondary chamber and collected in accordance with the selected treatment. Upon selection of one of the plurality of extracorporeal blood treatments available, the rates of blood flow, fluid flow and fluid collection during the extracorporeal treatment are automatically determined, established and monitored in accordance with the selected treatment. An apparatus which automatically performs and monitors the selected treatment is also described.

Priority:

Inventor: TRUITT LORI A [US]; CORBIN III FRANK [US]; LOBDELL DONN D [US]; MILLER DOUGLAS P [US]; MANICA KEITH [US]; EILERS GEORGE J [US]; JOHNSON STEVEN H [US]; LEPPERT LAWRENCE L [US]


Patent No.: US5914127A  Issued: 22/Jun/1999

Title: Isolation and uses of caveolae

Applicant/Assignee: BETH ISRAEL DEACONESS MEDICAL CENTER

Application No.: 24952   Filing Date: 17/Feb/1998

Abstract:

Methods of isolating and purifying caveolae, microdomains of GPI-anchored proteins, and membranes consisting essentially of caveolae associated with microdomains of GPI-anchored proteins from endothelial cell membranes are disclosed. The methods comprise coating a luminal surface of an endothelial cell membrane with an adherent first ionic material by perfusion from a luminal cavity adjacent to the endothelial cell membrane, forming a pellicle by contacting the first ionic material with a second ionic material, and isolating and purifying the pellicle. The pellicle is then processed to isolate the desired cellular component. Caveolae which are substantially free of microdomains of GPI-anchored proteins

microdomains of GPI-anchored proteins which are substantially free of caveolae

and membranes consisting essentially of caveolae, microdomains of GPI-anchored proteins, and caveolae associated with microdomains of GPI-anchored proteins

all of which are substantially free of other cellular elements, are also disclosed.

Priority: US1996-582917 Applic. Date: 1996-01-04; US19950003453P Applic. Date: 1995-09-08

Inventor: SCHNITZER JAN E [US]


Patent No.: US5916202A  Issued: 29/Jun/1999

Title: Umbilical cord blood collection

Applicant/Assignee:

Application No.: 707963   Filing Date: 30/Aug/1996

Abstract:

A device and method for the collection of umbilical cord blood during obstetrical delivery are disclosed. A pouch is attached to an obstetrical drape in a location convenient for filling with cord blood. The pouch includes a canal for the umbilical cord to be inserted into the pouch, and a sealing closure. The pouch may contain an anti-coagulant. One embodiment includes multiple compartments with various blood-treatment substances. After filling the pouch is closed and removed from the drape. The blood can be used for a variety of hematologic laboratory tests and for long term cryo-preservation for a stem cell transfusion to infants and adults.

Priority:

Inventor: HASWELL JOHN N [US]


Patent No.: US5919125A  Issued: 06/Jul/1999

Title: Centrifuge bowl for autologous blood salvage

Applicant/Assignee: COBE LABORATORIES, INC

Application No.: 891471   Filing Date: 11/Jul/1997

Abstract:

An improved centrifuge bowl and related system is disclosed which is particularly apt for enhanced autologous blood salvage applications. The centrifuge bowl assembly includes a rotatable outer bowl, an internal spacer interconnected therewithin, and a stator assembly for introducing/removing fluid during rotation of the outer bowl and internal spacer. The outer bowl and internal spacer are configured to define a lateral passageway at the bottom of the assembly which terminates in an upward-facing port for fluid passage therethrough into an annular, cylindrical collection region. The annular port may be defined by a peripheral fin on the spacer and may be of a width that is less than the width of the cylindrical, annular collection region, wherein separated blood components (e.g. red blood cells) will accumulate across the width of the port during blood fill/wash cycles. As a result, enhanced washing is realized while maintaining throughput rates.

Priority:

Inventor: BERCH STEPHEN WILLIAM [US]


Patent No.: US5919176A  Issued: 06/Jul/1999

Title: Apparatus and method for collecting blood from an umbilical cord

Applicant/Assignee: CHILDREN'S HOSPITAL MEDICAL CENTER OF NORTHERN CALIFORNIA

Application No.: 742438   Filing Date: 30/Oct/1996

Abstract:

An apparatus and method for collecting a large volume of blood from an umbilical cord in a sterile environment are shown and described. A housing having an inner region adapted to retain an umbilical cord in a desired location is provided, the housing having an opening through which the cord extends from the inner region of the housing to a region external to the housing. The cord is cut by a blade coupled to the housing, either by the motion of the blade from a first position to a second position, or by the movement of two portions of the housing from a first extended position to a second collapsed position. The newly cut end of the umbilical cord falls and hangs freely in the inner region of the housing, blood flowing from the placenta and umbilical cord via gravity into a blood collection region of the housing. The blood collection region may be flexible, and may be coupled to a conventional blood collection bag.

Priority: US19960017402P Applic. Date: 1996-05-14

Inventor: KUYPERS FRANCISCUS A [US]; COLE ROBERT B [US]; MEYST RICHARD P [US]; GORTON LANNY A [US]; WRIGHT JAMES I [US]


Patent No.: US5919419A  Issued: 06/Jul/1999

Title: Analyzer cuvette, method and diagnostic test kit for determination of analytes in whole blood samples

Applicant/Assignee: ORION-YHTYMA OY

Application No.: 696996   Filing Date: 09/Oct/1996

Abstract:

PCT No. PCT/FI95/00081 Sec. 371 Date Oct. 9, 1996 Sec. 102(e) Date Oct. 9, 1996 PCT Filed Feb. 17, 1995 PCT Pub. No. WO95/22764 PCT Pub. Date Aug. 24, 1995The present invention relates to a specific cuvette, an assay method and a diagnostic test kit where samples of whole blood can be used for quantitative diagnostic testing without need for centrifugation, even though the blood components to be analyzed are in the plasma fraction. Using the method of the present invention the blood sample is converted into a plasma fraction and a cell fraction by shaking in a cuvette in the presence of a special agglutinating reagent A plasma fraction is obtained which is suitable to be used in diagnostic tests using immunometric or colormetric methods or test strips without physically removing the blood cells from the sample.

Priority: FI19940000823 Applic. Date: 1994-02-22; WO1995FI00081 Applic. Date: 1995-02-17

Inventor: MAJURI RAIMO [FI]


Patent No.: US5922322A  Issued: 13/Jul/1999

Title: Fibrin(ogen) degradation and clot lysis by fibrinolytic matrix metalloproteinase

Applicant/Assignee: NEW YORK BLOOD CENTER, INC

Application No.: 765815   Filing Date: 17/Jan/1997

Abstract:

The invention provides a method of causing degradation of fibrin(ogen) (i.e., fibrin, fibrinogen, and related substances) by means of a fibrinolytic metalloproteinase, preferably an endogenous metalloproteinase such as MMP-3. The method of the invention can be performed in vitro to provide diagnostic information characterizing fibrin(ogen) and fibrinolytic physiology. The method can also be performed in vivo as a method of thrombolytic therapy in which a fibrinolytic metalloproteinase is administered to a subject to degrade thrombus in situ. The endogenous fibrinolytic metalloproteinase can be administered in conjunction with other active agents, preferably with agents having thrombolytic activity to improve thrombolytic and fibrinolytic therapy. The invention further provides compositions containing a fibrinolytic metalloproteinase for the performance of fibrinolytic or thrombolytic procedures. Also provided are kits which include a fibrinolytic metalloproteinase for performing fibrinolytic or thrombolytic procedures.

Priority: US1995-446887 Applic. Date: 1995-05-17

Inventor: BINI ALESSANDRA [US]


Patent No.: US5928214A  Issued: 27/Jul/1999

Title: High concentration white cells, a method for agglomeration of the high concentration and a bag set for use in conjunction therewith

Applicant/Assignee: NEW YORK BLOOD CENTER, INC

Application No.: 128208   Filing Date: 03/Aug/1998

Abstract:

A therapeutic product formed from a high concentration of white blood cells having a high degree of cell viability. The white blood cells are sequestered from their normal population presence in whole blood by placing the blood into a container and preventing coagulation of the blood, separating the blood into two components, one of which is extremely rich in white blood cells through the use of a reagent and centrifugation, sequestering the white cell concentration, and freezing the white cells.

Priority: US1994-349747 Applic. Date: 1994-12-05

Inventor: RUBINSTEIN PABLO [US]; COELHO PHILIP HENRY [US]; STEVENS CLADD E [US]


Patent No.: US5932582A  Issued: 03/Aug/1999

Title: Fibrinogen receptor antagonist prodrugs

Applicant/Assignee: MERCK & CO., INC

Application No.: 883107   Filing Date: 26/Jun/1997

Abstract:

Fibrinogen receptor antagonist alcohol prodrugs having the structure, for example, ofX-W-Y-Z-A-Bmore particularly,

Priority: US19960020877P Applic. Date: 1996-06-28

Inventor: YOUNG STEVEN D [US]; HARTMAN GEORGE D [US]; LIBBY LAURA A [US]; EGBERTSON MELISSA S [US]; SLAUGHTER DONALD E [US]


Patent No.: US5935802A  Issued: 10/Aug/1999

Title: Method of assaying a blood sample for prothrombin

Applicant/Assignee: EVANSTON NORTHWESTERN HEALTHCARE RESEARCH INSTITUTE

Application No.: 132091   Filing Date: 10/Aug/1998

Abstract:

An improved method of assaying undiluted whole blood or undiluted plasma for prothrombin is disclosed. The improved method utilizes carinactivase-1 and calcium ions, and eliminates the need for a prothrombin-deficient plasma as a reference plasma.

Priority:

Inventor: LIND STUART E [US]


Patent No.: US5944710A  Issued: 31/Aug/1999

Title: Electroporation-mediated intravascular delivery

Applicant/Assignee: GENETRONICS, INC

Application No.: 668725   Filing Date: 24/Jun/1996

Abstract:

A method for sustained intravascular delivery via electroporation is provided. The method is useful for delivery of therapeutic compositions such as antithrombotic and anticoagulant agents. The invention also provides a catheter apparatus for introducing a composition into at least one cell in a vessel in a subject.

Priority:

Inventor: DEV SUKHENDU B [US]; DEV NAGENDU B [US]; HOFMANN GUNTER A [US]


Patent No.: US5945545A  Issued: 31/Aug/1999

Title: Fibrinogen receptor antagonists

Applicant/Assignee: MERCK & CO., INC

Application No.: 988815   Filing Date: 11/Dec/1997

Abstract:

Compounds of this invention have the formula: and pharmaceutically acceptable salts, e.g.

Priority: US19960032888P Applic. Date: 1996-12-13

Inventor: EGBERTSON MELISSA S [US]; HARTMAN GEORGE D [US]; VASSALLO LAURA M [US]


Patent No.: US5951951A  Issued: 14/Sep/1999

Title: Platelet function evaluation technique for citrated whole blood

Applicant/Assignee: MEDTRONIC, INC

Application No.: 846318   Filing Date: 30/Apr/1997

Abstract:

An improved apparatus and method for evaluating platelet functionality of a blood sample. The apparatus includes a plurality of test cells. Each of the cells includes a platelet function restoration agent, an anticoagulant agent, and a clotting reagent. At least one of the cells also includes a platelet activating agent. The clotting time is determined for each of the aliquot portions, and the relative clotting times of the aliquot portions in the cells are determinative of the platelet functionality of the sample. The method includes the steps of combining a platelet function restoration agent, an anticoagulant agent, a platelet activating agent, and the sample of blood to be tested to form a test mixture. The platelets of the sample are activated by adding a clotting reagent to the test mixture at the start of the activated clotting time test, and the activated clotting time test is terminated upon detecting a predetermined change in a property of the test mixture. The activated clotting time of the sample of blood is calculated based on the elapsed time.

Priority:

Inventor: LANE CAROLE G [US]; WILSON ADRIAN C [US]; BAUGH ROBERT F [US]


Patent No.: US5955371A  Issued: 21/Sep/1999

Title: Apparatus for inhibiting glycolysis in blood samples

Applicant/Assignee: BECTON DICKINSON AND COMPANY

Application No.: 969628   Filing Date: 13/Nov/1997

Abstract:

A blood collection device comprising formed additive particles. The additive particles are an improvement over available additive formulations that are powder blended in that the components of the additive particles of the present invention are in each formed particle. The formed additive particles comprise a fluoride salt and an ethylenediaminetetraacetate salt or a heparin salt to consistently minimize glycolysis and coagulation of a blood specimen with low hemolysis.

Priority: US1996-643388 Applic. Date: 1996-05-06; US1994-287575 Applic. Date: 1994-08-09

Inventor: IKEDA TATSUHIKO [JP]; DASTANE AJIT N [US]; LOSADA ROBERT [US]


Patent No.: US5965559A  Issued: 12/Oct/1999

Title: Aminoheterocyclic derivatives as antithrombotic or anticoagulant

Applicant/Assignee: ZENECA LIMITED

Application No.: 817031   Filing Date: 26/Mar/1997

Abstract:

PCT No. PCT/GB95/02285 Sec. 371 Date Mar. 26, 1997 Sec. 102(e) Date Mar. 26, 1997 PCT Filed Sep. 25, 1995 PCT Pub. No. WO96/10022 PCT Pub. Date Apr. 4, 1996The invention concerns compounds of formula (I), wherein each of G1, G2 and G6 is CH or n

m is 1 or 2

R1 includes hydrogen, halogeno and (1-4C)alkyl

M1 is a group of formula: NR2-L1-T1R3, in which R2 and R3 together form a (1-4C)alkylene group, L1 includes (1-4C)alkylene, and T1 is CH or N

A may be a direct link

M2 is a group of the formula: (T2R4)r-L2T3R5 in which R is 0 or 1, each of T2 and T3 is CH or N, each of R4 and R5 is hydrogen or (1-4C)alkyl, or R4 and R5 together form a (1-4C)alkylene group, and L2 includes (1-4C)alkylene

M3 may be a direct link to X

X includes sulphonyl

and Q includes naphthyl and a heterocycle moiety

or a pharmaceutically-acceptable salt thereof

processes for their preparation, pharmaceutical compositions containing them and their use as antithrombotic or anticoagulant agents.

Priority: GB19940019341 Applic. Date: 1994-09-26; GB19940025789 Applic. Date: 1994-12-21; GB19950011051 Applic. Date: 1995-06-01; WO1995GB02285 Applic. Date: 1995-09-25

Inventor: FAULL ALAN WELLINGTON [GB]; STOCKER ANDREW [GB]; MAYO COLETTE MARIE [GB]; PRESTON JOHN [GB]


Patent No.: US5970423A  Issued: 19/Oct/1999

Title: Blood component collection system with optimizer

Applicant/Assignee: COBE LABORATORIES, INC

Application No.: 928329   Filing Date: 12/Sep/1997

Abstract:

A blood component collection system with optimization capabilities. In one embodiment, process parameters are derived from an input/configured predetermined blood component yield and which is based upon the maximization of at least one process parameter. Thereafter, the blood component collection procedure is performed with these derived process control parameters. In another embodiment, process parameters are derived from an input total procedure time from a maximized value for at least one of the other process control parameters so as to maximize blood component yield in this fixed time. Thereafter, the blood component collection procedure is performed with these derived parameters.

Priority: US1995-439649 Applic. Date: 1995-05-12; US1993-140254 Applic. Date: 1993-10-21; US1993-110432 Applic. Date: 1993-08-23; US1992-912973 Applic. Date: 1992-07-10; US1992-845677 Applic. Date: 1992-03-04

Inventor: LANGLEY ROBERT W [US]; KELLER JOHN J [US]; URDAHL STEVEN GAGE [US]


Patent No.: US5971948A  Issued: 26/Oct/1999

Title: Apparatus for collection, washing, and reinfusion of shed blood

Applicant/Assignee: HAEMONETICS CORPORATION

Application No.: 818314   Filing Date: 14/Mar/1997

Abstract:

An integrated, vacuum-driven shed blood processing system that collects, dilutes, filters and washes postoperatively shed blood and concentrates red blood cells for reinfusion to the patient. The location of the centrifuge bowl between the surgical site and the vacuum source used to clean the site allows the immediate collection of shed blood in the bowl without an intermediate reservoir or an additional pump. In conjunction with a modified centrifuge bowl having a sealed aperture in its floor that permits reinfusion directly from the bowl without an additional reinfusion bag or reverse pump, this configuration processes blood for reinfusion using fewer steps and components yet without loss of functionality. Dilution of the blood upon its introduction into the system reduces the tendency to coagulate and allows the use of lower bowl rotation speeds. Slower rotation reduces red blood cell damage and lowers power requirements, which improves portability.

Priority: US1995-571496 Applic. Date: 1995-12-13

Inventor: PAGES ETIENNE [FR]; PAPILLON JEAN [FR]


Patent No.: US5972712A  Issued: 26/Oct/1999

Title: Heparin-independent, high sensitivity platelet function evaluation technique

Applicant/Assignee: MEDTRONIC, INC

Application No.: 249349   Filing Date: 11/Feb/1999

Abstract:

An method for performing activated clotting time tests, including a method for evaluating platelet functionality of a blood sample. The method includes the steps of combining a heparin-inactivating agent, an anticoagulant agent, a sufficient amount of clotting reagent to achieve clotting, a platelet activating agent, and the sample of blood to be tested to form a test mixture. The platelet activating agent is a reagent other than the clotting reagent. The platelets of the sample are activated by agitating the test mixture, and the activated clotting time test is terminated upon detecting a predetermined change in a property of the test mixture. The activated clotting time of the sample of blood is calculated based on the elapsed time. The activated clotting time test may be performed using a plunger sensor apparatus which comprises a plurality of test cells. In this method, each of the cells of the apparatus includes a heparin-inactivating agent, an anticoagulant agent, and a sufficient amount of a clotting reagent to achieve clotting. At least one of the test cells further includes a platelet activating agent, which is a reagent other than the clotting reagent. The clotting time is determined for each of the aliquot portions, and the relative clotting times of the aliquot portions in the cells are determinative of the platelet functionality of the sample.

Priority: US1997-847152 Applic. Date: 1997-04-30

Inventor: BAUGH ROBERT F [US]; LANE CAROLE G [US]; WILSON ADRIAN C [US]


Patent No.: US5976388A  Issued: 02/Nov/1999

Title: Method and apparatus for autologous blood salvage

Applicant/Assignee: COBE CARDIOVASCULAR OPERATING CO., INC

Application No.: 859645   Filing Date: 20/May/1997

Abstract:

An improved autologous blood salvage system is provided in which blood is removed from a patient and may be processed in a manner wherein an anticoagulant solution is for cycled for reuse. Further, the system may be employed for contemporaneous blood filtering and red blood separation. In one embodiment, anticoagulated blood is contemporaneously filtered and defoamed within a rotating processing bowl, while red blood cells are separated, washed and collected within the bowl and an anticoagulant solution is cycled from the bowl for re-use. During a red blood cell removal mode, the flow of anticoagulated blood into the bowl may be suspended/terminated and the bowl pressurized to remove the red blood cells. The improved system provides for the recovery of a high quality red blood cell product, with reduced processing time requirements/user training, and reduced disposable componentry and related costs.

Priority:

Inventor: CARSON GARY ALLEN [US]


Patent No.: US5977056A  Issued: 02/Nov/1999

Title: Treatment of thrombotic events

Applicant/Assignee: BIOPHARM (UK) LIMITED

Application No.: 624760   Filing Date: 27/Mar/1996

Abstract:

A method for preventing the formation of platelet-rich clots or thrombus, and for deaggregating platelet-rich clots or thrombus, using hementin, a polypeptide derived from leech salivary glands. Hementin may be administered for this purpose in a pharmaceutically acceptable carrier or excipient, with or without additional anticoagulants such as hirudin, hirudin analogues, or an inhibitor of factor Xa.

Priority: GB19900008863 Applic. Date: 1990-04-20; GB19900007879 Applic. Date: 1990-04-06; WO1991GB00549 Applic. Date: 1991-04-08; US1995-433955 Applic. Date: 1995-05-04; US1992-834528 Applic. Date: 1992-02-06

Inventor: POWELL-JONES CHRISTOPHER [GB]; SAWYER ROY T [GB]; ELECTRICWALA ASGAR [GB]; ATKINSON ANTHONY [GB]


Patent No.: US5981285A  Issued: 09/Nov/1999

Title: Method and apparatus for determining anticoagulant therapy factors

Applicant/Assignee:

Application No.: 127423   Filing Date: 31/Jul/1998

Abstract:

A method and apparatuses are disclosed for determining an anticoagulant therapy factor (ATF), a corrected anticoagulant therapy factor (CATF), and a modified anticoagulant therapy factor (MATF), all selectively used for monitoring oral anticoagulant therapy to help prevent excessive bleeding or deleterious blood clots that might otherwise occur before, during or after surgery. The anticoagulant therapy factor (ATF), the corrected anticoagulant therapy factor (CATF), and a modified anticoagulant therapy factor (MATF) are based upon disclosed methods for determining the fibrinogen transformation rate (FTR) which, in turn, is dependent on a maximum acceleration point for fibrinogen (FBG) conversion. The ATF, CATF, and MATF quantities are also based upon the prothrombin time (PT), but have no need for the difficulty to obtain prior art International Normalized Ratio (INR) and International Sensitivity Index (ISI) parameters. The International Normalized Ratio (INR) was created to relate all species' clotting material to human clotting material. The AFT, CATF, and MATF quantities embody only human clotting material. The ATF, CATF, and MATF quantities and International Normalized Ratio (INR) are, hereby, species specific and provide the same results.

Priority: US1997-969316 Applic. Date: 1997-11-13; US1996-734343 Applic. Date: 1996-10-21; WO1998US15972 Applic. Date: 1998-07-31

Inventor: CARROLL WALLACE E [US]; JACKSON R DAVID [US]


Patent No.: US5981584A  Issued: 09/Nov/1999

Title: Fibrinogen receptor antagonist prodrugs

Applicant/Assignee: MERCK & CO., INC

Application No.: 23650   Filing Date: 03/Feb/1998

Abstract:

Fibrinogen receptor antagonist prodrugs having the structure, for example, of more particularly,

Priority: US19970036901P Applic. Date: 1997-02-06

Inventor: EGBERTSON MELISSA S [US]; YOUNG STEVE D [US]; HARTMAN GEORGE D [US]; COOK JACQUELYNN J [US]


Patent No.: US5985307A  Issued: 16/Nov/1999

Title: Device and method for non-occlusive localized drug delivery

Applicant/Assignee: EMORY UNIVERSITY

Application No.: 982537   Filing Date: 02/Dec/1997

Abstract:

A device for the local delivery of a substance into a natural tissue conduit in the mammalian body. The device provides a means for locally delivering a substance into the boundary layer of fluid flowing through the conduit without substantially disrupting the fluid flow therethrough. For example, an indwelling endovascular support device is provided for delivery of a substance locally to a targeted treatment area. Also provided are methods of locally delivering a substance into a natural tissue conduit in the mammalian body utilizing the device of the present invention.

Priority: US1996-660203 Applic. Date: 1996-06-03; US1994-188248 Applic. Date: 1994-01-28; US1993-046622 Applic. Date: 1993-04-14

Inventor: HANSON STEPHEN R [US]; SCOTT NEAL A [US]; KING III SPENCER B [US]; MARKOU CHRISTOS [US]


Patent No.: US5985539A  Issued: 16/Nov/1999

Title: Method of reconstructing animal organs

Applicant/Assignee: KYOWA HAKKO KOGYO CO., LTD

Application No.: 112211   Filing Date: 09/Jul/1998

Abstract:

The present invention relates to a method for reconstruction of animal organ which comprises perfusing a cell-dispersible solution to animal organ from vascular system and then perfusing a cell culture medium whereby the organ is reconstructed. According to the present invention, the organ can be reconstructed and cultured for long term without separating most of cells which constitute the animal organ.

Priority: JP19970185400 Applic. Date: 1997-07-10; JP19970265662 Applic. Date: 1997-09-30

Inventor: TAKEZAWA TOSHIAKI [JP]; HANAI NOBUO [JP]


Patent No.: US5990107A  Issued: 23/Nov/1999

Title: Fibrinogen receptor antagonist prodrugs

Applicant/Assignee: MERCK & CO., INC

Application No.: 883114   Filing Date: 26/Jun/1997

Abstract:

Fibrinogen receptor antagonist alcohol prodrugs having the structure, for example, of more particularly,

Priority: US19960020976P Applic. Date: 1996-06-28

Inventor: EGBERTSON MELISSA S [US]; HARTMAN GEORGE D [US]; LUMMA WILLIAM C [US]; WAI JOHN S [US]; YOUNG STEVEN D [US]


Patent No.: US5996811A  Issued: 07/Dec/1999

Title: Plasma collecting device

Applicant/Assignee: FUJI PHOTO FILM CO. LTD

Application No.: 994420   Filing Date: 19/Dec/1997

Abstract:

This invention relates to a plasma-collecting device which comprises a blood filtering material comprising glass fiber filter and microporous membrane, a holder having a blood inlet and a plasma outlet accommodating the blood filtering material, a blood-collecting needle being connected to the blood inlet, and a plasma receiver being provided on the plasma outlet side. The plasma-collecting device can collect a necessary amount of plasma for analysis from blood vessel directly, easily and surely.

Priority: JP19970028652 Applic. Date: 1997-02-13

Inventor: KITAJIMA MASAO [JP]; HIGO AKEMI [JP]


Patent No.: US5997496A  Issued: 07/Dec/1999

Title: System and method of extracorporeally treating blood to alleviate the symptoms of inflammatory diseases

Applicant/Assignee: ASAHI MEDICAL CO., LTD

Application No.: 983304   Filing Date: 30/Dec/1997

Abstract:

PCT No. PCT/JP96/01913 Sec. 371 Date Dec. 30, 1997 Sec. 102(e) Date Dec. 30, 1997 PCT Filed Jul. 10, 1996 PCT Pub. No. WO97/02851 PCT Pub. Date Jan. 30, 1997An extracorporeal blood circulation system for treating inflammatory diseases includes a blood collection device for collecting blood from a patient suffering from an inflammatory disease, an anticoagulant mixing device for mixing an anticoagulant into the collected blood, blood transportation device for transporting the anticoagulant-containing blood at a flow rate in the range of from 20 to 200 ml/minute, a blood treating device having a blood inlet and a blood outlet and containing a platelet activating device, and a blood returning device for returning the treated blood to the patient, each being liquid-tightly connected in this order through a tubing so that when extracorporeal blood circulation is conducted using the system with respect to blood from the patient, the system is capable of providing treated blood satisfying at least one requirement selected from requirement (1) of having a beta -thromboglobulin concentration in the range of from 1,000 to 20,000 ng/ml and requirement (2) of having a platelet factor 4 concentration in the range of from 500 to 10,000 ng/ml. Also disclosed is an extracorporeal blood circulation method which provides treated blood in which platelets are activated to a specific degree that the above-mentioned requirement (1) and/or requirement (2) is satisfied and so as to achieve a high therapeutic effect on inflammatory diseases.

Priority: JP19950195754 Applic. Date: 1995-07-10; WO1996JP01913 Applic. Date: 1996-07-10

Inventor: SEKIGUCHI MITSUYO [JP]; TAKENAKA YOSHINORI [JP]


Patent No.: US5998031A  Issued: 07/Dec/1999

Title: Dried chemical compositions

Applicant/Assignee: ABAXIS, INC

Application No.: 951617   Filing Date: 16/Oct/1997

Abstract:

The present invention provides dried chemical compositions comprising dried beads. Typically, the beads comprise reagents suitable for analysis of biological samples, in particular analysis of blood samples in centrifugal analyzers.

Priority: US1995-466155 Applic. Date: 1995-06-06; US1993-134574 Applic. Date: 1993-10-08; US1991-747179 Applic. Date: 1991-08-19

Inventor: BUHL STEVEN N [US]; BHAYANI BHASKAR [US]; YU CHI-SOU [US]; TANG THUY N [US]


Patent No.: US6001087A  Issued: 14/Dec/1999

Title: Collection assembly with a reservoir

Applicant/Assignee: BECTON DICKINSON AND COMPANY

Application No.: 724559   Filing Date: 30/Sep/1996

Abstract:

An assembly and method for storing and dispensing additives that are used in the preservation, separation or analysis of a blood sample. The assembly comprises a container, a reservoir and a cap wherein the reservoir is a liquid impermeable material.

Priority:

Inventor: ZURCHER ROBERT G [US]


Patent No.: US6001820A  Issued: 14/Dec/1999

Title: Compositions and methods for inhibiting thrombogenesis

Applicant/Assignee: HAMILTON CIVIC HOSPITALS RESEARCH DEVELOPMENT INC

Application No.: 870528   Filing Date: 06/Jun/1997

Abstract:

The present invention provides compositions and methods for the treatment of cardiovascular diseases. More particularly, the present invention relates to modifying thrombus formation by administering an agent which, inter alia, is capable of (1) selectively inactivating thrombin which is bound either to fibrin in a clot or to some other surface, but which has only minimal inhibitory activity against free thrombin, i.e., fluid-phase thrombin

(2) inhibiting the assembly of the intrinsic tenase complex, thereby inhibiting the activation of Factor X by Factor IXa

and (3) inhibiting the activation of Factor IX by Factor XIa. The compositions and methods of the present invention are particularly useful for preventing thrombosis in the circuit of cardiac bypass apparatus and in patients undergoing renal dialysis, and for treating patients suffering from or at risk of suffering from thrombus-related cardiovascular conditions, such as unstable angina, acute myocardial infarction (heart attack), cerebrovascular accidents (stroke), pulmonary embolism, deep vein thrombosis, arterial thrombosis, etc.

Priority: US1996-624327 Applic. Date: 1996-03-29; US1995-540324 Applic. Date: 1995-10-06; US1995-412332 Applic. Date: 1995-03-31

Inventor: HIRSH JACK [CA]; WEITZ JEFFREY I [CA]


Patent No.: US6004819A  Issued: 21/Dec/1999

Title: Blood testing device

Applicant/Assignee: XYLUM CORPORATION

Application No.: 78506   Filing Date: 14/May/1998

Abstract:

This invention relates to the measurement of various haemostatis, clotting, and the like properties of blood.

Priority: US1996-743911 Applic. Date: 1996-11-04

Inventor: GOROG PETER [GB]; KOVACS IREN [GB]


Patent No.: US6007509A  Issued: 28/Dec/1999

Title: Blood collection and separation system

Applicant/Assignee: TRANSFUSION TECHNOLOGIES CORP

Application No.: 835680   Filing Date: 09/Apr/1997

Abstract:

A system compact enough to be located entirely beside the donor's chair, and able to process the blood while the donor is still resting in the chair after having donated the blood. The separated blood components (plasma and red blood cells) may be stored in their individual optimum environments immediately after the whole blood is drawn, and the blood does not need to be transported back to a separation laboratory for processing. The system includes a needle (72) (or other cannula-like device) for insertion into a vein of the donor and drawing whole blood therethrough, a rotor (2a) for holding the blood after it is drawn, and a motor (50) for spinning the rotor so as to cause the blood to separate into components, for example, plasma and red blood cells. In a preferred embodiment two containers are used: the first container (92) for containing an anticoagulant, which is preferably added to the whole blood as it is drawn from the donor, and then for storing the plasma after it has been separated from the red blood cells, and the second container (91) for storing the separated red blood cells. The system further includes tubing (73), which may have valving (81) built into it and which may be acted on externally, so as to direct the blood components in the desired manner.

Priority: US1995-482617 Applic. Date: 1995-06-07

Inventor: KINGSLEY GORDON F [US]; HEADLEY THOMAS D [US]; HALPERN LISE N [US]


Patent No.: US6007725A  Issued: 28/Dec/1999

Title: Systems and methods for on line collection of cellular blood components that assure donor comfort

Applicant/Assignee: BAXTER INTERNATIONAL INC

Application No.: 975694   Filing Date: 21/Nov/1997

Abstract:

Systems and methods convey anticoagulated blood suspension from a donor into a separation device for component separation. One or more components are retained for therapeutic use, while one or more are returned to the donor. The systems and methods monitor the rate at which anticoagulant carried in the returned components is being returned. The rate, expressed in terms of milligram (mg) of anticoagulant per kilogram (kg) of donor body weight per unit of time of blood processing, is compared to a nominal rate that is correlated with donor comfort.

Priority: US1996-719312 Applic. Date: 1996-09-24; US1995-551579 Applic. Date: 1995-11-01; US1993-097967 Applic. Date: 1993-07-26; US1992-965088 Applic. Date: 1992-10-22; US1991-814403 Applic. Date: 1991-12-23

Inventor: BROWN RICHARD I [US]


Patent No.: US6010911A  Issued: 04/Jan/2000

Title: Apparatus for performing a heparin-independent high sensitivity platelet function evaluation technique

Applicant/Assignee: MEDTRONIC, INC

Application No.: 847152   Filing Date: 30/Apr/1997

Abstract:

An apparatus and method for performing activated clotting time tests, including their use for evaluating platelet functionality of a blood sample. The apparatus includes a plurality of test cells. Each of the cells comprises a heparin-inactivating agent, an anticoagulant agent, and a clotting reagent. At least one of the test cells further comprises a platelet activating agent. The clotting time is determined for each of the aliquot portions, and the relative clotting times of the aliquot portions in the cells are determinative of the platelet functionality of the sample. The method comprises the steps of combining a heparin-inactivating agent, an anticoagulant agent, a clotting reagent, a platelet activating agent, and the sample of blood to be tested to form a test mixture. The platelets of the sample are activated by agitating the test mixture, and the activated clotting time test is terminated upon detecting a predetermined change in a property of the test mixture. The activated clotting time of the sample of blood is calculated based on the elapsed time.

Priority:

Inventor: BAUGH ROBERT F [US]; LANE CAROLE G [US]; WILSON ADRIAN C [US]


Patent No.: US6019728A  Issued: 01/Feb/2000

Title: Catheter and sensor having pressure detecting function

Applicant/Assignee: KABUSHIKI KAISHA TOKAI RIKA DENKI SEISAKUSHO

Application No.: 852223   Filing Date: 06/May/1997

Abstract:

A catheter includes a longitudinally extending catheter tube to be inserted into a body. A plurality of sensing portions are arranged in the catheter tube for detecting at least two types of pressures acting on the catheter when inserted into the body. Each sensing portion is arranged along the longitudinal direction of the catheter tube. A silicone gel transmits the two types of pressures acting in the body to each sensing portion. The two types of pressures act on each sensing portion in a radial direction of the catheter tube by way of the silicone gel.

Priority: JP19960114005 Applic. Date: 1996-05-08; JP19960114006 Applic. Date: 1996-05-08

Inventor: IWATA HITOSHI [JP]; ITOIGAWA KOICHI [JP]


Patent No.: US6019742A  Issued: 01/Feb/2000

Title: Method for liquid separation

Applicant/Assignee: TRANSFUSION TECHNOLOGIES CORPORATION

Application No.: 800085   Filing Date: 12/Feb/1997

Abstract:

A rotor for collecting and centrifuging biological fluids in a range of volumes. The rotor includes an elastic impermeable diaphragm which defines at least a portion of a variable-volume processing chamber, where the fluid is centrifuged. The rotor includes a rigid mounting member, to which the diaphragm is mounted and which is held and spun by a chuck. Preferably, this rigid mounting member includes a boundary wall which together with the elastic diaphragm defines the chamber. The boundary wall may be a substantially imperforate circular wall which extends to the periphery of the processing chamber but defining one opening, preferably near the axis of rotation, permitting a conduit or conduits to pass therethrough so as to be in fluid communication with the processing chamber. The rotor may include a separate structure for controlling the flow of liquid out of the chamber into the conduit. In a preferred embodiment, this outlet-control structure is a perforate, substantially rigid wall or plate, located within the processing chamber and mounted adjacent the rigid boundary wall. In an alternative embodiment, the outlet-control structure for controlling flow from the processing chamber to the conduit may include at least one tube or preferably a set of tubes, wherein each tube provides fluid communication between the chamber and the conduit. In one preferred embodiment, grooves in the boundary wall may be used as the outlet-control structure.

Priority: US1994-322601 Applic. Date: 1994-10-13

Inventor: HEADLEY THOMAS D [US]; POWERS EDWARD T [US]


Patent No.: US6022869A  Issued: 08/Feb/2000

Title: Aminoheterocyclic compounds with antithrombotic/anticoagulant effect

Applicant/Assignee: ZENECA LIMITED

Application No.: 117673   Filing Date: 04/Aug/1998

Abstract:

PCT No. PCT/GB97/00270 Sec. 371 Date Aug. 4, 1998 Sec. 102(e) Date Aug. 4, 1998 PCT Filed Jan. 31, 1997 PCT Pub. No. WO97/29104 PCT Pub. Date Aug. 14, 1997The invention relates to compounds of formula (I), and pharmaceutically-acceptable salts thereof, which possess antithrombotic and anticoagulant properties

processes for preparing compounds of formula (I) and pharmaceutical compositions.

Priority: GB19960002294 Applic. Date: 1996-02-05; WO1997GB00270 Applic. Date: 1997-01-31

Inventor: FAULL ALAN WELLINGTON [GB]


Patent No.: US6024918A  Issued: 15/Feb/2000

Title: Method for attachment of biomolecules to surfaces of medical devices

Applicant/Assignee: MEDTRONIC, INC

Application No.: 41497   Filing Date: 13/Mar/1998

Abstract:

A method for making a medical device having a biomolecule immobilized on a substrate surface is provided. The method includes coating the substrate surface with an amino-functional polysiloxane

and contacting the amino-functional polysiloxane coated surface with a biomolecule under conditions effective to immobilize the biomolecule.

Priority:

Inventor: HENDRIKS MARC [NL]; VERHOEVEN MICHEL [NL]; CAHALAN PATRICK [NL]; CAHALAN LINDA [NL]; KOULIK EDOUARD [NL]; GILLISSEN MIRIAN [NL]


Patent No.: US6025201A  Issued: 15/Feb/2000

Title: Highly sensitive, accurate, and precise automated method and device for identifying and quantifying platelets and for determining platelet activation state using whole blood samples

Applicant/Assignee: BAYER CORPORATION

Application No.: 884595   Filing Date: 27/Jun/1997

Abstract:

The present invention provides a highly sensitive and accurate method and system for the discrimination and quantification of platelets in a whole blood sample using automated hematology instruments. The method and system of the invention provide the accurate measurements of platelet dry mass and platelet component concentration in both normal blood samples and in abnormal blood samples, such as those from thrombocytopenic patients. The determination of platelet dry mass and platelet component concentration can serve to assess the activation state of platelets since activated platelets possess measurably lower component concentrations and refractive indices than do non-activated platelets. The method and system of the invention also allows the clinician or skilled practitioner to determine the age of a blood sample on the basis of the measured parameter of platelet component concentration.

Priority: US1996-742889 Applic. Date: 1996-11-01; US1995-581293 Applic. Date: 1995-12-28

Inventor: ZELMANOVIC DAVID [US]; COLELLA GREGORY M [US]; HETHERINGTON EDWARD J [US]; CHAPMAN EVELYN SABRINAH [US]; PASELTINER LYNN [US]


Patent No.: US6027938A  Issued: 22/Feb/2000

Title: Micropathological patient replica based on unadulterated whole blood

Applicant/Assignee:

Application No.: 45291   Filing Date: 20/Mar/1998

Abstract:

A patient replica is created from a layered culture medium where solid culture medium is formed so that a discontinuity exists between the layers. An infusion port is provided in registration with the discontinuity so that a fresh unadulterated sample of patient blood can be infused into the discontinuity to form a thin layer of blood between the layers of culture medium. The thin layer obviates the requirement for any anticoagulant allowing blood-borne pathogens to be readily cultured without using broth. Further antibiotics or other drug samples may be placed on the surface of the culture medium above the blood layer so that the antibiotic can diffuse through the culture medium and reveal the sensitivities of the cultured pathogens. Other samples of pathogens or tissues can be placed on the surface of the culture medium so that effects of drugs or growth factors present in the patient blood can be observed thereby allowing the entrapped blood layer to act as a biological replica of the patient.

Priority: US1997-826429 Applic. Date: 1997-03-20

Inventor: BARNES ALLEN C [US]; BARNES JANICE S [US]


Patent No.: US6033436A  Issued: 07/Mar/2000

Title: Expandable stent

Applicant/Assignee: MD3, INC

Application No.: 24571   Filing Date: 17/Feb/1998

Abstract:

The present invention provides a lumen support stent for use in an artery or any body lumen. The stent is formed from a plurality of ladder elements having elongated ribs bowed to define a circumferential arc of the tubular member and end rungs affixed to the elongated ribs. The elongated ribs of adjacent ladder elements are substantially parallel to one another and slidably engaged by the end rungs of adjacent ladder elements. Sliding of the end rungs along the circumferential arc defined by the engaged ribs creates a variable circumferential distance between the end rungs of adjacent ladder elements. Consequently, the stent has a first diameter in which the circumferential distance between end rungs of adjacent ladder elements is collapsed, and a variable second diameter in which the circumferential distance between end rungs of adjacent ladder elements is expanded.

Priority:

Inventor: STEINKE THOMAS A [US]; ROSS STEPHEN O [US]


Patent No.: US6033561A  Issued: 07/Mar/2000

Title: Apheresis system incorporating alternative site for anticoagulant addition

Applicant/Assignee: BAXTER INTERNATIONAL INC

Application No.: 410940   Filing Date: 27/Mar/1995

Abstract:

An extracorporeal blood processing method and system wherein blood is extracted from a mammalian subject through a blood withdrawal tube having a blood pump, such as a peristaltic pump, positioned thereon. A "distal segment" of the blood withdrawal tube extends from the mammalian subject to the inlet side or withdrawal pump. A "proximal segment" of the blood withdrawal tube extends from the outlet side of the blood pump to an extracorporeal blood processing apparatus. An anticoagulant feed tube is connected to the "proximal segment" of the blood withdrawal tube such that a flow of anticoagulant solution may be combined with blood exiting the outlet of said blood pump and passing through the "proximal segment" of said blood withdrawal tubing.

Priority: US1993-019002 Applic. Date: 1993-02-18

Inventor: SCHOENDORFER DONALD W [US]


Patent No.: US6033719A  Issued: 07/Mar/2000

Title: Method for covalent attachment of biomolecules to surfaces of medical devices

Applicant/Assignee: MEDTRONIC, INC

Application No.: 12056   Filing Date: 22/Jan/1998

Abstract:

A method for making a medical device having at least one biomolecule immobilized on a substrate surface is provided. The method may include combining a biomolecule comprising a 1,2 dicarbonyl moiety with a material comprising a guanidino moiety to form an immobilized biomolecule on a medical device biomaterial surface through covalent bonds. Another method of the present invention may include combining a biomolecule comprising a guanidino moiety with a material comprising a 1,2 dicarbonyl moiety to form an immobilized biomolecule on a medical device biomaterial surface through covalent bonds. Additionally, one method of the present invention may be employed to crosslink biomolecules, located in solution or on a medical device biomaterial surface, thereby forming a crosslinked biomaterial or a crosslinked medical device coating.

Priority: US1996-635187 Applic. Date: 1996-04-25; US1997-001994 Applic. Date: 1997-12-31; US1996-694535 Applic. Date: 1996-08-09; US1997-984922 Applic. Date: 1997-12-04

Inventor: KEOGH JAMES R [US]


Patent No.: US6036958A  Issued: 14/Mar/2000

Title: Tsetse thrombin inhibitor

Applicant/Assignee: YALE UNIVERSITY

Application No.: 180605   Filing Date: 15/Jul/1999

Abstract:

PCT No. PCT/US97/07968 Sec. 371 Date Jul. 15, 1999 Sec. 102(e) Date Jul. 15, 1999 PCT Filed May 9, 1997 PCT Pub. No. WO97/43309 PCT Pub. Date Nov. 20, 1997A potent and specific inhibitor of thrombin is purified from salivary gland extracts of the tsetse fly, Glossina morsitans morsitans. The inhibitor has a molecular weight of 3530 Daltons as determined by laser desorption mass spectroscopy. The inhibitor is useful as an anticoagulant and an inhibitor of platelet aggregation and in pharmaceutical and immunogenic compositions.

Priority: WO1997US07968 Applic. Date: 1997-05-09; US19960017235P Applic. Date: 1996-05-10

Inventor: CAPPELLO MICHAEL [US]; AKSOY SERAP [US]


Patent No.: US6037181A  Issued: 14/Mar/2000

Title: Method and apparatus for determining blood oxygen transport

Applicant/Assignee:

Application No.: 5474   Filing Date: 12/Jan/1998

Abstract:

The present invention relates to a method and apparatus for determining blood oxygen transport, and to measure lipid levels by correlating these levels with the rate at which oxygen diffuses through the red blood cell membrane.

Priority:

Inventor: BUCHWALD HENRY [US]; MENCHACA HECTOR J [US]; MICHALEK VAN [US]; O'DEA THOMAS J [US]; ROHDE THOMAS D [US]


Patent No.: US6043871A  Issued: 28/Mar/2000

Title: System and method for measuring blood platelet function

Applicant/Assignee: BRIGHAM YOUNG UNIVERSITY

Application No.: 33919   Filing Date: 03/Mar/1998

Abstract:

An instrument is described for measuring the platelet aggregation in whole blood in response to standard aggregating agents. The instrument is designed to be used in the clinical laboratory to evaluate the functional status of platelets in blood samples drawn from patients suspected of abnormal platelet function, or in a research laboratory to evaluate the effectiveness of platelet agonists or antiplatelet agents. The measurement is based on the scattering of light in the blood sample and does not require separation of erythrocytes from blood and therefore helps minimize the need for handling of blood by the laboratory personnel. The instrument converts the light-scattering data to provide the number and average size of the aggregates per unit volume at various times during the process of aggregation.

Priority: US19970039755P Applic. Date: 1997-03-03

Inventor: SOLEN KENNETH A [US]; MOHAMMAD S FAZAL [US]


Patent No.: US6044845A  Issued: 04/Apr/2000

Title: Methods and systems for treating ischemia

Applicant/Assignee: SALIENT INTERVENTIONAL SYSTEMS, INC

Application No.: 18214   Filing Date: 03/Feb/1998

Abstract:

Methods for treating total and partial occlusions employ a perfusion conduit which is penetrated through the occlusive material. Oxygenated blood or other medium is then perfused through the conduit to maintain oxygenation and relieve ischemia in tissue distal to the occlusion. Optionally, the occlusion may be treated while perfusion is maintained, typically by introducing a thrombolytic or other agent into the occlusive material using the perfusion conduit. Such methods are particularly suitable for treating acute stroke to prevent irreversible damage to the cerebral tissue.

Priority:

Inventor: LEWIS BRIAN DOUGLAS [US]


Patent No.: US6046019A  Issued: 04/Apr/2000

Title: Diagnostic kits and methods for making granulocyte cell counts

Applicant/Assignee:

Application No.: 896209   Filing Date: 10/Jun/1992

Abstract:

Methods for detecting granulocytes and for providing an at least semiquantitative indication of granulocyte level and kits for implementing those methods. A blood sample is drawn, and components that might interfere with the assay are removed and/or neutralized. Granulocytes present in the sample are then disrupted to release intracellular myeloperoxidase, and the sample is contacted with a peroxide and a chromogenic donor dye. The myeloperoxidase enzyme catalyzes hydrogen peroxide-involved reactions which result in the dye changing color if, and to the extent that, granulocytes are present in the blood sample.

Priority: US1991-727582 Applic. Date: 1991-07-09

Inventor: GOUMENIOUK ALEXANDER P [CA]; RICHARDS B G [CA]


Patent No.: US6051434A  Issued: 18/Apr/2000

Title: Activated protein C resistance test

Applicant/Assignee: GRADIPORE LIMITED

Application No.: 776897   Filing Date: 24/Apr/1997

Abstract:

PCT No. PCT/AU95/00474 Sec. 371 Date Apr. 24, 1997 Sec. 102(e) Date Apr. 24, 1997 PCT Filed Aug. 7, 1995 PCT Pub. No. WO96/04560 PCT Pub. Date Feb. 15, 1996The method for determining functional activity of protein C in a human plasma sample includes incubating the human plasma sample with exogenous reagents that activate factor V and a common pathway of the blood coagulation mechanism through factor X, with activated exogenous protein C and with components that are necessary for efficient clotting of the human plasma sample, or incubating the human plasma sample with exogenous reagents that induce the presence of thrombin in a factor V dependent manner, with activated exogenous protein C and with components that are necessary for efficient clotting of the human plasma sample

monitoring a reaction indicative of a potential rate of coagulation of the plasma sample and comparing the resulting potential rate of coagulation with an equivalent rate for normal patient, or comparing the resulting potential rate of coagulation with an equivalent rate determined for the plasma sample in the absence of activated exogenous protein C

and determining the functional activity of the free protein C from this comparison.

Priority: AU1994PM07313 Applic. Date: 1994-08-05; WO1995AU00474 Applic. Date: 1995-08-07

Inventor: EXNER THOMAS [AU]


Patent No.: US6053901A  Issued: 25/Apr/2000

Title: Subcutaneously implanted cannula and method for arterial access

Applicant/Assignee: VASCA, INC

Application No.: 724948   Filing Date: 02/Oct/1996

Abstract:

A catheter with valve for implantation in a vascular structure of a living being. The catheter is in the general shape of a "T" with the top of the "T" implanted within the lumen of a vascular structure, and the leg of the "T" extending out of the vascular structure through an incision in the vascular structure. The lumen of the implanted portion of the catheter completely occupies the lumen of the vascular structure, causing all blood flow through the vascular structure to be directed through the implanted portion of the catheter. A valve is placed in the wall of the implanted portion of the catheter which opens into the lumen of the leg of the "T" of the catheter upon application of sufficient differential pressure between the lumens of the two portions of the catheter. The leg of the "T" is connected to the side wall of the implant portion of the catheter at an angle, such that the axis of the lumen of the leg of the "T" intersects the axis of the lumen of the implanted portion of the catheter at approximately a 45 degree angle.

Priority: US1995-539105 Applic. Date: 1995-10-04; US1994-183151 Applic. Date: 1994-01-18

Inventor: FINCH JR CHARLES D [US]; KUIPER HENDRIK E [US]; BURBANK JEFFREY H [US]; BRUGGER JAMES M [US]


Patent No.: US6054122A  Issued: 25/Apr/2000

Title: Supplemented and unsupplemented tissue sealants, methods of their production and use

Applicant/Assignee: THE AMERICAN NATIONAL RED CROSS

Application No.: 479034   Filing Date: 07/Jun/1995

Abstract:

This invention provides a fibrin sealant dressing, wherein said fibrin sealant may be supplemented with at least one composition selected from, for example, one or more regulatory compounds, antibody, antimicrobial compositions, analgesics, anticoagulants, antiproliferatives, anti-inflammatory compounds, cytokines, cytotoxins, drugs, growth factors, interferons, hormones, lipids, demineralized bone or bone morphogenetic proteins, cartilage inducing factors, oligonucleotides polymers, polysaccharides, polypeptides, protease inhibitors, vasoconstrictors or vasodilators, vitamins, minerals, stabilizers and the like. Also disclosed are methods of preparing and/or using the unsupplemented or supplemented fibrin sealant dressing.

Priority: US1994-351006 Applic. Date: 1994-12-07; US1994-328552 Applic. Date: 1994-10-25; US1993-031164 Applic. Date: 1993-03-12; US1990-618419 Applic. Date: 1990-11-27; US1991-798919 Applic. Date: 1991-11-27

Inventor: MACPHEE MARTIN JAMES [US]; DROHAN WILLIAM NASH [US]; WOOLVERTON CHRISTOPER J [US]


Patent No.: US6066778A  Issued: 23/May/2000

Title: Transgenic mice expressing APC resistant factor V

Applicant/Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN

Application No.: 746111   Filing Date: 06/Nov/1996

Abstract:

The present invention relates to compositions and methods for the screening of compounds for anticoagulant activity. In particular, the present invention relates to non-human transgenic animals expressing activated protein C ("APC")-resistant factor V proteins which display a predisposition toward spontaneous thrombosis. The present invention also provides methods for using these transgenic animals to screen compounds for anticoagulant activity.

Priority:

Inventor: GINSBURG DAVID [US]; CUI JISONG [US]


Patent No.: US6077232A  Issued: 20/Jun/2000

Title: Anticoagulant composition

Applicant/Assignee: SHERWOOD SERVICES AG

Application No.: 993369   Filing Date: 18/Dec/1997

Abstract:

A blood collection device including a sealed area with a soluvated, non-aqueous anticoagulant composition positioned therein. The preferred anticoagulant composition comprises heparin, polyethylene glycol and optionally, deionized water and one or more salts.

Priority: US19960034446P Applic. Date: 1996-12-27

Inventor: EARHART STEPHEN B [US]


Patent No.: US6083383A  Issued: 04/Jul/2000

Title: Apparatus for production of fibrin ogen or fibrin glue

Applicant/Assignee:

Application No.: 105286   Filing Date: 25/Jun/1998

Abstract:

This invention relates generally to apparatuses and processes for preparing fibrinogen glue from autologous plasma. More particularly, this invention relates to a novel apparatus comprising a plasma membrane separator to extract and separate the autologous plasma from other undesirable compositions in the blood. The autologous plasma is transferred to a membrane separator to provide separation of the fibrinogen from other compositions with a desirable amount of ether or other suitable solvents containing an-OH group in the presence of a mixing means. The fibrinogen so separated is transferred to a fibrinogen collector which is connected to a vacuum pump through a sterile filter to remove the ether or other suitable solvents contained thereof. A freezer is provided to maintain the autologous plasma in the membrane separator and the fibrinogen in the fibrinogen collector at a desirable temperature. Additionally, a constant temperature bisyringe serves to keep the fibrinogen liquid and mixed with thrombin to form a homogeneous clotting to achieve hemostasis and tissue approximation. A second embodiment which provides a method of producing fibrin glue without the need of ether or organic solvents is also disclosed.

Priority:

Inventor: HUANG XUN YANG [US]; LIANG GANG [US]; LIANG YAN [US]


Patent No.: US6102883A  Issued: 15/Aug/2000

Title: Blood collection and separation process

Applicant/Assignee: TRANSFUSION TECHNOLOGIES CORPORATION

Application No.: 964177   Filing Date: 04/Nov/1997

Abstract:

A system compact enough to be located entirely beside the donor's chair, and able to process the blood while the donor is still resting in the chair after having donated the blood. The separated blood components (plasma and red blood cells) may be stored in their individual optimum environments immediately after the whole blood is drawn, and the blood does not need to be transported back to a separation laboratory for processing. The system includes a needle (72) (or other cannula-like device) for insertion into a vein of the donor and drawing whole blood therethrough, a rotor (2a) for holding the blood after it is drawn, and a motor (50) for spinning the rotor so as to cause the blood to separate into components, for example, plasma and red blood cells. The system also provides for a container for collecting a separated component. In a preferred embodiment two containers are used: the first container (92) for containing an anticoagulant, which is preferably added to the whole blood as it is drawn from the donor, and then for storing the plasma after it has been separated from the red blood cells, and the second container (91) for storing the separated red blood cells.

Priority: US1996-662613 Applic. Date: 1996-06-13; US1996-662615 Applic. Date: 1996-06-13; US1995-482617 Applic. Date: 1995-06-07

Inventor: KINGSLEY GORDON F [US]; HEADLEY THOMAS D [US]; HALPERN LISE N [US]


Patent No.: US6106509A  Issued: 22/Aug/2000

Title: Closed circuit autologous sequestration reservoir system

Applicant/Assignee:

Application No.: 912742   Filing Date: 18/Aug/1997

Abstract:

An apparatus is provided for autologous sequestration of blood from a patient prior to, during and after surgery. Sequestered blood contained in an assembly of oxygenated blood collection bags is kept in fluid contact with the patient throughout surgery, thereby assuring continuity with the patient's circulatory system. The plurality of blood collection bags is interconnected with a corresponding plurality of valves which is interconnected with a plurality of flexible tubes which is attached to a patient's right atrium or a peripheral artery. Following induction of anesthesia in the operating room, a patient's blood is sequestered into a collection bag assembly which forms a closed circuit blood reservoir system. Collected blood during surgery trickles back into the patient's blood system, thereby emulating venous blood flow. The collection bags are agitated and oxygenated to promote the functionality and longevity of the platelets in the sequestered blood.

Priority: US1996-598688 Applic. Date: 1996-02-08

Inventor: LOUBSER PAUL G [US]


Patent No.: US6106779A  Issued: 22/Aug/2000

Title: Lysis chamber for use in an assay device

Applicant/Assignee: BIOSITE DIAGNOSTICS, INC

Application No.: 942370   Filing Date: 02/Oct/1997

Abstract:

A lysis chamber of an assay device capable of producing lysis of cells in a sample fluid such as whole blood, said chamber comprising a surface which contacts the sample fluid when the sample fluid is placed into the assay device

and a lytic material immobilized on the surface, whereby cells of the sample fluid are lysed when they contact the lytic material. The chamber can delimit a capillary space, and lytic material can be saponin or a detergent. Methods employing devices comprising such chambers can assay for whole blood amounts of cyclosporin or hemoglobin A1c.

Priority:

Inventor: BUECHLER KENNETH F [US]; BRIGGS JASON CHRISTOPHER [US]; RONGEY SCOTT HAROLD [US]


Patent No.: US6113554A  Issued: 05/Sep/2000

Title: Automatic whole blood collection system

Applicant/Assignee: HAEMONETICS CORPORATION

Application No.: 174495   Filing Date: 16/Oct/1998

Abstract:

A whole blood collection system includes an automated pump/control unit and an accompanying disposable blood set. When combined and connected to a source of anticoagulant, these elements allow automatic priming of the blood set with anticoagulant and automatic collection of anticoagulated blood product according to three different collection modes. The unit's pump and the blood set are specially designed to cooperate during the collection process to assure that the collected product has a precise blood to anticoagulant ratio. During the collection procedure, the pump/control unit automatically collects data relating to the procedure. Additional data specifically identifying components of the blood set, such as the blood collection bag, along with identification data on the donor's registration form may be scanned into the pump/controller unit by a scanner associated with the unit

this facilitates positive sample identification and tracking. At the end of the procedure, a printer in the pump/controller unit automatically prints out this information so that a detailed record is immediately available about the collected blood product, the procedure for collecting it and the source of the product, i.e., the donor.

Priority:

Inventor: GILCHER RONALD O [US]; CHAMMAS JACQUES [US]; MEDBERRY JOSEPH M [US]; STACEY GARY R [US]


Patent No.: US6117290A  Issued: 12/Sep/2000

Title: System and method for measuring a bioanalyte such as lactate

Applicant/Assignee: PEPEX BIOMEDICAL, LLC

Application No.: 122496   Filing Date: 24/Jul/1998

Abstract:

The present disclosure relates to an on-line lactate sensor arrangement. The sensor arrangement includes a lactate sensor, a catheter for withdrawing a test sample, and a first fluid flow line provided fluid communication between the lactate sensor and the catheter. The sensor arrangement also includes a source of sensor calibration and anticoagulant solution, and second fluid flow line providing fluid communication between the source of sensor calibration and anticoagulant solution and the lactate sensor.

Priority: US19970060142P Applic. Date: 1997-09-26

Inventor: SAY JAMES L [US]; LONG NATHAN R [US]; PEPER ERIC A [US]; SAKSLUND HENNING [US]


Patent No.: US6126618A  Issued: 03/Oct/2000

Title: Apparatus for obtaining liquid samples

Applicant/Assignee: BAXTER INTERNATIONAL INC

Application No.: 231682   Filing Date: 14/Jan/1999

Abstract:

An apparatus for obtaining liquid samples from a fluid flow path is disclosed. The apparatus includes a housing having an access site communicating with the flow path and carrying a piercing member at a location spaced from the access site. The housing allows for translational movement of the piercing member toward the access site and into the flow path from where the sample is removed.

Priority:

Inventor: BISCHOF DANIEL F [US]


Patent No.: US6126645A  Issued: 03/Oct/2000

Title: Medical devices subject to triggered disintegration

Applicant/Assignee: SCIMED LIFE SYSTEMS, INC

Application No.: 621866   Filing Date: 18/Mar/1996

Abstract:

The present invention provides medical devices comprised of ionically crosslinked polymer, especially, stents, catheter or cannula components, plugs, and constrictors. The medical devices of the present invention are prepared by treatment of ionically crosslinkable polymer compositions with crosslinking ion compositions to provide ionically crosslinked materials. An important aspect of the present invention is that these medical devices can be disintegrated in-vivo at a desired time through the exposure of the medical device to a chemical trigger which generally is described as an agent that acts to displace the crosslinking ion in the ionically crosslinked material through binding or simple replacement with a non-crosslinking ion.

Priority: US1993-128952 Applic. Date: 1993-09-29

Inventor: THOMPSON SAMUEL ANTHONY [US]


Patent No.: US6139878A  Issued: 31/Oct/2000

Title: Method for preparing a diafiltered stabilized blood product

Applicant/Assignee: AVENTIS BEHRING, LLC

Application No.: 66694   Filing Date: 27/Apr/1998

Abstract:

A method using diafiltration to prepare a blood product is described. The method removes contaminating plasma proteins from whole blood or blood products. Diafiltration may be used on paraformaldehyde-fixed platelets to remove formaldehyde to undetectable levels, and to suspend the platelets into a formulation buffer suitable for subsequent treatment, such as lyophilization. The manufacturing procedure can be divided into three steps, a first diafiltration, fixation, preferably with paraformaldehyde, and a second diafiltration. In the first step, plasma proteins are removed from fresh or stored platelets or blood cells. The technique is gentle to prevent the activation and aggregation of the platelets. Fixation stabilizes the platelets to withstand freezing, lyophilization and subsequent reconstitution, and also provides a viral and bacterial reduction. The second diafiltration removes the paraformaldehyde to undetectable levels, and suspends the platelets or blood cells into a formulation buffer for subsequent lyophilization.

Priority:

Inventor: SUMMARIA LOUIS [US]; ROTH NATHAN [US]; BERHE ABERASH [US]; EVEN MARK [US]


Patent No.: US6143567A  Issued: 07/Nov/2000

Title: Reagents and a method for the lysis of erythrocytes

Applicant/Assignee: IMMUNOTECH

Application No.: 305361   Filing Date: 05/May/1999

Abstract:

The lysis of erythrocytes is accomplished by subjecting whole blood treated with an anticoagulant at a pH between 4 and 9 with a nitrogenous heterocyclic compound, most preferably pyrrolidine chloride.

Priority: FR19980006055 Applic. Date: 1998-05-07

Inventor: VAN AGTHOVEN ANDRE [FR]; JARROSSAY DAVID [FR]


Patent No.: US6146363A  Issued: 14/Nov/2000

Title: Anti-infection catheter

Applicant/Assignee:

Application No.: 299362   Filing Date: 26/Apr/1999

Abstract:

An anti-infection catheter arrangement with catheter (1), which exhibits a rigid or flexible catheter tube with the connection piece (10) furnished at a rear side end, wherein the filling and suction device (1) with several reservoirs of active agent is connectable to the connection piece (10), wherein at least one of the active agent reservoirs is filled with a substance, containing at least one antibiotic, or, respectively chemo-therapeutic agent or, respectively, an anti-viral agent, preferably aminoglycoside, preferably gentamicin (13) in an at least minimum effective concentration, wherein a further one of the reservoirs is filled with a substance containing or forming at least one essentially non-damaging material to the tissue cells and blood cells, preferably an anticoagulant, in particular heparin (12), wherein the filling and suction device (1)

is constructed such that this substance essentially can be filled into the region of the tip of the catheter tube (15) and wherein the total volume of the reservoirs corresponds at least to the filling volume of the catheter, possibly additionally to the volume of intermediate pieces, in particular of a three-way cock.

Priority: WO1996EP04618 Applic. Date: 1996-10-24

Inventor: GIEBEL MARION [DE]; BOEMKE WILLEHAD [DE]; PALM UELO [US]


Patent No.: US6150085A  Issued: 21/Nov/2000

Title: Prolonged storage of red blood cells and composition

Applicant/Assignee: THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY

Application No.: 154102   Filing Date: 16/Sep/1998

Abstract:

Novel additive solutions useful for the storage of human red blood cells (RBCs) under refrigerated conditions are disclosed. Also disclosed is a method of using the additive solutions in an appropriate volume to preserve RBCs at about 1 to 6 DEG C. for up to 10 weeks. Additive solutions and processes in accordance with the present invention allow the viable storage of human RBCs for an extended period of time in a solution which is directly infusible in humans.

Priority:

Inventor: HESS JOHN R [US]; GREENWALT TIBOR J [US]


Patent No.: US6159142A  Issued: 12/Dec/2000

Title: Stent with radioactive coating for treating blood vessels to prevent restenosis

Applicant/Assignee: INFLOW DYNAMICS, INC

Application No.: 186574   Filing Date: 05/Nov/1998

Abstract:

A non-radioactive metallic stent is coated with a biodegradable thin coating of less than about 100 microns in thickness selected to avoid provoking any foreign body reaction. The biodegradable material in the coating disintegrates over time in the presence of body fluid. The coating contains a radioactive source of, for example, a beta radiation emitter for irradiation of tissue when the stent is implanted in a blood vessel treated by angioplasty, to inhibit proliferation of smooth muscle cells in response to trauma to the wall of the blood vessel from the angioplasty, and thereby to prevent rapid tissue growth and consequent restenosis of the vessel. The stent coating incorporating the radioactive source constitutes a first layer adherent to and overlying the surface of the stent. The coating may further include a second layer atop the first layer, incorporating an anti-coagulant substance to inhibit thrombus formation on the stent. The radioactive source has an activity level of, for example, approximately one microcurie, and a half life which is shorter than the time interval required for the biodegradable coating to completely disintegrate. Thus, by the time the coating disappears, the effective level of radioactivity of the radioactive substance has dissipated to an extent which avoids any lingering systemic effect.

Priority: US1996-762739 Applic. Date: 1996-12-10

Inventor: ALT ECKHARD [DE]


Patent No.: US6159232A  Issued: 12/Dec/2000

Title: Clotting cascade initiating apparatus and methods of use and methods of closing wounds

Applicant/Assignee: CLOSYS CORPORATION

Application No.: 212080   Filing Date: 15/Dec/1998

Abstract:

Wound closure methods and apparatus are provided which utilize blood fluid by activating the clotting cascade of the blood fluid outside the body within a substantially enclosed sterile container then introducing the blood fluid to the wound site to complete clotting. Methods and apparatus for providing ways of inhibiting anticoagulants and slowing fibrin clot degradation are also disclosed. Kits for practicing the invention singularly or in combination with and/or associated with preferred procedures are also disclosed.

Priority: US19970069834P Applic. Date: 1997-12-16

Inventor: NOWAKOWSKI KAROL L [US]


Patent No.: US6161399A  Issued: 19/Dec/2000

Title: Process for manufacturing a wire reinforced monolayer fabric stent

Applicant/Assignee: IOWA-INDIA INVESTMENTS COMPANY LIMITED

Application No.: 108774   Filing Date: 02/Jul/1998

Abstract:

A stent is made of a fabric interlaced in a knitting machine. The knitting machine receives a plurality of fabric strands and at least one wire strand from spools and knits them into a tubular fabric stent having at least one reinforcing wire interwoven in the fabric. If desired, the spool carrying the wire may rotate more slowly than the yarn spools so that the wire is braided about the yarn locking the yarn together. The wire may be made of materials such as Stainless Steel, Tungsten, Titanium, NITINOL a nickel-titanium alloy, Gold or Silver.

Priority: US1997-957514 Applic. Date: 1997-10-24

Inventor: JAYARAMAN SWAMINATHAN [US]


Patent No.: US6165795A  Issued: 26/Dec/2000

Title: Methods for performing fibrinogen assays using dry chemical reagents containing ecarin and magnetic particles

Applicant/Assignee: CARDIOVASCULAR DIAGNOSTICS, INC

Application No.: 104349   Filing Date: 25/Jun/1998

Abstract:

A method of performing a fibrinogen assay is provided using an assay reagent containing ecarin to give an assay that is insensitive to the presence of heparin and insensitive to hematocrit, while being useful as a point of care assay in both a dry chemistry and wet chemistry format.

Priority:

Inventor: MIZE PATRICK D [US]; STUDABAKER WILLIAM B [US]


Patent No.: US6166187A  Issued: 26/Dec/2000

Title: Method of concentrating prion proteins in blood samples

Applicant/Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Application No.: 264148   Filing Date: 05/Mar/1999

Abstract:

A sample is prepared from blood in a manner which makes it possible to further analyze proteins in the sample, e.g. to detect prions in the sample. Blood is extracted, allowed to clot and subjected to separation processing (e.g. centrifugation) to obtain serum. The serum is treated with a complexing agent which agent binds prions in the sample forming an agent/protein complex which makes it possible to concentrate the complex. Concentration of the complex results in a sample which can be successfully analyzed, e.g. assayed using a range of different types of assay methodologies for detecting prions.

Priority:

Inventor: PRUSINER STANLEY B [US]; SAFAR JIRI G [US]


Patent No.: US6168922B1  Issued: 02/Jan/2001

Title: Methods and devices for collecting and storing clinical samples for genetic analysis

Applicant/Assignee: SCHLEICHER & SCHUELL, INC

Application No.: 09/255151   Filing Date: 22/Feb/1999

Abstract:

The present invention relates to devices and methods for the collection, storage, and purification of nucleic acids, such as DNA or RNA, from fluid samples for subsequent genetic characterization, primarily by conventional amplification methods. The present invention can be used to collect, store, or purify nucleic acids either from a biological source other than untreated whole blood, the biological source having naturally occurring nucleic acid amplification inhibitors present, (including either a buccal swab, cerebrospinal fluid, feces, lymphatic fluid, a plasma sample, a saliva sample, a serum sample, urine, or a suspension of cells or viruses), or from a treated whole blood source that has naturally occurring nucleic acid amplification inhibitors present, as well as added blood stabilization components that also inhibit nucleic acid amplification. More importantly, these nucleic acids can be released after collection or storage in a manner that enables them to be amplified by conventional techniques such as polymerase chain reaction. In particular, an absorbent material that does not bind nucleic acids irreversibly is impregnated with a chaotropic salt. A biological source sample is contacted with the impregnated absorbent material. Any nucleic acids present in the biological source can be either eluted or resolubilized off the absorbent material.

Priority: US1997-835614 Applic. Date: 1997-04-09

Inventor: HARVEY MICHAEL A [US]; KREMER RICHARD D [US]; BURGHOFF ROBERT L [US]; KING THOMAS H [US]


Patent No.: US6190358B1  Issued: 20/Feb/2001

Title: Reinforced rapid exchange balloon catheter

Applicant/Assignee: MEDTRONIC AVE, INC

Application No.: 08/859654   Filing Date: 20/May/1997

Abstract:

The invention is a dilation catheter which comprises an elongated catheter shaft, a guide wire tube, and an angioplasty balloon. The distal end of the balloon is attached to the distal portion of the guide wire tube, and the proximal portion of the balloon is attached to the distal portion of the catheter shaft. A stiffening wire is attached to the inner wall of the catheter shaft at a plurality of points along its length. The distal extremity of the guide wire tube is decreased in size relative to the proximal portion of the guide wire tube. A fluid is contained within the guide wire lumen.

Priority: WO1995US02783 Applic. Date: 1995-02-24

Inventor: FITZMAURICE THOMAS K [IE]; GILSON PAUL [IE]; DUANE PATRICK J E [IE]


Patent No.: US6190368B1  Issued: 20/Feb/2001

Title: Apparatus and method for collecting blood from an umbilical cord

Applicant/Assignee: CHILDREN'S HOSPITAL MEDICAL CENTER OF NORTHERN CALIFORNIA

Application No.: 09/310895   Filing Date: 12/May/1999

Abstract:

An apparatus and method for collecting a large volume of blood from an umbilical cord in a sterile environment are shown and described. A housing having an inner region adapted to retain an umbilical cord in a desired location is provided, the housing having an opening through which the cord extends from the inner region of the housing to a region external to the housing. The cord is cut by a blade coupled to the housing, either by the motion of the blade from a first position to a second position, or by the movement of two portions of the housing from a first extended position to a second collapsed position. The newly cut end of the umbilical cord falls and hangs freely in the inner region of the housing, blood flowing from the placenta and umbilical cord via gravity into a blood collection region of the housing. The blood collection region may be flexible, and may be coupled to a conventional blood collection bag.

Priority: US1997-856252 Applic. Date: 1997-05-14; US1996-742438 Applic. Date: 1996-10-30; US19960017402P Applic. Date: 1996-05-14

Inventor: KUYPERS FRANCISCUS A [US]; COLE ROBERT B [US]; MEYST RICHARD P [US]; GORTON LANNY A [US]; WRIGHT JAMES I [US]


Patent No.: US6194138B1  Issued: 27/Feb/2001

Title: Method for flushing blood cells using gelatin

Applicant/Assignee:

Application No.: 09/134581   Filing Date: 14/Aug/1998

Abstract:

An aqueous solution of gelatin used as a flushing liquid for blood cells, in particular erythrocytes, in order to give no changes in the blood cells or at most slight, quality-impairing changes.

Priority: DE19971035460 Applic. Date: 1997-08-16

Inventor: ZANDER ROLF [DE]


Patent No.: US6197202B1  Issued: 06/Mar/2001

Title: Systems and methods for estimating platelet counts using a spleen mobilization function

Applicant/Assignee: BAXTER INTERNATIONAL INC

Application No.: 09/027638   Filing Date: 23/Feb/1998

Abstract:

Systems and methods separate platelets from a selected donor. The systems and methods convey anticoagulated blood containing plasma and platelets from the selected donor into the separation device for separating into a plasma yield and a platelet yield. The systems and methods estimate, at least in part while separation occurs, a count of platelets (PltCirc) available for collection from the selected donor by measuring the selected donor's platelet precount (Pltpre), estimating a dilution factor caused by addition of anticoagulant (Dilution), and estimating a depletion factor (Depletion) caused by removal of available platelets during blood processing. In estimating Depletion, the systems and methods take into account a splenic mobilization function (Spleen), which is derived from a population of donors and not specific to the selected donor, where Spleen comprises a function of PltPRE.

Priority: US1995-480601 Applic. Date: 1995-06-07

Inventor: BROWN RICHARD I [US]


Patent No.: US6197598B1  Issued: 06/Mar/2001

Title: Devices and methods for separating cellular components of blood from liquid portion of blood

Applicant/Assignee: BECKMAN COULTER, INC

Application No.: 08/914502   Filing Date: 19/Aug/1997

Abstract:

A device for the separation of the liquid portion of blood from the cellular components of blood comprises: (1) a pad of porous material permeable to the liquid portion of blood but capable of trapping the cellular components of blood

(2) a substrate supporting the pad

and (3) means, attached to the pad, for facilitating the flow of the liquid portion of the blood: (i) through interstices around the trapped cellular components of the blood and (ii) from the pad of porous material. The separation of the liquid portion of blood from the cellular components of the blood occurs by flow through the pad of porous material without significant hemolysis. The device can be incorporated into a device for the performance of specific binding assays such as immunoassays. The pad of porous material can contain an agglutinating agent such as a lectin or an anti-blood cell antibody, or a carbohydrate such as mannitol. Other devices and methods for the separation of the liquid portion of blood from the cellular components of the blood are also disclosed.

Priority: US1995-437850 Applic. Date: 1995-05-09

Inventor: SCHRIER WAYNE H [US]; JASEPH COREY L [US]; SCHOENGOLD RONALD J [US]; RUGGERI FRANCO [IT]


Patent No.: US6200287B1  Issued: 13/Mar/2001

Title: Extracorporeal blood processing methods and apparatus

Applicant/Assignee: GAMBRO, INC

Application No.: 08/924519   Filing Date: 05/Sep/1997

Abstract:

Improved extracorporeal blood processing methods and apparatus are disclosed. In one aspect of the invention, an extracorporeal method for the collection of platelets and red blood cells, and if desired plasma, is provided, wherein the collection of platelets and red blood cells may occur in differing time periods utilizing the same blood processing vessel. The flow of blood to the blood processing vessel and return of uncollected blood components may be provided via a single needle, wherein blood is removed and returned to a donor/patient during alternating blood removal and blood return submodes. Prior to red blood cell collection, a set-up phase may be carried out during which a predetermined hematocrit and AC ratio is established.

Priority:

Inventor: KELLER MURIEL [US]; BAINBRIDGE MARLENE [US]


Patent No.: US6200599B1  Issued: 13/Mar/2001

Title: Ortho ester lipids

Applicant/Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Application No.: 09/415016   Filing Date: 07/Oct/1999

Abstract:

The present invention provides ortho ester lipids and their derivatives that, upon certain pH conditions, undergo hydrolysis with concomitant or subsequent headgroup cleavage. These ortho ester lipids can advantageously be formulated into liposomes. The liposome formulations are useful in nucleic acid transfection and entrapment/delivery of conventional small molecules and therapeutic agents. Moreover, the liposomes comprising compounds of the present invention are useful as drug delivery vehicles.

Priority:

Inventor: NANTZ MICHAEL H [US]; ZHU JI [US]


Patent No.: US6203536B1  Issued: 20/Mar/2001

Title: Medical device for delivering a therapeutic substance and method therefor

Applicant/Assignee: MEDTRONIC, INC

Application No.: 08/877532   Filing Date: 17/Jun/1997

Abstract:

A device useful for localized delivery of a therapeutic material is provided. The device includes a structure including a porous material

and a water-insoluble salt of a therapeutic material dispersed in the porous material. The water-insoluble salt is formed by contacting an aqueous solution of a therapeutic salt with a heavy metal water-soluble salt dispersed throughout a substantial portion of the porous material. The heavy metal water-soluble salt can be dispersed in the porous material so that the device can be sterilized and the therapeutic material can be loaded in the device in situ, for example, just prior to use. The therapeutic material is preferably a heparin or heparin derivative or analog which renders the material antithrombotic as an implantable or invasive device.

Priority:

Inventor: BERG ERIC P [US]; DINH THOMAS Q [US]


Patent No.: US6204056B1  Issued: 20/Mar/2001

Title: Micropathological patient replica based on unadulterated whole blood

Applicant/Assignee:

Application No.: 09/390859   Filing Date: 03/Sep/1999

Abstract:

A patient replica is created from layered culture medium where solid culture medium is formed so that a discontinuity exists, for example, between layers of culture medium or between culture medium and the container holding the medium. An injection port is provided in registration with the discontinuity so that a sample of patient blood can be infused into the discontinuity to form a thin layer of blood in contact with a surface of culture medium. The thin layer of blood obviates the requirement for any anticoagulant allowing blood-borne pathogens to be readily cultured without using broth. Further antibiotics or other drug samples may be placed on an exposed surface of the culture medium above the blood layer so that the antibiotic can diffuse through the culture medium and reveal the sensitivities of the cultured pathogens. Other samples of pathogens or tissues can be placed on the surface of the culture medium so that effects of drugs or growth factors present in the patient blood can be observed thereby allowing the entrapped blood layer and culture medium, held to natural patient conditions, to act as a biological replica of the patient.

Priority: US1998-045291 Applic. Date: 1998-03-20; US1997-826429 Applic. Date: 1997-03-20

Inventor: BARNES ALLEN C [US]; BARNES JANICE S [US]


Patent No.: US6206914B1  Issued: 27/Mar/2001

Title: Implantable system with drug-eluting cells for on-demand local drug delivery

Applicant/Assignee: MEDTRONIC, INC

Application No.: 09/144420   Filing Date: 31/Aug/1998

Abstract:

An implantable system that includes a carrier and eukaryotic cells, which produce and release a therapeutic agent, and a stimulating element for stimulating the release of the therapeutic agent. The system can also include a sensing element for monitoring a physiological condition and triggering the stimulating element to stimulate the delivery device to release the therapeutic agent. Alternatively, the patient in which the system is implanted can activate the stimulating element to release the therapeutic agent.

Priority: US1998-070480 Applic. Date: 1998-04-30

Inventor: SOYKAN ORHAN [US]; DONOVAN MAURA G [US]


Patent No.: US6210340B1  Issued: 03/Apr/2001

Title: Blood pulse measuring device, pulsation measuring device, and pressure measuring device

Applicant/Assignee: SEIKO EPSON CORPORATION

Application No.: 09/117677   Filing Date: 20/Apr/1999

Abstract:

A pulse wave measuring device is provided with a plurality of pulse wave measuring units. Each pulse wave measuring unit has a supporting member to which a beam of a pressure measuring device is attached. Contact portions at the distal end of the beam is in contact with the patient's arm, so that piezoelectric elements mounted on the beam measures the stress variation according to pulsation of the patient's radial artery. The supporting member has two pressing legs between which the contact portions of the beam are situated. The distal ends of the pressing legs are also pressed against the patient's arm. The pressing legs are harder than the radial artery. The interval between the pressing legs can be altered by handling a micrometer head. The contact portions are situated back from the distal ends of the pressing legs.

Priority: JP19970090237 Applic. Date: 1997-03-25; JP19970126316 Applic. Date: 1997-04-30; JP19970301331 Applic. Date: 1997-10-31; WO1998JP01276 Applic. Date: 1998-03-24

Inventor: AMANO KAZUHIKO [JP]; HIGUCHI KOJI [JP]; TAKAHASHI OSAMU [JP]; FUNASAKA TSUKASA [JP]; MIYAZAKI HAJIME [JP]; YOSHINO MASAHITO [JP]


Patent No.: US6210976B1  Issued: 03/Apr/2001

Title: Methods for early detection of heart disease

Applicant/Assignee: MEDLYTE DIAGNOSTICS, INC

Application No.: 09/084069   Filing Date: 22/May/1998

Abstract:

The invention relates to methods, compositions, kits, and devices for detecting cardiac ischemia, hypoxia, or other causes of heart failure in a mammal by obtaining a test sample from a mammal, measuring a level of a non-polypeptidic cardiac marker in the test sample, and determining if the level of the cardiac marker measured in said test sample correlates with cardiac ischemia or hypoxia or another form of heart failure.

Priority: US19970049274P Applic. Date: 1997-06-10

Inventor: SABBADINI ROGER A [US]


Patent No.: US6221672B1  Issued: 24/Apr/2001

Title: Method for determining platelet inhibitor response

Applicant/Assignee: MEDTRONIC, INC

Application No.: 09/225051   Filing Date: 04/Jan/1999

Abstract:

A method of determining a dose response for a platelet inhibitor. The method includes the steps of placing a predetermined amount of heparin in each cell of a multicell test cartridge, placing an optimized amount of a clotting activator in each cell, and placing a measured amount of platelet inhibitor in each cell, the amount of inhibitor in each cell differing from the amount in each other cell. An aliquot of a blood sample is added to each cell, and the blood sample aliquot, clotting reagent and platelet inhibitor are mixed. Each cell sample is allowed to clot, and the clotting time for each cell is measured. The relative clotting times are used to calculate and determine the platelet inhibition effect of the platelet inhibitor.

Priority: US1996-640277 Applic. Date: 1996-04-30

Inventor: BAUGH ROBERT F [US]; LANE CAROLE G [US]; WILSON ADRIAN C [US]


Patent No.: US6221898B1  Issued: 24/Apr/2001

Title: Amidino derivatives and their use as thrombin inhibitors

Applicant/Assignee: ASTRA AKTIEBOLAG

Application No.: 08/894833   Filing Date: 29/Aug/1997

Abstract:

There is provided compounds of formula I,wherein R1, R2, R3, Y, n and B have meanings given in the description which are useful as competitive inhibitors of trypsin-like proteases, such as thrombin, and in particular in the treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulants.

Priority: SE19960002646 Applic. Date: 1996-07-04; WO1997SE01150 Applic. Date: 1997-06-26

Inventor: ANTONSSON THOMAS [SE]


Patent No.: US6225309B1  Issued: 01/May/2001

Title: Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents

Applicant/Assignee: ZENECA LIMITED

Application No.: 09/369857   Filing Date: 09/Aug/1999

Abstract:

The invention concernscompounds of formula (I), wherein each of G1, G2 and G3 is CH or N

m is 1 or 2

R1 includes hydrogen, halogeno and 1-C)alkyl

M1 is a group of formula: NR2-L1-T1R3, in which R2 and R3 together form a (1-4C)alylene group, L1 includes (1-4C)alkylene, and T1 is CH or N

A may be a direct link

M2 is a group of the formula: (T2R4)rL2-T3R5 in which R is 0 or 1, each of T2 and T3 is CH or N, each of R4 and R5 is hydrogen or (1-4C)alkyl, or R4 and R5 together form a (1-4C)alkylene group, and L2 includes (1-4C)alkylene

M3 may be a direct link to X

X includes sulphonyl

and Q includes naphthyl and a heterocyclic moiety

or a pharmaceutically-acceptable salt thereof

processes for their preparation, pharmaceutical compositions containing them and their use as antithrombotic or anticoagulant agents.

Priority: GB19940019341 Applic. Date: 1994-09-26; GB19940025789 Applic. Date: 1994-12-21; GB19950011051 Applic. Date: 1995-06-01

Inventor: FAULL ALAN WELLINGTON [GB]; STOCKER ANDREW [GB]; MAYO COLETTE MARIE [GB]; PRESTON JOHN [GB]


Patent No.: US6232127B1  Issued: 15/May/2001

Title: Platelet function evaluation technique for citrated whole blood

Applicant/Assignee: MEDTRONIC, INC

Application No.: 09/330545   Filing Date: 11/Jun/1999

Abstract:

An improved apparatus and method for evaluating platelet functionality of a blood sample. The apparatus includes a plurality of test cells. Each of the cells includes a platelet function restoration agent, an anticoagulant agent, and a clotting reagent. At least one of the cells also includes a platelet activating agent. The clotting time is determined for each of the aliquot portions, and the relative clotting times of the aliquot portions in the cells are determinative of the platelet functionality of the sample. The method includes the steps of combining a platelet function restoration agent, an anticoagulant agent, a platelet activating agent, and the sample of blood to be tested to form a test mixture. The platelets of the sample are activated by adding a clotting reagent to the test mixture at the start of the activated clotting time test, and the activated clotting time test is terminated upon detecting a predetermined change in a property of the test mixture. The activated clotting time of the sample of blood is calculated based on the elapsed time.

Priority: US1997-846318 Applic. Date: 1997-04-30

Inventor: LANE CAROLE G [US]; WILSON ADRIAN C [US]; BAUGH ROBERT F [US]


Patent No.: US6233525B1  Issued: 15/May/2001

Title: Blood component collection system with optimizer

Applicant/Assignee: GAMBRO, INC

Application No.: 09/361098   Filing Date: 26/Jul/1999

Abstract:

A blood component collection system is disclosed with optimization capabilities. In one embodiment, process parameters are derived from an input/configured predetermined blood component yield and which is based upon the maximization of at least one process parameters. Thereafter, the blood component collection procedure is performed with these derived process control parameters. In another embodiment, process parameters are derived from an input total procedure time from a maximized value for at least one of the other process control parameters so as to maximize blood component yield in this fixed time. Thereafter, the blood component collection procedure is performed with these derived parameters.

Priority: US1995-439649 Applic. Date: 1995-05-12; US1993-140254 Applic. Date: 1993-10-21; US1992-912973 Applic. Date: 1992-07-10; US1992-845677 Applic. Date: 1992-03-04; US1993-110432 Applic. Date: 1993-08-23; US1997-928329 Applic. Date: 1997-09-12

Inventor: LANGLEY ROBERT W [US]; KELLER JOHN J [US]; URDAHL STEVEN GAGE [US]


Patent No.: US6234951B1  Issued: 22/May/2001

Title: Intravascular radiation delivery system

Applicant/Assignee: SCIMED LIFE SYSTEMS, INC

Application No.: 08/782471   Filing Date: 10/Jan/1997

Abstract:

An intravascular radiation delivery system including a catheter, a radiation source disposed in an open-ended lumen in the catheter and a closed-ended sheath surrounding the radiation source so as to prevent blood and other fluids from coming into contact with the radiation source. Preferably, the open-ended lumen is centered in the balloon for uniform radiation delivery. The catheter may include a blood perfusion lumen under the balloon or around the balloon. The open-ended lumen in the catheter may have a reduced diameter adjacent the distal end of the catheter to prevent the radiation source from exiting the lumen. Methods of using the radiation delivery system are also disclosed.An alternative method of delivering radiation to a treatment site inside the vasculature of a patient using a gas-filled balloon catheter and a radiation source disposed in the balloon catheter. The treatment site is exposed to radiation, preferably beta radiation, through the gas-filled balloon.

Priority: US1996-608655 Applic. Date: 1996-02-29

Inventor: HASTINGS ROGER N [US]; HEKTNER THOMAS R [US]; KUME STEWART M [US]


Patent No.: US6235778B1  Issued: 22/May/2001

Title: Aminoguanidines and alkoxyguanidines as protease inhibitors

Applicant/Assignee: 3-DIMENSIONAL PHARMACEUTICALS, INC

Application No.: 08/979234   Filing Date: 26/Nov/1997

Abstract:

Aminoguanidine and alkoxyguanidine compounds, including compounds of the formula:wherein X is O or NR9 and R114 R4, R6-R9, R11, R12, Ra, Rb, Rc, Y, Z, n and mare set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit proteolytic enzymes such as thrombin are described. Also described are methods for preparing the compounds of Formula I. The novel compounds of the present invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, thrombin, plasmin and factor Xa. Certain of the compounds exhibit antithrombotic activity via direct, selective inhibition of thrombin, or are intermediates useful for forming compounds having antithrombotic activity. The invention includes a composition for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation in a mammal, comprising a compound of the invention in a pharmaceutically acceptable carrier. Other uses of compounds of the invention are as anticoagulants either embedded in or physically linked to materials used in the manufacture of devices used in blood collection, blood circulation, and blood storage, such as catheters, blood dialysis machines, blood collection syringes and tubes, blood lines and stents.

Priority: US19960031822P Applic. Date: 1996-11-26

Inventor: TOMCZUK BRUCE E [US]; SOLL RICHARD M [US]; LU TIANBAO [US]; FEDDE CYNTHIA L [US]; ILLIG CARL R [US]; MARKOTAN THOMAS P [US]; STAGNARO THOMAS P [US]


Patent No.: US6245244B1  Issued: 12/Jun/2001

Title: Method and kit for separating plasma from whole blood

Applicant/Assignee: MICRO DIAGNOSTIC INNOVATIONS NEDERLAND B.V

Application No.: 09/117790   Filing Date: 01/Sep/1998

Abstract:

A method and kit for separating plasma from small quantities of whole blood. A mixture of less than 100 mul of whole blood, a blood anticoagulant and a diluent, is formed in a container provided with a sealing cap. The mixture is forced through a filter containing glass fibers by applying sub-atmospheric pressure to a side of the filter opposite the mixture. The method can be performed in a hypodermic syringe, or in a capillary.

Priority: NL19961002296 Applic. Date: 1996-02-09; WO1997NL00046 Applic. Date: 1997-02-10

Inventor: DE ROOIJ FELIX WILHELMUS MARIE [NL]


Patent No.: US6245573B1  Issued: 12/Jun/2001

Title: Rapid assessment of the coagulant activity of blood

Applicant/Assignee: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY

Application No.: 09/022449   Filing Date: 12/Feb/1998

Abstract:

This invention relates to diagnostic methods and test kits for rapidly assessing the coagulant activity of blood by measuring the rate of blood clotting in the presence of certain metal ions. A modulator of coagulation may also be included. The coagulation activity of the blood of the patient in the presence of metal ions and an optional modulator is an indication of the presence or development of certain pathological conditions relating to the procoagulant activity of blood, including platelet function. The effect of metal ions on the viscosity of blood is also diagnostically useful.

Priority:

Inventor: SPILLERT CHARLES R [US]


Patent No.: US6248592B1  Issued: 19/Jun/2001

Title: Method for measuring lead concentrations in blood

Applicant/Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Application No.: 08/412235   Filing Date: 27/Mar/1995

Abstract:

Method for measuring lead concentrations in blood. The present invention includes the use of resonant laser ablation to analyze <=1 muL (or equivalent mass) samples of blood for lead content. A typical finger prick, for example, yields about 10 muL. Solid samples may also readily be analyzed by resonant laser ablation. The sample is placed on a lead-free, electrically conducting substrate and irradiated with a single, focused laser beam which simultaneously vaporizes, atomizes, and resonantly ionizes an analyte of interest in a sample. The ions are then sorted, collected and detected using a mass spectrometer.

Priority:

Inventor: NOGAR NICHOLAS S [US]


Patent No.: US6251284B1  Issued: 26/Jun/2001

Title: Systems and methods which obtain a uniform targeted volume of concentrated red blood cells in diverse donor populations

Applicant/Assignee: BAXTER INTERNATIONAL INC

Application No.: 08/979160   Filing Date: 26/Nov/1997

Abstract:

Blood separation systems and methods draw whole blood from a blood donor selected from a population of blood donors. The whole blood of the selected blood donor has a known hematocrit value that varies within the population of blood donors according to morphology of the selected blood donor. The systems and methods operate a pump in the inlet line to convey a volume of whole blood from the donor at a commanded flow rate for processing into plasma constituent and concentrated red blood cells. The systems and methods set the commanded flow rate to vary the volume of whole blood conveyed over time as a function of the known hematocrit value of the selected donor. The systems and methods obtain, after processing the whole blood volume, a targeted volume of concentrated red blood cells, which is substantially constant for the population of blood donors despite variances in known hematocrit values among the donors.

Priority: US1995-512807 Applic. Date: 1995-08-09

Inventor: BISCHOF DANIEL F [US]; LIKENS MATTHEW E [US]; GOLDHABER RICHARD P [US]


Patent No.: US6258577B1  Issued: 10/Jul/2001

Title: Method and apparatus for inactivation of biological contaminants using endogenous alloxazine or isoalloxazine photosensitizers

Applicant/Assignee: GAMBRO, INC

Application No.: 09/119666   Filing Date: 21/Jul/1998

Abstract:

Methods and apparatuses are provided for inactivation of microorganisms in a fluid containing blood or blood products and comprising biologically active proteins. The method includes the steps of adding an effective, non-toxic amount of an endogenous photosensitizer to the fluid

exposing the fluid to photoradiation sufficient to activate the endogenous photosensitizer

and allowing the activated endogenous photosensitizer to interfere with nucleic acid present in microorganisms in the fluid so that the microorganisms are inactivated. Isoalloxazines and K- and L-vitamins are among the preferred photosensitizers. Systems and apparatuses are also provided for decontamination of such fluids using photosensitizers which include means for adding photosensitizer to the fluid

a photopermeable container for exposing the fluid to an amount of photoradiation sufficient to activate the photosensitizer

and a photoradiation source, preferably comprising a light guide, for providing sufficient photoradiation of a type and amount selected to activate the photosensitizer. Means for controlling photosensitizer concentration in the fluid and rate of fluid flow through the container, including computer processors may be included in such systems.

Priority:

Inventor: GOODRICH JR RAYMOND PAUL [US]; CORBIN III FRANK [US]; WOOD JR EDWARD C [US]


Patent No.: US6258797B1  Issued: 10/Jul/2001

Title: Combating infection in delivery systems

Applicant/Assignee: ED. GEISTLICH SOEHNE AG FUER CHEMISCHE INDUSTRIE

Application No.: 09/331366   Filing Date: 21/Jun/1999

Abstract:

The use of taurolidine or taurultam in a method of combatting infection or sepsis in delivery systems is disclosed. In the method, taurolidine or taurultam solutions are used as a temporary seal or flush to prevent or reduce sepsis in delivery systems, such as port systems and/or catheters by which liquids are delivered into a patient.

Priority: GB19960026795 Applic. Date: 1996-12-23; WO1997GB03524 Applic. Date: 1997-12-23

Inventor: LEHNER JOACHIM HERMANN [DE]


Patent No.: US6261792B1  Issued: 17/Jul/2001

Title: Lipid-dependent diagnostic assays

Applicant/Assignee: THE LIPOSOME COMPANY, INC

Application No.: 08/441567   Filing Date: 15/May/1995

Abstract:

For use in a lipid-dependent diagnostic assay, a stable aqueous suspension of a phospholipid which normally has a hexagonal (HII) organization when dispersed in an aqueous medium without detergent, the suspension containing the phospholipid, a detergent, and an aqueous phase. In the stable suspension, the phospholipid remains in suspension at a temperature of 25 DEG C. for at least one hour. The suspension is suitable for providing the phospholipid to an assay for lupus anticoagulants which includes the step of pre-incubating a test sample with the phospholipid.

Priority: US1994-201718 Applic. Date: 1994-02-25; US1991-723497 Applic. Date: 1991-06-28; US1990-623340 Applic. Date: 1990-12-07

Inventor: JANOFF ANDREW S [US]; RAUCH JOYCE [CA]; TARASCHI THEODORE F [US]


Patent No.: US6264619B1  Issued: 24/Jul/2001

Title: Kit for drawing a blood sample

Applicant/Assignee: BECTON, DICKINSON AND COMPANY

Application No.: 09/387816   Filing Date: 01/Sep/1999

Abstract:

A kit containing all the materials needed to take a blood sample from a neonatal patient, a pediatric patient, a juvenile patient or an adult patient. The materials are supplied in a plastic package suitable for sterilization.

Priority:

Inventor: FERGUSON MARGIE [US]


Patent No.: US6264969B1  Issued: 24/Jul/2001

Title: Mole control system

Applicant/Assignee: GENESIS LABORATORIES, INC

Application No.: 09/277897   Filing Date: 29/Mar/1999

Abstract:

A method is described for controlling or exterminating moles through the use of a bait composition in the form of a gel, paste, or grease. The composition includes an attractant and an active ingredient capable of killing vertebrate pests. The composition is injected into a mole tunnel through a small diameter nozzle, tube or needle to avoid digging open the tunnel or causing it to collapse.

Priority:

Inventor: POCHE RICHARD M [US]


Patent No.: US6265715B1  Issued: 24/Jul/2001

Title: Non-porous membrane for MALDI-TOFMS

Applicant/Assignee:

Application No.: 09/239547   Filing Date: 29/Jan/1999

Abstract:

The use of non-porous membranes as sample supports for MALDI-TOFMS analysis of peptides and proteins as well as for the analysis of whole blood is herein described. Non-porous membranes have a uniform surface, allowing for greater sensitivity and accuracy. Specifically, the non-porosity favours crystal growth on the surface of the membrane only, thereby providing enhanced spectral quality over membranes with porous structures. Studies were performed using polyurethane (PU) membranes as an example of non-porous MALDI sample supports and showed that PU membranes yielded higher quality spectra compared with porous membrane sample supports such as polyether and poly(vinyl difluoride) and the spectra obtained from PU membranes are of comparable quality as those obtained with metallic targets. However, the sample preparation for use with PU membranes is much less arduous compared with the preparation necessary for metallic targets. On membrane proteolytic digestions of proteins were performed using trypsin. After the completion of the digests, buffer components were washed of leaving peptides bound to the membrane. Addition of matrix followed by MALDI analysis resulted in good quality mass spectra which enabled peptide mapping.

Priority: US19980073364P Applic. Date: 1998-02-02

Inventor: PERREAULT HELENE [CA]; CHOW ART [CA]; ENS WERNER [CA]; DUCKWORTH HARRY [CA]; DONALD LYNDA [CA]; OLESCHUK RICHARD [CA]; MANLEY DARREN [CA]; MCCOMB MARK [CA]; STANDING KENNETH [CA]; O'NEIL JOE [CA]


Patent No.: US6274158B1  Issued: 14/Aug/2001

Title: Treatment with recombinant human erythropoietin of bleeding in patients with normal and abnormal hemostasis

Applicant/Assignee:

Application No.: 09/335076   Filing Date: 17/Jun/1999

Abstract:

Recombinant human Erythropoietin is used in a method as a hemostatic agent for the treatment or prevention of bleeding from any organ or body part involved with benign or malignant lesions, surgical traumatic, non-healing/difficult to treat lesions, or radiation injury. The method can control or prevent the bleeding in patients with congenital or acquired disorders of coagulation, platelets, or blood vessels, patients on therapeutic or overdose of anticoagulants or antiplatelet drugs. The method consists of the subcutaneous, intravenous or oral administration of recombinant human Erythropoietin for the purpose of preventing or stopping bleeding.

Priority: US1998-018815 Applic. Date: 1998-02-04; US19980091598P Applic. Date: 1998-07-02; US19990125253P Applic. Date: 1999-03-19

Inventor: ZAHARIA CZEIZLER VERONICA L [US]


Patent No.: US6277556B1  Issued: 21/Aug/2001

Title: Controlling donor blood characteristics

Applicant/Assignee: BAXTER INTERNATIONAL INC

Application No.: 09/213214   Filing Date: 17/Dec/1998

Abstract:

A new citrate-based anticoagulant for donor whole blood provides good platelet yield and cell morphology at a significantly reduced risk of donor paresthesia during apheresis procedures. The primary citrate anticoagulant compositions include a citric acid to total citrate ratio greater than about 30%. The anticoagulants are mixed with whole blood to provide an anticoagulated blood mixture which contains a citric acid concentration of greater than about 5.0 mM, a total citrate concentration of less than about 20 mM, and an initial blood pH of less than about 6.75. The platelet rich products including PRP and PC prepared from blood collected in accordance with the invention exhibit better platelet yields and better platelet morphology on storage.

Priority: US1997-970249 Applic. Date: 1997-11-13; US1996-706381 Applic. Date: 1996-08-30; US1994-357812 Applic. Date: 1994-12-16

Inventor: GRODE GERALD A [US]; STEWART MARY A [US]


Patent No.: US6277557B1  Issued: 21/Aug/2001

Title: Infusible grade short-term cell storage medium

Applicant/Assignee: REGENTS OF THE UNIVERSITY OF MINNESOTA

Application No.: 09/376810   Filing Date: 18/Aug/1999

Abstract:

An infusible-grade storage medium that is capable of preserving the viability and function of stem cells, nucleated cells and other hematopoietic cells is provided.

Priority: US1997-955849 Applic. Date: 1997-10-21

Inventor: BURGER SCOTT ROBERT [US]; HUBEL ALLISON [US]; MCCULLOUGH JOHN JEFFREY [US]


Patent No.: US6291427B1  Issued: 18/Sep/2001

Title: Anticoagulant combination of LACI and sulfated polysaccharides

Applicant/Assignee: G.D. SEARLE & CO

Application No.: 08/453937   Filing Date: 30/May/1995

Abstract:

There is disclosed herein a combination of lipoprotein-associated coagulation inhibition (LACI) and sulfated polysaccharides, e.g. heparin, which exerts a synergistic anticoagulant action in whole plasma.

Priority: US1993-166186 Applic. Date: 1993-12-13; US1990-573083 Applic. Date: 1990-08-27

Inventor: WUN TZE-CHEIN [US]


Patent No.: US6299589B1  Issued: 09/Oct/2001

Title: Flow-through treatment method

Applicant/Assignee: DSU MEDICAL CORPORATION

Application No.: 09/038375   Filing Date: 11/Mar/1998

Abstract:

A flow-through blood treatment device such as a hemodialyzer comprises a housing, a blood inlet, a blood outlet, and at least one membrane in the housing defining a blood flow path between the blood inlet and outlet on one side of the membrane, plus a second flow path defined on the other side of the membrane. At least one of the blood inlet and outlet is connected to blood flow tubing, which blood flow tubing carries a connector spaced from the housing for access to the vascular system of a patient. The blood flow tubing also defines at least one connection site along its length permitting repeated, temporary connection and subsequent disconnection with branch conduits, for connection with sources of additive solutions or measuring devices. Typically, the blood flow tubing is free of permanently attached, flexible branch tubings a method of use in disclose.

Priority: US1996-771246 Applic. Date: 1996-12-20; US1995-373598 Applic. Date: 1995-01-17

Inventor: UTTERBERG DAVID S [US]


Patent No.: US6300135B1  Issued: 09/Oct/2001

Title: Blood component deposition-preventing agent, methods using them, and blood test ware and matrixes

Applicant/Assignee: SEKISUI KAGAKU KOGYO KABUSHIKI KAISHA

Application No.: 09/204065   Filing Date: 03/Dec/1998

Abstract:

This invention has for its object to provide a blood component deposition-preventing agent and a blood coagulation accelerator, which are substantially indifferent to blood coagulation activity and serum chemistry parameters and a plastic blood test ware and a blood test matrix which do not confound measured values. The invention relates to a blood component deposition-preventing agent comprising a random copolymer of a monomer component (a) giving a water-soluble homopolymer and a monomer component (b) giving a water-insoluble homopolymer, a blood coagulation accelerator comprising a substantially blood-insoluble antimicrobial composition comprising a carrier and, as supported thereon, an antimicrobial metal, and a blood test ware or matrix carrying them on its inside wall or surface.

Priority: JP19940223093 Applic. Date: 1994-09-19

Inventor: ISOGAWA HIRONOBU [JP]; ANRAKU HIDEO [JP]


Patent No.: US6306166B1  Issued: 23/Oct/2001

Title: Loading and release of water-insoluble drugs

Applicant/Assignee: SCIMED LIFE SYSTEMS, INC

Application No.: 09/172026   Filing Date: 14/Oct/1998

Abstract:

A medical device, polymer composition, and method for delivering substantially water-insoluble drugs to tissue at desired locations within the body. At least a portion of the exterior surface of the medical device is provided with a polymer coating. Incorporated in the polymer coating is a solution of at least one substantially water-insoluble drug in a volatile organic solvent. The medical device is positioned to a desired target location within the body, whereupon the drug diffuses out of the polymer coating.

Priority: US1998-133603 Applic. Date: 1998-08-13; US1997-910136 Applic. Date: 1997-08-13

Inventor: BARRY JAMES J [US]; PALASIS MARIA [US]


Patent No.: US6331610B1  Issued: 18/Dec/2001

Title: Method for treating AIDS and HIV infection using select peptides from the beta subunit of human chorionic gonadotropin

Applicant/Assignee: METATRON, INC

Application No.: 08/908371   Filing Date: 07/Aug/1997

Abstract:

The present invention relates to select peptides of the carboxy terminal and aminoterminal portion of the beta unit of hCG and pharmaceutically acceptable derivatives thereof that can be used for controlling retroviral, e.g., human immunodeficiency virus (BV infections. The invention comprises a method in vitro as well as in vivo for prevention and/or treatment of acquired immune deficiency syndrome (AIDS) at pharmacological doses of beta hCG-derived peptides and pharmaceutically acceptable derivatives thereof which are sufficient to exert an anti-HIV effect for a sufficient period of time.

Priority: US19970044937P Applic. Date: 1997-04-25

Inventor: BOURINBAIAR ALDAR S [US]


Patent No.: US6336910B1  Issued: 08/Jan/2002

Title: Extracorporeal circulation apparatus for selective cooling method

Applicant/Assignee: TOMIO OHTA

Application No.: 09/187986   Filing Date: 09/Nov/1998

Abstract:

An extracorporeal circulation apparatus capable of maintaining hypothermia for a prolonged period when used in the selective cooling method.The extracorporeal circulation apparatus used in the selective cooling method includes (1) a diluent supply unit for cooling a diluent and metering the diluent into a blood vessel

(2) a blood concentration unit for metering a diluted blood out from a blood vessel and concentrating the diluted blood thus drawn out by filtering the diluted blood

and (3) a blood supply unit for heating the concentrated blood and metering the concentrated blood into a blood vessel, wherein a flow rate of the injected diluent flow rate, Vd and a flow rate of a filtrate, Vb are so controlled that a relationship 0.1 Vd<=Vb<=Vd is maintained.

Priority: JP19960106849 Applic. Date: 1996-04-26

Inventor: OHTA TOMIO [JP]; KOBAYASHI TAKUICHI [JP]


Patent No.: US6340354B1  Issued: 22/Jan/2002

Title: Automated compulsory blood extraction system

Applicant/Assignee:

Application No.: 08/858097   Filing Date: 17/May/1997

Abstract:

A method and apparatus for the treatment of thrombosis, venous insufficiency, and the like, and in particular to an Automated Compulsory Blood Extraction System (ACBES) configured to provide an efficient and safe means for the measured extraction of blood utilizing a device providing, in effect, an artificial leech, but without the infection, control, care, and other limitations associated with the medicinal leech. The preferred embodiment of the present invention utilizes recent micro technological advances to provide a micro mechanical device which mimics and improves upon the bloodletting properties of the medicinal leech utilizing a micro mechanical valve, micropump, and micro sensor arraignment cooperating with a tertiary jaw array having teeth situated thereon. The preferred embodiment of the present invention contemplates an extraction device which may have a head size of one centimeter or less, and which may be utilized in number about the affected area of the patient to provide controlled, precision, pulsed blood extraction via vacuum induction, supplying a controlled dosage of anticoagulant, histamine anesthetic, or the like. Alternative embodiments of the present invention include an independent, single needle, stationary design configured primarily for emergency use, a multi-needle piston design, a large extraction area array design including concentric needles of adjustable depth, and a deep extraction needle design.

Priority: US19960017633P Applic. Date: 1996-05-17

Inventor: RAMBIN CHRISTOPHER L [US]


Patent No.: US6340675B1  Issued: 22/Jan/2002

Title: Process for the production of an anticoagulant composition

Applicant/Assignee: SHERWOOD SERVICES AG

Application No.: 08/712249   Filing Date: 11/Sep/1996

Abstract:

A process is disclosed for the production of an anticoagulant composition which allows for the accurate analysis of blood electrolyte concentrations. Also disclosed is the anticoagulant composition produced in accordance with the disclosed method and an apparatus containing said composition useful in the selection and sampling of blood.

Priority: US1994-235622 Applic. Date: 1994-06-29; US1993-096123 Applic. Date: 1993-07-22; US1993-009627 Applic. Date: 1993-01-27

Inventor: MANCILLA EDWARD [US]; LAGWINSKA ELIZABETH M [US]


Patent No.: US6350251B1  Issued: 26/Feb/2002

Title: Biocidal locks

Applicant/Assignee: BIOLINK CORPORATION

Application No.: 09/483966   Filing Date: 18/Jan/2000

Abstract:

Disclosed herein is an internal prosthetic device comprising:(a) device for providing a continuous flowpath, crossing a patient's skin, between an external-to-patient site and an internal-to-patient site

(b) means for blocking the flowpath

and(c) a biocidal lock including:(i) an anticoagulant

and(ii) a non-antibiotic biocide.

Priority:

Inventor: PROSL FRANK R [US]; ESTABROOK BRIAN K [US]; SODEMANN KLAUS [DE]


Patent No.: US6368298B1  Issued: 09/Apr/2002

Title: Preparing autologous fibrin glue

Applicant/Assignee:

Application No.: 09/446729   Filing Date: 03/Mar/2000

Abstract:

A method of preparing a solid-fibrin web is disclosed. The method includes drawing blood from a patient, separating plasma from the blood, contacting the plasma with a calcium-coagulation activator and concurrently coagulating and centrifuging the plasma to form the solid-fibrin web. The solid-fibrin web is suitable for regenerating body tissue in a living organism.

Priority: IT1997MI01490 Applic. Date: 1997-06-24; WO1998IT00173 Applic. Date: 1998-06-24

Inventor: BERETTA ROBERTO [IT]; LODI SERGIO [IT]


Patent No.: US6375986B1  Issued: 23/Apr/2002

Title: Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate

Applicant/Assignee: ELAN PHARMA INTERNATIONAL LTD

Application No.: 09/666539   Filing Date: 21/Sep/2000

Abstract:

Disclosed are solid dose nanoparticulate compositions comprising a poorly soluble active agent, at least one polymeric surface stabilizer, and dioctyl sodium sulfosuccinate (DOSS). The solid dose compositions exhibit superior redispersibility of the nanoparticulate composition upon administration to a mammal, such as a human or animal. The invention also describes methods of making and using such compositions.

Priority:

Inventor: RYDE NIELS P [US]; RUDDY STEPHEN B [US]


Patent No.: US6379318B1  Issued: 30/Apr/2002

Title: Method for preventing blood denaturation and blood test tool to be used therein

Applicant/Assignee: ARKRAY, INC

Application No.: 09/786147   Filing Date: 11/May/2001

Abstract:

A blood test tool with which blood in a dried state can be held without denaturation. In the blood test tool wherein a card made of filter paper is impregnated with the blood and then the blood is held in a dried state, a carboxylic acid such as citric acid is added to the part for holding blood. Thus, the carboxylic acid exerts an effect of preventing the blood in the dried state from denaturation. It is preferable to add a non-reducing sugar (sucrose, etc.), an anticoagulant (EDTA, etc.) and an antioxidant (glutathione, etc.) together with the carboxylic acid. This blood test tool can be produced by impregnating a filter paper card with a solution containing citric acid, etc. dissolved therein and then air-drying.

Priority: JP19980248653 Applic. Date: 1998-09-02; JP19990203401 Applic. Date: 1999-07-16; WO1999JP04691 Applic. Date: 1999-08-30

Inventor: NISHIMURA SATOSHI [JP]; HIGASHINO KOUJI [JP]


Patent No.: US6379322B1  Issued: 30/Apr/2002

Title: Blood collection and separation system

Applicant/Assignee: TRANSFUSION TECHNOLOGIES CORPORATION

Application No.: 09/027072   Filing Date: 20/Feb/1998

Abstract:

A system for collecting and processing blood from a donor (70), wherein the system may be compact enough to be located entirely beside the donor's chair, and be able to process the blood while the donor is still resting in the chair after having donated the blood. Thus, the separated blood components (plasma and red blood cells) may be stored in their individual optimum environments immediately after the whole blood is drawn, and the blood does not need to be transported back to a separation laboratory for processing. The system includes a needle (72) (or other cannula-like device) for insertion into a vein of the donor and drawing whole blood therethrough, a variable-volume rotor (2a) for holding the blood after it is drawn, and a motor (50) for spinning the rotor so as to cause the blood to separate into components, for example, plasma and red blood cells. The system also provides for a container for collecting a separated component. In a preferred embodiment two containers are used: the first container (92) for containing an anticoagulant, which is preferably added to the whole blood as it is drawn from the donor, and then for storing the plasma after it has been separated from the red blood cells, and the second container (91) for storing the separated red blood cells. The system further includes tubing (73), which may have valving (81) built into it and which may be acted on externally, so as to direct the blood components in the desired manner.

Priority: US1996-662617 Applic. Date: 1996-06-13; US1995-482617 Applic. Date: 1995-06-07; US1994-322601 Applic. Date: 1994-10-13

Inventor: KINGSLEY GORDON F [US]; HEADLEY THOMAS D [US]; HALPERN LISE N [US]


Patent No.: US6380170B1  Issued: 30/Apr/2002

Title: Nucleic acid construct for the cell cycle regulated expression of structural genes

Applicant/Assignee: AVENTIS PHARMA DEUTSCHLAND GMBH

Application No.: 09/025343   Filing Date: 18/Feb/1998

Abstract:

The invention refers to a nucleic acid construct comprising at least one activator sequence, at least one chimeric promoter module comprising a nucleotide sequence which binds a protein of the E2F family and a protein of the CDF-1 family, and at least one gene, wherein said chimeric promoter module promotes expression of the gene in the cell cycle later than the B-myb promoter but earlier than the cdc25C promoter. The invention also concerns the purification and identification of CDF-1 protein, and use of this protein to develop new control systems.

Priority: EP19970102547 Applic. Date: 1997-02-18

Inventor: MUELLER ROLF [DE]; LIU NINGSHU [DE]; ZWICKER JOERK [DE]; SEDLACEK HANS-HARALD [DE]


Patent No.: US6394978B1  Issued: 28/May/2002

Title: Interventional procedure expandable balloon expansion enabling system and method

Applicant/Assignee: ADVANCED CARDIOVASCULAR SYSTEMS, INC

Application No.: 09/634217   Filing Date: 09/Aug/2000

Abstract:

A system used in a blood vessel when an interventional procedure is being performed in a stenosed or occluded region, which is capable of enabling an expandable balloon to be expandable in a blood vessel, from unexpanded condition thereof wherein portions of the expandable balloon are in contact, while preventing the unexpanded in-contact portions of the balloon from sticking together during expansion and deployment of the expandable balloon. The system includes a catheter which is positionable in a blood vessel at the interventional procedure site., The system further includes an expandable member such as an expandable balloon, which is expandable and which may be deployed in the blood vessel at the interventional procedure site, which includes portions thereof which are in contact in the unexpanded condition, wherein the expandable balloon is capable of expanding while preventing the unexpanded in-contact portions thereof from sticking together during expansion and deployment thereof.

Priority:

Inventor: BOYLE WILLIAM JOSEPH [US]; DENISON ANDY EDWARD [US]; HUTER BENJAMIN CURTIS [US]; HUTER SCOTT JASON [US]


Patent No.: US6395015B1  Issued: 28/May/2002

Title: Temporary vascular seal for anastomosis

Applicant/Assignee: MEDTRONIC INC

Application No.: 09/463746   Filing Date: 22/Mar/2000

Abstract:

A temporary intravascular arteriotomy seal for insertion into and retrieval from a blood vessel through an opening in the wall of the vessel. The seal comprises a thin flexible sheet material. According to one embodiment, in an untensioned state, the seal is curved and foldable in the width direction. It is adapted to be folded in the width direction upon exertion for a force on the gripping element directed in the length direction, and upon contacting of the sheet material by the sides of the opening in the vessel wall. By use of the sealing device, arterial by-pass grafting in a briefly-occlusive or non-occlusive end-to-side or side-to-side anastomosis technique is possible with virtually no obstruction to flow, little endothelial denudation and otherwise no wall damage by the intravascular device, and without blocking of side branches. A further embodiment of a device according to the present invention is characterized in that the gripping element is formed by a supply duct which ends in an opening in the flexible sheet material for administration of substances to the supply duct into a blood vessel for rescue arterial perfusion purposes. Optionally, the seal may be inflatable.

Priority: EP19970202393 Applic. Date: 1997-07-31; EP19980200847 Applic. Date: 1998-03-18; WO1998NL00430 Applic. Date: 1998-07-29

Inventor: BORST CORNELIUS [NL]; HEIJMEN ROBIN HENRICUS [NL]; VAN DALEN ROBERT [NL]; GRUNDEMAN PAUL FREDERIK [NL]; VERLAAN CORNELIUS WILHELMUS JO [NL]; MANSVELT BECK HENRICUS JACOBUS [NL]; SCHELTES JULES [NL]; HEIKENS MARTIJN [NL]


Patent No.: US6395501B1  Issued: 28/May/2002

Title: In vitro methods for screening for blood coagulation disorders using metal ions

Applicant/Assignee: INSTRUMENTATION LABORATORY, S.P.A

Application No.: 09/273413   Filing Date: 19/Mar/1999

Abstract:

In vitro methods for qualitative screening and quantitative determination of the functional activity of components of the Protein C anticoagulant pathway of the blood coagulation system are provided. The methods entail providing a blood sample to be analyzed, activating the coagulation cascade, triggering coagulation by adding calcium ions, adding metal ions selected from the group consisting of divalent metal ions and monovalent copper ions at a concentration that enhances the anticoagulant activity of the Protein C anticoagulant pathway, adding an exogenous substrate for an enzyme related to Protein C anticoagulant activity, measuring the conversion rate of a the exogenous substrate by the enzyme, and comparing the conversion rate of the substrate in blood sample to be analyzed with the conversion rate the substrate in a normal blood sample.

Priority: EP19980105043 Applic. Date: 1998-03-19

Inventor: ROSEN BERT STEFFEN [SE]; HALL CHRISTINA MARIA YVONNE [SE]


Patent No.: US6398972B1  Issued: 04/Jun/2002

Title: Method for producing platelet rich plasma and/or platelet concentrate

Applicant/Assignee: HARVEST TECHNOLOGIES CORPORATION

Application No.: 09/582730   Filing Date: 30/Jun/2000

Abstract:

Platelet rich plasma and/or platelet concentrate is prepared by placing whole blood in a first chamber of a sterile processing disposable having two chambers. The processing disposable is subjected to a first centrifugation to separate red blood cells, and the resulting platelet rich plasma supernatant is decanted to the second chamber. The processing disposable is subjected to a second centrifugation to concentrate platelets. A volume of the platelet poor plasma supernatant in the second chamber is removed, and the platelets are re-suspended in the remaining plasma. The second chamber may contain anticoagulant to preclude aggregation of the platelets.

Priority: US19990128800P Applic. Date: 1999-04-12; WO2000US08718 Applic. Date: 2000-04-11

Inventor: BLASETTI LOU [US]; KEVY SHERWIN V [US]


Patent No.: US6402702B1  Issued: 11/Jun/2002

Title: Automatic whole blood collection system

Applicant/Assignee: HAEMONETICS CORPORATION

Application No.: 09/572357   Filing Date: 17/May/2000

Abstract:

A whole blood collection system includes an automated pump/control unit and an accompanying disposable blood set. When combined and connected to a source of anticoagulant, these elements allow automatic priming of the blood set with anticoagulant and automatic collection of anticoagulated blood product according to three different collection modes. The unit's pump and the blood set are specially designed to cooperate during the collection process to assure that the collected product has a precise blood to anticoagulant ratio. During the collection procedure, the pump/control unit automatically collects data relating to the procedure. Additional data specifically identifying components of the blood set, such as the blood collection bag, along with identification data on the donor's registration form may be scanned into the pump/controller unit by a scanner associated with the unit

this facilitates positive sample identification and tracking. At the end of the procedure, a printer in the pump/controller unit automatically prints out this information so that a detailed record is immediately available about the collected blood product, the procedure for collecting it and the source of the product, i.e., the donor.

Priority: US1998-174495 Applic. Date: 1998-10-16

Inventor: GILCHER RONALD O [US]; CHAMMAS JACQUES [US]; MEDBERRY JOSEPH M [US]; STACEY GARY R [US]


Patent No.: US6403381B1  Issued: 11/Jun/2002

Title: Inhibition of coagulation in blood and blood products

Applicant/Assignee: UNIVERSITY OF VERMONT AND STATE AGRICULTURE COLLEGE

Application No.: 09/327806   Filing Date: 08/Jun/1999

Abstract:

The present invention provides methods for inhibiting blood clotting. In general, the methods include adding corn trypsin inhibitor (CTI) to blood or a blood product in an amount sufficient to inhibit the clotting. The CTI can be used alone or in combination with other anti-coagulants. In one aspect, the invention features plasma clotting assays featuring substantially prolonged clotting times. Clotting assays using whole or minimally altered blood are also provided. Further provided are methods for storing blood or blood products at low temperature with the CTI.

Priority: US19980088488P Applic. Date: 1998-06-08

Inventor: MANN KENNETH G [US]; RAND MATHEW D [US]; CAWTHERN KEVIN M [US]


Patent No.: US6406919B1  Issued: 18/Jun/2002

Title: Whole blood collection device and method

Applicant/Assignee: BIOSAFE LABORATORIES, INC

Application No.: 09/464757   Filing Date: 16/Dec/1999

Abstract:

A system for collecting whole blood includes a metering chamber and a reservoir. A movable gasket or seal is positioned to a fill position, and whole blood is added to the metering chamber until the metering chamber is full. Then the gasket is moved to a closed position, thereby moving blood from the metering chamber to the reservoir and sealing the reservoir. A diluting liquid contained in the reservoir is mixed with the whole blood to dilute and stabilize the whole blood in the reservoir for later analysis of one or more selected blood components.

Priority:

Inventor: TYRRELL STEVEN P [US]


Patent No.: US6410334B1  Issued: 25/Jun/2002

Title: Method for determining the immune defense of blood and test kit for the same and use of a suitable blood sampling system

Applicant/Assignee: EDI (EXPERIMENTELLE & DIAGNOSTISCHE IMMUNOLOGIE) GMBH

Application No.: 09/762189   Filing Date: 16/Mar/2001

Abstract:

The invention relates to a method for the determination of the immune defence activity of blood by the stimulation of white cells in the whole blood, incubation of the whole blood, separation of the supernatant from the sediment and determination of the activity from the separated supernatant. he invention also relates to a test kit for performing the method and to the use of a suitable blood sampling system, particularly a syringe cylinder for this purpose.

Priority: DE19981035721 Applic. Date: 1998-08-07; WO1999EP05635 Applic. Date: 1999-08-04

Inventor: SCHMOLZ MANFRED [DE]


Patent No.: US6410538B2  Issued: 25/Jun/2002

Title: Benzamidine derivatives

Applicant/Assignee: AJINOMOTO CO., INC

Application No.: 09/731729   Filing Date: 08/Dec/2000

Abstract:

Benzamidine derivatives of the following formula, analogs thereof and pharmaceutically acceptable salts thereof are provided. These compounds have an effect of inhibiting activated blood-coagulation factor X, and they are useful as agents for preventing or treating various diseases caused by thrombi or emboli.

Priority: JP19980159627 Applic. Date: 1998-06-08; JP19980159628 Applic. Date: 1998-06-08; WO1999JP03055 Applic. Date: 1999-06-08

Inventor: NAKAGAWA TADAKIYO [JP]; SAGI KAZUYUKI [JP]; YOSHIDA KAORU [JP]; FUKUDA YUMIKO [JP]; SHOJI MASATAKA [JP]; TAKEHANA SHUNJI [JP]; KAYAHARA TAKASHI [JP]; TAKAHARA AKIRA [JP]


Patent No.: US6423050B1  Issued: 23/Jul/2002

Title: Method and apparatus for locking of central-vein catheters

Applicant/Assignee:

Application No.: 09/595611   Filing Date: 16/Jun/2000

Abstract:

A central-vein cathether is locked by anticoagulant and bactericidal solutions separated by an air bubble. The anticoagulant is injected first, then the air bubble, and then the bactericidal solution, so that the anticoagulant is located close to the catheter tip in contact with the blood and the bacterial solution is located close to the catheter hub, where bacteria contamination is common. The air bubble prevents mixing of the solutions. A multi-chamber syringe facilitates sequential injection of the anticoagulant, air and bactericidal agent with only one connection, decreasing chances of contamination. The syringe includes internal and external coaxial barrels separated by seals, the external barrel having a discharge opening located off center in the barrel bottom, and the internal barrel having two or three chambers, each with an outlet opening. The internal barrel is rotatable relative to the external barrel to consecutively align the outlet openings with the discharge opening, allowing sequential injection of the contents. The syringe may also be used for aspiration of the locking fluid from the catheter with only one connection.

Priority:

Inventor: TWARDOWSKI ZBYLUT J [US]


Patent No.: US6423348B1  Issued: 23/Jul/2002

Title: Anticoagulant compositions

Applicant/Assignee:

Application No.: 09/212221   Filing Date: 15/Dec/1998

Abstract:

What is shown is an animal blood anticoagulant compound useful in the meat packing industry generally, and in slaughterhouse operations, particularly. The anticoagulant is effective when diluted with water at higher dilution ratios than earlier anticoagulants. In some field trials, this anticoagulant was at least as effective as previously known commercial anticoagulants when diluted by an additional 30%. The present anticoagulant preparation concentrate is an aqueous mixture of soft water (55.0%-65.0/%, w/w)

tetrasodium ethylene diamine tetraacetate (Na4EDTA) (0.5%-3.0%, w/w)

sodium hexametaphosphate (17.0%-24.0%, w/w)

citric acid (5.0%-9.0%, w/w)

and sodium hydroxide (4.0%-7.0%, w/w) to obtain a balanced pH that provides optimal chelating and anticoagulant activity. Optimal anticoagulant performance has been found to occur in the range of between pH 6.6 and pH 7.2. The degree to which the product may be diluted varies with the characteristics of the facility, the diluent water, the species of animal blood being treated, and the breed of the species, among other things.

Priority:

Inventor: MICKUS JAMES C [US]


Patent No.: US6428318B2  Issued: 06/Aug/2002

Title: Dental implant and operative method of implantation

Applicant/Assignee: ARTAL CARLOS ARRUGA

Application No.: 09/823090   Filing Date: 30/Mar/2001

Abstract:

Dental implant and operative method of implantation, being of the type of implant comprising a body that is threaded into the jawbone via which the appropriate securing and fastening bodies for the dental prosthesis are located, the implant body (1) displaying an axial cavity (2) along its entire length, and whose internal base for implantation displays certain drilled holes and/or angular cuts (3) in its lateral surface that define end tabs, the implants being presented individually in their respective sterilized receptacles (5), being joined to the cap body (6) of the receptacle (5) via an intermediate body (7), the cap body (6) defining a cavity (11) with respect to its external base, in which is housed a body (12) made of rubber or similar material.

Priority: ES20000000984 Applic. Date: 2000-04-14

Inventor: ARTAL ALBERTO ARRUGA [ES]


Patent No.: US6428527B1  Issued: 06/Aug/2002

Title: Method for coating a blood collection device

Applicant/Assignee: BECTON, DICKINSON AND COMPANY

Application No.: 09/189643   Filing Date: 10/Nov/1998

Abstract:

A blood collection assembly includes a tube having an open end with a puncturable stopper therein. A thixotropic gel for separating blood components is in the tube and a layer of additive particles is spray dried from an air nozzle onto the inside tube wall. The invention includes a method to make the tube.

Priority:

Inventor: JONES HUW DAVID [GB]; PATRAS KENT [US]


Patent No.: US6428814B1  Issued: 06/Aug/2002

Title: BIOADHESIVE NANOPARTICULATE COMPOSITIONS HAVING CATIONIC SURFACE STABILIZERS

Applicant/Assignee: ELAN PHARMA INTERNATIONAL LTD

Application No.: 09/414159   Filing Date: 08/Oct/1999

Abstract:

Bioadhesive nanoparticulate compositions, comprising active agent particles and one or more cationic surface stabilizers, are described. The cationic surface stabilizers prevent aggregation of the nanoparticles and increase bioadhesion of the nanoparticles to biological substrates, such as an insect, teeth, bone, nails, chitin, feathers, scales, mucous, skin, hair, plant tissue, etc. The particles may consist of pharmacologically active compounds (e.g., drug compounds for human or veterinary use), agricultural chemicals (pesticides, herbicides, fertilizers, and the like), cosmetic agents, consumer products (coloring agents, flavors, or fragrances), or other materials which function by interacting with biological substrates. In addition, the invention relates to methods of preparing and using such bioadhesive nanoparticulate compositions.

Priority:

Inventor: BOSCH H WILLIAM [US]; COOPER EUGENE R [US]; MCGURK SIMON L [US]


Patent No.: US6433186B1  Issued: 13/Aug/2002

Title: Amidino derivatives and their use as thormbin inhibitors

Applicant/Assignee: ASTRAZENECA AB

Application No.: 09/900903   Filing Date: 10/Jul/2001

Abstract:

There is provided compounds of formula I,wherein Y and R1 have meanings given in the description, and pharmaceutically acceptable derivatives (including prodrugs) thereof, which compounds and derivatives are useful as, or are useful as prodrugs of, competitive inhibitors of trypsin-like proteases, such as thrombin, and thus, in particular, in the treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulants.

Priority: SE20000002921 Applic. Date: 2000-08-16; SE20000002922 Applic. Date: 2000-08-16

Inventor: INGHARDT TORD [SE]; SVENSSON ARNE N [SE]


Patent No.: US6447987B1  Issued: 10/Sep/2002

Title: Prolonged storage of red blood cells

Applicant/Assignee: THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY

Application No.: 09/664635   Filing Date: 19/Sep/2000

Abstract:

Novel additive solutions useful for the storage of human red blood cells (RBCs) under refrigerated conditions are disclosed. Also disclosed is a method of using the additive solutions in an appropriate volume to preserve RBCs at about 1 to 6 DEG C. for up to at least about 11 weeks or more. Additive solutions and processes in accordance with the present invention allow the viable storage of human RBCs for an extended period of time in a solution which is directly infusible in humans.

Priority: US1998-154102 Applic. Date: 1998-09-16; US19780099594P Applic. Date: 1978-09-09; US19980098520P Applic. Date: 1998-08-31

Inventor: HESS JOHN R [US]; GREENWALT TIBOR J [US]


Patent No.: US6458548B2  Issued: 01/Oct/2002

Title: CONTAINERS AND KITS FOR THE DETERMINATION OF CELL FUNCTIONS, AND METHOD FOR THE DETERMINATION THEREOF

Applicant/Assignee: SEKISUI KAGAKU KOGYO KABUSHIKI KAISHA

Application No.: 09/068027   Filing Date: 01/Apr/1998

Abstract:

A container for measurement of cell functions, for use in the determination of a physiologically active substance produced by blood cells, is constituted such that an amount of material capable of inducing production of the physiologically active substance, when extracted by collecting water of a volume equal to a liquid volume to be subjected to measurement, is controlled at a level insufficient to induce production of the physiologically active substance from the blood cells.

A container for measurement of cell functions in which a material capable of inducing production of a physiologically active substance in blood when contacted with the blood is accommodated in such a condition as being contactable with blood, and in which an amount of the material capable of inducing production of the physiologically active substance in the container before use is limited to a level insufficient to influence a measured value of the physiologically active substance.

Priority: JP19960212488 Applic. Date: 1996-08-12; JP19960264832 Applic. Date: 1996-10-04; JP19970040814 Applic. Date: 1997-02-25; JP19970050403 Applic. Date: 1997-03-05; JP19970132445 Applic. Date: 1997-05-22; WO1997JP02776 Applic. Date: 1997-08-08

Inventor: KOBAYASHI KOJI [JP]; SETOGUCHI YUJI [JP]; KURIYAMA KIYOSHI [JP]


Patent No.: US6465010B1  Issued: 15/Oct/2002

Title: Means for creating a mass having structural integrity

Applicant/Assignee: DRUGTECH CORPORATION

Application No.: 09/902751   Filing Date: 12/Jul/2001

Abstract:

The present invention relates to a means for creating a mass having structural integrity, including a rapidly disintegratable tablet for administration with or without the use of water. The present invention has a wide variety of different uses and applications. One embodiment is a tablet intended for oral administration. The tablet comprises at least one active ingredient and a mixture of excipients. The excipients provide desired characteristics and physical properties and when the tablet is sintered or heated, excellent tablet binding characteristics are obtained. The tablet is intended primarily for oral administration and dissolves in the presence of water. Also disclosed is a process for the preparation of a rapidly disintegratable tablet for administration with or without the use of water. The process comprising dissolving at least one bulking agent and at least one structural agent in a suitable solvent, wherein the solvent provides high porosity upon drying

spray-drying or dispersing said dissolved mixture to obtain a bead or granulated product

dry blending at least one binding agent, and at least one active ingredient with the bead or granulated product to obtain a preformulation product or adding at least one active ingredient to the preformulation product dissolved or dispersed components before spray-drying or dispersing

compressing the preformulation product

and sintering or heating the preformulation product for a sufficient time and temperature to allow the binding agent to change status or melt and allow the binding agent to resolidify as the temperature is reduced to ambient temperature.

Priority: US1999-366686 Applic. Date: 1999-08-04

Inventor: LAGOVIYER YURY [US]; LEVINSON R SAUL [US]; STOTLER DENIS [US]; RILEY THOMAS C [US]


Patent No.: US6465202B1  Issued: 15/Oct/2002

Title: Method for stabilizing aminotransferase activity in a biological fluid

Applicant/Assignee: BIOSAFE LABORATORIES, INC

Application No.: 09/506305   Filing Date: 17/Feb/2000

Abstract:

Methods and compositions for the stabilization of aminotransferase activity of plasma or serum are provided. Such methods will be useful in the accurate determination of tests associated with liver toxicity.

Priority:

Inventor: TYRRELL STEVEN P [US]


Patent No.: US6466879B1  Issued: 15/Oct/2002

Title: Systems and methods for monitoring introduction of a processing fluid during a fluid processing procedure

Applicant/Assignee: BAXTER INTERNATIONAL INC

Application No.: 09/615390   Filing Date: 13/Jul/2000

Abstract:

Fluid processing systems and methods make use of a replenishable source containing a volume of a processing fluid that is dispensed during a processing period. A processor serves to sequentially pause and resume the processing period. The processor records weight values of the source at commencement of the processing period

upon pauses in the processing period

and upon resumptions of the processing period. At termination of the processing period, the processor generates a total volume value of processing fluid dispensed from the source during the processing period, which takes into account replenishment of the processing fluid when the processing period is paused. The systems and methods can be integrated into blood processing circuits to monitor the introduction of anticoagulant.

Priority:

Inventor: CANTU ROBERT J [US]; STINOFF RUSSEL [US]


Patent No.: US6471978B1  Issued: 29/Oct/2002

Title: Localized use of nitric oxide-adducts to prevent internal tissue damage

Applicant/Assignee: BRIGHAM AND WOMEN'S HOSPITAL NITROMED, INC

Application No.: 09/621610   Filing Date: 21/Jul/2000

Abstract:

A method for preventing adverse effects associated with the use of a medical device in a patient by introducing into the patient a device of which at least a portion includes a prophylactic or therapeutic amount of a nitric oxide adduct. The nitric oxide adduct can be present in a matrix coating on a surface of the medical device

can be coated per se on a surface of the medical device

can be directly or indirectly bound to reactive sites on a surface of the medical device

or at least a portion of the medical device can be formed of a material, such as a polymer, which includes the nitric oxide adduct. Also disclosed is a method for preventing adverse effects associated with the use of a medical device in a patient by introducing the device during a medical procedure and before or during said procedure locally administering a nitric oxide adduct to the site of contact of said device with any internal tissue.

Priority: US1999-433550 Applic. Date: 1999-11-04; US1995-460465 Applic. Date: 1995-06-02; US1993-123331 Applic. Date: 1993-09-17

Inventor: STAMLER JONATHAN S [US]; LOSCALZO JOSEPH [US]; FOLTS JOHN D [US]


Patent No.: US6472161B1  Issued: 29/Oct/2002

Title: Method of evaluating blood clot lysis condition

Applicant/Assignee:

Application No.: 08/583761   Filing Date: 11/Jan/1996

Abstract:

Blood is tested for clot lysis conditions such as natural lytic capabilities, the effect of previously administered thrombolytic and anti-thrombolytic agents, and dose responses thereto, by forming a clot in a sample of blood, lysing the clot, and measuring the elapsed time period from initial clot formation to clot lysis, all while continuously evaluating the blood sample. Thrombolytic agents include streptokinase, urokinase and recombinant tissue plasminogen activator. Plasmin and plasminogen activator inhibitors, clot activating agents (e.g. kaolin), and agents to deactivate anticoagulants (e.g. heparinase) may also be used as reagents during testing.

Priority: US1994-296862 Applic. Date: 1994-08-26; US1992-962900 Applic. Date: 1992-10-15

Inventor: BAUGH ROBERT F [US]


Patent No.: US6475235B1  Issued: 05/Nov/2002

Title: Encapsulated stent preform

Applicant/Assignee: IOWA-INDIA INVESTMENTS COMPANY, LIMITED

Application No.: 09/440926   Filing Date: 16/Nov/1999

Abstract:

The invention relates to a stent preform for implantation in a body lumen. The stent preform includes an elongated metal core having first and second core ends, a contact surface, and a solid cross-section, and a hollow outer sheath made of a biocompatible polymer and having first and second sheath ends, caps disposed on the sheath ends, and an interior surface. The outer sheath surrounds and contacts the contact surface of the core to prevent the core from directly contacting the body lumen. In another embodiment, the biocompatible polymer of the outer sheath is formed of a heat-shrinkable polymer material, and the elongated core is formed of a shape-memory alloy. In another embodiment, the outer sheath is formed from a polymer tape.

Priority:

Inventor: JAYARAMAN SWAMINATHAN [US]


Patent No.: US6475801B1  Issued: 05/Nov/2002

Title: Anticoagulant and hemanalysis method

Applicant/Assignee: SYSMEX CORPORATION

Application No.: 09/385249   Filing Date: 12/May/2000

Abstract:

An anticoagulant for blood cell counting containing at least two kinds of the following antiplatelet agents: theophyllines, adenosines and dipyridamoles. The anticoagulant also contains citric acid, an alkali metal salt thereof or a mixture of citric acid and an alkali metal salt thereof.

Priority: JP19980249265 Applic. Date: 1998-09-03

Inventor: NISHIZAKI MIKIKO [JP]; AKAI YASUMASA [JP]; NAKAMURA SAYAKA [JP]


Patent No.: US6478808B2  Issued: 12/Nov/2002

Title: Clotting cascade initiating apparatus and methods of use and methods of closing wounds

Applicant/Assignee: CLOSYS CORPORATION

Application No.: 09/732423   Filing Date: 07/Dec/2000

Abstract:

Wound closure methods and apparatus are provided which utilize blood fluid by activating the clotting cascade of the blood fluid outside the body within a substantially enclosed sterile container then introducing the blood fluid to the wound site to complete clotting. Methods and apparatus for providing ways of inhibiting anticoagulants and slowing fibrin clot degradation are also disclosed. Kits for practicing the invention singularly or in combination with and/or associated with preferred procedures are also disclosed.

Priority: US1998-212080 Applic. Date: 1998-12-15; US19970069894P Applic. Date: 1997-12-17

Inventor: NOWAKOWSKI KAROL L [US]


Patent No.: US6482214B1  Issued: 19/Nov/2002

Title: Intravascular seal with mesh reinforcement and method for using same

Applicant/Assignee: MEDTRONIC, INC

Application No.: 09/559471   Filing Date: 27/Apr/2000

Abstract:

An intravascular device is provided. The device comprises a sealing member, the member including a mesh material and a gripping element operatively attached to the sealing member, the gripping element operatively adapted to allow a user to position the sealing member to seal a blood vessel. Methods of using the device are also provided.

Priority:

Inventor: SIDOR JR WILLIAM E [US]; BOCHEFF CAROLYN [US]; HALL JOHN D [US]; MARINI GREGORY [US]; GOODMAN JACK [US]


Patent No.: US6497721B2  Issued: 24/Dec/2002

Title: Method and apparatus for regional and whole body temperature modification

Applicant/Assignee: RADIANT MEDICAL, INC

Application No.: 09/739427   Filing Date: 15/Dec/2000

Abstract:

Methods and apparatus for temperature modification of selected body regions including an induced state of local hypothermia of the brain region for neuroprotection. A heat exchange catheter is provided with heat transfer fins projecting or extending outward from the catheter which may be inserted into selected blood vessels or body regions to transfer heat with blood or fluid in the selected blood vessels or body regions. Another aspect of the invention further provides methods and apparatus for controlling the internal body temperature of a patient. By selectively heating or cooling a portion of the catheter lying within a blood vessel, heat may be transferred to or from blood flowing within the vessel to increase or decrease whole body temperature or the temperature of a target region.

Feed back from temperature sensors located within the patient's body allow for control of the heat transfer from the catheter to automatically control the temperature of the patient or of the target region within the patient. The apparatus may include a blood channeling sleeve that directs body fluid over a heat exchanger where the body fluid's temperature is altered, and then is discharged out the distal end of the sleeve to a desired location, for example, cooled blood to the brain for neuroprotection. The catheter may be used alone or in conjunction with other heat exchangers to cool one region of a patient's body while heating another.

Priority: US1998-138830 Applic. Date: 1998-08-24; US1996-584013 Applic. Date: 1996-01-08; US1994-324853 Applic. Date: 1994-10-18; US1993-015774 Applic. Date: 1993-02-10; US1996-769931 Applic. Date: 1996-12-19

Inventor: GINSBURG INCAPACITED ROBERT [US]; MACHOLD TIMOTHY R [US]; DINEEN MICHAEL T [US]


Patent No.: US6503724B1  Issued: 07/Jan/2003

Title: Fibrinopeptides in saliva as indicator of blood coagulation status

Applicant/Assignee: LINK ENTERPRISES CORPORATION

Application No.: 09/673085   Filing Date: 11/Oct/2000

Abstract:

A non invasive method for determining the blood coagulation status of a human or an animal is described. F1+2, F1, F2, FpA, D-dimers, F1+2 combined with F1, or F1+2 combined with F2 are measured in saliva, sputum and related biological samples. The respective concentrations are inversely correlated to the time it takes blood to coagulate and the probability of bleeding, and directly correlated to the probability of in-vivo formation of a thrombus or emboli. The method can be used in any coagulation disorder study, including congenital, acquired or drug-induced.

Priority: EP19980820460 Applic. Date: 1998-05-18; WO1999IB00869 Applic. Date: 1999-05-14

Inventor: DE NORA MATTEO [MC]; BLASIUS JACOB R [US]


Patent No.: US6508778B1  Issued: 21/Jan/2003

Title: System for withdrawal of blood

Applicant/Assignee: HARVEST TECHNOLOGIES CORPORATION

Application No.: 09/701424   Filing Date: 29/Nov/2000

Abstract:

The invention comprises a disposable tubing set (4) for connection to a rigid canister (2) that is maintained at a controlled reduced (vacuum) pressure. The set is used for collecting and anti-coagulating a patient's blood for later re-infusion into the same patient

Priority: US19980087398P Applic. Date: 1998-06-01; WO1999US10485 Applic. Date: 1999-06-01

Inventor: VERKAART WESLEY H [US]; CRIMI THOMAS G [US]


Patent No.: US6514236B1  Issued: 04/Feb/2003

Title: Method for treating a cardiovascular condition

Applicant/Assignee:

Application No.: 09/874719   Filing Date: 05/Jun/2001

Abstract:

A pair of vascular interventional devices, at least one of which includes a hollow, flexible tube and a dilator that is adapted for insertion into and through the tube and over a guidewire, may be utilized to treat or study a cardiovascular condition, or to measure the blood pressure across a vascular segment. The first device also includes a hub with an end port through which a second device may be introduced into and through the tube. The hub also includes a side port through which a fluid agent may be injected for delivery through the tube or through which pressures can be measured. A guidewire is inserted into a vessel of the cardiovascular system of a patient in the conventional manner. The dilator of the first device is then inserted into the tube and the dilator and tube are then inserted into the vessel over the guidewire and positioned in the target area. The dilator is then withdrawn through the tube from the cardiovascular system of the patient. A second interventional device is selected to treat or study the cardiovascular condition, and the second device is introduced through the end port of the hub of the first device. The second interventional device is advanced over the guidewire to the distal end of the tube of the first device, and the guidewire is then removed. The second interventional device is employed to treat or study the cardiovascular condition. If a pressure transducer is placed on the side port of the first device, as well as on the second device, the second device may be advanced beyond the end of the first device so that the blood pressure may be measured simultaneously at the end of the tube of the first interventional device (the first location) and at the end of the second interventional device (the second location). The difference in blood pressure, if any, between the first and second locations may then be calculated.

Priority: US1999-296581 Applic. Date: 1999-04-23

Inventor: STRATIENKO ALEXANDER A [US]


Patent No.: US6514766B2  Issued: 04/Feb/2003

Title: Modified erythrocyte sedimentation rate

Applicant/Assignee:

Application No.: 09/915198   Filing Date: 25/Jul/2001

Abstract:

Methods for enhancing the value of the traditional erythrocyte sedimentation rate (ESR) test are provided by including an ESR-modifying agent, such as a metal ion, in the sample. Results of the resulting modified ESR are correlated with the health status of the animal.

Priority: US20000221464P Applic. Date: 2000-07-26

Inventor: SPILLERT CHARLES R [US]; KHALIL MARCELLE [US]


Patent No.: US6515023B2  Issued: 04/Feb/2003

Title: Thrombin receptor antagonists

Applicant/Assignee: MERCK & CO., INC

Application No.: 09/772353   Filing Date: 30/Jan/2001

Abstract:

A thrombin receptor antagonist having the formulauseful for inhibiting the aggregation of blood platelets. The compounds can be used in a method of acting upon a thrombin receptor which comprises administering a therapeutically effective but non-toxic amount of such compound to a mammal, preferably a human.

Priority: US20000179184P Applic. Date: 2000-01-31

Inventor: BARROW JAMES C [US]; NANTERMET PHILIPPE G [US]; SELNICK HAROLD G [US]; HUTCHINSON JOHN H [US]; BRESLIN MICHAEL J [US]; GLASS KRISTEN L [US]; CONNOLLY THOMAS M [US]; STERN ANDREW [US]


Patent No.: US6518010B2  Issued: 11/Feb/2003

Title: Use of defibrinated blood for manufacture of a hemoglobin-based oxygen carrier

Applicant/Assignee: BIOPURE CORPORATION

Application No.: 09/795821   Filing Date: 28/Feb/2001

Abstract:

Red blood cells are purified by defibrinating whole blood and then filtering the defibrinated whole blood, whereby at least a portion of a plasma component is separated from the red blood cells to form a suspension of red blood cells, thereby purifying the red blood cells. Whole blood is defibrinated by, for example, using a chemical coagulating agent or mechanical agitation. Separation of the plasma component from red blood cells can be completed by, for example, diafiltration. The suspension of red blood cells can then be employed to produce a hemoglobin-based oxygen carrier.

Priority:

Inventor: GAWRYL MARIA S [US]; HOUTCHENS ROBERT A [US]; LIGHT WILLIAM R [US]


Patent No.: US6518310B2  Issued: 11/Feb/2003

Title: Aminoguanidines and alkoxyguanidines as protease inhibitors

Applicant/Assignee: 3-DIMENSIONAL PHARMACEUTICALS, INC

Application No.: 09/809293   Filing Date: 16/Mar/2001

Abstract:

Aminoguanidine and alkoxyguanidine compounds, including compounds of the formula:wherein X is O or NR9 and R1-R4, R6-R9, R11, R12, Ra, Rb, Rc, Y, Z, n and m are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit proteolytic enzymes such as thrombin are described. Also described are methods for preparing the compounds of Formula I. The novel compounds of the present invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, thrombin, plasmin and factor Xa. Certain of the compounds exhibit antithrombotic activity via direct, selective inhibition of thrombin, or are intermediates useful for forming compounds having antithrombotic activity.

The invention includes a composition for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation in a mammal, comprising a compound of the invention in a pharmaceutically acceptable carrier. Other uses of compounds of the invention are as anticoagulants either embedded in or physically linked to materials used in the manufacture of devices used in blood collection, blood circulation, and blood storage, such as catheters, blood dialysis machines, blood collection syringes and tubes, blood lines and stents.

Priority: US1997-979234 Applic. Date: 1997-11-26; US19960031822P Applic. Date: 1996-11-26

Inventor: TOMCZUK BRUCE E [US]; SOLL RICHARD M [US]; LU TIANBAO [US]; FEDDE CYNTHIA L [US]; ILLIG CARL R [US]; MARKOTAN THOMAS P [US]; STAGNARO THOMAS P [US]


Patent No.: US6521182B1  Issued: 18/Feb/2003

Title: Fluidic device for medical diagnostics

Applicant/Assignee: LIFESCAN, INC

Application No.: 09/333765   Filing Date: 15/Jun/1999

Abstract:

A fluidic medical diagnostic device permits measurement of analyte concentration or a property of a biological fluid, particularly the coagulation time of blood. The device has at one end a sample port for introducing a sample and at the other end a bladder for drawing the sample to a measurement area. A channel carries the sample from the sample port to the measurement area, and a stop junction, between the measurement area and bladder, halts the sample flow. The desired measurement can be made by placing the device into a meter which measures a physical property of the sample-typically, optical transmittance-after it has interacted with a reagent in the measurement area.

Priority: US19980093421P Applic. Date: 1998-07-20

Inventor: SHARTLE ROBERT JUSTICE [US]; CHOW HERBERT [US]; HARTMANN CHRISTA [US]


Patent No.: US6521460B1  Issued: 18/Feb/2003

Title: Method of carrying out blood tests

Applicant/Assignee: RHEIN BIOTECH GESELLSCHAFT FUR NEUE BIOTECHNOLOGISCHE PROZESSE UND PRODUKTE MBH

Application No.: 09/180806   Filing Date: 08/Feb/1999

Abstract:

The present invention relates to a method of carrying out blood tests. The invention is based on the finding that clinico-chemical blood parameters can be determined using not only blood serum but also blood plasma. Therefore, freshly taken blood samples, which are mixed with at least one thrombin inhibitor, can be used for determining both clinico-chemical parameters and hematological parameters. The clinico-chemical parameters can thus be determined using blood plasma, a separation of coagulable components being not required any more.

Priority: WO1997EP02343 Applic. Date: 1997-05-07; DE19961020443 Applic. Date: 1996-05-21

Inventor: STRASSER ALEXANDER W M [DE]; MELBER KARL [DE]; MENSSEN HANS DIETRICH [DE]; THIEL ECKARD [DE]


Patent No.: US6521663B2  Issued: 18/Feb/2003

Title: Aminoguanidinyl- and Alkoxyguanidinyl-substituted phenyl acetamides as protease inhibitors

Applicant/Assignee: 3-DIMENSIONAL PHARMACEUTICALS 3-DIMENSIONAL PHARMACEUTICALS, INC

Application No.: 09/971000   Filing Date: 05/Oct/2001

Abstract:

Phenyl acetamide compounds are described, including compounds of Formula I:or a solvate, hydrate or pharmaceutically acceptable salt thereof

wherein R3-R6, R11, B, Y and W are set forth in the specification. The compounds of the invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as thrombin and factor Xa. Compositions for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation are described. Other uses of compounds of the invention are as anticoagulants either embedded in or physically linked to materials used in the manufacture of devices used in blood collection, blood circulation, and blood storage, such as catheters, blood dialysis machines, blood collection syringes and tubes, blood lines and stents.

Additionally, the compounds can be detectably labeled and employed for in vivo imaging of thrombi.

Priority: US20000238132P Applic. Date: 2000-10-06

Inventor: PAN WENXI [US]; LU TIANBAO [US]; MARKOTAN THOMAS P [US]; TOMCZUK BRUCE E [US]


Patent No.: US6527798B2  Issued: 04/Mar/2003

Title: Method and apparatus for regional and whole body temperature modification

Applicant/Assignee: RADIANT MEDICAL, INC

Application No.: 09/739134   Filing Date: 15/Dec/2000

Abstract:

Methods and apparatus for temperature modification of selected body regions including an induced state of local hypothermia of the brain region for neuroprotection. A heat exchange catheter is provided with heat transfer fins projecting or extending outward from the catheter which may be inserted into selected blood vessels or body regions to transfer heat with blood or fluid in the selected blood vessels or body regions. Another aspect of the invention further provides methods and apparatus for controlling the internal body temperature of a patient. By selectively heating or cooling a portion of the catheter lying within a blood vessel, heat may be transferred to or from blood flowing within the vessel to increase or decrease whole body temperature or the temperature of a target region.

Feed back from temperature sensors located within the patient's body allow for control of the heat transfer from the catheter to automatically control the temperature of the patient or of the target region within the patient. The apparatus may include a blood channeling sleeve that directs body fluid over a heat exchanger where the body fluid's temperature is altered, and then is discharged out the distal end of the sleeve to a desired location, for example, cooled blood to the brain for neuroprotection. The catheter may be used alone or in conjunction with other heat exchangers to cool one region of a patient's body while heating another.

Priority: US1998-138830 Applic. Date: 1998-08-24; US1996-584013 Applic. Date: 1996-01-08; US1994-324853 Applic. Date: 1994-10-18; US1993-015774 Applic. Date: 1993-02-10; US1996-769931 Applic. Date: 1996-12-19

Inventor: GINSBURG ROBERT [US]; MACHOLD TIMOTHY R [US]; DINEEN MICHAEL T [US]


Patent No.: US6527957B1  Issued: 04/Mar/2003

Title: Methods for separating, collecting and storing red blood cells

Applicant/Assignee: BAXTER INTERNATIONAL INC

Application No.: 09/287671   Filing Date: 07/Apr/1999

Abstract:

Methods are disclosed for the collection of red blood cells whereby whole blood is combined with an anticoagulant, red cells are separated from the whole blood and the separated red cells are combined with a storage solution. The red cells may be stored for an extended period of time.

Priority: US1998-072961 Applic. Date: 1998-05-05; US1997-819106 Applic. Date: 1997-03-17; US1995-512807 Applic. Date: 1995-08-09

Inventor: DENIEGA JOSE C [US]; DUFF DANIEL H [US]; GUDINO MARIA D [US]; BUCHHOLZ DONALD H [US]


Patent No.: US6534016B1  Issued: 18/Mar/2003

Title: Additive preparation and method of use thereof

Applicant/Assignee:

Application No.: 09/717417   Filing Date: 21/Nov/2000

Abstract:

The present invention is an additive preparation which contains an additive, an organic acid, a metal carbonate compound, and a surfactant agent which is capable of rendering the surface of a collection device to have properties that cause the surface to repel the adsorption of components of a body fluid sample. The preparation effervesces when in contact with a body fluid sample, thereby efficiently dispersing the additive and surfactant in a body fluid sample.

Priority: US1997-911394 Applic. Date: 1997-08-14; US19970045159P Applic. Date: 1997-04-30

Inventor: COHEN RICHMOND [US]; DASTANE AJIT N [US]


Patent No.: US6534629B1  Issued: 18/Mar/2003

Title: Nematode-extracted serine protease inhibitors and anticoagulant proteins

Applicant/Assignee: CORVAS INTERNATIONAL, INC

Application No.: 09/249473   Filing Date: 12/Feb/1999

Abstract:

Proteins which have activity as anticoagulants and/or serine protease inhibitors and have at least one NAP domain and are described. Certain of these proteins have factor Xa inhibitory activity and others have activity as inhibitors of factor VIIa/TF. These proteins can be isolated from natural sources as nematodes, chemically synthesized or made by recombinant methods using various DNA expression systems.

Priority: US1995-461965 Applic. Date: 1995-06-05; US1995-465380 Applic. Date: 1995-06-05; US1995-486397 Applic. Date: 1995-06-05; US1995-486399 Applic. Date: 1995-06-05; US1994-326110 Applic. Date: 1994-10-18

Inventor: VLASUK GEORGE PHILLIP [US]; STANSSENS PATRICK ERIC HUGO [BE]; MESSENS JORIS HILDA LIEVEN [BE]; LAUWEREYS MARC JOSEF [BE]; LAROCHE YVES RENE [BE]; JESPERS LAURENT STEPHANE [BE]; GANSEMANS YANNICK GEORGES JOZE [BE]; MOYLE MATTHEW [US]; BERGUM PETER W [US]


Patent No.: US6544282B1  Issued: 08/Apr/2003

Title: Inhibition of platelet activation, aggregation and/or adhesion by hypothermia

Applicant/Assignee: RADIANT MEDICAL, INC

Application No.: 09/790249   Filing Date: 21/Feb/2001

Abstract:

A method for treating acute coronary syndromes (i.e., unstable angina or non-Q-wave MI) or transient ischemic attacks in a human or animal patient by placing a heat exchange apparatus in the patient's vasculature and using that heat exchange apparatus to cool the patient to a temperature (e.g. 30-36 DEG C.) at which platelet inhibition (i.e., inhibition of platelet activation and/or aggregation and/or adhesion) occurs. Anti-shivering drugs or anesthesia may be administered to patients whose body temperature is cooled below that patient's shivering threshold (typically approximately 35.5 C.). If it is determined that platelet inhibition is no longer desirable, such as when the patient is about to undergo a surgical or interventional procedure wherein bleeding could be problematic, the hypothermia-induced platelet inhibition may be rapidly reversed by using the intravascular heat exchange apparatus to re-warm the patient's body to normothermia or near normothermia.

Priority:

Inventor: DAE MICHAEL W [US]; MACHOLD TIMOTHY R [US]; KELLER WADE A [US]


Patent No.: US6548241B1  Issued: 15/Apr/2003

Title: Storage solution containing photosensitizer for inactivation of biological contaminants

Applicant/Assignee: GAMBRO, INC

Application No.: 09/725426   Filing Date: 28/Nov/2000

Abstract:

A platelet/additive solution comprising bicarbonate, citrate and glucose. Additionally, a platelet/additive and treatment solution comprising bicarbonate, citrate, glucose and a photosensitizer.

Priority:

Inventor: MCBURNEY LAURA [US]; GOODRICH JR RAYMOND P [US]


Patent No.: US6551303B1  Issued: 22/Apr/2003

Title: Barrier device for ostium of left atrial appendage

Applicant/Assignee: ATRITECH, INC

Application No.: 09/428008   Filing Date: 27/Oct/1999

Abstract:

A membrane applied to the ostium of an atrial appendage for blocking blood from entering the atrial appendage which can form blood clots therein is disclosed. The membrane also prevents blood clots in the atrial appendage from escaping therefrom and entering the blood stream which can result in a blocked blood vessel, leading to strokes and heart attacks. The membranes are percutaneously installed in patients experiencing atrial fibrillations and other heart conditions where thrombosis may form in the atrial appendages. A variety of means for securing the membranes in place are disclosed. The membranes may be held in place over the ostium of the atrial appendage or fill the inside of the atrial appendage. The means for holding the membranes in place over the ostium of the atrial appendages include prongs, stents, anchors with tethers or springs, disks with tethers or springs, umbrellas, spiral springs filling the atrial appendages, and adhesives. After the membrane is in place a filler substance may be added inside the atrial appendage to reduce the volume, help seal the membrane against the ostium or clot the blood in the atrial appendage. The membranes may have anticoagulants to help prevent thrombosis. The membranes be porous such that endothelial cells cover the membrane presenting a living membrane wall to prevent thrombosis. The membranes may have means to center the membranes over the ostium. Sensors may be attached to the membrane to provide information about the patient.

Priority:

Inventor: VAN TASSEL ROBERT A [US]; HAUSER ROBERT G [US]


Patent No.: US6555064B2  Issued: 29/Apr/2003

Title: Method for determining platelet inhibitor response

Applicant/Assignee: MEDTRONIC, INC

Application No.: 09/811216   Filing Date: 16/Mar/2001

Abstract:

An apparatus is provided for performing an activated clotting time test on a sample of blood containing platelets using a plunger sensor technique, the apparatus comprising a test cell, and wherein the test cell comprises an anticoagulant, a contact activator, and a predetermined amount of a platelet inactivating agent.

Priority: US1999-225051 Applic. Date: 1999-01-04; US1996-640277 Applic. Date: 1996-04-30

Inventor: BAUGH ROBERT F [US]; LANE CAROLE G [US]; WILSON ADRIAN C [US]


Patent No.: US6555066B2  Issued: 29/Apr/2003

Title: Apparatus for performing a platelet inhibition test

Applicant/Assignee: MEDTRONIC, INC

Application No.: 09/810747   Filing Date: 16/Mar/2001

Abstract:

An apparatus for performing a platelet inhibition test on a sample of blood is provided, comprising a plurality of test cells, the cells being adapted for receiving an aliquot portion of the sample, wherein each of the cells comprises an anticoagulant and a clotting activator, and wherein at least one of the cells further comprises a platelet inactivating agent, wherein a clotting time is determined for each of the aliquot portions, and wherein a relative clotting time for each of the aliquot portions comprising the platelet inhibitor is determined as compared to a reference clotting time for a cell containing no platelet inhibitor, wherein the relative clotting times for the cells are determinative of the platelet inhibition of the sample.

Priority: US1999-225051 Applic. Date: 1999-01-04; US1996-640277 Applic. Date: 1996-04-30

Inventor: BAUGH ROBERT F [US]; LANE CAROLE G [US]; WILSON ADRIAN C [US]


Patent No.: US6555381B2  Issued: 29/Apr/2003

Title: Method for determining a contact activator for platelet activation

Applicant/Assignee: MEDTRONIC, INC

Application No.: 09/810740   Filing Date: 16/Mar/2001

Abstract:

A method of determining a contact activator for platelet activation and/or clotting activation is provided, comprising placing a predetermined amount of an anticoagulant in each cell of a multicell test cartridge, placing a predetermined amount of a platelet inactivating agent in each cell, and placing a measured amount of contact activator in each cell, the amount of contact activator in each cell differing from the amount in each other cell. An aliquot of a blood sample is added to each cell, and the blood sample aliquot, clotting reagent and platelet inactivating agent are mixed. Each cell sample is allowed to clot, and the clotting time for each cell is measured. The relative clotting times are used to determine the platelet activation and/or clotting activation effect of the clotting activator.

Priority: US1999-225051 Applic. Date: 1999-01-04; US1996-640277 Applic. Date: 1996-04-30

Inventor: BAUGH ROBERT F [US]; LANE CAROLE G [US]; WILSON ADRIAN C [US]


Patent No.: US6561997B1  Issued: 13/May/2003

Title: Extracorporeal fluid circuit and related methods

Applicant/Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN NEPHROS THERAPEUTICS, INC

Application No.: 09/553772   Filing Date: 21/Apr/2000

Abstract:

A circuit for extracorporeal treatment of a body fluid, the circuit including in serial fluidic communication an inlet for receiving the body fluid from a patient, a first pump, a first treatment device for processing the body fluid, a second pump, an outlet for returning processed body fluid to the patient

and a shunt. The shunt is upstream from the first pump and downstream from the second pump.

Priority: US19990130688P Applic. Date: 1999-04-23

Inventor: WEITZEL WILLIAM FREDERICK [US]; HUMES H DAVID [US]; PAGANINI EMIL PRESLEY [US]; BUFFINGTON DEBORAH ANN [US]; FUNKE ANGELA J [US]


Patent No.: US6565738B1  Issued: 20/May/2003

Title: Diagnostic test for the measurement of analyte in abiological fluid

Applicant/Assignee: ABBOTT LABORATORIES

Application No.: 09/239200   Filing Date: 28/Jan/1999

Abstract:

A biosensor for determining the concentration of an analyte, such as, for example, ALT, in a sample of biological fluid, such as, for example, whole blood, comprising:(a) a base layer

(b) a detecting layer comprising a reference electrode and a working electrode, the surface of the electrically conductive portion of the working electrode being sufficiently smooth so that determination of the concentration of an analyte present in a low concentration, e.g., less than 1 mM, can be made

(c) a layer overlying said electrodes, said layer comprising dried reagents

and(d) an anticoagulant disposed in such a location that it will prevent the sample from coagulating during the determination.The biosensor preferably further includes a fluid-transporting layer to aid in delivering the sample from a sample application zone to the electrodes. The biosensor preferably further includes a covering layer overlying the electrode area to reduce evaporation of the sample during the assay and to help define the fluid transport path and the volume of fluid over the detecting layer.

Priority:

Inventor: HENNING TIMOTHY P [US]; COUSINEAU KRISTEN L [US]


Patent No.: US6565806B1  Issued: 20/May/2003

Title: Apheresis system with anticoagulant flow control

Applicant/Assignee: BAXTER INTERNATIONAL INC

Application No.: 09/042260   Filing Date: 13/Mar/1998

Abstract:

An apheresis system is disclosed which may include a separation chamber

a suspension flow path which communicates at one end with the separation chamber and includes a connector at the other end for connecting to a source of cellular suspension

an anticoagulant flow path which communicates at one end with the suspension flow path and includes a connector at the other end for connecting to an anticoagulant source

and a return flow path which communicates at one end with the separation chamber and communicates at the other end with a connector for connection directly to the suspension source or to the suspension flow path for returning one or more suspension components to the source. The anticoagulant flow path includes a flow restriction, such as an internal flow restriction, which limits the free flow of anticoagulants into the suspension flow path while preferably not completely stopping the flow of anticoagulant. The restriction may take various forms, but the preferred construction comprises a tubing segment of reduced inside diameter, providing resistance to the free flow of anticoagulant in the event of operator error or mechanical failure.

Priority:

Inventor: GRIMM DANIEL J [US]


Patent No.: US6569427B1  Issued: 27/May/2003

Title: Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood

Applicant/Assignee: PHARMASTEM THERAPEUTICS, INC

Application No.: 08/442277   Filing Date: 16/May/1995

Abstract:

The present invention relates to hematopoietic stem and progenitor cells of neonatal or fetal blood that are cryopreserved, and the therapeutic uses of such stem and progenitor cells upon thawing. In particular, the present invention relates to the therapeutic use of fetal or neonatal stem cells for hematopoietic (or immune) reconstitution. Hematopoietic reconstitution with the cells of the invention can be valuable in the treatment or prevention of various diseases and disorders such as anemias, malignancies, autoimmune disorders, and various immune dysfunctions and deficiencies. In another embodiment, fetal or neonatal hematopoietic stem and progenitor cells which contain a heterologous gene sequence can be used for hematopoietic reconstitution in gene therapy. In a preferred embodiment of the invention, neonatal or fetal blood cells that have been cryopreserved and thawed can be used for autologous (self) reconstitution.

Priority: US1992-950356 Applic. Date: 1992-09-24; US1988-269926 Applic. Date: 1988-11-10; US1987-119746 Applic. Date: 1987-11-12

Inventor: BOYSE EDWARD A [US]; BROXMEYER HAL E [US]; DOUGLAS GORDON W [US]


Patent No.: US6575900B1  Issued: 10/Jun/2003

Title: Meter with integrated database and simplified telemedicine capability

Applicant/Assignee: BECKMAN COULTER, INC

Application No.: 09/536881   Filing Date: 27/Mar/2000

Abstract:

Medical devices and methods for diagnostic data collection and transmission are described.Medical devices and methods for diagnostic data collection and transmission are described

Priority: US19990126979P Applic. Date: 1999-03-29

Inventor: ZWEIG STEPHEN E [US]; DOWNEY THOMAS D [US]


Patent No.: US6579223B2  Issued: 17/Jun/2003

Title: Blood pump

Applicant/Assignee:

Application No.: 09/928386   Filing Date: 13/Aug/2001

Abstract:

A pump especially designed for pumping blood comprises a bladder, the interior surface area and volume of which is changeable, i.e., it stretches and expands during the filling phase, and elastically contracts to its normal relaxed size during the ejection phase. The bladder has a fluid inlet and a fluid outlet. A device, such as a vacuum pump, alternately expands and contracts the interior surface area and volume of the bladder. Most of the interior surface area of the bladder expands and contracts in each cycle. One or more check valves or other means for causing substantially one-way fluid flow through the bladder are also provided.

The pump of the invention decreases the likelihood of blood clots forming in the pump, decreases the risk of damage to blood cells, improves the pumping characteristics of the device, and decreases or eliminates the chance of foreign fluids passing into the blood stream should a tear or break occur in the bladder.

Priority:

Inventor: PALMER ARTHUR [US]


Patent No.: US6579672B1  Issued: 17/Jun/2003

Title: Specimen collection fluid

Applicant/Assignee: NORTHERN GENERAL HOSPITAL CENTRAL SHEFFIELD UNIVERSITY HOSPITALS NHS TRUST ROYAL HALLAMSHIRE HOSPITAL

Application No.: 09/194333   Filing Date: 26/Apr/1999

Abstract:

A sterile aqueous specimen collection fluid containing a buffer, an aliphatic aldehyde at a concentration of 0.15M to 3.4M, and one or more heavy metal salts at a concentration of 0.2x10-3M to 0.2M, and having a pH of 6.8 to 8.0. Also disclosed is a method of colleting a specimen with such a fluid for haematological analysis.

Priority: GB19960011000 Applic. Date: 1996-05-24; WO1997GB01418 Applic. Date: 1997-05-23

Inventor: GRANGER VIVIAN [GB]; BARNETT DAVID [GB]


Patent No.: US6589169B1  Issued: 08/Jul/2003

Title: Systems, methods and computer program products for monitoring, diagnosing and treating medical conditions of remotely located patients undergoing anticoagulation therapy

Applicant/Assignee: HEALTHWARE CORPORATION

Application No.: 09/470774   Filing Date: 23/Dec/1999

Abstract:

Medical conditions of a plurality of remotely located patients are monitored, diagnosed, prioritized and treated using a central data processing system configured to communicate with and receive data from a plurality of respective patient monitoring systems. Patient monitoring systems are capable of receiving and storing patient data and may include a medicine dosage algorithm for using the stored patient data to generate medicine dosage recommendations to a patient. A central data processing system is configured to obtain patient data from each patient monitoring system and analyze the obtained patient data to identify medical conditions of each respective patient. A central data processing system may include medicine dosage algorithms. Identified patient medical conditions for each respective patient are displayed in selectable, prioritized order according to medical severity via one or more remotely located clients in communication with a central data processing system. Modifications to medicine dosages, medicine dosage algorithms, patient fixed or contingent self-monitoring schedules, as well as other treatment information, may be communicated directly to a patient or to a patient monitoring system.

Priority: US1998-042048 Applic. Date: 1998-03-13

Inventor: SURWIT RICHARD S [US]; ALLEN III LYLE M [US]; CUMMINGS SANDRA E [US]


Patent No.: US6592903B2  Issued: 15/Jul/2003

Title: Nanoparticulate dispersions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate

Applicant/Assignee: ELAN PHARMA INTERNATIONAL LTD

Application No.: 10/075443   Filing Date: 15/Feb/2002

Abstract:

Disclosed are solid dose nanoparticulate compositions comprising a poorly soluble active agent, at least one polymeric surface stabilizer, and dioctyl sodium sulfosuccinate (DOSS). The solid dose compositions exhibit superior redispersibility of the nanoparticulate composition upon administration to a mammal, such as a human or animal. The invention also describes methods of making and using such compositions.

Priority: US2000-666539 Applic. Date: 2000-09-21

Inventor: RYDE NIELS P [US]; RUDDY STEPHEN B [US]


Patent No.: US6593291B1  Issued: 15/Jul/2003

Title: Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease

Applicant/Assignee: ENTREMED, INC

Application No.: 09/418546   Filing Date: 14/Oct/1999

Abstract:

Compositions and methods effective in inhibiting abnormal or undesirable cell proliferation, particularly endothelial cell proliferation and angiogenesis related to neovascularization and tumor growth are provided. The compositions comprise naturally occurring, or synthetic proteins, peptides, or protein fragments capable of binding to components of the blood coagulation pathway. The compositions may be administered using a pharmaceutically acceptable carrier. The methods involve administering to a human or animal the composition described herein in a dosage sufficient to inhibit cell proliferation, particularly endothelial cell proliferation. The methods are useful for treating diseases and processes mediated by undesired and uncontrolled cell proliferation, such as cancer, particularly by inhibiting angiogenesis. Administration of the composition to a human or animal having prevascularized metastasized tumors is useful for preventing the growth or expansion of such tumors.

Priority: US1997-796850 Applic. Date: 1997-02-06

Inventor: GREEN SHAWN J [US]; PAPATHANASSIU ADONIA E [US]


Patent No.: US6605057B2  Issued: 12/Aug/2003

Title: Reinforced monorail balloon catheter

Applicant/Assignee: AVE CONNAUGHT MEDTRONIC AVE, INC

Application No.: 09/788896   Filing Date: 19/Feb/2001

Abstract:

The invention is a dilation catheter which comprises an elongated catheter shaft, a guide wire tube, and an angioplasty balloon. The distal end of the balloon is attached to the distal portion of the guide wire tube, and the proximal portion of the balloon is attached to the distal portion of the catheter shaft. A stiffening wire is attached to the inner wall of the catheter shaft at a plurality of points along its length. The distal extremity of the guide wire tube is decreased in size relative to the proximal portion of the guide wire tube. A fluid is contained within the guide wire lumen.

Priority: US1997-859654 Applic. Date: 1997-05-20; US1996-737055 Applic. Date: 1996-10-24

Inventor: FITZMAURICE THOMAS K [IE]; GILSON PAUL [IE]; DUANE PATRICK J E [IE]


Patent No.: US6608968B2  Issued: 19/Aug/2003

Title: CONVECTION BLOOD WARMING SYSTEM WITH DISPOSABLE FLATTENED TUBE ENVELOPE INCORPORATING PAPERBOARD "NEEDLE" FOR INSERTING ENVELOPE BETWEEN HEATING PLATES AND EMPLOYING ACTIVE AND PASSIVE INSULATION OF OUTLET FLOW PATH TO PROVIDE NORMOTHERMIC FLUID AT ZERO TO 600 MILLILITERS PER MINUTE

Applicant/Assignee:

Application No.: 10/292749   Filing Date: 12/Nov/2002

Abstract:

A thin, flat paperboard inserter or "needle" which is longer than the blood warmer heating plates is attached to the edge of the flattened tube envelope to enter the very narrow gap between the heating plates. The inserter is fed between the heating plates and advanced to emerge from the other end of the blood warmer where it is grasped and used to pull the envelope into operational position. A high air flow hydrophobic vent with check valve to prevent reverse flow is incorporated into the drip chamber to allow automatic priming and venting of air bubbles. A conductively heated and externally insulated drip chamber holder and a patient intravenous line that is passively insulated by a small annular air space extruded as part of the tube preserve heat in the warmed fluid, improving low flow rate performance.

A reusable external heater may optionally be applied to the distal portion of the patient line to provide normothermic fluid to the patient down to essentially zero flow rate.

Priority: US20010335862P Applic. Date: 2001-11-23

Inventor: BAKKE ALLAN P [US]


Patent No.: US6610027B1  Issued: 26/Aug/2003

Title: Hemodialysis

Applicant/Assignee:

Application No.: 09/570782   Filing Date: 17/Aug/2000

Abstract:

Accelerated hemodialysis is a novel method of extracorporeal blood tratment in which a high blood flow rate through the filter and a low blood flow to and from the patient is achieved by using accelerated hemodialysis lines composed of arterial line connecting blood from the patient to the filter, venous line connecting blood from the filter to the patient and a recirculation line carrying part of the blood from the venous line to the arterial line and is controlled by using 2 adjustable blood pumps or one blood pump and an adjustable valve situated at suitable sites of the circuit, with an optional safety program comparing the blood flow rates in different parts of the blood lines and the ultrafilteration rate to ensure safe operation.

Priority:

Inventor: EL HATU MOHAMED KALED MOHAMED [EG]


Patent No.: US6613573B1  Issued: 02/Sep/2003

Title: Method and apparatus for monitoring anti-platelet agents

Applicant/Assignee: HAEMOSCOPE CORPORATION

Application No.: 09/591371   Filing Date: 09/Jun/2000

Abstract:

A blood coagulation analyzer, such as the Thrombelastograph(R) (TEG(R)) blood coagulation analyzer is utilized to measure continuously in real time, the clotting process from the initial fibrin formation, through platelet-fibrin interaction and lysis to generate blood coagulation parameters. The measured blood coagulation parameters permit confirmation of the attainment of therapeutic level of GPIIb/IIIa receptor blockade

individualized dosing assessment to evaluate attainment of adequate GPIIb/IIIa receptor blockade

individualized dosing assessment required to reach adequate GPIIb/IIIa receptor blockade

illustration of the rate of diminishment of platelet inhibition or inhibition recovery after treatment with platelet-inhibition drugs

evaluation of the interaction effect of a combination of thrombolytic or any other agents or conditions effecting hemostasis and platelet-inhibiting agents on patient hemostasis.

Priority: US1999-255099 Applic. Date: 1999-02-22

Inventor: COHEN ELI [US]


Patent No.: US6617166B2  Issued: 09/Sep/2003

Title: Measurement of accelerated whole blood clotting time

Applicant/Assignee: PROPHYLAXIS LIMITED

Application No.: 09/907280   Filing Date: 17/Jul/2001

Abstract:

Disclosed is The method of in vitro testing of the state of the blood coagulation system. The Accelerated Whole Blood Clotting Time (A. W. B. C. T.) reflects the degree of over or under activity of the coagulation system of the blood.

Priority: GB19990001504 Applic. Date: 1999-01-22; WO2000GB00170 Applic. Date: 2000-01-24

Inventor: WHITE GRAY CHARLES RICHARDSON [GB]


Patent No.: US6620188B1  Issued: 16/Sep/2003

Title: Methods and apparatus for regional and whole body temperature modification

Applicant/Assignee: RADIANT MEDICAL, INC

Application No.: 09/138830   Filing Date: 24/Aug/1998

Abstract:

Methods and apparatus for temperature modification of selected body regions including an induced state of local hypothermia of the brain region for neuroprotection. A heat exchange catheter is provided with heat transfer fins projecting or extending outward from the catheter which may be inserted into selected blood vessels or body regions to transfer heat with blood or fluid in the selected blood vessels or body regions. Another aspect of the invention further provides methods and apparatus for controlling the internal body temperature of a patient. By selectively heating or cooling a portion of the catheter lying within a blood vessel, heat may be transferred to or from blood flowing within the vessel to increase or decrease whole body temperature or the temperature of a target region. Feed back from temperature sensors located within the patient's body allow for control of the heat transfer from the catheter to automatically control the temperature of the patient or of the target region within the patient. The apparatus may include a blood channeling sleeve that directs body fluid over a heat exchanger where the body fluid's temperature is altered, and then is discharged out the distal end of the sleeve to a desired location, for example, cooled blood to the brain for neuroprotection. The catheter may be used alone or in conjunction with other heat exchangers to cool one region of a patient's body while heating another.

Priority:

Inventor: GINSBURG LEGALLY INCAPACITATED [US]; MACHOLD TIMOTHY R [US]; DINEEN MICHAEL T [US]


Patent No.: US6620382B1  Issued: 16/Sep/2003

Title: Method and compositions for treatment of cancers

Applicant/Assignee: BIOPHERESIS TECHNOLOGIES, LLC

Application No.: 09/083307   Filing Date: 22/May/1998

Abstract:

A method to treat cancer uses ultrapheresis, refined to remove compounds of less than 120,000 daltons molecular weight, followed by administration of replacement fluid, to stimulate the patient's immune system to attack solid tumors. In the preferred embodiment, the patient is ultrapheresed using a capillary tube ultrafilter having a pore size of 0.02 to 0.05 microns, with a molecular weight cutoff of 120,000 daltons, sufficient to filter one blood volume. The preferred replacement fluid is ultrapheresed normal plasma. The patient is preferably treated daily for three weeks, diagnostic tests conducted to verify that there has been shrinkage of the tumors, then the treatment regime is repeated. The treatment is preferably combined with an alternative therapy, for example, treatment with an anti-angiogenic compound, one or more cytokines such as TNF, gamma interferon, or IL-2, or a procoagulant compound. The treatment increases endogenous, local levels of cytokines, such as TNF. This provides a basis for an improved effect when combined with any treatment that enhances cytokine activity against the tumors, for example, treatments using alkylating agents, doxyrubicin, carboplatinum, cisplatinum, and taxol. Alternatively, the ultrapheresis treatment can be combined with local chemotherapy, systemic chemotherapy, and/or radiation.

Priority:

Inventor: LENTZ M RIGDON [US]


Patent No.: US6623444B2  Issued: 23/Sep/2003

Title: Ultrasonic catheter drug delivery method and device

Applicant/Assignee: ADVANCED MEDICAL APPLICATIONS, INC

Application No.: 09/813577   Filing Date: 21/Mar/2001

Abstract:

An ultrasonic catheter drug delivery device comprises an ultrasound transducer to produce ultrasonic waves, which transducer is mechanically attached to a catheter body or chamber. The ultrasonic transducer has a distal tip with a distal radiation surface, and when a therapeutic agent from a fluid source is directed to the catheter body or chamber, the radiation surface creates ultrasonic pressure and delivers liquid and simultaneously ultrasonic energy to a patient's vascularity or a selected body lumen. The method applies therapeutic agent and ultrasonic waves to the vascular area, lung or any body lumen without requiring direct contact between ultrasound transducer and body, dissolves blood clots, and stimulates tissue cells.

Priority:

Inventor: BABAEV ELIAZ [US]


Patent No.: US6623472B1  Issued: 23/Sep/2003

Title: Method for inducing therapeutically-effective proteins

Applicant/Assignee: ORTHOGEN GENTECHNOLOGIC. GMBH

Application No.: 09/485836   Filing Date: 06/Jul/2000

Abstract:

A method for inducing therapeutically-effective protein includes selecting a syringe having inner structures coated with an inductor, disposing a therapeutically-effective protein therein with a body fluid and incubating the syringe and its contents. The inductor can be coated onto the interior of the syringe itself or can be placed on other structures and inserted into the interior of the syringe. A variety of inductors and body fluids may be used. Anticoagulants may also be used.

Priority: DE19971035537 Applic. Date: 1997-08-16; EP19980109186 Applic. Date: 1998-05-20; WO1998EP04866 Applic. Date: 1998-08-05

Inventor: REINCKE JULIO [DE]; MEIJER HANS [DE]; WEHLING PETER [DE]


Patent No.: US6625486B2  Issued: 23/Sep/2003

Title: Method and apparatus for intracellular delivery of an agent

Applicant/Assignee: ADVANCED CARDIOVASCULAR SYSTEMS, INC

Application No.: 09/833149   Filing Date: 11/Apr/2001

Abstract:

A method and an apparatus for electropermeabilization-mediated intracellular delivery of an agent are provided.

Priority:

Inventor: LUNDKVIST ANDRE-JEAN S [US]; ALDRIDGE ELISA J [US]; BHAT VINAYAK D [US]; SLATER RENEE C [US]


Patent No.: US6627193B1  Issued: 30/Sep/2003

Title: Methods and compositions for control of blood coagulation

Applicant/Assignee: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC

Application No.: 09/482500   Filing Date: 13/Jan/2000

Abstract:

Methods for controlling blood coagulation, and suitable pharmaceutical compositions that include a polypeptide that enhances the anticoagulation process (or inhibitors thereof for reversing the anticoagulation process) are provided.

Priority: US19990115869P Applic. Date: 1999-01-13

Inventor: TRAVIS JAMES [US]; IMAMURA TAKAHISA [JP]; POTEMPA JAN [US]


Patent No.: US6638931B1  Issued: 28/Oct/2003

Title: Aminoguanidines and alkoxyguanidines as protease inhibitors

Applicant/Assignee: 3-DIMENSIONAL PHARMACEUTICALS, INC

Application No.: 09/722363   Filing Date: 28/Nov/2000

Abstract:

Aminoguanidine and alkoxyguanidine compounds, including compounds of the formula:wherein X is O or NR<9 >and R<1>-R<4>, R<6>-R<9>, R<11>, R<12>, R, R, R, Y, Z, n and m are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit proteolytic enzymes such as thrombin are described. Also described are methods for preparing the compounds of Formula I. The novel compounds of the present invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, thrombin, plasmin and factor Xa. Certain of the compounds exhibit antithrombotic activity via direct, selective inhibition of thrombin, or are intermediates useful for forming compounds having antithrombotic activity. The invention includes a composition for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation in a mammal, comprising a compound of the invention in a pharmaceutically acceptable carrier. Other uses of compounds of the invention are as anticoagulants either embedded in or physically linked to materials used in the manufacture of devices used in blood collection, blood circulation, and blood storage, such as catheters, blood dialysis machines, blood collection syringes and tubes, blood lines and stents.

Priority: US1997-979234 Applic. Date: 1997-11-26; US19960031822P Applic. Date: 1996-11-26

Inventor: TOMCZUK BRUCE E [US]; SOLL RICHARD M [US]; LU TIANBAO [US]; FEDDE CYNTHIA L [US]; ILLIG CARL R [US]; MARKOTAN THOMAS P [US]; STAGNARO THOMAS P [US]


Patent No.: US6641552B1  Issued: 04/Nov/2003

Title: Blood collection and separation system

Applicant/Assignee: HAEMONETICS CORPORATION

Application No.: 09/494848   Filing Date: 01/Feb/2000

Abstract:

A system compact enough to be located entirely beside the donor's chair, and able to process the blood while the donor is still resting in the chair after having donated the blood. The separated blood components (plasma and red blood cells) may be stored in their individual optimum environments immediately after the whole blood is drawn, and the blood does not need to be transported back to a separation laboratory for processing. The system includes a needle (72) (or other cannula-like device) for insertion into a vein of the donor and drawing whole blood therethrough, a rotor (2a) for holding the blood after it is drawn, and a motor (50) for spinning the rotor so as to cause the blood to separate into components, for example, plasma and red blood cells. In a preferred embodiment two containers are used: the first container (92) for containing an anticoagulant, which is preferably added to the whole blood as it is drawn from the donor, and then for storing the plasma after it has been separated from the red blood cells, and the second container (91) for storing the separated red blood cells. The system further includes tubing (73), which may have valving (81) built into it and which may be acted on externally, so as to direct the blood components in the desired manner.

Priority: US1998-027072 Applic. Date: 1998-02-20; US1996-662617 Applic. Date: 1996-06-13; US1995-482617 Applic. Date: 1995-06-07

Inventor: KINGSLEY GORDON F [US]; HEADLEY THOMAS D [US]; HALPERN LISE N [US]


Patent No.: US6645157B2  Issued: 11/Nov/2003

Title: Cuff for blood pressure monitor

Applicant/Assignee: OMRON CORPORATION

Application No.: 10/047994   Filing Date: 17/Jan/2002

Abstract:

To provide a cuff for a blood pressure monitor having a curled elastic member which is easily attached to an arm, does not make the subject feel pain when attached, and exhibits a characteristic of excellent fitting.A curled elastic member 1A has one end portion 12 extending outward so as to enwind the other end portion 11 inward. Specifically, from the other end portion 11 to a position where the other end portion 11 is mutually opposite, the radius of curvature gently increases. From the mutually opposite portion to the one end portion 12, the radius of curvature largely increases.

Priority: JP20010013921 Applic. Date: 2001-01-23

Inventor: INAGAKI TAKASHI [JP]


Patent No.: US6645768B1  Issued: 11/Nov/2003

Title: Reagent and kit for determining global coagulability and hemostatic potential

Applicant/Assignee: BIOMERIEUX, INC

Application No.: 09/698589   Filing Date: 27/Oct/2000

Abstract:

A reagent and kit are disclosed for determining if a patient is hypercoagulable, hypocoagulable or normal. The test involves providing a test sample from the patient and initiating coagulation in the sample in the presence of an activator, which is added to the sample in an amount which will result in intrinsic tenase-dependent fibrin. Then the formation of the intrinsic tenase-dependent fibrin polymerization is monitored over time so as to derive a time-dependent profile, with the results of the fibrin polymerization monitoring determining whether the patient is hypercoagulable, normal or hypocoagulable. The coagulation activator is added in an amount that triggers a thrombin explosion that is dependent on the propagation phase and amplification pathways. In this way, a single assay can assess the hemostatic potential of a sample.

Priority:

Inventor: TEJIDOR LILIANA [US]; BAGLIN TREVOR [GB]; DOOBAY HEMA [US]; LUDDINGTON ROGER [GB]; FISCHER TIMOTHY J [US]


Patent No.: US6652476B2  Issued: 25/Nov/2003

Title: Method and apparatus for producing blood component products

Applicant/Assignee: GAMBRO, INC

Application No.: 09/981932   Filing Date: 17/Oct/2001

Abstract:

A method and apparatus for producing blood component products. In one embodiment, a plurality of a predetermined type of blood component is harvested from a source of whole blood. At least two on-line yield determination techniques are utilized to determine the yield for the harvested blood components. One is a predetermined yield prediction technique and the second is a predetermined yield monitoring technique, each of which are individually calibrated in relation to a predetermined off-line yield determination technique. The predetermined yield prediction and monitoring techniques each provide the yield for the harvested blood components and each is then utilized to provide a determined yield. Consequently, when the harvested blood components are packaged the determined yield my be associated therewith, thereby providing a blood component product.

Priority: US1992-912973 Applic. Date: 1992-07-10

Inventor: LANGLEY ROBERT WARNER [US]; DUMONT LARRY JOE [US]


Patent No.: US6673627B2  Issued: 06/Jan/2004

Title: Whole blood collection device

Applicant/Assignee: BIOSAFE MEDICAL TECHNOLOGIES, INC

Application No.: 10/131768   Filing Date: 24/Apr/2002

Abstract:

A system for collecting a whole blood sample includes a fill port (32), a metering chamber (72), a gasket or seal (16) and a reservoir (74). The gasket or seal (16) is positioned to a fill position, and a sample of whole blood is received in the metering chamber (72) until the metering chamber (72) is full. Then the seal (16) is moved to a closed position, thereby moving blood from the metering chamber (72) to the reservoir (74) and also sealing the reservoir (74). The seal (16), metering chamber (72) and fill port (32) together define a passageway at least a portion of which is coated with an anticoagulant. A diluting liquid contained in the reservoir (74) is mixed with the whole blood to dilute and stabilize the whole blood in the reservoir (74) for later analysis of one or more selected blood components.

Priority: US1999-464757 Applic. Date: 1999-12-16

Inventor: TYRRELL STEVEN P [US]; GRZEDA BARBARA R [US]


Patent No.: US6682502B2  Issued: 27/Jan/2004

Title: APPARATUS FOR EMERGENCY TREATMENT OF PATIENTS EXPERIENCING A THROMBOTIC VASCULAR OCCLUSION

Applicant/Assignee: TRANSON, LLC

Application No.: 10/016773   Filing Date: 02/Nov/2001

Abstract:

Acute care method and apparatus for treating a patient experiencing thrombotic vascular occlusion includes introducing a selected dose of an active agent proximate a vascular occlusion in the patient in order to lyse the vascular occlusion and radiating the vascular occlusion and active agent.

Priority: US1999-277359 Applic. Date: 1999-03-26

Inventor: BOND GEOFFREY [US]; PETERSON THOMAS M [US]


Patent No.: US6693177B1  Issued: 17/Feb/2004

Title: Process for preparation of a biomarker specific for O-acetylated sialic acid useful for diagnosing, monitoring treatment outcome, and predicting relapse of lymphoblastic leukemia

Applicant/Assignee:

Application No.: 09/453555   Filing Date: 03/Dec/1999

Abstract:

The invention relates to a novel process for preparation of a biomarker specific for O-acetylated sialic acid and useful for the diagnosis, monitoring outcome of treatment and prediction of relapse of acute lymphoblastic leukemia, said process comprising the steps of (I) separating serum from the blood of patients of acute lymphoblastic leukemia

(ii) separation of low molecular weight fractions and galactose binding proteins from the serum on affinity matrix

(iii) passing the galactose free protein fraction obtained in step (ii) over another affinity matrix to capture O-acetyl sialic acid specific protein fraction

(iv) eluting specific protein fraction with a buffer at alkaline pH in the range of 8.0-11.0 followed by immediate neutralization of the fraction

(v) passing O-acetyl sialic acid specific protein obtained in step (iv) over Agarose column to get O-acetyl sialic acid specific antibody and eluting the said antibody with an appropriate buffer at acidic pH, followed by immediate neutralization of the fraction and dialyzing the neutralized protein to get purified disease specific antibody as biomarker and a method of diagnosing, monitoring outcome of treatment and prediction of relapse of acute lymphoblastic leukemia using the biomarker obtained by the novel process.

Priority: IN1999DE01192 Applic. Date: 1999-09-08

Inventor: MANDAL CHITRA [IN]; PAL SANTANU [IN]; CHATTERJEE MITALI [IN]


Patent No.: US6696261B2  Issued: 24/Feb/2004

Title: Pyrogenicity test for use with automated immunoassay systems

Applicant/Assignee: BAXTER INTERNATIONAL INC NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL

Application No.: 09/727561   Filing Date: 01/Dec/2000

Abstract:

The invention concerns an improved pyrogenicity test for use in automated immunoassay systems, in which a sample is incubated with a monocyte-containing reagent in a pyrogen-free assay system preferably comprising a surface coated with pyrogen-free anti-cytokine antibodies. The invention also concerns pyrogen-free assay systems coated with pyrogen-free antibodies for use in these tests. The invention also relates to a test to measure the basal production of endogenous mediators of the inflammatory response by leukocytes and a method of measuring the capacity of a leukocyte to respond to a stimuli.

Priority: US19990168972P Applic. Date: 1999-12-03

Inventor: PATEL MEHUL [US]; POOLE STEPHEN [GB]


Patent No.: US6699994B1  Issued: 02/Mar/2004

Title: Biaryl compounds as serine protease inhibitors

Applicant/Assignee: BIOCRYST PHARMACEUTICALS, INC

Application No.: 10/127460   Filing Date: 23/Apr/2002

Abstract:

Compounds of formula (I) are useful as inhibitors of trypsin like serine protease enzymes such as thrombin, factor VIIa, factor Xa, TF/FVIIa, and trypsin. These compounds could be useful to treat and/or prevent clotting disorders, and as anticoagulating agents.

Priority: WO2001US32582 Applic. Date: 2001-10-22; US20010281735P Applic. Date: 2001-04-06

Inventor: BABU YARLAGADDA S [US]; ROWLAND R SCOTT [US]; CHAND POORAN [US]; KOTIAN PRAVIN L [US]; EL-KATTAN YAHYA [US]; NIWAS SHRI [US]


Patent No.: US6706283B1  Issued: 16/Mar/2004

Title: Controlled release by extrusion of solid amorphous dispersions of drugs

Applicant/Assignee: PFIZER INC

Application No.: 09/495061   Filing Date: 31/Jan/2000

Abstract:

Controlled release dosage forms for low solubility drugs are disclosed wherein an amorphous solid dispersion of the drug is coated with a non-dissolving and non-eroding coating that controls the influx of water to the core so as to cause extrusion of a portion of the core, as well as a method of treating a disease or disorder comprising administering such dosage form to a person.

Priority: US19990119406P Applic. Date: 1999-02-10

Inventor: APPEL LEAH E [US]; CURATOLO WILLIAM J [US]; HERBIG SCOTT M [US]; NIGHTINGALE JAMES A S [US]; THOMBRE AVINASH G [US]


Patent No.: US6706536B1  Issued: 16/Mar/2004

Title: Method and apparatus for processing coagulation studies, chemistry procedures and the like

Applicant/Assignee: WADA, INC

Application No.: 09/724529   Filing Date: 28/Nov/2000

Abstract:

A method and apparatus for processing coagulation studies, chemistry procedures and the like, the apparatus including a container having a space for containing a body fluid sample therein, a covered opening and being provided with optically clear sides and a uniform cross-sectional configuration over at least a portion of the container, the cover being pierceable to permit the selective addition of reagents to be delivered into the container space, and the apparatus and method facilitating carrying out analytical procedures on body fluid sample when it is contained in the container. The apparatus further including instrumentation for optically reading and analyzing the fluid sample and adding appropriate reagents while the sample it is in the container.

Priority:

Inventor: CARROLL WALLACE E [US]; JACKSON R DAVID [US]


Patent No.: US6706765B2  Issued: 16/Mar/2004

Title: Aminoguanidines and alkoxyguanidines as protease inhibitors

Applicant/Assignee: 3-DIMENSIONAL PHARMACEUTICALS, INC

Application No.: 10/359078   Filing Date: 06/Feb/2003

Abstract:

Aminoguanidine and alkoxyguanidine compounds, including compounds of the formula:wherein X is O or NR<9 >and R<1>-R<4>, R<6>-R<9>, R<11>, R<12>, R, R, R, Y, Z, n and m are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit proteolytic enzymes such as thrombin are described. Also described are methods for preparing the compounds of Formula I. The novel compounds of the present invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, thrombin, plasmin and factor Xa. Certain of the compounds exhibit antithrombotic activity via direct, selective inhibition of thrombin, or are intermediates useful for forming compounds having antithrombotic activity.

The invention includes a composition for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation in a mammal, comprising a compound of the invention in a pharmaceutically acceptable carrier. Other uses of compounds of the invention are as anticoagulants either embedded in or physically linked to materials used in the manufacture of devices used in blood collection, blood circulation, and blood storage, such as catheters, blood dialysis machines, blood collection syringes and tubes, blood lines and stents.

Priority: US1997-979234 Applic. Date: 1997-11-26; US19960031822P Applic. Date: 1996-11-26

Inventor: TOMCZUK BRUCE E [US]; SOLL RICHARD M [US]; LU TIANBAO [US]; FEDDE CYNTHIA L [US]; ILLIG CARL R [US]; MARKOTAN THOMAS P [US]; STAGNARO THOMAS P [US]


Patent No.:
US6713246B1  Issued: 30/Mar/2004

Title: Method of producing interleukin-1 receptor antagonist in a syringe filled with blood

Applicant/Assignee: ORTHOGEN AG

Application No.: 09/890723   Filing Date: 01/Aug/2001

Abstract:

The present invention relates to a method for producing interleukin-1 receptor antagonists, a prophylatically or therapeutically effective protein. A syringe is filled with a body fluid and incubated. The prophylatically or therapeutically effective protein is then produced in the body fluid.

Priority: DE19991003876 Applic. Date: 1999-02-01; WO2000EP00762 Applic. Date: 2000-01-31

Inventor: REINECKE JULIO [DE]; MEIJER HANS [DE]; WEHLING PETER [DE]


Patent No.: US6718208B2  Issued: 06/Apr/2004

Title: Method and system for nerve stimulation prior to and during a medical procedure

Applicant/Assignee: MEDTRONIC, INC

Application No.: 10/207725   Filing Date: 29/Jul/2002

Abstract:

A method of performing a medical procedure, such as surgery, is provided. A nerve is stimulated in order to adjust the beating of the heart to a first condition, such as a stopped or slowed condition. The medical procedure is performed on the heart or another organ. The stimulation of the nerve is stopped in order to adjust the beating of the heart to a second condition, such as a beating condition. The heart itself may also be stimulated to a beating condition, such as by pacing. The stimulation of the nerve may be continued in order to allow the medical procedure to be continued. Systems and devices for performing the medical procedure are also provided.

Priority: US2000-670441 Applic. Date: 2000-09-26; US1999-433323 Applic. Date: 1999-11-03; US1998-070506 Applic. Date: 1998-04-30; US1996-640013 Applic. Date: 1996-04-30

Inventor: HILL MICHAEL R S [US]; JAHNS SCOTT E [US]; KEOGH JAMES R [US]


Patent No.: US6719724B1  Issued: 13/Apr/2004

Title: Central venous line catheter having multiple heat exchange elements and multiple infusion lumens

Applicant/Assignee: ALSIUS CORPORATION

Application No.: 09/816645   Filing Date: 23/Mar/2001

Abstract:

An intravenous catheter system (apparatus and method) for controlling patient temperature includes a generally tubular elongated body having lumens for circulating a heat exchange fluid in a plurality of heat exchange elements provided at spaced intervals along the length of the elongated body. The heat exchange elements preferably comprise inflatable balloons. Heat exchange occurs between the fluid in the balloons and blood in the blood vessel. Each balloon preferably is sized such that, when inflated, each balloon blocks no more than approximately 30% to 75% of the blood vessel in which it is intubated. The catheter preferably has two to four balloons, each of which may have a different shape. The catheter also preferably has three to five infusion lumens for providing access to the patient's blood at different locations in the patient's bloodstream.

Priority: US1999-253109 Applic. Date: 1999-02-19

Inventor: WALKER BLAIR D [US]; EVANS SCOTT M [US]; NODA WAYNE A [US]


Patent No.: US6730054B2  Issued: 04/May/2004

Title: Blood collection systems and methods that derive estimated effects upon the donor's blood volume and hematocrit

Applicant/Assignee: BAXTER INTERNATIONAL INC

Application No.: 09/789183   Filing Date: 20/Feb/2001

Abstract:

Blood processing systems and methods convey blood drawn from a donor through a blood processing circuit to separate the blood into at least one targeted blood component for collection. The systems and methods derive an estimated effect of the procedure upon the donor. The estimated effect can be expressed in terms of a net blood fluid volume loss, or as a hematocrit of the donor after completion of the desired blood collection procedure. The systems and methods present the estimated effect to an operator for viewing, reading, or offloading.

Priority: US1999-419742 Applic. Date: 1999-10-16

Inventor: PIERCE JENNIFER A [US]; PATNO TIMOTHY J [US]; CAIRONE ROBERT [US]; FOLEY JOHN T [US]


Patent No.: US6730055B2  Issued: 04/May/2004

Title: Extracorporeal blood processing methods and apparatus

Applicant/Assignee: GAMBRO INC

Application No.: 09/803304   Filing Date: 09/Mar/2001

Abstract:

Methods and apparatus particularly involving the separation of blood into blood components and the collection of such components are disclosed. In one aspect, an extracorporeal method for the collection of plasma and red blood cells is provided, wherein the collection of plasma and red blood cells may occur simultaneously or subsequently utilizing the same dual stage blood processing vessel. The flow of blood to the blood processing vessel and return of uncollected blood components may be provided via a single needle, wherein blood is removed from and returned to a donor/patient during alternating blood removal and blood return submodes. Platelet separation and collection options are also described. In either case, prior to red blood cell collection, a set-up phase may be carried out to set a predetermined hematocrit and AC ratio.

Replacement fluid delivery may optionally also be provided either substantially continuously during any collection phase(s) and/or in a bolus mode.

Priority: US20000188133P Applic. Date: 2000-03-09

Inventor: BAINBRIDGE MARLENE [US]; KELLER MURIEL [US]; GORDON TIMOTHY M [US]; MCATEER MICHAEL J [US]; BUTZKE SCOTT D [US]


Patent No.: US6730120B2  Issued: 04/May/2004

Title: Medical device for delivering a therapeutic substance and method therefor

Applicant/Assignee: MEDTRONIC, INC

Application No.: 09/769423   Filing Date: 26/Jan/2001

Abstract:

A device useful for localized delivery of a therapeutic material is provided. The device includes a structure including a porous material

and a water-insoluble salt of a therapeutic material dispersed in the porous material. The water-insoluble salt is formed by contacting an aqueous solution of a therapeutic salt with a heavy metal water-soluble salt dispersed throughout a substantial portion of the porous material. The heavy metal water-soluble salt can be dispersed in the porous material so that the device can be sterilized and the therapeutic material can be loaded in the device in situ, for example, just prior to use. The therapeutic material is preferably a heparin or heparin derivative or analog which renders the material antithrombotic as an implantable or invasive device.

Priority: US1997-877532 Applic. Date: 1997-06-17

Inventor: BERG ERIC P [US]; DINH THOMAS Q [US]


Patent No.: US6730490B2  Issued: 04/May/2004

Title: In vitro methods for screening for blood coagulation disorders using metal ions

Applicant/Assignee: INSTRUMENTATION LABORATORY, S.P.A

Application No.: 10/050441   Filing Date: 16/Jan/2002

Abstract:

In vitro methods for qualitative screening and/or quantitative determination of the functional activity of components of the Protein C anticoagulant pathway of blood coagulation are described. The methods entail measuring the conversion rate of a substrate by an enzyme, the activity of which is related to the Protein C anticoagulant activity, in a blood sample of a human comprising coagulation factors and said substrate, after at least partial activation of coagulation through the intrinsic, extrinsic or common pathway and triggering coagulation by adding calcium ions

and comparing said conversion rate with the conversion rate of a normal human blood sample determined in the same way. The methods include the addition of additional metal ions to the sample to enhance activity, sensitivity and resolution. Kits and reagents for use in the methods are also provided.

Priority: EP19980105043 Applic. Date: 1998-03-19; US1999-273413 Applic. Date: 1999-03-19

Inventor: ROSEN BERT STEFFEN [SE]; HALL CHRISTINA MARIA YVONNE [SE]


Patent No.: US6730672B2  Issued: 04/May/2004

Title: Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents

Applicant/Assignee: ZENECA LIMITED

Application No.: 09/800745   Filing Date: 08/Mar/2001

Abstract:

The invention concerns compounds of formula (I)wherein each of G<1>, G<2 >and G<3 >is CH or N

m is 1 or 2

R<1 >includes hydrogen, halogeno and (1-4C)alkyl

M<1 >is a group of the formula: NR<2-L> <1>-T<1>R<3 >in which R<2 >and R<3 >together form a (1-4C)alkylene group, L<1 >includes (1-4C)alkylene, and T<1 >is CH or N

A may be a direct link

M<2 >is a group of the formula: (T<2>R<4>)r-L<2>-T<3>R<5 >in which r is 0 or 1, each of T<2 >and T<3 >is CH or N, each of R<4 >and R<5 >is hydrogen or (1-4C)alkyl, or R<4 >and R<5 >together form a (1-4C)alkylene group, and L<2 >includes (1-4C)alkylene

M<3 >may be a direct link to X

X includes sulphonyl

and Q includes naphthyl and a heterocyclic moiety

or a pharmaceutically-acceptable salt thereof

processes for their preparation, pharmaceutical compositions containing them and their use as antithrombotic or anticoagulant agents.

Priority: GB19940019341 Applic. Date: 1994-09-26; GB19940025789 Applic. Date: 1994-12-21; GB19950011051 Applic. Date: 1995-06-01; WO1995GB02285 Applic. Date: 1995-09-25; US1999-369857 Applic. Date: 1999-08-09; US1997-817031 Applic. Date: 1997-03-26

Inventor: FAULL ALAN WELLINGTON [GB]; STOCKER ANDREW [GB]; MAYO COLETTE MARIE [GB]; PRESTON JOHN [GB]


Patent No.: US6738661B1  Issued: 18/May/2004

Title: Apparatus and methods for the controllable modification of compound concentration in a tube

Applicant/Assignee: BIOSYNERGETICS, INC

Application No.: 09/692857   Filing Date: 20/Oct/2000

Abstract:

Apparatus and methods for delivery of a drug or compound into a fluid flowing within a tube or catheter. In one embodiment a catheter includes an inner surface coated with a polymer matrix such as a hydrogel. The hydrogel includes captured within it a therapeutic agent. The method of capture may be by various means, including photolabile bonds between the therapeutic agent and the hydrogel. The therapeutic agent is released from the hydrogel by the application of energy to the hydrogel, such as by a laser emitting a wavelength which resonates and breaks the photolabile bond. The released therapeutic agent diffuses out of the hydrogel into the liquid flowing within a lumen of the catheter.

Priority: US19990170051P Applic. Date: 1999-12-10; US19990161130P Applic. Date: 1999-10-22

Inventor: NYHART JR ELDON H [US]


Patent No.: US6740331B1  Issued: 25/May/2004

Title: Apparatus for the delivery of drugs or gene therapy into a patient's vasculature and methods of use

Applicant/Assignee: GLOBAL GENE THERAPIES, INC

Application No.: 09/648257   Filing Date: 25/Aug/2000

Abstract:

Methods and apparatus are provided for delivering drugs or gene therapy within a patient's vessel. In a preferred embodiment, the apparatus comprises a material eluting a bioactive substance held in place within the patient's vessel by an anchor. The anchor and eluting material are sized and/or collapsible from a delivery configuration, in which the anchor and material may be delivered into the patient's vasculature within a delivery sheath, to a deployed configuration, wherein the anchor engages an interior wall of the patient's vessel. The eluting material may elute recombinant genes, drugs, or any other bioactive substance.

Priority:

Inventor: BATES MARK C [US]; HORZEWSKI MICHAEL J [US]


Patent No.: US6743191B1  Issued: 01/Jun/2004

Title: Substitution infusion fluid and citrate anticoagulation

Applicant/Assignee: EDWARDS LIFESCIENCES AG

Application No.: 09/959543   Filing Date: 23/Oct/2001

Abstract:

The invention relates to a substitution infusion fluid for hemofiltration of a specific composition. The use of said substitution infusion fluid significantly reduces the risk of the occurrence of abnormalities in a patient undergoing pure hemofiltration. The invention also relates to process for pure hemofiltration of blood wherein said substitution infusion fluid is used. The invention also relates to a matching citrate anticoagulation fluid of a specific composition. The invention also relates to a process for pure hemofiltration of blood wherein said substitution infusion fluid is used in combination with said citrate anticoagulation fluid. The use of said substitution infusion fluid in combination with said citrate anticoagulation fluid significantly further reduces the risk of the occurrence of abnormalities in a patient undergoing pure hemofiltration.

Priority: EP19990201302 Applic. Date: 1999-04-26; WO2000EP03583 Applic. Date: 2000-04-20

Inventor: CHANG PE CHOU [NL]


Patent No.: US6743192B1  Issued: 01/Jun/2004

Title: Apheresis apparatus and method for producing blood products

Applicant/Assignee:

Application No.: 09/392880   Filing Date: 09/Sep/1999

Abstract:

An apheresis machine is provided, which can efficiently produce concentrated platelets products without excessively collecting platelets.The apheresis machine 10 comprises a centrifuge 11 having an inlet port PT1 and an outlet port PT2 for separating whole blood into a lower density component, an intermediate density component and a higher density component, a first container 18 connected to receive the lower density component from the outlet port PT2 and return it through the inlet port PT1 to the centrifuge 11, a first pump P1 operated to collect whole blood from the inlet port PT1 to the centrifuge 11, a second pump P2 operated to supply the lower density component from the first container 18, and means for variable controlling the centrifuge 11 and/or the second pump P2 for increasing or decreasing a process volume of whole blood in the centrifuge in response to at least one characteristic associated with the whole blood.

Priority: JP19980258631 Applic. Date: 1998-09-11

Inventor: SAKOTA KOICHIRO [JP]; KAWAMURA MASAHIRO [JP]


Patent No.: US6745962B2  Issued: 08/Jun/2004

Title: Small-scale mill and method thereof

Applicant/Assignee: ELAN CORPORATION, PLC

Application No.: 10/037566   Filing Date: 19/Oct/2001

Abstract:

A small-scale or micro media-mill and a method of milling materials or products, especially pharmaceutical products, use a dispersion containing attrition milling media and the product to be milled. The milling media can be polymeric, formed of polystyrene or cross-linked polystyrene, having a nominal diameter of no greater than 500 microns. Other sizes include 200 microns and 50 microns and a mixture of these sizes. The mill has a relatively small vessel having an opening, an agitator, a coupling and a motor. The agitator can have a rotor and a shaft extending therefrom. The rotor can be cylindrical or have other configurations, and can have tapered end surfaces. The coupling can close the vessel opening, or attaching the coupling to the motor can close the opening. The coupling has an opening through which the rotor shaft extends into the motor.

A sealing mechanism, such as a mechanical or lip seals the shaft while permitting the rotor shaft to rotate. The vessel can contain one or more ports for circulating the dispersion, where milling can be made in batches or recirculated through the milling chamber. The media can be retained in the vessel or recirculated along with the process fluid. The rotor is dimensioned so that its outer periphery is spaced with a small gap from an inner surface of the vessel. The vessel also can have a way of cooling the dispersion.

Priority: US2000-583893 Applic. Date: 2000-05-31; US19990137142P Applic. Date: 1999-06-01

Inventor: REED ROBERT GARY [US]; CZEKAI DAVID A [US]; BOSCH HENRY WILLIAM [US]; RYDE NIELS-PETER MOESGAARD [US]


Patent No.: US6746478B2  Issued: 08/Jun/2004

Title: Stent formed from encapsulated stent preforms

Applicant/Assignee: IOWA-INDIA INVESTMENTS COMPANY, LIMITED VASCULAR CONCEPTS HOLDINGS LIMITED

Application No.: 10/286805   Filing Date: 04/Nov/2002

Abstract:

The invention relates to a stent for implantation in a body lumen. The stent is formed from stent preforms. Each stent preform includes an elongated metal core, an outer sheath disposed about the core, and caps disposed on the ends of the outer sheath. The outer sheath and caps encapsulate the metal core to prevent the core from directly contacting the body lumen. In an alternative embodiment, an intermediate sleeve is disposed between the core and outer sheath. In another embodiment, a cover or coating may be disposed about the outer sheath.

Priority: US1999-440926 Applic. Date: 1999-11-16

Inventor: JAYARAMAN SWAMINATHAN [US]


Patent No.: US6752777B1  Issued: 22/Jun/2004

Title: Blood component collecting apparatus

Applicant/Assignee: TERUMO KABUSHIKI KAISHA

Application No.: 09/412571   Filing Date: 05/Oct/1999

Abstract:

Platelets are collected from blood by delivering blood from a blood source to a centrifugal separator and operating the separator to separate plasma from the blood. The separated plasma is collected in a plasma collecting bag. After a predetermined amount of plasma has been collected in the bag, the plasma is circulated between the bag and the separator. That procedure is repeated at least once to build-up the amount of collected blood. Then platelets are collected by delivering additional blood to the separator and circulating plasma between the separator and the plasma collecting bag at an accelerating circulation rate while rotating the rotor to remove platelets from the separator. The platelets are collected in a platelet collecting bag. Then, blood remaining in the separator is returned to the blood source.

Priority: JP19970176499 Applic. Date: 1997-06-16; JP19980299135 Applic. Date: 1998-10-05; US1998-094593 Applic. Date: 1998-06-15

Inventor: TAKAGI YOSHIKI [JP]; SUZUKI ATSUSHI [JP]


Patent No.: US6755802B2  Issued: 29/Jun/2004

Title: Whole blood sampling device

Applicant/Assignee: BECKMAN COULTER, INC

Application No.: 10/139569   Filing Date: 06/May/2002

Abstract:

A portable hand-held blood sampling device having a self-filling capability includes a blood separation filter. The filter has a plurality of pores sized to permit passage of selected blood constituents such as blood plasma through the device. The device has a separated blood conduit that extends beyond the outlet of the device and is shaped for easy penetration into a self-sealing septum of a blood analyzer. An annular shield extends from the device outlet beyond the conduit to prevent inadvertent contact of the conduit by a user.

Priority:

Inventor: BELL MICHAEL L [US]


Patent No.: US6761856B2  Issued: 13/Jul/2004

Title: Apparatus for determining platelet inhibitor response

Applicant/Assignee: MEDTRONIC, INC

Application No.: 10/410003   Filing Date: 09/Apr/2003

Abstract:

An apparatus is provided for performing an activated clotting time test on a sample of blood containing platelets, the apparatus comprising a plurality of test cells, said cells being adapted for receiving an aliquot portion of said sample, wherein each of said cells comprises an anticoagulant and a platelet inactivating agent, and wherein at least one of said cells further comprises a clotting activator, wherein a clotting time is determined for each of said aliquot portions, and wherein a relative clotting time for each of said aliquot portions comprising the clotting activator is determined as compared to a reference clotting time for said at least one cell containing no clotting activator, wherein said relative clotting times in said cells are determinative of the clotting activation of said clotting activator.

Priority: US2001-811216 Applic. Date: 2001-03-16; US1999-225051 Applic. Date: 1999-01-04; US1996-640277 Applic. Date: 1996-04-30

Inventor: BAUGH ROBERT F [US]; LANE CAROLE G [US]; WILSON ADRIAN C [US]


Patent No.: US6761895B2  Issued: 13/Jul/2004

Title: Drug delivery system for averting pharmacokinetic drug interaction and method thereof

Applicant/Assignee: YAMANOUCHI PHARMACEUTICAL CO., LTD

Application No.: 09/834414   Filing Date: 12/Apr/2001

Abstract:

The present invention is a system for averting undesirable pharmacokinetic drug interaction between a drug and concomitant drug(s), which consists of controlling the in vivo release time and/or release site of the drug and/or the concomitant drug.

Priority: US20000197574P Applic. Date: 2000-04-17

Inventor: SAWADA TOYOHIRO [JP]; SAKO KAZUHIRO [JP]; YOSHIOKA TATSUNOBU [JP]; WATANABE SHUNSUKE [JP]


Patent No.: US6761903B2  Issued: 13/Jul/2004

Title: Clear oil-containing pharmaceutical compositions containing a therapeutic agent

Applicant/Assignee: LIPOCINE, INC

Application No.: 09/877541   Filing Date: 08/Jun/2001

Abstract:

The present invention relates to pharmaceutical compositions and methods for improved solubilization of triglycerides and improved delivery of therapeutic agents. Compositions of the present invention include a carrier, where the carrier is formed from a combination of a triglyceride and at least two surfactants, at least one of which is hydrophilic. Upon dilution with an aqueous medium, the carrier forms a clear, aqueous dispersion of the triglyceride and surfactants.

Priority: US1999-345615 Applic. Date: 1999-06-30; US2000-751968 Applic. Date: 2000-12-29; US1999-375636 Applic. Date: 1999-08-17

Inventor: CHEN FENG-JING [US]; PATEL MAHESH V [US]; FIKSTAD DAVID T [US]


Patent No.: US6763607B2  Issued: 20/Jul/2004

Title: Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus

Applicant/Assignee: PFIZER INC

Application No.: 10/353746   Filing Date: 28/Jan/2003

Abstract:

Conventional spray-drying methods are improved by incorporation of a pressure nozzle and a diffuser plate to improve the flow of drying gas and a drying chamber extension to increase drying time, such improvements leading to the formation of homogeneous solid dispersions of drugs in concentration-enhancing polymers.

Priority: US20020354080P Applic. Date: 2002-02-01

Inventor: BEYERINCK RONALD A [US]; DEIBELE HEATHER L M [US]; DOBRY DAN E [US]; RAY RODERICK J [US]; SETTELL DANA M [US]; SPENCE KEN R [US]


Patent No.: US6773413B2  Issued: 10/Aug/2004

Title: Extracorporeal blood processing methods and apparatus

Applicant/Assignee: GAMERO INC

Application No.: 09/729578   Filing Date: 04/Dec/2000

Abstract:

An extracorporeal blood processing method includes a set-up phase establishing certain conditions in blood being processed prior to separation of the blood into components. Also, a blood processing method contemporaneously extracts selected multiple blood components from a blood processing vessel. Blood is separated into components in the blood processing vessel in a centrifugal field. Further, an extracorporeal blood processing method establishes a packing factor in the blood processing vessel prior to collecting red blood cells.

Priority: US1997-924519 Applic. Date: 1997-09-05

Inventor: KELLER MURIEL [US]; BAINBRIDGE MARLENE [US]


Patent No.: US6800450B2  Issued: 05/Oct/2004

Title: Vitro methods for screening for blood coagulation disorders using metal ions

Applicant/Assignee: INSTRUMENTATION LABORATORY, S.P.A

Application No.: 10/331731   Filing Date: 30/Dec/2002

Abstract:

In vitro methods for qualitative screening and/or quantitative determination of the functional activity of components of the Protein C anticoagulant pathway of blood coagulation are described. The methods entail measuring the conversion rate of a substrate by an enzyme, the activity of which is related to the Protein C anticoagulant activity, in a blood sample of a human comprising coagulation factors and said substrate, after at least partial activation of coagulation through the intrinsic, extrinsic or common pathway and triggering coagulation by adding calcium ions

and comparing said conversion rate with the conversion rate of a normal human blood sample determined in the same way. The methods include the addition of additional metal ions to the sample to enhance activity, sensitivity and resolution. Kits and reagents for use in the methods are also provided.

Priority: EP19980105043 Applic. Date: 1998-03-19; US2002-050441 Applic. Date: 2002-01-16; US1999-273413 Applic. Date: 1999-03-19

Inventor: ROSEN BERT STEFFEN [SE]; HALL CHRISTINA MARIA YVONNE [SE]


Patent No.: US6806091B1  Issued: 19/Oct/2004

Title: Method and apparatus for determining blood oxygen transport

Applicant/Assignee:

Application No.: 09/600094   Filing Date: 22/Aug/2000

Abstract:

The present invention relates to a method and apparatus for determining blood oxygen transport, and to measure lipid levels by correlating these levels with the rate at which oxygen diffuses through the red blood cell membrane.

Priority: WO1999US00613 Applic. Date: 1999-01-12

Inventor: BUCHWALD HENRY [US]; MENCHACA HECTOR J [US]; MICHALEK VAN [US]; O'DEA THOMAS J [US]; ROHDE THOMAS D [US]


Patent No.: US6809076B2  Issued: 26/Oct/2004

Title: Use of anticoagulant agents in the extracorporeal treatment of blood

Applicant/Assignee:

Application No.: 09/811410   Filing Date: 20/Mar/2001

Abstract:

The present invention relates to the use of anticoagulant agents for the treatment of individuals with extracorporeal circulation as anticoagulant during the extracorporeal circulation and for prophylaxis of vascular complications after the extracorporeal circulation. It is thus possible in particular to treat individuals with chronic renal insufficiency requiring regular hemodialysis and moreover prevent vascular complications which, on use of conventional anticoagulants, result in a high morbidity and mortality rate for dialysis patients treated longer-term.

Priority: EP20000105867 Applic. Date: 2000-03-20; US20000190103P Applic. Date: 2000-03-20

Inventor: SCHERHAG RUDI [DE]; BACHER PETER [DE]; PAROW CHRISTOPHER [DE]; ESSLINGER HANS-ULRICH [DE]; ABEL FLORIAN [DE]


Patent No.: US6812031B1  Issued: 02/Nov/2004

Title: Regeneration of biosensors

Applicant/Assignee: SENZIME POINT OF CARE AB

Application No.: 09/462394   Filing Date: 03/May/2000

Abstract:

The invention comprises a method of regenerating a biosensor. It involves passing a background flow of fluid without reactive components through the flow passage. At a selected point in time a sample aliquot is injected into said background flow. At a point in time when a signal from said sensor is obtained the flow rate of the background fluid is increased. The invention also comprises a system for continuous monitoring of analytes in a biological fluid, the system having increased life by virtue of inherent regeneration of sensors employed. It comprises a biosensor (26, 30, 32), a sampling device (4) for providing a sample of said biological fluid, and means (10, 15, 18, 24) for passing a flow of a background fluid through said flow passage at selectable flow rates, means (20, 50, 55) for injecting said sample into said flow of background fluid, and means (50, 55) for increasing the flow rate of said combined flow. Means for achieving a washing action at the signal generating portion are provided.

Priority: SE19970002658 Applic. Date: 1997-07-09; WO1998SE01352 Applic. Date: 1998-07-08

Inventor: CARLSSON THOMAS [SE]


Patent No.: US6821726B1  Issued: 23/Nov/2004

Title: Method for quantitatively analyzing tumor cells in a body fluid and test kits suited therefor

Applicant/Assignee:

Application No.: 09/601645   Filing Date: 04/Aug/2000

Abstract:

The invention relates to a method for quantitatively analyzing tumor cells in a body fluid. According to the inventive method, the test sample to be examined is first subjected to a method for accumulating or depleting tumor cells, and a reaction is carried out on the accumulated or depleted tumor cells. During the reaction, the mRNA which codes for the catalytic subunit of the telomerase is specifically amplified, and afterwards, the quantity of amplified nucleic acid is quantitatively analyzed. The invention also relates to test kits suited for the invented method.

Priority: DE19981004372 Applic. Date: 1998-02-04; WO1999EP00716 Applic. Date: 1999-02-03

Inventor: DAHM MICHAEL W [DE]; PHELPS ROBERT C [DE]; BROCKMEYER CARSTEN [DE]


Patent No.: US6825208B2  Issued: 30/Nov/2004

Title: Tetrahydroquinoline derivatives as antithrombotic agents

Applicant/Assignee: BRISTOL-MYERS SQUIBB PHARMA COMPANY

Application No.: 10/223860   Filing Date: 20/Aug/2002

Abstract:

This invention relates generally to tetracyclic tetrahydroquinoline compounds, and analogues thereof, and pharmaceutically acceptable salt forms thereof, which are selective inhibitors of serine protease enzymes, especially factor VIIa

pharmaceutical compositions containing the same

and methods of using the same as anticoagulant agents for modulation of the coagulation cascade.

Priority: US20010313549P Applic. Date: 2001-08-20

Inventor: ZHOU JINGLAN [US]; ROBINSON LESLIE [US]; GUBERNATOR NIKOLAUS M [US]; SAIAH EDDINE [US]; BAI XU [US]; GU XIN [US]


Patent No.: US6827926B2  Issued: 07/Dec/2004

Title: Metallotetrapyrrolic photosensitizing agents for use in photodynamic therapy

Applicant/Assignee: MIRAVANT PHARMACEUTICALS, INC

Application No.: 10/159005   Filing Date: 31/May/2002

Abstract:

Metallotetrapyrrolic compounds having photherapeutic properties useful in photodetection and phototherapy of target issues, particularly porphyrins and azaporphyrins that including gallium in the central pyrrolic core. Also disclosed are methods of using metallotetrapyrrolic compounds for the treatment or detection of cardiovascular disease.

Priority: US20010295345P Applic. Date: 2001-05-31

Inventor: ROBINSON BYRON C [US]; LEITCH IAN M [US]; GREENE STEPHANIE [US]; RYCHNOVSKY STEVE [US]


Patent No.: US6833267B1  Issued: 21/Dec/2004

Title: Tissue collection devices containing biosensors

Applicant/Assignee: CLINICAL MICRO SENSORS, INC

Application No.: 09/472657   Filing Date: 27/Dec/1999

Abstract:

The present disclosure provides tissue collection devices comprising biosensors that can be used for the detection of target analytes, such as nucleic acids and proteins, including antibodies and enzymes.

Priority: US19980114178P Applic. Date: 1998-12-30

Inventor: KAYYEM JON FAIZ [US]


Patent No.: US6846161B2  Issued: 25/Jan/2005

Title: Blood component processing systems and methods using fluid-actuated pumping elements that are integrity tested prior to use

Applicant/Assignee: BAXTER INTERNATIONAL INC

Application No.: 10/280108   Filing Date: 24/Oct/2002

Abstract:

Blood component processing systems and methods are coupled to a blood component processing device. The systems and methods include a fluid circuit that comprises at least one fluid pressure actuated pump station, at least one fluid flow path communicating with the pump station, and at least one valve in the fluid flow path. A control module is sized and configured to interact with the fluid circuit. The control module includes an actuator to selectively apply fluid pressure to the pump station in concert with operation of the valve to pump fluid through the fluid flow path in response to a control program. A controller coupled to the control module includes the control program and a fluid circuit integrity test function.

The fluid circuit integrity test function commands the control module to selectively apply fluid pressure to the pump station in concert with operation of the valve to introduce a fluid within a region of the fluid circuit and to confine the fluid within the region while applying fluid pressure to the pump chamber. The fluid circuit integrity test function generates an integrity output in response to sensing leakage of fluid from the region.

Priority:

Inventor: KLINE TIFFANY [US]; BEDARD PETER [US]; INGO CARSON [US]; BONIQUIT CHRISTOPHER [US]; SCHEIDT ROBERT [US]; NAYAK ABINASH [US]


Patent No.: US6855120B2  Issued: 15/Feb/2005

Title: Apheresis system with anticoagulant flow control

Applicant/Assignee: BAXTER INTERNATIONAL INC

Application No.: 10/372882   Filing Date: 24/Feb/2003

Abstract:

An apheresis system is disclosed which may include a separation chamber

a suspension flow path which communicates at one end with the separation chamber and includes a connector at the other end for connecting to a source of cellular suspension

an anticoagulant flow path which communicates at one end with the suspension flow path and includes a connector at the other end for connecting to an anticoagulant source

and a return flow path which communicates at one end with the separation chamber and communicates at the other end with a connector for connection directly to the suspension source or to the suspension flow path for returning one or more suspension components to the source.

The anticoagulant flow path includes a flow restriction, such as an internal flow restriction, which limits the free flow of anticoagulants into the suspension flow path while preferably not completely stopping the flow of anticoagulant. The restriction may take various forms, but the preferred construction comprises a tubing segment of reduced inside diameter, providing resistance to the free flow of anticoagulant in the event of operator error or mechanical failure.

Priority: US1998-042260 Applic. Date: 1998-03-13

Inventor: GRIMM DANIEL J [US]


Patent No.: US6866636B2  Issued: 15/Mar/2005

Title: Cuff for blood pressure monitor

Applicant/Assignee: OMRON CORPORATION

Application No.: 10/461868   Filing Date: 16/Jun/2003

Abstract:

In a cuff of a blood pressure monitor, a distance along bending of a first expandable portion is set so as to be different from a distance along bending of a second expandable portion at the time of deflation. When a fluid bladder for pressurizing is inflated with a fluid fed thereinto, the second expandable portion expands longer. As a result, force, which is generated on a cuff fixing element which is pushed by the fluid bladder for pressurizing, acts to a vertical direction with respect to an axial direction of a subject.

Priority: JP20020177273 Applic. Date: 2002-06-18

Inventor: INOUE TOMONORI [JP]; SANO YOSHIHIKO [JP]; TANAKA TAKAHIDE [JP]; INAGAKI TAKASHI [JP]; TANIGUCHI MINORU [JP]


Patent No.: US6900008B2  Issued: 31/May/2005

Title: Methods and formulations for minimizing spasticity in blood vessel grafts

Applicant/Assignee: EMORY UNIVERSITY

Application No.: 10/285219   Filing Date: 31/Oct/2002

Abstract:

The present invention relates to me methods for minimizing spasticity in blood vessels during transplantation and more particularly for minimizing spasticity in arterial transplants, for both ex-vivo and in-vivo procedures. The invention also relates to formulations, which can be used in these methods.

Priority: US20010335642P Applic. Date: 2001-10-31; US20010336090P Applic. Date: 2001-10-31

Inventor: VINTEN-JOHANSEN JAKOB [US]; VELEZ DANIEL A [US]


Patent No.: US6900231B2  Issued: 31/May/2005

Title: Aminopyridyl-substituted phenyl acetamides as protease inhibitors

Applicant/Assignee: 3-DIMENSIONAL PHARMACEUTICALS, INC

Application No.: 10/262871   Filing Date: 03/Oct/2002

Abstract:

Phenyl acetamide compounds are described, including compounds of or a solvate, hydrate or pharmaceutically acceptable salt thereof

wherein R<3>-R<6>, R<11>, B, Y and W are set forth in the specification. The compounds of the invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as thrombin and factor Xa. Compositions for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation are described. Other uses of compounds of the invention are as anticoagulants either embedded in or physically linked to materials used in the manufacture of devices used in blood collection, blood circulation, and blood storage, such as catheters, blood dialysis machines, blood collection syringes and tubes, blood lines and stents.

Additionally, the compounds can be detectably labeled and employed for in vivo imaging of thrombi.

Priority: US2001-971000 Applic. Date: 2001-10-05; US20000238132P Applic. Date: 2000-10-06

Inventor: PAN WENXI [US]; LU TIANBAO [US]; MARKOTAN THOMAS P [US]; TOMCZUK BRUCE E [US]


Patent No.: US6902743B1  Issued: 07/Jun/2005

Title: Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix

Applicant/Assignee: THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY

Application No.: 09/055505   Filing Date: 06/Apr/1998

Abstract:

Novel burst-free, sustained release biocompatible and biodegrable microcapsules which can be programmed to release their active core for variable durations ranging from 1-100 days in an aqueous physiological environment. The microcapsules are comprised of a core of polypeptide or other biologically active agent encapsulated in a matrix of poly(lactide/glycolide) copolymer having a molar composition of lactide/glycolide from 90/10 to 40/60, which may contain a pharmaceutically-acceptable adjuvant, as a blend of uncapped free carboxyl end group and end-capped forms ranging to ratios from 100/0 to 1/99.

Priority: US1997-920326 Applic. Date: 1997-08-21; US1997-088961 Applic. Date: 1997-07-17; US1997-788734 Applic. Date: 1997-01-23; US1996-086988 Applic. Date: 1996-08-16; US1996-675895 Applic. Date: 1996-07-05; US1996-598874 Applic. Date: 1996-02-09; US1996-590973 Applic. Date: 1996-01-24; US1995-446149 Applic. Date: 1995-05-22; US1995-446148 Applic. Date: 1995-05-22

Inventor: SETTERSTROM JEAN A [US]; TICE THOMAS R [US]; JACOB ELLIOT [US]; REID ROBERT H [US]; VAN HAMONT JOHN [US]; BOEDECKER EDGAR C [US]; JEYANTHI RAMASSUBBU [US]; FRIDEN PHIL [US]; ROBERTS F DONALD [US]; MCQUEEN CHARLES E [US]; BHATTACHARJEE APURBA [US]; CROSS ALAN [US]; SADOFF JERALD [US]; ZOLLINGER WENDELL [US]


Patent No.: US6903069B2  Issued: 07/Jun/2005

Title: Factor VII glycoforms

Applicant/Assignee: NOVO NORDISK HEALTH CARE A/S

Application No.: 09/969357   Filing Date: 02/Oct/2001

Abstract:

The present invention provides preparations of Factor VIIa polypeptides or Factor VIIa-related polypeptides that exhibit predetermined glycoform patterns. The preparations of the invention exhibit improved functional properties and are useful for treating Factor VII-mediated conditions.

Priority: DK20000001456 Applic. Date: 2000-10-02; DK20010000262 Applic. Date: 2001-02-16; DK20010000430 Applic. Date: 2001-03-14; DK20010000751 Applic. Date: 2001-05-14; US20000238944P Applic. Date: 2000-10-10; US20010271581P Applic. Date: 2001-02-26; US20010276322P Applic. Date: 2001-03-16

Inventor: PINGEL HANS KURT [DK]; KLAUSEN NIELS KRISTIAN [DK]


Patent No.: US6903107B1  Issued: 07/Jun/2005

Title: Serine protease inhibitor

Applicant/Assignee: AKZO NOBEL N.V

Application No.: 09/830227   Filing Date: 11/Jun/2001

Abstract:

A serine protease inhibitor having the formula (I), in which J is H, R<1>, R<1>-O-C(O)-, R<1>-C(O-, R<1>-SO2-, R<3>OOC-(CHR<2>)p-, (R<2a>,R<2b>)N-CO-(CHR<2>)p- or Het-CO-(CHR<2>)p-

W is an amino-acid of the formula -NH-CHR<1>-C(O)-, -NR<4>-CH((CH2)qC(O)OR<1>)-C(O)-, -NR<4>-CH((CH2)qC(O)N(R<2a>,R<2b>))-C(O)-, -NR<4>-CH((CH2)qC(O)Het)-C(O)-, D-1-Tiq, D-3-Tiq, D-Atc, Aic, D-1-Piq, D-3 Piq, glutanyl or a (C1-C6) alkylester thereof

E is -NR<2>-CH2- or the fragment which is unsubstituted or substituted with (1-6C)alkyl, (1-6C)alkoxy or benzyloxy

R<1 >is selected form (1-12C)alkyl, (2-12C)alkenyl, (2-12C)alkynyl, (3-12C)cycloalkyl and (3-12C)cycloalkyl(1-6C)alkylene, which groups are unsubstituted or substituted with (3-12C)cycloalkyl, (1-6C)alkoxy, oxo, OH, CF3 or halogen, and from (6-14C)aryl, (7-15C)aralkyl, (8-16C)aralkenyl and (14-20C)(bisary)alkyl, wherein the aryl groups are unsubstituted or substituted with (1-6C)alkyl, (3-12C)cycloalkyl, (1-6C)alkoxy, OH, CF3 or halogen

R<2>, R<2a >and R<2b >are each independently selected from H, (1-C)alkyl, (3-8C)alkenyl, (3-8C)alkynyl, (3-8C)cycloalkyl and (3-6C)cycloalkyl(1-4C)alkylene, which are unsubstituted or substituted with (3-6C)cycloalkyl, (1-6C)alkoxy, CF3 or halogen, and from (6-14C)aryl and (7-15C)aralkyl, wherein the aryl groups are unsubstituted or substituted with (1-6C)alkyl, (3-6C)cycloalkyl, (1-6C)alkoxy, CF3 or halogen

R<3 >is the same as R<2 >or is Het-(1-6C)alkyl

R<4 >is H or (1-3C)alkyl

X and Y are CH or N, with the proviso that they are not both N

Het is a 4-, 5- or 6-membered heterocycle containing one or more heteroatoms selected from O, N and S

m is 1 or 2

p is 1, 2 or 3

q is 1, 2 or 3

t is 2, 3 or 4

or a pharmaceutically acceptable addition salt or solvate thereof.

Priority: EP19980203559 Applic. Date: 1998-10-23; WO1999EP07928 Applic. Date: 1999-10-19

Inventor: TIMMERS CORNELIS MARIUS [NL]; REWINKEL JOHANNES BERNARDUS MA [NL]


Patent No.: US6908593B1  Issued: 21/Jun/2005

Title: Capillary flow control in a fluidic diagnostic device

Applicant/Assignee: LIFESCAN, INC

Application No.: 09/541376   Filing Date: 31/Mar/2000

Abstract:

A medical diagnostic device for measuring an analyte concentration or property of a biological fluid includes capillary flow channels to convey a sample of the fluid from an inlet to a branching point, and then to a measurement area and, alternatively, through a bypass channel to an overflow region. A first stop junction stops fluid flow after it enters the measurement area. The bypass channel has a capillary dimension in at least one direction. A second stop junction, in the bypass channel, has boundary region that has a dimension that is greater in that direction and forms an angle that points toward the branching point. With this construction, the second stop junction initially prevents flow to the overflow region, but permits the flow after the measurement area is filled. The device is particularly suited for measuring coagulation time of blood.

Priority:

Inventor: SHARTLE ROBERT JUSTICE [US]


Patent No.: US6908626B2  Issued: 21/Jun/2005

Title: Compositions having a combination of immediate release and controlled release characteristics

Applicant/Assignee: ELAN PHARMA INTERNATIONAL LTD

Application No.: 10/268928   Filing Date: 11/Oct/2002

Abstract:

Disclosed are compositions exhibiting a combination of immediate release and controlled release characteristics. The compositions comprise at least one poorly soluble active ingredient having a nanoparticulate particle size, at least one surface stabilizer adsorbed onto the surface of the nanoparticulate active agent particles, and at least one active ingredient having a microparticulate particle size.

Priority: US20010328405P Applic. Date: 2001-10-12

Inventor: COOPER EUGENE R [US]; RUDDY STEPHEN B [US]


Patent No.: US6913588B2  Issued: 05/Jul/2005

Title: Extracorporeal fluid circuit and related methods

Applicant/Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN

Application No.: 10/402912   Filing Date: 28/Mar/2003

Abstract:

A circuit for extracorporeal treatment of a body fluid, the circuit including in serial fluidic communication an inlet for receiving the body fluid from a patient, a first pump, a first treatment device for processing the body fluid, a second pump, an outlet for returning processed body fluid to the patient

and a shunt. The shunt is upstream from the first pump and downstream from the second pump.

Priority: US2000-553772 Applic. Date: 2000-04-21; US19990130688P Applic. Date: 1999-04-23

Inventor: WEITZEL WILLIAM FREDERICK [US]; HUMES H DAVID [US]; PAGANINI EMIL PRESLEY [US]; BUFFINGTON DEBORAH ANN [US]; FUNKE ANGELA J [US]


Patent No.: US6913932B2  Issued: 05/Jul/2005

Title: Formaldehyde-ammonium salt complexes for the stabilization of blood cells

Applicant/Assignee: BECKMAN COULTER, INC

Application No.: 10/226825   Filing Date: 23/Aug/2002

Abstract:

A stabilization reagent composition, particularly desirable for stabilizing blood samples containing platelets, contains reactants that generate multiple species of formaldehyde-ammonium complexes

at least one inhibitor of phosphatase enzymatic activity

and at least one inhibitor of protease enzymatic activity. Blood samples and other tissues are stabilized by this composition. Such stabilized samples are produced by methods for stabilizing the tissue by contacting the sample with the composition.

Priority:

Inventor: MAPLES JOHN A [US]; CHARIE LORI A [US]; FLAGLER DANIEL JAMES [US]; MILLS RHONDA ANN [US]; TIMMONS RICHARD [US]


Patent No.: US6916837B2  Issued: 12/Jul/2005

Title: Amidino derivatives and anticoagulants and thrombosis therapeutic agents containing them

Applicant/Assignee: EISAI CO., LTD

Application No.: 10/294198   Filing Date: 14/Nov/2002

Abstract:

Amidino derivatives represented by the following general formula (I): {where X is a group represented by R<1>SO2NR<2>- (wherein R<1 >represents optionally substituted C6-14 aryl, etc. and R<2 >represents hydrogen atom, etc.), etc., Ar<1 >represents 2,6-naphthylene, etc., R<3 >represents hydrogen atom, etc. and Y represents carboxyphenyl, etc.} and their pharmacologically acceptable salts or solvates.

Priority: JP20010350637 Applic. Date: 2001-11-15; JP20020307358 Applic. Date: 2002-10-22

Inventor: SATOH TAKASHI [JP]; OKAMOTO YASUSHI [JP]; ASANO OSAMU [JP]; WATANABE NOBUHISA [JP]; NAGAKURA TADASHI [JP]; SAEKI TAKAO [JP]; INOUE ATSUSHI [JP]; SAKURAI MASAHIRO [JP]


Patent No.: US6924114B2  Issued: 02/Aug/2005

Title: Method for monitoring resting and activated platelets in unfixed blood samples

Applicant/Assignee: SURROMED, INC

Application No.: 09/957624   Filing Date: 20/Sep/2001

Abstract:

The amount of platelet surface proteins in a sample may be measured by collecting a sample containing platelets into a collection tube containing a platelet stabilizing composition, labeling the platelet surface protein and detecting by cytometry.

Priority: US20000234065P Applic. Date: 2000-09-20

Inventor: WYANT TIMOTHY L [US]; RAJU PAUL A [US]; KANTOR AARON B [US]


Patent No.: US6926735B2  Issued: 09/Aug/2005

Title: Multi-lumen vascular grafts having improved self-sealing properties

Applicant/Assignee: SCIMED LIFE SYSTEMS, INC

Application No.: 10/328081   Filing Date: 23/Dec/2002

Abstract:

The present invention provides an implantable graft, including a primary tubular body having a first outer wall surface and a first inner wall surface defining a primary blood contacting lumen, and a secondary tubular body having a second outer wall surface and a second inner wall surface. The secondary tubular body is located about the primary tubular body to form a space therebetween. The primary and secondary tubular bodies are joined by at least one rib.

Priority:

Inventor: HENDERSON JAMIE S [US]


Patent No.: US6929908B1  Issued: 16/Aug/2005

Title: Method of processing blood samples in order to produce DNA complex patterns for diagnostic applications

Applicant/Assignee: OPTO GENETICS, INC

Application No.: 09/764783   Filing Date: 17/Jan/2001

Abstract:

A method for processing blood samples in order to produce DNA complex patterns for diagnostic applications.

Priority:

Inventor: DE RODRIGUEZ GLORIA ELENA LOEN [US]; WU GIN [US]


Patent No.: US6936719B2  Issued: 30/Aug/2005

Title: Biaryl compounds as serine protease inhibitors

Applicant/Assignee: BIOCRYST PHARMACEUTICALS, INC

Application No.: 10/738027   Filing Date: 18/Dec/2003

Abstract:

Compounds of formula (I) are useful as inhibitors of trypsin like serine protease enzymes such as thrombin, factor VIIa, factor Xa, TF/FVIIa, and trypsin. These compounds could be useful to treat and/or prevent clotting disorders, and as anticoagulating agents.

Priority: US2002-127460 Applic. Date: 2002-04-23; WO2001US32582 Applic. Date: 2001-10-22; US20010281735P Applic. Date: 2001-04-06

Inventor: BABU YARLAGADDA S [US]; ROWLAND R SCOTT [US]; CHAND POORAN [US]; KOTIAN PRAVIN L [US]; EL-KATTAN YAHYA [US]; NIWAS SHRI [US]


Patent No.: US6945948B2  Issued: 20/Sep/2005

Title: Extra-corporeal Dual Stage Blood Processing Method and Apparatus

Applicant/Assignee: GAMBRO, INC

Application No.: 10/709194   Filing Date: 20/Apr/2004

Abstract:

Methods and apparatus particularly involving the separation of blood into blood components and the collection of such components are disclosed. In one aspect, an extra-corporeal method for the collection of plasma and red blood cells is provided, wherein the collection of plasma and red blood cells may occur simultaneously or subsequently utilizing the same dual stage blood processing vessel. The flow of blood to the blood processing vessel and return of uncollected blood components may be provided via a single needle, wherein blood is removed from and returned to a donor/patient during alternating blood removal and blood return submodes. Platelet separation and collection options are also described. In either case, prior to red blood cell collection, a set-up phase may be carried out to set a predetermined hematocrit and AC ratio.

Replacement fluid delivery may optionally also be provided either substantially continuously during any collection phase(s) and/or in a bolus mode.

Priority: US2001-803304 Applic. Date: 2001-03-09; US20000188133P Applic. Date: 2000-03-09

Inventor: BAINBRIDGE MARLENE [US]; KELLER MURIEL [US]; GORDON TIMOTHY M [US]; MCATEER MICHAEL J [US]; BUTZKE SCOTT D [US]


Patent No.: US6945989B1  Issued: 20/Sep/2005

Title: Apparatus for delivering endoluminal prostheses and methods of making and using them

Applicant/Assignee: ENDOTEX INTERVENTIONAL SYSTEMS, INC

Application No.: 09/664970   Filing Date: 18/Sep/2000

Abstract:

An apparatus for delivering a stent into a blood vessel includes a sheath having a rounded bullet-shaped distal portion including a plurality of flexible leaflets integrally molded thereto. The stent is disposed in its contracted condition within a lumen of the sheath proximate the distal portion. A bumper is slidably disposed within the lumen that includes a helical compression coil, a bumper element attached to the helical coil including a blunt distal edge for abutting the stent, and an extension element extending distally from the bumper element through the stent and between the leaflets to facilitate introducing the apparatus over a guidewire. The sheath is formed by inserting a bullet into a blunt-ended tube, and inserting the tube into a bullet-shaped bore in a heated die until the tube material is softened and deforms into a rounded bullet shape. Slits are then cut into the distal portion to create the leaflets.

Priority:

Inventor: BETELIA RAINIER [US]; GILLIS EDWARD M [US]; ROURKE JONATHAN M [US]; YANG YI [US]


Patent No.: US6946079B1  Issued: 20/Sep/2005

Title: Centrifugal filtration method for separating fibrin monomer from blood

Applicant/Assignee: BRISTOL-MYERS SQUIBB COMPANY

Application No.: 10/996995   Filing Date: 16/Jul/1998

Abstract:

A method and a device for separating a component, such as fibrin I from blood, by centrifugation. The method involves feeding of blood admixed an anticlotter to a first annular chamber in a device, where the annular chamber is defined by a cylindrical outer wall and a cylindrical inner wall, both walls extending coaxially about a common axis, as well as by a top wall and a bottom wall, where the top wall or the bottom wall is formed by a piston body displaceable within the first chamber. The method involves furthermore a centrifugation of the device about the said common axis followed by a resulting liquid fraction being transferred while influenced by the piston body to a second chamber defined by an outer cylindrical wall, which extends coaxially with said common axis. As a result the liquid fraction present in the second chamber is caused to be further separated by a continued centrifugation and addition of suitable compositions promoting the separation and returning of the non-utilizable portion to the first chamber. In addition, the portion of the liquid fraction remaining in the second chamber is transferred to a liquid-receiving container through a filter optionally after addition of a solvent. The portion of the liquid fraction remaining in the second chamber prior to the transfer to the liquid-receiving container is transferred to a third chamber coaxially accommodated with the other chambers, and the liquid now present in said third chamber is caused to pass through an annular filter during the centrifugation so as to enter an annular outer compartment which is adapted to be connected to the liquid-receiving member.

Priority: US1996-745763 Applic. Date: 1996-11-08; US1994-348672 Applic. Date: 1994-12-02

Inventor: HOLM NIELS ERIK [DK]


Patent No.: US6949079B1  Issued: 27/Sep/2005

Title: Programmable, fluid pressure actuated blood processing systems and methods

Applicant/Assignee: BAXTER INTERNATIONAL INC

Application No.: 09/390268   Filing Date: 03/Sep/1999

Abstract:

Programmable, fluid pressure actuated blood processing systems and methods are used in association a blood separation device. The systems and methods employ a cassette, which contains several preformed, pneumatically actuated pump stations, several preformed fluid flow paths, and several preformed, pneumatically actuated valves in the fluid flow paths. The systems and methods also employ a programmable pneumatic actuator to hold the cassette and selectively apply pneumatic force to the valves and pump stations.

Priority:

Inventor: WESTBERG TOM [US]; VISHNOI ROHIT [US]


Patent No.: US6949113B2  Issued: 27/Sep/2005

Title: Barrier device for ostium of left atrial appendage

Applicant/Assignee: ATRITECH, INC

Application No.: 10/308032   Filing Date: 03/Dec/2002

Abstract:

A membrane applied to the ostium of an atrial appendage for blocking blood from entering the atrial appendage which can form blood clots therein is disclosed. The membrane also prevents blood clots in the atrial appendage from escaping therefrom and entering the blood stream which can result in a blocked blood vessel, leading to strokes and heart attacks. The membranes are percutaneously installed in patients experiencing atrial fibrillations and other heart conditions where thrombosis may form in the atrial appendages. A variety of means for securing the membranes in place are disclosed. The membranes may be held in place over the ostium of the atrial appendage or fill the inside of the atrial appendage.

The means for holding the membranes in place over the ostium of the atrial appendages include prongs, stents, anchors with tethers or springs, disks with tethers or springs, umbrellas, spiral springs filling the atrial appendages, and adhesives. After the membrane is in place a filler substance may be added inside the atrial appendage to reduce the volume, help seal the membrane against the ostium or clot the blood in the atrial appendage. The membranes may have anticoagulants to help prevent thrombosis. The membranes be porous such that endothelial cells cover the membrane presenting a living membrane wall to prevent thrombosis. The membranes may have means to center the membranes over the ostium. Sensors may be attached to the membrane to provide information about the patient.

Priority: US1999-428008 Applic. Date: 1999-10-27

Inventor: VAN TASSEL ROBERT A [US]; HAUSER ROBERT G [US]


Patent No.: US6955682B2  Issued: 18/Oct/2005

Title: Wound closure system and methods

Applicant/Assignee: BIOINTERACTIONS, LTD

Application No.: 10/143495   Filing Date: 09/May/2002

Abstract:

A wound closure system and methods utilizes a patient's own blood. The system preferably includes a chamber with a needle and a plunger for transferring and storing blood prior to surgery and the use of reversible anticoagulants. The chamber is pre-loaded with a reversible anticoagulant to prevent the blood from clotting during storage. When the surgery is complete, a counteracting agent is mixed with the withdrawn blood to counteract the reversible anticoagulant and allow the blood to clot. The clottable blood is then reintroduced into the patient to close a wound.

Priority: US20010289754P Applic. Date: 2001-05-09

Inventor: LUTHRA AJAY K [GB]; SANDHU SHIVPAL S [GB]; ONIS SIMON JON [GB]


Patent No.: US6960179B2  Issued: 01/Nov/2005

Title: Wearable continuous renal replacement therapy device

Applicant/Assignee: NATIONAL QUALITY CARE, INC

Application No.: 10/085349   Filing Date: 16/Nov/2001

Abstract:

A continuous renal replacement therapy device adapted to be worn on a portion of the body of a patient, including: a plurality of contoured dialyzers, which are connected in series and utilize dialysate to remove impurities from the blood of the patient

and a plurality of contoured sorbent device, which are connected in series and are for regenerating the spent dialysate.

Priority:

Inventor: GURA VICTOR [US]


Patent No.: US6969367B2  Issued: 29/Nov/2005

Title: Extracorporeal pathogen reduction system

Applicant/Assignee: XEPMED, INC

Application No.: 10/720811   Filing Date: 24/Nov/2003

Abstract:

The invention relates to an apparatus system and methods for treatment of virus-infected or pathogen-loaded human blood components separated from normal components comprising a separation apparatus and treatment apparatus system that inactivate pathogens in an extracorporeal body fluid system.

Priority: US2002-195814 Applic. Date: 2002-07-15; US2000-496613 Applic. Date: 2000-02-02; US20020429126P Applic. Date: 2002-11-26; US20030494895P Applic. Date: 2003-08-13

Inventor: TU HOSHENG [US]; LIN HUN-CHI [US]; CHANG YU-AN [US]


Patent No.: US6969529B2  Issued: 29/Nov/2005

Title: Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers

Applicant/Assignee: ELAN PHARMA INTERNATIONAL LTD

Application No.: 10/345312   Filing Date: 16/Jan/2003

Abstract:

The present invention is directed to nanoparticulate compositions comprising a poorly soluble drug and at least one copolymer of vinyl pyrrolidone and vinyl acetate as a surface stabilizer adsorbed to the surface of the drug. Also encompassed by the invention are pharmaceutical compositions comprising a nanoparticulate composition of the invention, methods of making and using such nanoparticulate and pharmaceutical compositions.

Priority: US2000-715117 Applic. Date: 2000-11-20; US2002-075443 Applic. Date: 2002-02-15; US2000-666539 Applic. Date: 2000-09-21

Inventor: BOSCH H WILLIAM [US]; RYDE NIELS P [US]


Patent No.: US6973741B2  Issued: 13/Dec/2005

Title: Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus

Applicant/Assignee: PFIZER, INC

Application No.: 10/766450   Filing Date: 27/Jan/2004

Abstract:

Conventional spray-drying methods are improved by incorporation of a pressure nozzle and a diffuser plate to improve the flow of drying gas and a drying chamber extension to increase drying time, such improvements leading to the formation of homogeneous solid dispersions of drugs in concentration-enhancing polymers.

Priority: US2003-353746 Applic. Date: 2003-01-28; US20020354080P Applic. Date: 2002-02-01

Inventor: BEYERINCK RONALD A [US]; DIEBELE HEATHER L M [US]; DOBRY DAN E [US]; RAY RODERICK J [US]; SETTELL DANA M [US]; SPENCE KEN R [US]


Patent No.: US6974476B2  Issued: 13/Dec/2005

Title: Percutaneous aortic valve

Applicant/Assignee: REX MEDICAL REX MEDICAL, L.P

Application No.: 10/429536   Filing Date: 05/May/2003

Abstract:

The present invention provides a valve configured for insertion on the proximal and distal sides of a heart valve annulus to replace the heart valve of a patient. The valve comprises a first substantially annular portion adapted to be positioned on a proximal side of the annulus of a patient and a second substantially annular portion adapted to be positioned on a distal side of the annulus of a patient, wherein at least one of the first and second substantially annular portions is movable towards the other portion to a clamped position to clamp around the annulus. The second portion has a flow restricting portion extending therefrom and is movable between a first position to permit the flow of blood and a second position to restrict the flow of blood.

In one embodiment, the valve has a suture joining the first and second portions to draw the first and second portions into closer proximity and a cinch member to secure the suture to maintain the first and second portions in the clamped position. In another embodiment, the first and second portions are connected by a first segment which biases the first and second portions toward the clamped position.

Priority:

Inventor: MCGUCKIN JR JAMES F [US]; HINCHLIFFE PETER W J [US]


Patent No.: US6974701B2  Issued: 13/Dec/2005

Title: Erythrocyte sedimentation rate (ESR) test measurement instrument of unitary design and method of using the same

Applicant/Assignee: HEMOVATIONS, LLC

Application No.: 10/395860   Filing Date: 21/Mar/2003

Abstract:

An erythrocyte sedimentation rate (ESR) measurement instrument having a Blood Collection Configuration and an ESR Measurement Configuration. The ESR measurement instrument includes a sedimentation measurement tube having an hollow interior volume containing a predetermined quantity of blood sample diluting agent therewithin and being air/fluid sealed with respect to the ambient environment

and a blood collection tube having a hollow interior volume containing a predetermined quantity of anti-coagulant and being vacuum-sealed with respect to the ambient environment, and physically coupled to the air-sealed sedimentation measurement tube, by at least a portion of the sedimentation measurement tube being inserted within a portion of the hollow interior volume of the blood collection tube.

The sedimentation measurement tube and the blood collection tube are maintained stationarily fixed relative to each other as a unitary assembly having a syringe-like form factor when the ESR measurement instrument is arranged in the Blood Collection Configuration. During this configuration, a needle-supporting connector can be connected to the blood collection tube and a sample of whole blood from a patient vacuum-drawn and injected into the blood collection tube.

After the sample of anti-coagulated blood has been collected in the blood collection tube and the needle-supporting connector is disconnected therefrom, the air/fluid seal of the sedimentation measurement tube can be broken and then the sedimentation measurement tube can be manually plunged into and to the bottom of the hollow interior volume of said blood collection tube, using a single-handed operation to rearrange the ESR measurement instrument into the ESR Measurement Configuration.

The anti-coagulated sample of blood fills up a substantially portion of the sedimentation measurement tube and mixes with the blood sample diluting agent to enable the blood plasma/erythrocyte cell (P/E) interface level within the sedimentation measurement tube to settle downwards toward the blood collection tube during a predetermined time period when said ESR measurement instrument is oriented in a gravity vertical position. By virtue of the present invention, the erythrocyte sedimentation rate (ESR) of the collected blood sample can be measured by determining how far the P/E interface level has moved against graduation markings formed along the length of the sedimentation measurement tube during the predetermined time period.

Priority:

Inventor: BOUBOULIS DENIS A [US]


Patent No.: US6976647B2  Issued: 20/Dec/2005

Title: System and method for milling materials

Applicant/Assignee: ELAN PHARMA INTERNATIONAL, LIMITED

Application No.: 10/732801   Filing Date: 11/Dec/2003

Abstract:

A system for milling at least one material, e.g., a drug, is described. The system includes a milling apparatus. In another embodiment of the invention, the system includes at least one milling medium. The milling apparatus includes a chamber having a rotary milling head located in it. The milling head is rotated within the chamber by a magnetic drive system.

Priority: US20010295965P Applic. Date: 2001-06-05; US2002-162333 Applic. Date: 2002-06-04

Inventor: REED ROBERT G [US]; CZEKAI DAVID [US]


Patent No.: US6977105B1  Issued: 20/Dec/2005

Title: Multilayered tube and medical supply comprising multilayered tube

Applicant/Assignee: KAWASUMI LABORATORIES, INC

Application No.: 09/926817   Filing Date: 21/Dec/2001

Abstract:

A multi-layered tube composed of at least two layers, each formed from a different resin, e.g. resin (I) or resin (II). Resin (I) contains 5 to 40 mass % of a polypropylene resin and 95 to 60 mass % of at least one hydrogenated copolymer. Resin (II) contains 45 to 100 mass % of a polypropylene resin and 55 to 0 mass % of a hydrogenated copolymer. The multi-layered tubes may be used in the field of medicine and provide tubing which is excellent in transparency, flexibility and anti-kinking properties, and which is durable during sterilization procedures with high-pressure steam. The multilayer tubing may also be safely disposed of as it generates no toxic gases, such as dioxin, when incinerated. The multilayered tubing has excellent connectability and may be bonded to other tubing using hot solvent bonding or solvent adhesion. The multilayered tubing which is free from generation of any toxic gas when incinerated, and which is excellent in hot solvent bonding or solvent adhesion to other tube.

Priority: JP20000120270 Applic. Date: 2000-04-21; WO2000JP06493 Applic. Date: 2000-09-22

Inventor: FUJIEDA YUKIHIRO [JP]; OGUSHI MASAYASU [JP]; FUKUDA MOTOHIRO [JP]; ZENTO TOSHIYUKI [JP]; WADA KOICHI [JP]; ICHIKAWA TOSHIJI [JP]; ISHIDA AKIRA [JP]


Patent No.: US6979307B2  Issued: 27/Dec/2005

Title: Systems and methods for preparing autologous fibrin glue

Applicant/Assignee: CASCADE MEDICAL ENTERPRISES LLC

Application No.: 10/053247   Filing Date: 15/Jan/2002

Abstract:

The invention provides a system for preparing an autologous solid-fibrin web suitable for regenerating tissue in a living organism. The system includes a sealed primary container containing a separation medium and a low-density high-viscosity liquid. The separation medium separates red blood cells from plasma when the container contains blood and is centrifuged, and the primary container has a first pressure. The system further includes a sealed secondary container containing a calcium-coagulation activator. The secondary container has a second pressure that is less than the first pressure. The system also comprises a transfer device including a cannula having a first end and a second end. The first and second ends puncture the sealed primary and secondary containers in order to provide fluid communication between the first and second containers.

The low-density high-viscosity liquid of the primary container blocks flow through the cannula upon entering therein.

Priority: IT1997MI01490 Applic. Date: 1997-06-24; US2000-446729 Applic. Date: 2000-03-03; WO1998IT00173 Applic. Date: 1998-06-24

Inventor: BERETTA ROBERTO [IT]; GRIPPI NICHOLAS A [US]


Patent No.: US6989022B2  Issued: 24/Jan/2006

Title: Clotting cascade initiating apparatus and methods of use and methods of closing wounds

Applicant/Assignee: CLOSYS CORPORATION

Application No.: 10/291278   Filing Date: 08/Nov/2002

Abstract:

Wound closure methods and apparatus are provided which utilize blood fluid by activating the clotting cascade of the blood fluid outside the body within a substantially enclosed sterile container then introducing the blood fluid to the wound site to complete clotting. Methods and apparatus for providing ways of inhibiting anticoagulants and slowing fibrin clot degradation are also disclosed. Kits for practicing the invention singularly or in combination with and/or associated with preferred procedures are also disclosed.

Priority: US2000-732423 Applic. Date: 2000-12-07; US1998-212080 Applic. Date: 1998-12-15; US19970069834P Applic. Date: 1997-12-16

Inventor: NOWAKOWSKI KAROL L [US]


Patent No.: US6991191B2  Issued: 31/Jan/2006

Title: Method of using a small scale mill

Applicant/Assignee: ELAN PHARMA INTERNATIONAL LTD ELAN PHARMA INTERNATIONAL, LIMITED

Application No.: 10/833045   Filing Date: 28/Apr/2004

Abstract:

A small-scale or micro media-mill and a method of milling materials or products, especially pharmaceutical products, use a dispersion containing attrition milling media and the product to be milled. The milling media can be polymeric, formed of polystyrene or cross-linked polystyrene, having a nominal diameter of no greater than 500 microns. Other sizes include 200 microns and 50 microns and a mixture of these sizes. The mill has a relatively small vessel having an opening, an agitator, a coupling and a motor. The agitator can have a rotor and a shaft extending therefrom. The rotor can be cylindrical or have other configurations, and can have tapered end surfaces. The coupling can close the vessel opening, or attaching the coupling to the motor can close the opening. The coupling has an opening through which the rotor shaft extends into the motor.

A sealing mechanism, such as a mechanical or lip seals the shaft while permitting the rotor shaft to rotate. The vessel can contain one or more ports for circulating the dispersion, where milling can be made in batches or recirculated through the milling chamber. The media can be retained in the vessel or recirculated along with the process fluid. The rotor is dimensioned so that its outer periphery is spaced with a small gap from an inner surface of the vessel. The vessel also can have a way of cooling the dispersion.

Priority: US2001-037566 Applic. Date: 2001-10-19; US2000-583893 Applic. Date: 2000-05-31; US19990137142P Applic. Date: 1999-06-01

Inventor: REED ROBERT GARY [US]; CZEKAI DAVID A [US]; BOSCH HENRY WILLIAM [US]; RYDE NIELS-PETER MOESGAARD [US]


Patent No.: US6994781B2  Issued: 07/Feb/2006

Title: Medical system, method and apparatus employing mems

Applicant/Assignee: BAXTER INTERNATIONAL INC

Application No.: 10/031112   Filing Date: 14/Jan/2002

Abstract:

A biological suspension processing system is disclosed that may include a suspension treatment device for treating one or more components of a biological suspension, a first fluid flow path for introducing a suspension into the treatment device and a second fluid flow path for withdrawing a constituent of the suspension from the device. At least on microelectromechanical (MEM) sensor communicates with one of the fluid flow paths for sensing a selected characteristic of the fluid therewith. The MEM sensor may be located elsewhere, such as on a container or bag and communicate with the interior for sensing a characteristic of the fluid contained therein. A wide variety of characteristics may be sensed, such as flow rate, pH, cell type, cell antigenicity, DNA, viral or bacterial presence, cholesterol, hematocrit, cell concentration, cell count, partial pressure, pathogen presence, or viscosity.

Priority: US20000216640P Applic. Date: 2000-07-07; WO2001US21188 Applic. Date: 2001-07-03

Inventor: CORK WILLIAM H [US]; ULMES JAMES J [US]; WEST RICHARD L [US]; LO YING-CHENG [US]; WEBER MARK C [US]; MIN KYUNGYOON [US]


Patent No.: US6994790B2  Issued: 07/Feb/2006

Title: Whole blood collection and processing method

Applicant/Assignee: GAMBRO, INC

Application No.: 10/358381   Filing Date: 03/Feb/2003

Abstract:

A method is disclosed for collecting and processing whole blood. Whole blood is collected at several remote donor sites and transported to a central blood-processing center, where information regarding demand for blood products is used to direct processing of whole blood into blood products. Whole blood is initially collected in collection bags unattached to satellite bags instead of commonly used multiple bag sets. When the determination is made at the blood processing center as to which blood products are to be made, the appropriate satellite bags and/or other system components are sterile docked to the blood-collection bag and the whole blood is processed. The use of blood-collection bags initially unattached to satellite bags eliminates waste and simplifies the transportation and processing of whole blood.

Also disclosed are blood collection systems that remove leukocytes and collect whole blood into blood-collection bags unattached to satellite bags.

Priority: US20020353277P Applic. Date: 2002-02-01

Inventor: CORBIN III FRANK [US]; URDAHL STEVEN GAGE [US]


Patent No.: US6994984B2  Issued: 07/Feb/2006

Title: Hematological assay

Applicant/Assignee: PENTAPHARM AG

Application No.: 10/168473   Filing Date: 29/Aug/2002

Abstract:

A hematological assay is described in which the blood coagulation potential of a body fluid is assessed by reacting a sample of the body fluid with an amount of an activator reagent comprising: (a) a predetermined amount of factor Xa or a hematologically equivalent mutant thereof, and (b) a predetermined amount of factor Va, a hematologically equivalent mutant thereof or an enzyme activating endogenous factor V, (c) (optionally) phospholipids. The reagent may be dry (e.g. lyophilised) or in an aqueous solution preferably buffered to a pH from 6 to 10 (preferably 7 to 8), if desired incubating, if necessary inducing coagulation by the addition of one or more coagulation accelerants such as calcium chloride, and establishing a value indicative of the coagulation potential, e.g. by measuring the time to clotting on an optical coagulometer or through use of a chromogenic substrate.

It is preferred to use at (b) factor V activator from purified Russell's Viper venom (RVV-V). An activator reagent is also described containing the components mentioned above preferably in one or more buffer solutions or in dried, e.g. lyophilised form.

Priority: WO1999EP09952 Applic. Date: 1999-12-15; WO2000EP12753 Applic. Date: 2000-12-14

Inventor: GEMPELER PATRIZIA MARIA [CH]; CALATZIS ANDREAS [DE]


Patent No.: US6997893B2  Issued: 14/Feb/2006

Title: Confined air tube and methods for handling air in closed blood processing systems

Applicant/Assignee: BAXTER INTERNATIONAL INC

Application No.: 10/619870   Filing Date: 15/Jul/2003

Abstract:

A confined air tube is intended to be placed into in-line communication with the transfer tubing of a blood processing system. The confined air tube provides an incremental volume of air, which keeps the transfer tubing from collapsing and sticking together during heat sterilization. After sterilization, the confined air tube accommodates conveyance of a blood component into an associated downstream transfer container. The confined air tube can also receive air vented from the transfer container, so that the blood component can undergo further processing or be stored in an air-depleted environment within the transfer container.

Priority: US2001-902313 Applic. Date: 2001-07-10; US1998-082946 Applic. Date: 1998-05-21

Inventor: MATHIAS JEAN-MARIE [BE]; PAYRAT JEAN-MARC [BE]; CONEYS THOMAS [FR]; VAN HEEMS PHILIPPE [FR]


Patent No.: US7004928B2  Issued: 28/Feb/2006

Title: Autonomous, ambulatory analyte monitor or drug delivery device

Applicant/Assignee: SARNOFF CORPORATION ROSEDALE MEDICAL, INC

Application No.: 10/131268   Filing Date: 23/Apr/2002

Abstract:

The invention relates to analyte monitoring/drug (pharmaceutical agent) delivery device. The invention is suited for monitoring various blood constituents such as glucose. The device has a housing that at least partially encloses a plurality of microneedles disposed on a carrier and an electronics portion. Each microneedle is in fluid communication with a corresponding microchannel. Each microneedle is individually addressable. That is, each microneedle can be extended and retracted individually via an actuator. The electronics portion includes a processor and associated circuitry (e.g., memory, supporting electronics and the like), a motor or the like, a sensor, a power supply (e.g., battery) and optionally an interface. In general, the processor controls the operation of the device and is data communication with the actuator, motor, sensor and interface.

The invention provides for autonomous operation, that is, without intervention of the user. The invention can optionally provide for calibration without intervention of the user. The invention can also provide for semi-continuous monitoring for day and night time. The invention can provide for up to four, or more, weeks of operation. The invention can provide for a device that is relative small in size, and therefore unobtrusive. The invention can also provide for device with remote control and interactive electronics. The invention may be also used for the delivery of various pharmaceutical agents including high potency drugs to minimize patient intervention and minimize discomfort.

Priority: US20020355195P Applic. Date: 2002-02-08

Inventor: ACETI JOHN GREGORY [US]; MCBRIDE STERLING EDUARD [US]; MORONEY III RICHARD MORGAN [US]; GREGORY CHRISTOPHER CARTER [US]; ZANZUCCHI PETER JOHN [US]


Patent No.: US7011938B2  Issued: 14/Mar/2006

Title: Method of measuring platelet activation

Applicant/Assignee: BARTS AND THE LONDON NHS TRUST

Application No.: 10/415336   Filing Date: 02/Sep/2003

Abstract:

Platelet activation is measured by determining Mean Platelet Component (MPC) of suspended blood platelets, using a specific anticoagulant composition. The composition comprises at least one component for effecting platelet sphering (for example EDTA), and at least one platelet antagonist (for example at least one of, and preferably all three of theophylline, adenosine and dipyridamole).

Priority: GB20000027309 Applic. Date: 2000-11-08; WO2001GB04946 Applic. Date: 2001-11-08

Inventor: MACEY MARION G [GB]


Patent No.: US7022689B2  Issued: 04/Apr/2006

Title: 5-amidino-n-(2-aminophenethyl)-n-hydroxy-benzenesulffonamide derivative, medical composition containing the same, pharmaceutical use thereof and intermediate therefor

Applicant/Assignee: KISSEI PHARMACEUTICAL CO., LTD

Application No.: 10/486137   Filing Date: 06/Feb/2004

Abstract:

The present invention relates to a 5-amidino-N-(2-aminophenethyl)-2-hydroxybenzenesulfonamide derivative represented by the general formula: wherein R<1 >is a hydrogen atom or a lower alkyl group

R<2 >represents a hydrogen atom, an optionally substituted lower alkyl group, etc.

R<3 >is a di(lower alkyl)amino group, a lower alkyl group, a cycloalkyl group, etc.

Q is a hydrogen atom or an optionally substituted lower alkyl group

and Z is a hydrogen atom or a hydroxy group, etc., or a pharmaceutically acceptable salt thereof, which exerts a potent and selective activated blood coagulation factor X inhibitory activity and is useful as an agent for the prevention or treatment of a disease occurred associating an activated blood coagulation factor X, a pharmaceutical composition comprising the same, a pharmaceutical use thereof and an intermediate thereof.

Priority: JP20010242905 Applic. Date: 2001-08-09; WO2002JP08093 Applic. Date: 2002-08-08

Inventor: OKAZAKI KOSUKE [JP]; UCHIDA MASAHIKO [JP]; KOBAYASHI HIROAKI [JP]; KAI YUICHIRO [JP]; TAKEUCHI HIDEKI [JP]; YOKOYAMA KENJI [JP]; TERAO YOSHIHIRO [JP]; SUZUKI RITSU [JP]


Patent No.: US7029456B2  Issued: 18/Apr/2006

Title: Medical fluid therapy flow balancing and synchronization system

Applicant/Assignee: BAXTER HEALTHCARE S.A

Application No.: 10/685724   Filing Date: 15/Oct/2003

Abstract:

Systems, apparatus and methods that allow external infusion, IV or administration pumps to be synchronized with the internal pumps for a medical fluid therapy machine are provided. The system reduces the time and effort needed to calculate, set-up, enter and maintain flowrates of various fluids, maintained internally or externally with respect to the medical fluid therapy machine. The system also automatically follows therapy requirements, for example, a requirement that one pump/fluid be running/flowing for another pump/fluid to be enabled to run/flow. The system further automatically adjusts for variations in flowrate of one fluid with respect to another. In short, the system provides a more "hands-off", safe and effective method and apparatus for medical fluid therapy fluid delivery.

Priority:

Inventor: WARE LEE C [US]; BOEHNLEIN ARNOLD F [US]


Patent No.: US7045148B2  Issued: 16/May/2006

Title: Method of collecting placental stem cells

Applicant/Assignee: ANTHROGENESIS CORPORATION

Application No.: 10/004942   Filing Date: 05/Dec/2001

Abstract:

A method of collecting embryonic-like stem cells from a placenta which has been treated to remove residual cord blood by perfusing the drained placenta with an anticoagulant solution to flush out residual cells, collecting the residual cells and perfusion liquid from the drained placenta, and separating the embryonic-like cells from the residual cells and perfusion liquid. Exogenous cells can be propagated in the placental bioreactor and bioactive molecules collected therefrom.

Priority: US20000251900P Applic. Date: 2000-12-06

Inventor: HARIRI ROBERT J [US]


Patent No.: US7049110B2  Issued: 23/May/2006

Title: Inactivation of West Nile virus and malaria using photosensitizers

Applicant/Assignee: GAMBRO, INC

Application No.: 10/358073   Filing Date: 03/Feb/2003

Abstract:

Methods and apparatuses are provided for inactivation of microorganisms in fluids or on surfaces. Preferably the fluids contain blood or blood products and comprise biologically active proteins. Preferred methods include the steps of adding an effective, non-toxic amount of a photosensitizer to a fluid and exposing the fluid to photoradiation sufficient to activate the photosensitizer whereby microorganisms are inactivated.

Priority: US2000-586147 Applic. Date: 2000-06-02; US20020353162P Applic. Date: 2002-02-01; US1999-357188 Applic. Date: 1999-07-20; US1998-119666 Applic. Date: 1998-07-21

Inventor: REDDY HEATHER [US]; GOODRICH RAYMOND P [US]


Patent No.: US7056458B2  Issued: 06/Jun/2006

Title: Non-thrombogenic semipermeable membrane and method for making same

Applicant/Assignee: HOSPAL INDUSTRIE

Application No.: 09/937558   Filing Date: 03/Jan/2002

Abstract:

The invention concerns a non-thrombogenic semipermeable membrane comprising a support semipermeable membrane and an anticoagulant suitable for treating blood and plasma by extracorporeal circulation. The invention is characterized in that: the support membrane is made essentially of a polyacrylinitrile, bearing anionic groups or groups capable of being anionic

the surface of the support semipermeable membrane designed to be in contact with blood or plasma is coated successively with a cationic polymer and an anticoagulant. The invention also concern an exchanger for treating blood or plasma by extracorporeal circulation comprising two sections separated by a non-thrombogenic semipermeable, membrane and a method for making the exchanger.

Priority: FR20000001065 Applic. Date: 2000-01-27; WO2001FR00248 Applic. Date: 2001-01-26

Inventor: CROST THIERRY [FR]; RENAUX JEAN-LOUIS [FR]; THOMAS MICHEL [FR]


Patent No.: US7060494B2  Issued: 13/Jun/2006

Title: Growth of human Mesenchymal Stem Cells (hMSC) using umbilical cord blood serum and the method for the preparation thereof

Applicant/Assignee: RELIANCE LIFE SCIENCES PVT. LTD

Application No.: 10/409458   Filing Date: 08/Apr/2003

Abstract:

A method of isolating and growing human mesenchymal stem calls (hMSC) by culturing human stem cells in human umbilical cord blood serum. For this purpose blood is collected from the umbilical cord at the time of birth, after the infant is separated from the umbilical cord, and the blood is collected from an umbilical vein free of anticoagulants. The blood is collected in a blood bag having a collecting needle which is inserted into the umbilical vein and the blood is allowed to flow from the vein into the blood bag, and the blood is allowed to clot at room temperature and the bag is transported to a processing area which is a cGMP clean room. The method also includes aspirating Human Mesenchymal Stem Cells (hMSC) present in bone marrow, diluting bone marrow aspirate with tissue culture medium

plating cell suspension into tissue culture flasks so that Human Mesenchymal Stem Cells (hMSC) can adhere for 24 hours

transferring the resulting supernatant to fresh flasks for the remaining Human Mesenchymal Stem Cells (hMSC) to adhere, feeding cultures every 3 days using the medium and cultures reach confluence by 3 weeks, adding 5-aza cytidine reagent to these cultures at final concentration of 5-20 micro molars and allowing the culture to grow for another 3 days.

Priority: US20020371137P Applic. Date: 2002-04-09

Inventor: BHAT ARAVIND VENKATRAO [IN]


Patent No.: US7074191B2  Issued: 11/Jul/2006

Title: Method and device for non-intrusive measurement of blood pressure in a circuit of a dialysis machine

Applicant/Assignee: GAMBRO LUNDIA AB

Application No.: 10/479796   Filing Date: 05/Dec/2003

Abstract:

A method for the non-intrusive measurement of blood pressure in a circuit of a dialysis machine, using a device provided with a sleeve forming a portion of the blood circuit and having at least one part which moves according to the pressure difference between the inside and the outside of the sleeve, and with an emitter and a receiver of electromagnetic waves. The method comprising the emission of a beam of electromagnetic waves and the receiving of a beam of electromagnetic waves reflected from the moving part, in order to measure the displacement of the moving part in such a way as to establish a relationship between the position of the moving part and the pressure of the blood circulating in the sleeve.

Priority: WO2002IB01775 Applic. Date: 2002-05-16; IT2001BO00355 Applic. Date: 2001-06-05

Inventor: BOSETTO ANTONIO [IT]; DELNEVO ANNALISA [IT]


Patent No.: US7094378B1  Issued: 22/Aug/2006

Title: Method and apparatus for inactivation of biological contaminants using photosensitizers

Applicant/Assignee: GAMBRO, INC

Application No.: 09/596429   Filing Date: 15/Jun/2000

Abstract:

Methods and apparatuses for treating fluids to inactivate microorganisms which may be present therein, said fluid containing one or more components selected from the group consisting of protein, blood and blood constituents are provided. The methods comprise adjusting the percentage of plasma in said fluid to a desired value

mixing an inactivation-effective, substantially non-toxic amount of an endogenous photosensitizer or endogenously-based derivative photosensitizer to said fluid

exposing said fluid to photoradiation of sufficient wavelength and energy to activate the photosensitizer, whereby said microorganisms are inactivated.

Priority:

Inventor: GOODRICH JR RAYMOND PAUL [US]; HLAVINKA DENNIS [US]


Patent No.: US7105018B1  Issued: 12/Sep/2006

Title: Drug-eluting stent cover and method of use

Applicant/Assignee: ADVANCED CARDIOVASCULAR SYSTEMS, INC

Application No.: 10/334034   Filing Date: 30/Dec/2002

Abstract:

An intravascular stent includes an eluting sheath fabricated from a mesh for controlled release of therapeutic drugs and for delivery of the therapeutic drugs in localized drug therapy in a blood vessel. The eluting sheath is attached to at least a portion of an outside surface area of the stent structure and is fabricated from a mesh designed to neck down in response to a radially outward directed force resulting in the uniform expansion of the stent. The eluting sheath can be loaded with at least one therapeutic drug for the release thereof at a treatment site to facilitate repair of a damaged vessel. The stent has a high degree of flexibility in the longitudinal direction, yet has adequate vessel wall coverage and radial strength sufficient to hold open an artery or other body lumen.

Priority:

Inventor: YIP PHILIP S [US]; JACOBS JAMES [US]; HOSSAINY SYED [US]; BECKER JON [US]; LIMON TIMOTHY A [US]


Patent No.: US7109332B2  Issued: 19/Sep/2006

Title: 2,4-dioxo-3-quinazolinylaryl sulfonylureas

Applicant/Assignee: PORTOLA PHARMACEUTICALS, INC

Application No.: 10/956004   Filing Date: 29/Sep/2004

Abstract:

2,4-Dioxo-3-quinazolinylaryl sulfonylurea compounds having the formula: wherein R is a member selected from the group consisting of H and C1-6 alkyl

R<1 >is a member selected from the group consisting of H, C1-6 alkyl, C1-6 haloalkyl, C3-5 cycloalkyl and C3-5 cycloalkyl-alkyl

R<2 >is a member selected from the group consisting of H, halogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 alkoxy, cyano and -C(O)R<2a>, wherein R<2a >is a member selected from the group consisting of C1-6 alkoxy and (C1-6 alkyl)0-2 amino

L is a 1 to 3 carbon linking group selected from the group consisting of -CH2-, -CH(CH3)-, -CH2CH2-, -CH2CH(CH3)- and -CH2CH2CH2-

L<1 >is a linking group selected from the group consisting of a bond and -CH2-

L<2 >is a linking group selected from the group consisting of a bond, -NH- and -CH2-

and Ar<1 >is an aromatic ring selected from the group consisting of benzene, pyridine and pyrimidine

are provided. The compounds are useful for the inhibition of ADP-platelet aggregation, particularly in the treatment of thrombosis and thrombosis related conditions or disorders.

Priority: US20030508564P Applic. Date: 2003-10-03

Inventor: SCARBOROUGH ROBERT M [US]; HUANG WOLIN [US]; PANDEY ANJALI [US]; BAUER SHAWN M [US]; ZHANG XIAOMING [US]; JIA ZHAOZHONG J [US]


Patent No.: US7112590B2  Issued: 26/Sep/2006

Title: Thrombin inhibitors

Applicant/Assignee: UNIVERSITY OF LJUBLJANA, FACULTY OF PHARMACY

Application No.: 10/275215   Filing Date: 31/Jan/2003

Abstract:

The invention relates to compounds that are heterocyclic derivatives of dipeptides and dipeptides mimetics and pharmaceutically acceptable salts thereof. The compounds are used as thrombin inhibitors

Priority: SI20000000111 Applic. Date: 2000-05-05; WO2001GB01997 Applic. Date: 2001-05-04

Inventor: KIKELJ DANIJEL [SI]; PETERLIN LUCIJA [SI]; MARINKO PETRA [SI]; BREZNIK MATEJ [SI]; STREGNAR MOJCA [SI]; TRAMPUZ BAKIJA ALENKA [SI]; FORTUNA MARJANA [SI]


Patent No.: US7115205B2  Issued: 03/Oct/2006

Title: Method of simultaneous blood collection and separation using a continuous flow centrifuge having a separation channel

Applicant/Assignee: MISSION MEDICAL, INC

Application No.: 10/891343   Filing Date: 14/Jul/2004

Abstract:

A system for automatically collecting and separating whole blood into its components is described. The system includes a console, which contains all motors, pumps, sensors, valves and control circuitry, and a unique disposable set that includes a cassette supporting a centrifuge with an improved design, pump interfaces with an improved design, component and solution bags, and tubing. Various processes are implemented using a specific disposable set for each process which allows automatic identification of the process to be performed the console.

Priority: US2002-179920 Applic. Date: 2002-06-24; US20010300873P Applic. Date: 2001-06-25; US20020374141P Applic. Date: 2002-04-19

Inventor: ROBINSON THOMAS C [US]; ROBINSON THOMAS P [US]; D ELIA RICHARD [US]; SAHINES THOMAS [US]; EIBE PAUL [US]


Patent No.: US7115588B2  Issued: 03/Oct/2006

Title: Methods for treating a breach or puncture in a blood vessel

Applicant/Assignee: MARINE POLYMER TECHNOLOGIES INC

Application No.: 10/194740   Filing Date: 12/Jul/2002

Abstract:

The present invention relates to compositions comprising semi-crystalline beta-1-4-N-acetylglucosamine polymers (p-GlcNac) and methods utilizing such polymers modulation of vascular structure and/or function. The compositions and methods disclosed are useful for stimulating, in a p-GlcNac concentration-dependent manner, endothelin-1 release, vasoconstriction, and/or reduction in blood flow out of a breached vessel, as well as for contributing to or effecting cessation of bleeding. The methods of the present invention comprise topical administration of materials comprising semi-crystalline p-GlcNac polymers that are free of proteins, and substantially free of single amino acids as well as other organic and inorganic contaminants, and whose constituent monosaccharide sugars are attached in a beta-1-4 conformation.

Priority: US2001-781182 Applic. Date: 2001-02-12

Inventor: VOURNAKIS JOHN N [US]; FINKIELSZTEIN SERGIO [US]


Patent No.: US7125860B1  Issued: 24/Oct/2006

Title: Cross-linked derivatives of hyaluronic acid

Applicant/Assignee: FIDIA FARMACEUTICI S.P.A

Application No.: 10/363273   Filing Date: 23/Jun/2003

Abstract:

The present invention describes a new class of cross-linked derivatives of partially N-deacetylated hyaluronic acid or derivatives thereof, comprising at least one repeating unit of formula (I) hereinafter depicted and a process for the preparation of said cross-linked derivatives, comprising a multicomponent condensation reaction involving the carboxy groups and the amino groups originating from a partial N-deacetylation of hyaluronic acid or derivatives, together with an aldeyde and an isocyanide. The derivatives thus obtained can be used, alone or in association with biologically and/or pharmacologically active substances, for the preparation of pharmaceutical compositions, biomaterials, surgical and healthcare articles, slow release systems and for the coating of biomedical objects.

Priority: IT2000PD00207 Applic. Date: 2000-08-31; WO2001EP10063 Applic. Date: 2001-08-31

Inventor: RENIER DAVIDE [IT]; CRESCENZI VITTORIO [IT]; FRANCESCANGELI ANDREA [IT]


Patent No.: US7131958B2  Issued: 07/Nov/2006

Title: Placental blood collection line including a rinsing bag

Applicant/Assignee: MACO PHARMA MACOPHARMA

Application No.: 10/160756   Filing Date: 31/May/2002

Abstract:

The invention relates to a placental blood collection line including a collection bag ( 1 ) in fluid communication with at least one collection needle ( 4, 5 ) via a first tube ( 2 ) associated with an inlet orifice ( 3 ) of the bag ( 1 ), said line further including a bag ( 6 ) containing a rinsing solution and which is connected to or is organized to be connected to said first tube ( 2 ) via a second tube ( 7 ). The invention also relates to a method of collecting placental 10 blood by using such a line.

Priority: FR20010007262 Applic. Date: 2001-06-01

Inventor: DEVERRE FREDERIC [FR]


Patent No.: US7131959B2  Issued: 07/Nov/2006

Title: Apparatus and methods for occluding an access tube anastomosed to sidewall of an anatomical vessel

Applicant/Assignee: INTEGRATED VASCULAR INTERVENTIONAL TECHNOLOGIES, L.C., ("IVIT LC")

Application No.: 10/351172   Filing Date: 23/Jan/2003

Abstract:

The invention provides vascular access methods, systems and devices facilitating long-term, repeated, percutaneous access to a patient's blood stream. This is provided by an access tube apparatus adapted for anastomosis to the sidewall of a target anatomical vessel. The access tube has a replaceable occluder that fits within the conduit of the access tube in between blood treatments or when vascular access is otherwise not needed. When such access is desired, the percutaneously accessible occluder is simply removed from the access tube.

Priority:

Inventor: BLATTER DUANE D [US]; ORR TROY J [US]; BARRUS MICHAEL C [US]


Patent No.: US7135305B2  Issued: 14/Nov/2006

Title: Methods for controlling the lysis of coagulated blood with apolipoprotein e4 phenotype

Applicant/Assignee:

Application No.: 10/398882   Filing Date: 17/Jul/2003

Abstract:

Methods for inhibiting lysis of coagulated blood and reducing risk of excessive lysis comprising administration of lysis-inhibiting amounts of apolipoprotein E4, and methods for inhibiting lysis of coagulated blood and reducing risk of excessive lysis comprising administration of a specific level of a lysis-inhibiting agent wherein the specific level is based on the apolipoprotein phenotype of an individual, are provided. Methods for enhancing lysis of coagulated blood by administration of an Apo E peptide fragment to blood containing a clot lysis agent are also provided.

Priority: US20000240174P Applic. Date: 2000-10-13; WO2001US31909 Applic. Date: 2001-10-12

Inventor: BRODERICK JOSEPH P [US]; CLARK JOSEPH F [US]; WOO DANIEL [US]


Patent No.: US7135329B2  Issued: 14/Nov/2006

Title: Immunoassay device for diagnosing congestive heart failure and predicting mortality in congestive heart failure patients

Applicant/Assignee: PRINCETON BIOMEDITECH CORPORATION

Application No.: 10/359047   Filing Date: 04/Feb/2003

Abstract:

An immunochemical assay device for determining the presence of NT-proBNP alone or conjunctively with Cardiac Troponin I comprising a base member, an array disposed on the base member, and at least one assay indicia zone. The array comprises (i) a reservoir pad to receive sample liquid, (ii) a wicking membrane, and (iii) at least one filter zone interposed between the wicking membrane and the reservoir pad. The filter zone being operable to permit passage of any specific immunocomplex to the wicking membrane while impeding passage of larger components.

Priority: US2002-299583 Applic. Date: 2002-11-18

Inventor: KANG JEMO [US]; KIM KYUNG-AH [US]; CHOI JOO YOUNG [US]; JACKOWSKI GEORGE [CA]


Patent No.: US7144382B2  Issued: 05/Dec/2006

Title: Device for treating a fluid-like sample such as a whole blood, with treatment fluid, use of such a device and kit containing such a device

Applicant/Assignee: BEST QUALITY B.V

Application No.: 10/476598   Filing Date: 31/Oct/2003

Abstract:

A device for treating a fluid-like sample, in particular whole blood, with treatment fluid. The device comprises a tubular container with a first piston and a second piston, with a piston gap between them in which the treatment fluid is located in the initial position. The device further comprises an inlet port to which a capillary can be connected and an outlet port to which a filter can be connected. Furthermore, the device comprises a tubular container so that when the plunger is pushed in the first piston, the first piston moves away from the second piston in order to draw in sample from the inlet port, the two pistons are then moved jointly away from the inlet port to in front of the outlet port, after which the second piston is pushed towards the first piston in order to drive out the mixture of sample and treatment fluid, via the outlet port, through the filter

Priority: NL20001016646 Applic. Date: 2000-11-17; WO2001NL00836 Applic. Date: 2001-11-19

Inventor: BROEK ARJAN JACOB [NL]; VAN DEN BERG MAX [NL]; DE ROOIJ FELIX WILHELMUS MARIE [NL]


Patent No.: US7144422B1  Issued: 05/Dec/2006

Title: Drug-eluting stent and methods of making the same

Applicant/Assignee: ADVANCED CARDIOVASCULAR SYSTEMS, INC

Application No.: 10/293108   Filing Date: 13/Nov/2002

Abstract:

An intravascular stent having a prefabricated, patterned polymeric sleeve for controlled release of therapeutic drugs and for delivery of the therapeutic drugs in localized drug therapy in a blood vessel is disclosed. The polymeric sleeve is attached to at least a portion of an outside surface area of the stent structure. Alternatively, a plurality of individual microfilament strands are longitudinally attached to an outer surface of a stent structure in a spaced apart orientation and loaded with at least one therapeutic drug for the release thereof at a treatment site. The stent has a high degree of flexibility in the longitudinal direction, yet has adequate vessel wall coverage and radial strength sufficient to hold open an artery or other body lumen. Methods for making the same are also disclosed.

Priority:

Inventor: RAO K T VENKATESWARA [US]


Patent No.: US7148209B2  Issued: 12/Dec/2006

Title: Composition and method for the repair and regeneration of cartilage and other tissues

Applicant/Assignee: BIO SYNTECH CANADA INC ECOLE POLYTECHNIQUE

Application No.: 11/031325   Filing Date: 07/Jan/2005

Abstract:

The present invention relates to a new method for repairing human or animal tissues such as cartilage, meniscus, ligament, tendon, bone, skin, cornea, periodontal tissues, abscesses, resected tumors, and ulcers. The method comprises the step of introducing into the tissue a temperature-dependent polymer gel composition such that the composition adhere to the tissue and promote support for cell proliferation for repairing the tissue. Other than a polymer, the composition preferably comprises a blood component such as whole blood, processed blood, venous blood, arterial blood, blood from bone, blood from bone-marrow, bone marrow, umbilical cord blood, placenta blood, erythrocytes, leukocytes, monocytes, platelets, fibrinogen, thrombin and platelet rich plasma. The present invention also relates to a new composition to be used with the method of the present invention.

Priority: US2001-896912 Applic. Date: 2001-06-29; US20000214717P Applic. Date: 2000-06-29

Inventor: HOEMANN CAROLINE D [CA]; BUSCHMANN MICHAEL D [CA]; MCKEE MARC D [CA]


Patent No.: US7156836B2  Issued: 02/Jan/2007

Title: Cannula assembly

Applicant/Assignee:

Application No.: 10/258826   Filing Date: 25/Oct/2002

Abstract:

A double cannula assembly for medical or veterinary use includes a first cannula ( 10 ) for insertion into a blood vessel in a conventional manner. This first cannula is an outer cannula and a second or inner cannula ( 12 ) is subsequently inserted through said first cannula to extend beyond the distal tip of the outer cannula. The inner cannula and outer cannula are formed to prevent blood entering between the engaging surfaces.

Priority: SG20000002344 Applic. Date: 2000-04-28; WO2001SG00068 Applic. Date: 2001-04-19

Inventor: TEO RICHARD KENG SIANG [SG]


Patent No.: US7156869B1  Issued: 02/Jan/2007

Title: Drug-eluting stent and delivery system with tapered stent in shoulder region

Applicant/Assignee: ADVANCED CARDIOVASCULAR SYSTEMS, INC

Application No.: 10/353219   Filing Date: 27/Jan/2003

Abstract:

A drug-eluting stent delivery system for the treatment of edge restenosis in a blood vessel. The drug-eluting stent delivery system has a balloon disposed about at least a portion of a catheter, the balloon having a first end and a second end and a working length therebetween, the first end and the second end each including a tapered portion, each tapered portion being attached to the catheter, the balloon being inflatable from a collapsed configuration to an inflated configuration. A drug-eluting stent contacts a wall of the blood vessel to maintain the patency of the vessel. The drug-eluting stent has a first end and a second end, the first end and the second end each including a tapered portion, wherein the drug-eluting stent is disposed over the balloon such that at least a portion of the first end and the second end of the balloon are covered by the tapered drug-eluting stent. A method for making the same is also disclosed herein.

Priority:

Inventor: PACETTI STEPHEN DIRK [US]


Patent No.: US7157470B2  Issued: 02/Jan/2007

Title: Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors

Applicant/Assignee: BRISTOL-MYERS SQUIBB COMPANY

Application No.: 10/429461   Filing Date: 05/May/2003

Abstract:

The present application describes sulfonylaminovalerolactams and derivatives thereof of Formula I: or pharmaceutically acceptable salt forms thereof, wherein ring G is a mono- or bicyclic carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.

Priority: US20020378313P Applic. Date: 2002-05-06

Inventor: SMALLHEER JOANNE M [US]; PINTO DONALD J [US]; WANG SHUAIGE [US]; QIAO JENNIFER X [US]; HAN WEI [US]; HU ZILUN [US]


Patent No.: US7159593B2  Issued: 09/Jan/2007

Title: Methods for reduction of pressure effects of cardiac tricuspid valve regurgitation

Applicant/Assignee: 3F THERAPEUTICS, INC

Application No.: 10/418663   Filing Date: 17/Apr/2003

Abstract:

A method of protecting an upper body and a lower body of a patient from high venous pressures comprising implanting a first stented valve at the superior vena cava and a second stented valve at the inferior vena cava, wherein the first and second valves are configured to permit blood flow towards a right atrium of the patient and prevent blood flow in an opposite direction.

Priority:

Inventor: MCCARTHY PATRICK M [US]; QUIJANO RODOLFO C QUIJANO [US]


Patent No.: US7163521B2  Issued: 16/Jan/2007

Title: Integrated infusion and aspiration system and method

Applicant/Assignee: BREG, INC

Application No.: 10/896515   Filing Date: 22/Jul/2004

Abstract:

An integrated infusion and aspiration system includes a flow control system and a catheter assembly. The catheter assembly includes an infusion catheter and an aspiration catheter, each having ports located at the distal end of thereof. The distal ends of the catheters are separated so that the aspiration catheter ports can be positioned on an opposing side of a surgical wound site from the infusion catheter ports. Methods of operation of the integrated infusion and aspiration system provide for uninterrupted aspiration with concurrent controlled delivery of an infusion solution such that the infusion solution is substantially evenly dispersed of over the wound site.

Priority: US2002-218106 Applic. Date: 2002-08-12

Inventor: GOBLE E MARLOWE [US]; HOWARD MARK E [US]; MASON JEFFREY T [US]; FALLIN T WADE [US]


Patent No.: US7169352B1  Issued: 30/Jan/2007

Title: Extracorporeal blood processing methods and apparatus

Applicant/Assignee: GAMBRO, INC

Application No.: 10/681035   Filing Date: 08/Oct/2003

Abstract:

This invention provides a method for controlling a fluid separation system, preferably a blood apheresis system having a leukocyte reduction chamber. The method utilizes a three-level alarm system. A first-level alarm condition is triggered in response to a pressure drop in the system to less than or equal to a specified system pressure and pauses fluid flow in at least a portion of the system. A second-level alarm condition is triggered in response to a specified number of said pressure drops within a specified period and reduces the flow rate of the fluid in the system. The alarm conditions may also trigger a visible and/or audible alarm. These alarm levels permit flow through the leukocyte reduction chamber to continue when the pressure drop is caused by a non-serious, self-resolving or easily-correctable condition such as misalignment of system components.

Priority: US2000-746987 Applic. Date: 2000-12-22; US19990171932P Applic. Date: 1999-12-22

Inventor: FELT THOMAS J [US]; BAINBRIDGE MARLENE ADELE [US]


Patent No.: US7169547B2  Issued: 30/Jan/2007

Title: High concentration white blood cells as a therapeutic product

Applicant/Assignee: NEW YORK BLOOD CENTER, INC

Application No.: 09/855789   Filing Date: 15/May/2001

Abstract:

A therapeutic product formed from a high concentration of white blood cells having a high degree of cell viability. The white blood cells are sequestered from their normal population presence in whole blood by placing the blood into a container and preventing coagulation of the blood, separating the blood into two components, one of which is extremely rich in white blood cells through the use of a reagent and centrifugation, sequestering the white cell concentration, and freezing the white cells.

Priority: US1999-313816 Applic. Date: 1999-05-18; US1998-128208 Applic. Date: 1998-08-03; US1994-349747 Applic. Date: 1994-12-05

Inventor: RUBINSTEIN PABLO [US]; COELHO PHILIP HENRY [US]; STEVENS CLADD E [US]


Patent No.: US7169572B1  Issued: 30/Jan/2007

Title: Assays for determining anticoagulant cofactor activity

Applicant/Assignee: T.A.C. THROMBOSIS AND COAGULATION AB

Application No.: 08/500917   Filing Date: 20/Oct/1995

Abstract:

Methods are disclosed for determining, in a sample derived from a human, the functional activity of a component of the human blood coagulation system, which activity can be correlated to conversion of a substrate specific for activated Protein C (APC), by measuring in an assay medium containing the sample and a substrate for APC, the conversion of the substrate by APC and correlating the conversion to the functional activity of the component. When the component is anticoagulant Factor V, at least one of exogenous APC, Protein S or an inhibitor of Protein S activity is added to the medium. When the component is Protein C, APC, or Protein S, exogenous anticoagulant Factor V or an inhibitor of anticoagulant activity of Factor V is added to the medium. Methods are also disclosed for diagnosing a blood coagulation/anticoagulation disorder or for determining a predisposition thereto in a human by determining anticoagulant Factor V activity in an assay medium containing a sample derived from the human.

Priority: SE19930000300 Applic. Date: 1993-01-29; SE19930002457 Applic. Date: 1993-07-20; WO1994SE00070 Applic. Date: 1994-01-28

Inventor: DAHLBAECK BJOERN [SE]


Patent No.: US7169573B2  Issued: 30/Jan/2007

Title: METHOD FOR MONITORING COAGULABILITY AND HYPERCOAGULABLE STATES

Applicant/Assignee: OKLAHOMA MEDICAL RESEARCH FOUNDATION

Application No.: 10/028741   Filing Date: 20/Dec/2001

Abstract:

The assay of soluble endothelial protein C receptor (sEPCR) is useful to monitor effective thrombin levels and a hypercoagulable state. An assay for sEPCR is therefore useful to monitor ongoing effectiveness of anticoagulant therapy. A sEPCR ELISA assay is particularly useful for this purpose. A state of hypercoagulability in patients or normal individuals can also be identified by such an assay.

Priority: US20010270066P Applic. Date: 2001-02-20

Inventor: KUROSAWA SHINICHIRO [US]; STEARNS-KUROSAWA DEBORAH J [US]


Patent No.: US7179838B2  Issued: 20/Feb/2007

Title: Coumarin analog compounds for safer anticoagulant treatment

Applicant/Assignee: NEW CENTURY PHARMACEUTICALS, INC

Application No.: 10/629858   Filing Date: 30/Jul/2003

Abstract:

The present invention relates to the albumin-guided development of coumarin analogs and the analogs developed thereby. The coumarin analogs of the present invention are identified and isolated by the fact that they have binding sites to albumin which are different than the binding sites of conventional coumarin analogs such as sodium warfarin, and as a result will be less prone to be displaced since the binding site of sodium warfarin is shared by numerous drugs such as aspirin. The coumarin analogs of the invention are advantageous because they can achieve the effects of the prior coumarin analogs with a minimum of metabolic complications and undesirable side effects.

Priority: US20020399126P Applic. Date: 2002-07-30

Inventor: CARTER DANIEL C [US]


Patent No.: US7186420B2  Issued: 06/Mar/2007

Title: Multi-part substitution infusion fluids and matching anticoagulants

Applicant/Assignee: EDWARDS LIFESCIENCES CORPORATION

Application No.: 10/742137   Filing Date: 19/Dec/2003

Abstract:

A multi-part substitution infusion fluid for an extracorporeal blood treatment and methods for using same are provided. Generally, the multi-part substitution fluid comprises a first solution composed of electrolites but without divalent cations and a second solution comprising divalent cations. Another embodiment includes a third solution comprising a matching citrate/citric acid anticoagulant. The described methods of using the multi-part substitution infusion fluids significantly reduce risks associated with various extracorporeal blood treatments.

Priority: EP19990201302 Applic. Date: 1999-04-26; US2001-959543 Applic. Date: 2001-10-23; WO2000EP03583 Applic. Date: 2000-04-20

Inventor: CHANG PETER C [NL]; LANNOY JEAN-MICHEL [FR]


Patent No.: US7198795B2  Issued: 03/Apr/2007

Title: In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions

Applicant/Assignee: ELAN PHARMA INTERNATIONAL LTD

Application No.: 10/323736   Filing Date: 20/Dec/2002

Abstract:

Disclosed are in vitro methods for evaluating the in vivo redispersibility of dosage forms of poorly water-soluble active agents. The methods utilize media representative of in vivo human physiological conditions.

Priority: US2002-075443 Applic. Date: 2002-02-15; US2000-666539 Applic. Date: 2000-09-21

Inventor: COOPER EUGENE R [US]; BULLOCK JOHN A [US]; CHIPPARI JOHN R [US]; SCHAEFER JOHN L [US]; PATEL RAKESH A [US]; JAIN RAJEEV [US]; STRASTERS JOOST [US]; RYDE NIELS P [US]; RUDDY STEPHEN B [US]


Patent No.: US7202048B2  Issued: 10/Apr/2007

Title: Onset of force development as a marker of thrombin generation

Applicant/Assignee: HEMODYNE, INC

Application No.: 10/405472   Filing Date: 03/Apr/2003

Abstract:

Platelet contractile force (PCF) is used as a surrogate marker of thrombin generation. PCF generation occurs concomitant with the burst of prothrombin fragment F 1+2 release. The time between assay start and PCF onset is identified as the thrombin generation time (TGT), and is used in assessing risk of bleeding, in diagnosing various disorders, and in monitoring the effects of pharmaceutical and other treatments. TGT is prolonged in clotting factor deficiencies and in the presence of direct and indirect thrombin inhibitors. TGT shortens to normal with clotting factor replacement and shortens with administration of rVIIa. TGT is short in thrombophilic states such as coronary artery disease, diabetes and thromboangiitis obliterans and prolongs toward normal with oral and intravenous anticoagulants.

Priority: US20020369559P Applic. Date: 2002-04-04; US20020387409P Applic. Date: 2002-06-11

Inventor: CARR JR MARCUS [US]


Patent No.: US7205296B2  Issued: 17/Apr/2007

Title: Substituted 2H-1,3-benzoxazin-4(3H)-ones

Applicant/Assignee: PORTOLA PHARMACEUTICALS, INC

Application No.: 11/236051   Filing Date: 26/Sep/2005

Abstract:

Substituted benzoxazin-4(3H)-ones are provided which are useful for treating thrombosis and for reducing the likelihood and/or severity of a secondary ischemic event in a patient.

Priority: US20040614564P Applic. Date: 2004-09-29

Inventor: SCARBOROUGH ROBERT M [US]; VENKATRAMAN MEENAKSHI S [US]; ZHANG XIAOMING [US]; PANDEY ANJALI [US]


Patent No.: US7205382B2  Issued: 17/Apr/2007

Title: Peptides, the production and use thereof for binding immunoglobulins

Applicant/Assignee: FRESENIUS MEDICAL CARE AFFINA GMBH

Application No.: 10/415665   Filing Date: 08/Aug/2003

Abstract:

Peptides having the following amino acid sequence as well as peptides or proteins which contain this amino acid seque

Priority: EP20000124418 Applic. Date: 2000-11-08; WO2001EP12933 Applic. Date: 2001-11-08

Inventor: ROENSPECK WOLFGANG [DE]; EGNER RALF [DE]; WINKLER DIRK [DE]; KUNZE RUDOLF [DE]


Patent No.: US7208288B2  Issued: 24/Apr/2007

Title: Methods for enhancing the lysis of coagulated blood with apolipoprotein E2 phenotype

Applicant/Assignee:

Application No.: 10/398880   Filing Date: 17/Jul/2003

Abstract:

Methods for enhancing the lysis of coagulated blood comprise administering to coagulated blood a combination of clot clysis agent and a lysis enhancing amount of apolipoprotein E2 (Apo E2) or a therapeutic derivative thereof. Methods for reducing the risk of blood coagulation comprise administering to blood a combination of a clot lysis agent and a lysis enhancing amount of Apo E2 or a therapeutic derivative thereof. Additional methods for enhancing the lysis of coagulated blood comprise administering to an individual a specific level of clot lysis agent wherein the specific level is based upon the apolipoprotein phenotype of the individual. Further methods for reducing the risks of blood coagulation comprise administering to blood a specific level of a clot lysis agent wherein the specific level is based upon the apolipoprotein phenotype of the individual.

Priority: WO2001US42719 Applic. Date: 2001-10-12; US20000240407P Applic. Date: 2000-10-13

Inventor: BRODERICK JOSEPH P [US]; CLARK JOSEPH F [US]; WOO DANIEL [US]


Patent No.: US7211433B1  Issued: 01/May/2007

Title: Method for the enriching or depleting tumor cells obtained from a body fluid and kit suitable for this purpose

Applicant/Assignee: HEXAL GENTECH FORSCHUNGS GMBH

Application No.: 09/890649   Filing Date: 02/Feb/2000

Abstract:

The invention relates to a method for the enrichment or depletion of tumor cells from a body fluid, in which a cell separation medium of specific density is overlaid with the body fluid and is centrifuged. A kit suitable for this method is likewise provided.

Priority: DE19991004267 Applic. Date: 1999-02-03; WO2000EP00831 Applic. Date: 2000-02-02

Inventor: DAHM MICHAEL W [DE]; PHELPS ROBERT C [DE]; BROCKMEYER CARSTEN [DE]


Patent No.: US7217282B2  Issued: 15/May/2007

Title: Methods and apparatus for regional and whole body temperature modification

Applicant/Assignee: RADIANT MEDICAL INC RADIANT MEDICAL, INC

Application No.: 10/626007   Filing Date: 24/Jul/2003

Abstract:

Methods and apparatus for temperature modification of selected body regions including an induced state of local hypothermia of the brain region for neuroprotection. A heat exchange catheter is provided with heat transfer fins projecting or extending outward from the catheter which may be inserted into selected blood vessels or body regions to transfer heat with blood or fluid in the selected blood vessels or body regions. Another aspect of the invention further provides methods and apparatus for controlling the internal body temperature of a patient. By selectively heating or cooling a portion of the catheter lying within a blood vessel, heat may be transferred to or from blood flowing within the vessel to increase or decrease whole body temperature or the temperature of a target region.

Feed back from temperature sensors located within the patient's body allow for control of the heat transfer from the catheter to automatically control the temperature of the patient or of the target region within the patient. The apparatus may include a blood channeling sleeve that directs body fluid over a heat exchanger where the body fluid's temperature is altered, and then is discharged out the distal end of the sleeve to a desired location, for example, cooled blood to the brain for neuroprotection. The catheter may be used alone or in conjunction with other heat exchangers to cool one region of a patient's body while heating another.

Priority: US1998-138830 Applic. Date: 1998-08-24; US1996-584013 Applic. Date: 1996-01-08; US1994-324853 Applic. Date: 1994-10-18; US1993-015774 Applic. Date: 1993-02-10

Inventor: GINSBURG LEGAL REPRESENTATIVE [US]; MACHOLD TIMOTHY R [US]; DINEEN MICHAEL T [US]


Patent No.: US7217356B2  Issued: 15/May/2007

Title: Medical system, method and apparatus employing MEMS

Applicant/Assignee: FENWAL, INC

Application No.: 11/198804   Filing Date: 05/Aug/2005

Abstract:

A biological suspension processing system is disclosed that may include a suspension treatment device for treating one or more components of a biological suspension, a first fluid flow path for introducing a suspension into the treatment device and a second fluid flow path for withdrawing a constituent of the suspension from the device. At least one microelectromechanical (MEM) sensor communicates with one of the fluid flow paths for sensing a selected characteristic of the fluid therewith. The MEM sensor may be located elsewhere, such as on a container or bag and communicate with the interior for sensing a characteristic of the fluid contained therein. A wide variety of characteristics may be sensed, such as flow rate, pH, cell type, cell antigenicity, DNA, viral or bacterial presence, cholesterol, hematocrit, cell concentration, cell count, partial pressure, pathogen presence, or viscosity.

Priority: US2002-031112 Applic. Date: 2002-01-14; WO2001US21188 Applic. Date: 2001-07-03; US20000216640P Applic. Date: 2000-07-07

Inventor: CORK WILLIAM H [US]; ULMES JAMES J [US]; WEST RICHARD L [US]; LO YING-CHENG [US]; WEBER MARK C [US]; MIN KYUNGYOON [US]


Patent No.: US7225518B2  Issued: 05/Jun/2007

Title: Apparatus for crimping a stent assembly

Applicant/Assignee: BOSTON SCIENTIFIC SCIMED, INC

Application No.: 10/784337   Filing Date: 23/Feb/2004

Abstract:

A stent assembly comprises a rotatable sheath and a stent. The assembly is crimped or reduced in diameter prior to loading onto a catheter by one or more crimping apparatuses. One crimping apparatus comprises a blade having a stepped configuration. A mandrel may be used to support the assembly during crimping. The mandrel may have an expandable region. A protective sheath may be used to protect the stent during crimping and to redirect the crimping forces to desired locations about the assembly.

Priority:

Inventor: EIDENSCHINK TRACEE [US]; WEBER JAN [US]; JAGGER KARL A [US]; BROWN TERRY V [US]


Patent No.: US7244451B2  Issued: 17/Jul/2007

Title: METHODS OF MAKING NANOPARTICULATE DRUG COMPOSITIONS COMPRISING COPOLYMERS OF VINYL PYRROLIDONE AND VINYL ACETATE AS SURFACE STABILIZERS

Applicant/Assignee: ELAN PHARMA INTERNATIONAL LTD

Application No.: 11/213765   Filing Date: 30/Aug/2005

Abstract:

The present invention is directed to nanoparticulate compositions comprising a poorly soluble drug and at least one copolymer of vinyl pyrrolidone and vinyl acetate as a surface stabilizer adsorbed to the surface of the drug. Also encompassed by the invention are pharmaceutical compositions comprising a nanoparticulate composition of the invention, methods of making and using such nanoparticulate and pharmaceutical compositions.

Priority: US2003-345312 Applic. Date: 2003-01-16; US2000-715117 Applic. Date: 2000-11-20; US2002-075443 Applic. Date: 2002-02-15; US2000-666539 Applic. Date: 2000-09-21

Inventor: BOSCH H WILLIAM [US]; RYDE NIELS P [US]


Patent No.: US7244574B2  Issued: 17/Jul/2007

Title: Method of assaying lupus anticoagulant and assay reagent

Applicant/Assignee: EISAI CO., LTD

Application No.: 10/472283   Filing Date: 18/Sep/2003

Abstract:

A monoclonal antibody having inhibitory activity on blood coagulation reactions, which reacts with prothrombin forming a complex with phosphatidylserine but does not react with prothrombin not forming a complex with phosphatidylserine

and a method for measuring inhibitory activity of test plasma on blood coagulation reactions, which comprises the steps of (1) measuring inhibitory activity of the test plasma on the blood coagulation reactions and inhibitory activity of this on the blood coagulation reactions, and (2) comparing the inhibitory activity of the test plasma with the inhibitory activity of this antibody.

Priority: JP20010077366 Applic. Date: 2001-03-19; WO2002JP02599 Applic. Date: 2002-03-19

Inventor: ATSUMI TATSUYA [JP]; KOIKE TAKAO [JP]


Patent No.: US7247488B2  Issued: 24/Jul/2007

Title: Method and kit for testing a multi-channel blood assay cartridge

Applicant/Assignee: MEDTRONIC, INC

Application No.: 10/430623   Filing Date: 06/May/2003

Abstract:

A method and kit for testing a multi-channel blood-testing cartridge. In particular, blood-testing cartridges are tested with plasma samples with clotting times measured to indicate whether a batch of cartridges is suitable for testing the blood of a patient.

Priority:

Inventor: GHAI JYOTSNA [US]; THOMPSON MARK A [US]; LUTZ COLLEEN [US]; RAMAMURTHY NARAYANAN [US]; YUAN CHARLENE X [US]


Patent No.: US7250168B2  Issued: 31/Jul/2007

Title: Tissue factor targeted thrombomodulin fusion proteins as anticoagulants

Applicant/Assignee: SCHERING AKTIENGESELLSCHAFT BAYER SCHERING PHARMA AG

Application No.: 10/427805   Filing Date: 30/Apr/2003

Abstract:

This invention relates to novel fusion proteins which are comprised of a targeting protein that binds tissue factor (TF), which is operably linked to the thrombomodulin (TM) EGF456 domain alone or in combination with at least one other TM domain selected from the group consisting of the N-terminal hydrophobic region domain, the EGF123 domain, the interdomain loop between EGF3 and EGF4, and the O-glycosylated Ser/Thr-rich domain, or analogs, fragments, derivatives or variants thereof. The fusion protein binds at the site of injury and prevents the initiation of thrombosis. The fusion protein can be used to treat a variety of thrombotic conditions including but not limited to deep vein thrombosis, disseminated intravascular coagulation, and acute coronary syndrome.

Priority: US20020376566P Applic. Date: 2002-05-01

Inventor: LIGHT DAVID [US]; MCLEAN KIRK [US]


Patent No.: US7255659B2  Issued: 14/Aug/2007

Title: Formulation for blood clot inhibitor for use with bow hunting broadheads and method for using same

Applicant/Assignee:

Application No.: 11/206463   Filing Date: 18/Aug/2005

Abstract:

A method and formulation are disclosed toward the enhancing of a blood trail by a wounded target animal. A topical application for use with broadheads is disclosed as well as a method for using same.

Priority: US20040603691P Applic. Date: 2004-08-21

Inventor: JONES BRANDON CHAD [US]


Patent No.: US7255879B2  Issued: 14/Aug/2007

Title: Post-partum mammalian placenta, its use and placental stem cells therefrom

Applicant/Assignee: ANTHROGENESIS CORPORATION

Application No.: 10/640428   Filing Date: 12/Aug/2003

Abstract:

The present invention provides a method of extracting and recovering embryonic-like stem cells, including, but not limited to pluripotent or multipotent stem cells, from an exsanguinated human placenta. A placenta is treated to remove residual umbilical cord blood by perfusing an exsanguinated placenta, preferably with an anticoagulant solution, to flush out residual cells. The residual cells and perfusion liquid from the exsanguinated placenta are collected, and the embryonic-like stem cells are separated from the residual cells and perfusion liquid. The invention also provides a method of utilizing the isolated and perfused placenta as a bioreactor in which to propagate endogenous cells, including, but not limited to, embryonic-like stem cells.

The invention also provides methods for propagation of exogenous cells in a placental bioreactor and collecting the propagated exogenous cells and bioactive molecules therefrom.

Priority: US2002-076180 Applic. Date: 2002-02-13; US2001-004942 Applic. Date: 2001-12-05; US20010268560P Applic. Date: 2001-02-14; US20000251900P Applic. Date: 2000-12-06

Inventor: HARIRI ROBERT J [US]


Patent No.: US7276377B2  Issued: 02/Oct/2007

Title: Method and apparatus for determining anticoagulant therapy factors

Applicant/Assignee: WADA, INC

Application No.: 11/359667   Filing Date: 22/Feb/2006

Abstract:

Methods and apparatus are disclosed for determining a new anticoagulant therapy factor (nATF) for monitoring oral anticoagulant therapy to help prevent excessive bleeding or deleterious blood clots that might otherwise occur before, during or after surgery. In one embodiment, the new anticoagulant therapy factor is based upon a determination of a new fibrinogen transformation rate (nFTR) which, in turn, is dependent on a maximum acceleration point (MAP) for fibrinogen (FBG) conversion. The new anticoagulant therapy factor quantity is also based upon the time to maximum acceleration from the time of reagent injection (TX) into a plasma sample, but does not require the difficulty of obtaining prior art International Normalized Ratio (INR) and International Sensitivity Index (ISI) parameters.

Other embodiments provide methods and apparatus for determining an anticoagulant therapy factor without requiring use of a mean normal prothrombin time determination or ISI.

Priority: US2003-662043 Applic. Date: 2003-09-12; US2003-428708 Applic. Date: 2003-05-02; US20050679423P Applic. Date: 2005-05-10

Inventor: CARROLL WALLACE E [US]; JACKSON R DAVID [US]


Patent No.: US7276491B2  Issued: 02/Oct/2007

Title: Anticoagulant and fibrinolytic therapy using p38 MAP kinase inhibitors

Applicant/Assignee: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG

Application No.: 11/009480   Filing Date: 10/Dec/2004

Abstract:

Disclosed are methods for a treating a disease or condition relating to blood coagulation and fibrinolysis using p38 MAP kinase inhibitors.

Priority: US2003-630599 Applic. Date: 2003-07-30; US20020403422P Applic. Date: 2002-08-14

Inventor: WOOD CHESTER C [US]; VAN DER POLL THOMAS [NL]


Patent No.: US7279175B2  Issued: 09/Oct/2007

Title: Stent coated with a sustained-release drug delivery and method for use thereof

Applicant/Assignee: PSIVIDA INC

Application No.: 10/245840   Filing Date: 17/Sep/2002

Abstract:

An intraluminal medical device comprises a stent having a coating applied to at least part of an interior surface, an exterior surface, or both. The coating comprises a sustained release formulation of a combination of pharmaceutical compounds dispersed within a biologically tolerated polymer composition. The choice of the combination of pharmaceutical compounds are intended to reduce neointimal hyperplasia restenosis.

Priority: US20010322428P Applic. Date: 2001-09-17; US20020372761P Applic. Date: 2002-04-15

Inventor: CHEN JIANBING [US]; ASHTON PAUL [US]


Patent No.: US7288267B2  Issued: 30/Oct/2007

Title: Bioadhesive nanoparticulate compositions having cationic surface stabilizers

Applicant/Assignee: ELAN PHARMA INTERNATIONAL LTD

Application No.: 10/004808   Filing Date: 07/Dec/2001

Abstract:

Bioadhesive nanoparticulate compositions, comprising active agent particles and one or more cationic surface stabilizers, are described. The cationic surface stabilizers prevent aggregation of the nanoparticles and increase bioadhesion of the nanoparticles to biological substrates, such as an insect, teeth, bone, nails, chitin, feathers, scales, mucous, skin, hair, plant tissue, etc. The particles may consist of pharmacologically active compounds (e.g., drug compounds for human or veterinary use), agricultural chemicals (pesticides, herbicides, fertilizers, and the like), cosmetic agents, consumer products (coloring agents, flavors, or fragrances), or other materials which function by interacting with biological substrates. In addition, the invention relates to methods of preparing and using such bioadhesive nanoparticulate compositions.

Priority: US1999-414159 Applic. Date: 1999-10-08

Inventor: BOSCH H WILLIAM [US]; COOPER EUGENE R [US]; MCGURK SIMON L [US]


Patent No.: US7294479B2  Issued: 13/Nov/2007

Title: Compositions, kit and one-step method for monitoring compounds having anti-factor Xa and/or anti factor IIa activities

Applicant/Assignee:

Application No.: 11/127540   Filing Date: 11/May/2005

Abstract:

Provided are compositions and methods for accurate determination of the concentration of anticoagulant in a sample such as a blood or plasma sample. The compositions can contain a Factor X compound and Factor V compound, and additional components as well. Methods for performing the assay include one-step methods in which a sample is added to a coagulation assay composition, and time is monitored from the point of adding the sample and coagulation assay composition to an endpoint, such as clot formation.

Priority: US20040570312P Applic. Date: 2004-05-11

Inventor: YIN THYE [US]


Patent No.: US7294635B2  Issued: 13/Nov/2007

Title: Substituted isoquinolinones

Applicant/Assignee: PORTOLA PHARMACEUTICALS, INC

Application No.: 10/956006   Filing Date: 29/Sep/2004

Abstract:

Isoquinolinone compounds are provided that are useful for the inhibition of ADP-platelet aggregation, particularly in the treatment of thrombosis and thrombosis related conditions or disorders.

Priority: US20030508402P Applic. Date: 2003-10-03

Inventor: SCARBOROUGH ROBERT M [US]; KANE-MAGUIRE KIM A [US]; MARLOWE CHARLES K [US]; SMYTH MARK S [US]; ZHANG XIAOMING [US]


Patent No.: US7300797B2  Issued: 27/Nov/2007

Title: Lysis reagent for blood cell analysis

Applicant/Assignee: IMMUNOTECH IMMUNOTECH, S.A

Application No.: 09/951903   Filing Date: 14/Sep/2001

Abstract:

A multifunctional reagent for erythrocytes containing an amount sufficient to produce the lysis of erythrocytes or the sphering of erythrocytes in such a way that they can be detected by a cytometer or an automatic counting device, of a carbamate or of an agent inducing the formation by the erythrocytes, from carbonate and from a nitrogenated heterocycle or ammonium ions, of a carbamate combined with the absorption of CO2 by said erythrocytes, process for lysing or sphering erythrocytes and preparation process for leucocytes.

Priority: FR20000011746 Applic. Date: 2000-09-14

Inventor: VAN AGTHOVEN ANDRE [FR]; DAZIANO JEAN-PIERRE [FR]; MAPLES JOHN ALLEN [US]


Patent No.: US7306812B2  Issued: 11/Dec/2007

Title: Dissolvable backing layer for use with a transmucosal delivery device

Applicant/Assignee: CEPHALON, INC

Application No.: 10/841893   Filing Date: 07/May/2004

Abstract:

A dissolvable backing layer for use with transmucosal drug delivery devices includes a dissolvable hydrophilic region and a non-hydrophilic region that inhibits or slows migration of water, drugs, other active agents, or other molecules through the backing layer. The non-hydrophilic region can be a disperse phase of gaseous voids, droplets of a hydrophobic liquid, solid particles of a hydrophobic material, or water insoluble particles that are not necessarily hydrophobic. In the alternative, the non-hydrophilic region may comprise a continuous layer or component that is readily dispersible upon dissolving of the hydrophilic region. The backing layers may be used within any transmucosal delivery device used to delivery drugs or other active agents across a mucosal surface.

Priority: US20030469507P Applic. Date: 2003-05-09

Inventor: ZHANG HAO [US]


Patent No.: US7308303B2  Issued: 11/Dec/2007

Title: Thrombolysis and chronic anticoagulation therapy

Applicant/Assignee: ADVANCED BIONICS CORPORATION

Application No.: 10/285803   Filing Date: 01/Nov/2002

Abstract:

Thrombolytic and/or anticoagulation therapy of the present invention includes implantation of the discharge portion(s) of a catheter and, optionally, one or more electrodes on a lead, adjacent tissue(s) to be stimulated. Stimulation pulses, i.e., drug infusion pulses and optional electrical pulses, are supplied by a stimulator implanted remotely, and through the catheter or lead, which is tunneled subcutaneously between the stimulator and stimulation site. Stimulation sites include the coronary arteries, coronary veins, cerebral arteries, other blood vessels, chambers of the heart, mesenteric vessels, deep vessels of the leg, and other locations. Disclosed treatments include drugs used for chronic treatment and/or prevention of thromboembolic disease, for acute treatment of thromboembolic disease, for acute treatment of thrombosis, and combinations of these.

The invention reduces or eliminates the incidence of thromboembolic disease and related morbidities, improve symptoms resulting from thromboembolic disease, and improve patient quality of life.

Priority: US20010340076P Applic. Date: 2001-11-01

Inventor: WHITEHURST TODD K [US]; MCCLURE KELLY H [US]; THACKER JAMES R [US]


Patent No.: US7309323B2  Issued: 18/Dec/2007

Title: Wearable continuous renal replacement therapy device

Applicant/Assignee: NATIONAL QUALITY CARE, INC

Application No.: 10/940862   Filing Date: 14/Sep/2004

Abstract:

A continuous renal replacement therapy (CRRT) device adapted to be worn on a portion of the body of a patient. The CRRT device is worn by the patient and operates on rechargeable batteries for more than 5 hours. Dialysate is used to remove impurities from the blood. The dialysate is recycled and refreshed by a filter section. Less than one liter of dialysate is required to circulate through the wearable CRRT device.

Priority: US2001-085349 Applic. Date: 2001-11-16

Inventor: GURA VICTOR [US]; RAMBOD EDMOND [US]


Patent No.: US7309468B2  Issued: 18/Dec/2007

Title: Protease inhibitor sample collection system

Applicant/Assignee: BECTON, DICKINSON AND COMPANY

Application No.: 10/436263   Filing Date: 13/May/2003

Abstract:

A collection container and a method for collecting a biological sample, particularly whole blood, that includes at least one stabilizing agent in an amount effective to stabilize and inhibit protein degradation and/or fragmentation. The stabilizing agent is able to stabilize proteases in the biological sample, particularly at the point of collection, by inhibiting protein degradation and/or fragmentation in the sample when the sample is stored. The stabilizing agent includes one or more protease inhibitors.

Priority: US20020379399P Applic. Date: 2002-05-13

Inventor: STEVENS TIMOTHY [US]; HAYWOOD BRUCE [US]; DASTANE AJIT [US]; LIN FU-CHUNG [US]


Patent No.: US7314554B2  Issued: 01/Jan/2008

Title: Extracorporeal blood treatment machine

Applicant/Assignee: GAMBRO LUNDIA AB

Application No.: 10/771377   Filing Date: 05/Feb/2004

Abstract:

The invention relates to an extracorporeal blood treatment machine in which a blood circuit ( 3 ) is equipped with an inlet line leading to a filtration unit ( 2 ) and with an outlet line ( 3 b) from the filtration unit

a fluid circuit comprises an inlet line ( 4 a) leading to the filtration unit and an outlet line ( 4 b) from the filtration unit so as to allow a fluid taken from a primary container ( 5 ) to circulate within the filtration unit, thus enabling the treatment of the patient's blood. There is further an infusion line ( 6 ) acting on the outlet line of the blood circuit, which is supplied by an auxiliary fluid container ( 7 ). The inlet line of the fluid circuit is equipped with at least an infusion branch ( 8 ) acting on the outlet line of the blood circuit so as to enable the intensive therapy machine to manage therapies with large exchange of fluids.

Priority: IT2003MI00212 Applic. Date: 2003-02-07; US20030469839P Applic. Date: 2003-05-13

Inventor: DELNEVO ANNALISA [IT]; RIBOLZI FRANCESCO [IT]; TONELLI CLAUDIO [IT]; BARALDI VINCENZO [IT]; ZACCARELLI MASSIMO [IT]; CHEVALLET JACQUES [FR]; DUCHAMP JACQUES [FR]; ABERKANE AZIZ [FR]; MEYSSONNIER GABRIEL [FR]; POUCHOULIN DOMINIQUE [FR]


Patent No.: US7316657B2  Issued: 08/Jan/2008

Title: Massage appliance with adjustable massage characteristics and storage container

Applicant/Assignee: BEIERSDORF AG

Application No.: 10/917586   Filing Date: 13/Aug/2004

Abstract:

The present invention is a massage appliance comprising a preparation, a storage container containing the preparation, and a closure for the storage container. The closure comprises a massage device comprising an outlet opening through which the preparation can be applied to the surface to be massaged and an adjustment device comprising a first element with at least one first surface wherein the first surface contacts the surface to be massaged during a massage, and a second element arranged to be moveable relative to the first element. The adjustment device may be used to adjust a massage characteristic value of the first surface. The massage device is positioned at an angle with respect to the main axis of the storage container.

The present invention also includes a method of applying a preparation to the skin, a method of treating rheumatoid arthritis, and a method of warming up using the massage appliance.

Priority: DE20021006257 Applic. Date: 2002-02-15; WO2003EP01350 Applic. Date: 2003-02-12

Inventor: KLEINHENZ SVEN [DE]; FELTEN BERNHARD [DE]


Patent No.: US7318892B2  Issued: 15/Jan/2008

Title: Method and apparatus for kidney dialysis

Applicant/Assignee: BAXTER INTERNATIONAL INC

Application No.: 11/175072   Filing Date: 05/Jul/2005

Abstract:

A number of improvements relating to methods and apparatuses for kidney dialysis are disclosed. These include checking of dialysate bypass status using flow measurement

using a flow sensor to confirm the absence of ultrafiltration during bypass

automatic testing of ultrafiltration function by removal of a discrete volume from a portion of the dialysate flow path coupled with a pressure test of that part of the flow path

using a touch screen user interface

bar graph profile programming of ultrafiltration, sodium, and bicarbonate parameters

using a RAM card to upload treatment instructions to, and to download treatment data from, the machine

automatic setting of proportioning mode (acetate or bicarbonate) based on connections of concentrate lines

predicting dialysate conductivity values based on brand and formulation of concentrates

minimizing no-flow dead time between dialysate pulses

initiating operation in a timed mode from a machine power-off condition

preserving machine mode during machine power-fail condition

calibration scheduling and reminding

automatic level adjusting

and blood leak flow rate detecting.

Priority: US2004-938486 Applic. Date: 2004-09-09; US2003-695526 Applic. Date: 2003-10-27; US2000-711240 Applic. Date: 2000-11-13; US1998-067922 Applic. Date: 1998-04-28; US1995-479688 Applic. Date: 1995-06-07; US1993-122047 Applic. Date: 1993-09-14; US1991-688174 Applic. Date: 1991-04-19

Inventor: CONNELL MARK E [US]; BEDIENT ROBERT A [US]; ELSEN RAYMOND [BE]; HOGARD MICHAEL E [US]; JOHNSON HARLEY D [US]; KELLY THOMAS D [US]; LONG JEAN MCEVOY [US]; PETERSON BRUCE A [US]; PRESTON JR WILLIAM G [US]; SMEJTEK DALIBOR J [US]


Patent No.: US7323191B2  Issued: 29/Jan/2008

Title: Transdermal warfarin system

Applicant/Assignee: ALZA CORPORATION

Application No.: 10/900804   Filing Date: 27/Jul/2004

Abstract:

Composition of matter for application to a body surface or membrane to administer warfarin by permeation through the body surface or membrane, the composition comprising warfarin to be administered, at a therapeutically effective rate, alone or in combination with a permeation enhancer or mixture. Also disclosed are drug delivery devices containing the warfarin or warfarin and enhancer composition and methods for the transdermal administration of the warfarin and warfarin/enhancer composition.

Priority: US20030490739P Applic. Date: 2003-07-28

Inventor: GALE ROBERT M [US]


Patent No.: US7335187B2  Issued: 26/Feb/2008

Title: Safety dialysis needle/catheter system and method of use

Applicant/Assignee: SDA PRODUCT, INC

Application No.: 10/685546   Filing Date: 14/Oct/2003

Abstract:

The present invention provides a safety needle/catheter system and method of use for dialysis procedures. The invention includes a safety feature that prevents inadvertent needle sticks by administrators. The invention further includes a catheter portion composed of shape memory materials. The catheter portion has a deformed shape and size that facilitates insertion of the catheter portion and closure of the catheter incision and a recovered shape and size that can reduce the severity of infection and/or clotting, as well as provide improved maintenance and control over proper fluid volume flow during dialysis.

Priority:

Inventor: ALTMAN SANFORD D [US]


Patent No.: US7335648B2  Issued: 26/Feb/2008

Title: Non-nucleotide composition and method for inhibiting platelet aggregation

Applicant/Assignee: INSPIRE PHARMACEUTICALS, INC

Application No.: 11/124619   Filing Date: 05/May/2005

Abstract:

This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis or related disorders. The method comprises administering to a compounds useful for this invention include compounds of general Formulae I and III-XII, or salts, hydrates, and solvates thereof. The present invention also provides novel compounds of Formulae I and III-XII.

Priority: US2004-971766 Applic. Date: 2004-10-21; US20030513845P Applic. Date: 2003-10-21

Inventor: PLOURDE JR ROBERT [US]; SHAVER SAMMY R [US]; DOUGLASS III JAMES G [US]; WATSON PAUL S [US]; BOYER JOSE L [US]; TU CHI [US]; ABREO MELWYN A [US]; ALFARO-LOPEZ LORENZO J [US]; FENG YANGBO [US]; HARVEY DANIEL F [US]; KHASONOVA TATYANA V [US]


Patent No.: US7351218B2  Issued: 01/Apr/2008

Title: Device and process for extracorporeal treatment by citrate anticoagulant

Applicant/Assignee: HOSPAL INTERNATIONAL MARKETING MANAGEMENT SNC GAMBRO LUNDIA AB

Application No.: 10/739273   Filing Date: 19/Dec/2003

Abstract:

A device for treating blood by extracorporeal circulation comprising a filter having a first chamber and a second chamber separated by a semi-permeable membrane. The device has an arterial line connected to the first chamber of the filter, a venous line issuing from the first chamber of the filter, a channel used for pre-infusion of a substance for regional anticoagulation and linked to the arterial line, a purge channel issuing from the second chamber of the filter, and an air separator on the venous line. The device also includes a line for post-infusion of a solution at least partially re-establishing the ionic equilibrium of the blood downstream of the air separator, the post-infusion line being configured immediately upstream of an air detector.

Priority: FR20020016228 Applic. Date: 2002-12-20; US20030453967P Applic. Date: 2003-03-13

Inventor: BENE BERNARD [FR]


Patent No.: US7354415B2  Issued: 08/Apr/2008

Title: Extra-corporeal Blood Processing Method and Apparatus Based on Donor Characteristics

Applicant/Assignee: GAMBRO, INC GAMBRO BCT, INC

Application No.: 10/709196   Filing Date: 20/Apr/2004

Abstract:

Methods and apparatus particularly involving the separation of blood into blood components and the collection of such components are disclosed. In one aspect, an extra-corporeal method for the collection of plasma and red blood cells is provided, wherein the collection of plasma and red blood cells may occur simultaneously or subsequently utilizing the same dual stage blood processing vessel. The flow of blood to the blood processing vessel and return of uncollected blood components may be provided via a single needle, wherein blood is removed from and returned to a donor/patient during alternating blood removal and blood return submodes. Platelet separation and collection options are also described. In either case, prior to red blood cell collection, a set-up phase may be carried out to set a predetermined hematocrit and AC ratio.

Replacement fluid delivery may optionally also be provided either substantially continuously during any collection phase(s) and/or in a bolus mode.

Priority: US2001-803304 Applic. Date: 2001-03-09; US20000188133P Applic. Date: 2000-03-09

Inventor: BAINBRIDGE MARLENE [US]; KELLER MURIEL [US]; GORDON TIMOTHY M [US]; MCATEER MICHAEL J [US]; BUTZKE SCOTT D [US]


Patent No.: US7358091B2  Issued: 15/Apr/2008

Title: Device and methods for identifying and treating aspirin non-responsive patients

Applicant/Assignee: PORTOLA PHARMACEUTICALS, INC

Application No.: 11/304054   Filing Date: 14/Dec/2005

Abstract:

The present invention relates to methods and compositions for identifying and treating subjects in need of antithrombotic therapies but who are not responsive to aspirin.

Priority: US20040636744P Applic. Date: 2004-12-14

Inventor: PHILLIPS DAVID R [US]; ANDRE PATRICK [US]; STEPHENS GILLIAN [US]


Patent No.: US7358337B2  Issued: 15/Apr/2008

Title: Assay for low molecular weight heparin

Applicant/Assignee: INTERNATIONAL TECHNIDYNE CORPORATION

Application No.: 10/222345   Filing Date: 16/Aug/2002

Abstract:

A prothrombin time reagent for determination of low molecular weight heparin in frsh whole blood and in anti-coagulant treated blood is provided. The reagent is composed of recombinant animal tissue factor, and a mixture of synthetic phospholipids, which mixture includes a phosphatidylalcohol. A formulation buffer which includes a sensitivity adjuster is used in formulating the reagent. The recombinant animal tissue factor includes rabbit brain. The synthetic phospholipids of the mixture include palmitoyloleoylphosphatidylcholine (POPC), palmitoyloleoyl-phosphatidylserine (POPS), and a phosphatidylalcohol. The phosphatidyl alcohol includes dioleoylphosphatidylethanol, dioleoylphosphatidylmethanol, dioleoylphosphatidylpropanol, dioleoylphosphatidylbutanol, and dioleoylphosphatidylinositol. The sensitivity adjuster included in the formulation buffer is gamma-Cyclodextrin.

The formulated reagent is air-dried and remains stable for at least 3 weeks at 37 DEG C.

Priority:

Inventor: LEE TED C K [US]; MCBRIDE AMANDA B [US]; LADUCA FRANK M [US]


Patent No.: US7368438B2  Issued: 06/May/2008

Title: Non-nucleotide compositions and method for inhibiting platelet aggregation

Applicant/Assignee: INSPIRE PHARMACEUTICALS, INC

Application No.: 10/971766   Filing Date: 21/Oct/2004

Abstract:

This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis or related disorders. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a non-nucleotide compound, preferably a P2Y12 receptor antagonist compound, wherein said amount is effective to inhibit platelet aggregation. The compounds useful for this invention include compounds of general Formula I and III-XI, or salts, hydrates, and solvates thereof. The present invention also provides novel compounds according to Formula I and III-XI.

Priority: US20030513845P Applic. Date: 2003-10-21

Inventor: PLOURDE JR ROBERT [US]; SHAVER SAMMY R [US]; BOYER JOSE L [US]; ABREO MELWYN A [US]; ALFARO-LOPEZ LORENZO J [US]; FENG YANGBO [US]; HARVEY DANIEL F [US]; KHASONOVA TATYANA V [US]; TU CHI [US]


Patent No.: US7371257B2  Issued: 13/May/2008

Title: Stent lining

Applicant/Assignee: BOSTON SCIENTIFIC SCIMED, INC

Application No.: 10/997088   Filing Date: 23/Nov/2004

Abstract:

The invention features a catheter assembly and methods for delivering a hydrogel-lined stent to a body lumen, and methods for lining a stent with a hydrogel. The assembly includes a catheter which has a balloon at least a portion of which is coated with a hydrogel and an expansible stent mounted on the balloon in a contracted condition for passage with the catheter to a site of a body. Expansion of the balloon lodges the stent in the body with hydrogel coated on the inner surfaces of the stent as a lining.

Priority: US2002-059420 Applic. Date: 2002-01-31; US1998-129280 Applic. Date: 1998-08-05; US1996-717290 Applic. Date: 1996-09-20; US1995-507844 Applic. Date: 1995-07-27; US1994-268999 Applic. Date: 1994-06-30; US1993-097248 Applic. Date: 1993-07-23; US1991-795976 Applic. Date: 1991-11-22; US1990-635732 Applic. Date: 1990-12-28; US1989-451507 Applic. Date: 1989-12-15

Inventor: SAHATJIAN RONALD A [US]; BARRY JAMES J [US]; PALASIS MARIA [US]


Patent No.: US7371258B2  Issued: 13/May/2008

Title: Valved prosthesis with porous substrate

Applicant/Assignee: ST. JUDE MEDICAL, INC

Application No.: 10/004504   Filing Date: 26/Oct/2001

Abstract:

An implantable prosthesis can be formed from an improved biocompatible material that provides for cellular colonization of the biocompatible material. Specifically, the biocompatible material is a rigid porous material. In embodiments of particular interest, the implantable prosthesis is a mechanical heart valve prosthesis with a rigid occluder. In some embodiments, the rigid occluder is formed from the biocompatible material. A filler comprising a hydrogel or a structural protein can be located within the pores. In some embodiments, a bioactive agent is within the pores. In some embodiments, the rigid occluder is formed from a polymer material, a carbonaceous solid or a ceramic material. The pores can extend through the rigid material.

Priority:

Inventor: WOO YI-REN [US]; PANDIT ABHAY S [US]


Patent No.: US7374677B2  Issued: 20/May/2008

Title: Two stage hemofiltration that generates replacement fluid

Applicant/Assignee: KKJ, INC

Application No.: 10/922763   Filing Date: 20/Aug/2004

Abstract:

The present invention relates to a system for two-stage blood dialysis of a patient. In one embodiment, the system comprises a first filtration device for receiving the blood from the patient and for producing a first filtrate and processed blood. The system further comprises a second filtration device for receiving the first filtrate and producing replacement fluid and waste product. At least one of the first and second filtration devices preferably comprises a Taylor vortex-enhanced blood filtration device.

Priority:

Inventor: MCLAUGHLIN JENNIFER K [US]; SCHOENDORFER DON [US]


Patent No.: US7378393B2  Issued: 27/May/2008

Title: Recombinant anticoagulant proteins

Applicant/Assignee:

Application No.: 10/516908   Filing Date: 17/Mar/2005

Abstract:

Novel recombinant anticoagulation proteins, methods of their use and methods of their production are described. In particular, recombinant fusions of annexin V (ANV) and Kunitz protease inhibitors (KPI) that possess potent anticoagulant activity are provided. The fusions, abbreviated ANV:KPI, utilize ANV having high affinity for phosphatidyl-L-serine with various KPI's to target serine proteases in membrane-associated coagulation complexes in the blood coagulation cascade. ANV:KPIs are potentially useful antithrombotic drugs permitting localized passivation of thrombogenic vessel walls and associated thrombi.

Priority: US20020386932P Applic. Date: 2002-06-06; WO2003US17442 Applic. Date: 2003-06-04

Inventor: WUN TZE CHEIN [US]


Patent No.: US7387880B2  Issued: 17/Jun/2008

Title: Method for monitoring resting and activated platelets in unfixed blood samples

Applicant/Assignee: PPD BIOMARKER DISCOVERY SCIENCES, LLC

Application No.: 11/075024   Filing Date: 07/Mar/2005

Abstract:

The amount of platelet surface proteins in a sample may be measured by collecting a sample containing platelets into a collection tube containing a platelet stabilizing composition, labeling the platelet surface protein and detecting by cytometry.

Priority: US2001-957624 Applic. Date: 2001-09-20; US20000234065P Applic. Date: 2000-09-20

Inventor: WYANT TIMOTHY L [US]; RAJU PAUL A [US]; KANTOR AARON B [US]


Patent No.: US7390505B2  Issued: 24/Jun/2008

Title: Nanoparticulate topiramate formulations

Applicant/Assignee: ELAN PHARMA INTERNATIONAL, LTD

Application No.: 10/766960   Filing Date: 30/Jan/2004

Abstract:

The present invention is directed to nanoparticulate compositions comprising topiramate. The topiramate particles of the composition have an effective average particle size of less than about 2 microns.

Priority: US20030444377P Applic. Date: 2003-01-31; US20030477789P Applic. Date: 2003-06-12; US20030511318P Applic. Date: 2003-10-16

Inventor: GUSTOW EVAN [US]; RYDE TUULA [US]; COOPER EUGENE R [US]


Patent No.: US7390663B2  Issued: 24/Jun/2008

Title: Process, composition and kit for providing a stable whole blood calibrator/control

Applicant/Assignee: STRECK, INC

Application No.: 11/362362   Filing Date: 23/Feb/2006

Abstract:

The present invention is directed toward a stable calibrator and/or control, kit and process for using in a glucose monitoring instrumentation. Principally, the instant invention teaches a glycolyzed red blood cell component which has been treated with a glycolysis stabilizing effective amount of at least one non-crosslinking aldehyde compound which may be added to fresh plasma along with an amount of glucose to form a simulated whole blood glucose control product, effective for maintaining a particular and essentially stable glucose concentration over a period of time sufficient for accurate measurement and calibration of a glucose measuring instrument.

Priority: US20050656154P Applic. Date: 2005-02-23

Inventor: RYAN WAYNE L [US]; HUNSLEY BRADFORD A [US]


Patent No.: US7402131B2  Issued: 22/Jul/2008

Title: Multiple laminar flow-based particle and cellular separation with laser steering

Applicant/Assignee: ARRYX, INC

Application No.: 11/543773   Filing Date: 06/Oct/2006

Abstract:

The invention provides a method, apparatus and system for separating blood and other types of cellular components, and can be combined with holographic optical trapping manipulation or other forms of optical tweezing. One of the exemplary methods includes providing a first flow having a plurality of blood components

providing a second flow

contacting the first flow with the second flow to provide a first separation region

and differentially sedimenting a first blood cellular component of the plurality of blood components into the second flow while concurrently maintaining a second blood cellular component of the plurality of blood components in the first flow. The second flow having the first blood cellular component is then differentially removed from the first flow having the second blood cellular component.

Holographic optical traps may also be utilized in conjunction with the various flows to move selected components from one flow to another, as part of or in addition to a separation stage.

Priority: US2004-934597 Applic. Date: 2004-09-03; US2004-867328 Applic. Date: 2004-06-13; US20040571141P Applic. Date: 2004-05-14; US20030499957P Applic. Date: 2003-09-04; US20030511458P Applic. Date: 2003-10-15

Inventor: MUETH DANIEL [US]; PLEWA JOSEPH [US]; SHIREMAN JESSICA [US]; ANDERSON AMY [US]; GRUBER LEWIS [US]; ROSENBAUM NEIL HARRIS [US]


Patent No.: US7407672B2  Issued: 05/Aug/2008

Title: Composition derived from biological materials and method of use and preparation

Applicant/Assignee: NATIONAL UNIVERSITY OF SINGAPORE NATIONAL HEART CENTER

Application No.: 10/288166   Filing Date: 04/Nov/2002

Abstract:

The invention provides a novel composition and methods of its preparation and uses. The composition comprises as main components serum and a gelling agent and is useful in various medical applications. The composition may be used to coat a medical device, as a biological glue, or as dressings, membranes, scaffolding or hydrogel useful in bioengineering applications. One or more therapeutic products may be added to the composition and the composition is also a vehicle for delivery of therapeutic products.

Priority:

Inventor: PEDDAREDDIGARI VIJAY GOPAL RED [US]; LIM TAI TIAN [SG]; EL OAKLEY REIDA MENSHAWE [SG]


Patent No.: US7416558B2  Issued: 26/Aug/2008

Title: Drug-eluting stent cover and method of use

Applicant/Assignee: ADVANCED CARDIOVASCULAR SYSTEMS, INC

Application No.: 11/497706   Filing Date: 01/Aug/2006

Abstract:

An intravascular stent includes an eluting sheath fabricated from a mesh for controlled release of therapeutic drugs and for delivery of the therapeutic drugs in localized drug therapy in a blood vessel. The eluting sheath is attached to at least a portion of an outside surface area of the stent structure and is fabricated from a mesh designed to neck down in response to a radially outward directed force resulting in the uniform expansion of the stent. The eluting sheath can be loaded with at least one therapeutic drug for the release thereof at a treatment site to facilitate repair of a damaged vessel. The stent has a high degree of flexibility in the longitudinal direction, yet has adequate vessel wall coverage and radial strength sufficient to hold open an artery or other body lumen.

Priority: US2002-334034 Applic. Date: 2002-12-30

Inventor: YIP PHILIP S [US]; JACOBS JAMES [US]; HOSSAINY SYED [US]; BECKER JON [US]; LIMON TIMOTHY A [US]


Patent No.: US7422903B2  Issued: 09/Sep/2008

Title: Multi-analyte reference solutions

Applicant/Assignee: INSTRUMENTATION LABORATORY COMPANY

Application No.: 10/733871   Filing Date: 11/Dec/2003

Abstract:

The present invention provides a reference solution for use in instruments that determine hematocrit levels in biological samples by measuring the resistance and/or conductivity of the biological samples. A reference solution according to the invention achieves conductivities representative of known hematocrit levels in blood, while maintaining tolerable levels of interference with the measurement of other analytes in the reference solution.

Priority: US20020432373P Applic. Date: 2002-12-11

Inventor: CONLON DENNIS ROBERT [US]; MANSOURI SOHRAB [US]; VAGO GIANNANTONIO [IT]


Patent No.: US7427278B2  Issued: 23/Sep/2008

Title: Extraction device with tubes having different cross-sections

Applicant/Assignee: MACOPHARMA

Application No.: 10/291977   Filing Date: 12/Nov/2002

Abstract:

An extraction device for a biological fluid with an additive solution in which it is desirable for the additive solution to be present in a particular volume proportion to the biological fluid. The volume proportion of the additive solution is determined by the ratio of cross sections of two tubes, one which supplies the biological fluid to a collecting bag and a second which supplies the additive solution to a collecting bag. The tubes are periodically constricted in constriction areas by a pump. The tubes are configured so that the additive solution and the biological fluid only mix downstream of the constriction areas, thereby reducing the risk of supplying the additive solution to the source of the biological fluid. In an exemplary embodiment the biological fluid is blood collected from a patient or donor and the additive solution is an anticoagulant and/or preservation solution.

Priority: FR20000006081 Applic. Date: 2000-05-12; WO2001FR01329 Applic. Date: 2001-04-27

Inventor: GOUDALIEZ FRANCIS [FR]; VERPOORT THIERRY [FR]


Patent No.: US7431733B2  Issued: 07/Oct/2008

Title: Vascular prosthesis

Applicant/Assignee: UNIVERSITY OF SOUTH FLORIDA

Application No.: 10/561929   Filing Date: 28/Jun/2004

Abstract:

The subject invention concerns vascular prosthetic devices and methods for ascending aorta and/or valve replacement in humans and animals. In one embodiment, a device of the invention includes a vessel-like structure having a first end adapted for surgical attachment to a left ventricle, a second end adapted for surgical attachment to an aorta, and, interposed between the first and second ends, a sinus portion configured in the shape of the sinuses of Valsalva in a human aortic valve.

Priority: US20030483035P Applic. Date: 2003-06-27; WO2004US21046 Applic. Date: 2004-06-28

Inventor: KNIGHT JOSEPH ALLEN [US]


Patent No.: US7439013B2  Issued: 21/Oct/2008

Title: Biocompatible polymer and filter for selectively eliminating leucocytes using the same

Applicant/Assignee: ASAHI KASEI KURARAY MEDICAL CO., LTD

Application No.: 10/518351   Filing Date: 30/Aug/2005

Abstract:

It is intended to provide a polymer which is scarcely eluted, has a high biocompatibility and is useful in a filter for selectively eliminating leucocytes. It is also intended to provide a filter for selectively eliminating leucocytes, a filtration apparatus for selectively eliminating leucocytes and a system for selectively eliminating leucocytes, each having the above-described polymer. The above objects can be achieved by providing a polymer which comprises from 8% by mol to 45% by mol of a unit originating in a polymerizable monomer having a polyalkylene oxide chain, from 30% by mol to 90% by mol of a unit originating in a polymerizable monomer having a hydrophobic group, and from 2% by mol to 50% by mol of a unit originating in polymerizable monomer having a hydroxyl group.

Priority: JP20020176332 Applic. Date: 2002-06-17; JP20020176333 Applic. Date: 2002-06-17; WO2003JP07687 Applic. Date: 2003-06-17

Inventor: KUNO SUSUMU [JP]; ONODERA HIROKAZU [JP]; SAKURAI MASAMI [JP]


Patent No.: US7439077B2  Issued: 21/Oct/2008

Title: Coumarin analog compounds for safer anticoagulant treatment

Applicant/Assignee: NEW CENTURY PHARMACEUTICALS, INC

Application No.: 11/708004   Filing Date: 20/Feb/2007

Abstract:

The present invention relates to the albumin-guided development of coumarin analogs and the analogs developed thereby. The coumarin analogs of the present invention are identified and isolated by the fact that they have binding sites to albumin which are different than the binding sites of conventional coumarin analogs such as sodium warfarin, and as a result will be less prone to be displaced since the binding site of sodium warfarin is shared by numerous drugs such as aspirin. The coumarin analogs of the invention are advantageous because they can achieve the effects of the prior coumarin analogs with a minimum of metabolic complications and undesirable side effects.

Priority: US2003-629858 Applic. Date: 2003-07-30; US20020399126P Applic. Date: 2002-07-30

Inventor: CARTER DANIEL C [US]


Patent No.: US7445632B2  Issued: 04/Nov/2008

Title: Percutaneous aortic valve

Applicant/Assignee: REX MEDICAL REX MEDICAL, L.P

Application No.: 11/222570   Filing Date: 09/Sep/2005

Abstract:

The present invention provides a valve configured for insertion on the proximal and distal sides of a heart valve annulus to replace the heart valve of a patient. The valve comprises a first substantially annular portion adapted to be positioned on a proximal side of the annulus of a patient and a second substantially annular portion adapted to be positioned on a distal side of the annulus of a patient, wherein at least one of the first and second substantially annular portions is movable towards the other portion to a clamped position to clamp around the annulus. The second portion has a flow restricting portion extending therefrom and is movable between a first position to permit the flow of blood and a second position to restrict the flow of blood.

In one embodiment, the valve has a suture joining the first and second portions to draw the first and second portions into closer proximity and a cinch member to secure the suture to maintain the first and second portions in the clamped position. In another embodiment, the first and second portions are connected by a first segment which biases the first and second portions toward the clamped position.

Priority: US2003-429536 Applic. Date: 2003-05-05

Inventor: MCGUCKIN JR JAMES F [US]; HINCHLIFFE PETER W J [US]


Patent No.: US7456148B2  Issued: 25/Nov/2008

Title: Method of producing an anticoagulation effect

Applicant/Assignee: CRYPTOME PHARMACEUTICALS LTD HEALTHLINX LIMITED

Application No.: 10/897068   Filing Date: 23/Jul/2004

Abstract:

A method for producing an anticoagulation effect in a blood coagulation assay, said method comprising contacting a sample of blood with an effective amount of apolipoprotein CIII or fragment, derivative, homologue, analogue, chemical equivalent, functional equivalent or mimetic thereof.

Priority: AU20030903906 Applic. Date: 2003-07-25

Inventor: AUTELITANO DOMINIC J [AU]; BERNDT MICHAEL C [AU]; RAJIC ANTONIO [AU]; SMITH A IAN [AU]; TALBO GERT HOY [AU]


Patent No.: US7459283B2  Issued: 02/Dec/2008

Title: Nanoparticulate compositions having lysozyme as a surface stabilizer

Applicant/Assignee: ELAN PHARMA INTERNATIONAL LTD ELAN PHARMA INTERNATIONAL LIMITED

Application No.: 10/357514   Filing Date: 04/Feb/2003

Abstract:

The present invention is directed to nanoparticulate active agent compositions comprising lysozyme as a surface stabilizer. Also encompassed by the invention are pharmaceutical compositions comprising a nanoparticulate active agent composition of the invention and methods of making and using such nanoparticulate and pharmaceutical compositions.

Priority: US20020353230P Applic. Date: 2002-02-04

Inventor: WERTZ CHRISTIAN F [US]; RYDE NIELS P [US]


Patent No.: US7465285B2  Issued: 16/Dec/2008

Title: Control system for driving fluids through an extracorporeal blood circuit

Applicant/Assignee: THERAKOS, INC

Application No.: 11/444721   Filing Date: 01/Jun/2006

Abstract:

A control deck and system for controlling and driving blood fluids through an extracorporeal blood circuit kit. In one aspect, the invention is a deck having an improved mechanism for securing a cassette in place during treatment operations. The improved deck comprises catches for slidably receiving tabs of the cassette and one or more rotating clamps for locking and securing the cassette in a loaded position. In another aspect the invention is a system for controlling and driving blood fluids having infrared communication abilities to transmit and receive real time data. In still another aspect, the invention is a system for controlling and driving blood fluids having an upright tower design that reduces the footprint of the system.

In this embodiment, a centrifuge chamber is positioned in an upper portion of the system while the control deck and photoactivation chamber are located in a base portion of the system.

Priority: US2003-654670 Applic. Date: 2003-09-03

Inventor: HUTCHINSON MCHAEL [US]; BRIGGS DENNIS [US]; GARA STEPHEN [US]; WALTERS TOM [US]


Patent No.: US7465293B2  Issued: 16/Dec/2008

Title: Syringe for inducing therapeutically-effective proteins

Applicant/Assignee: ORTHOGEN GENTECHNOLOGIE GMBH

Application No.: 10/378175   Filing Date: 03/Mar/2003

Abstract:

A syringe for inducing therapeutically-effective proteins includes a syringe and an inner structure having an inductor disposed thereon for encouraging development of a desired protein.

Priority: US2000-485836 Applic. Date: 2000-07-06; EP19980109186 Applic. Date: 1998-05-20; DE19971035537 Applic. Date: 1997-08-16; WO1998EP04866 Applic. Date: 1998-08-05

Inventor: REINECKE JULIO [DE]; MEIJER HANS [DE]; WEHLING PETER [DE]


Patent No.: US7470538B2  Issued: 30/Dec/2008

Title: Cell-based therapies for ischemia

Applicant/Assignee: CASE WESTERN RESERVE UNIVERSITY

Application No.: 10/875643   Filing Date: 24/Jun/2004

Abstract:

The invention provides, among other things, methods for treating an ischemic tissue in a subject in need thereof. The invention further provides methods for increasing the blood flow to an ischemic tissue in a subject in need thereof, such as to ischemic myocardium. The invention further provides cell-based formulations and related kits.

Priority: US2003-730549 Applic. Date: 2003-12-05; US20020431347P Applic. Date: 2002-12-05

Inventor: LAUGHLIN MARY J [US]; HAYNESWORTH STEPHEN [US]; POMPILI VINCENT [US]


Patent No.: US7473548B2  Issued: 06/Jan/2009

Title: Optical detector for enzyme activation

Applicant/Assignee: MEDTRONIC, INC

Application No.: 10/423112   Filing Date: 25/Apr/2003

Abstract:

Activation of an enzyme in a bodily fluid is detected based on the amount of cleavage of a substrate for the enzyme. The substrate is tagged with two fluorescent dyes-a donor and an acceptor. The tagged substrate is presented to the bodily fluid. A device emits energy at a first wavelength into the bodily fluid, and detects energy at second and third wavelengths emitted by the dyes in response to the energy at the first wavelength. Prior to enzymatic cleavage of the substrate, the acceptor emits energy at the third wavelength in response to energy at the second wavelength received through fluorescent resonant energy transfer (FRET) from the donor. After enzymatic cleavage of the substrate, the donor emits energy at the second wavelength.

The device can determine the concentration of activated enzyme within the bodily fluid based on the relative intensities of energy at the second and third wavelengths.

Priority:

Inventor: SOYKAN ORHAN [US]; DONOVAN MAURA G [US]; THOMPSON AMY E [US]


Patent No.: US7476209B2  Issued: 13/Jan/2009

Title: Method and apparatus for collecting a blood component and performing a photopheresis treatment

Applicant/Assignee: THERAKOS, INC

Application No.: 11/304092   Filing Date: 15/Dec/2005

Abstract:

Methods and apparatus for collecting and treating blood component. An apparatus and methods for improvement of an extracorporeal photopheresis treatment is described. A cassette having flexible tubes inside its housing and on the bottom surface outside the cassette housing for ease of manufacturing is operated with a centrifuge bowl having an inlet and two outlets, pressure domes for measuring pressures in tubes, an improved irradiation plate, and a dual chamber bag in an extracorporeal photopheresis treatment.

Priority: US20040637985P Applic. Date: 2004-12-21

Inventor: GARA STEPHEN [US]; STAR CYNTHIA [US]; BRIGGS DENNIS [US]; HUTCHINSON MICHAEL [US]; WATTERS TOM [US]


Patent No.: US7476210B2  Issued: 13/Jan/2009

Title: Apparatus and method for in-vivo plasmapheresis using periodic backflush containing anticoagulant

Applicant/Assignee: TRANSVIVO INC

Application No.: 11/320866   Filing Date: 29/Dec/2005

Abstract:

Method for in-vivo plasmapheresis utilizing a plurality of elongated hollow microporous filter fibers periodically interrupt diffusion of blood plasma from a patient, and, for a selected time, directing backflush fluid into the fibers at a pressure and interval sufficient to cleanse the fiber pores, after which plasma diffusion is resumed. The backflush fluid, preferably a normal saline solution, may contain an anticoagulant such as heparin, citrate or NO donor in suitable concentration for systemic anti-coagulation or for treating the fiber for thromboresistance.

Priority: US2003-408657 Applic. Date: 2003-04-04; US2001-754773 Applic. Date: 2001-01-04

Inventor: GORSUCH REYNOLDS G [US]; COOPER TOMMY GENE [US]; HANDLEY JR HAROLD H [US]; PETERS HAROLD W [US]


Patent No.: US7479123B2  Issued: 20/Jan/2009

Title: Method for collecting a desired blood component and performing a photopheresis treatment

Applicant/Assignee: THERAKOS, INC

Application No.: 10/654803   Filing Date: 03/Sep/2003

Abstract:

An improved method for separating whole blood into components and collecting a desired blood component. The method allows a desired blood component to be subjected to centrifugal forces within a separator for prolonged periods of time, yielding a cleaner cut and higher yield of the desired blood component. Whole blood is drawn from a source and pumped into a separator, the undesired blood components are removed from the separator at rates so as to build up the desired blood component in the separator. The desired blood component is only removed after a predetermined amount of the desired blood component has built up in the separator. It is preferred that the desired blood component be buffy coat and that the method be used to perform photopheresis treatments.

In another aspect, the invention is a method of performing a full photopheresis treatment to treat diseases in a reduced time, preferably less than about 70 minutes, and more preferably less than about 45 minutes.

Priority: US2003-375628 Applic. Date: 2003-02-26; US20020361287P Applic. Date: 2002-03-04; US2003-654794 Applic. Date: 2003-09-03; US2003-375629 Applic. Date: 2003-02-27; US2003-654742 Applic. Date: 2003-09-03

Inventor: BRIGGS DENNIS [US]


Patent No.: US7479124B2  Issued: 20/Jan/2009

Title: Device for treatment of venous congestion

Applicant/Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION

Application No.: 10/273215   Filing Date: 16/Oct/2002

Abstract:

A device for treatment of venous congestion provides for subcutaneous introduction of anticoagulant through an incision positioned within a collection shell for withdrawal of an effused material. A widened delivery tip provides dispersal of the anticoagulant and may be agitated to disrupt clot formation.

Priority: US2000-745298 Applic. Date: 2000-12-20; US19990171351P Applic. Date: 1999-12-22

Inventor: HARTIG GREGORY K [US]; CONNOR NADINE P [US]; CONFORTI MICHAEL L [US]


Patent No.: US7479130B2  Issued: 20/Jan/2009

Title: Apparatus and method for autologous normovolemic hemodilution

Applicant/Assignee: UNIVERSITY HOSPITALS OF CLEVELAND CASE WESTERN RESERVE UNIVERSITY

Application No.: 11/318286   Filing Date: 23/Dec/2005

Abstract:

A system and method for autologous normovolemic hemodilution (ANH) are disclosed. The system can include a vacuum canister, which is sized to accept donor bags of a predetermined capacity. The vacuum canister is connected to a vacuum source which applies a suction to the donor bag within the canister. The system can include a canister having a self-generated vacuum, which includes compressible sidewalls that are spring-loaded to provide negative pressure needed to collect blood from a patient without the use of a gravity-induced siphon gradient. Also disclosed are ANH systems and kits that rely on a gravity-induced siphon gradient for blood collection.

Priority: US20040639246P Applic. Date: 2004-12-27

Inventor: TRICKETT JAMES R [US]


Patent No.: US7485472B2  Issued: 03/Feb/2009

Title: Simple method for quantitative measuring the adhesion of platelets ex vivo

Applicant/Assignee: JENAFFIN GMBH

Application No.: 10/344359   Filing Date: 07/Aug/2003

Abstract:

The invention relates to measuring of the adhesion of platelets ex vivo. In this method, monodisperse polymer particles are added to blood, and the number of platelets in the blood are measured before and after shaking of the sample. The level of adhesion of the platelets is determined by comparing the number of platelets prior to shaking with the number of platelets after shaking. Methods of establishing an adhesion index and diagnosis of a patient are also provided.

Priority: DE20001038900 Applic. Date: 2000-08-09; WO2001DE03041 Applic. Date: 2001-08-09

Inventor: NOWAK GOTZ [DE]; BUCHA ELKE [DE]


Patent No.: US7488313B2  Issued: 10/Feb/2009

Title: Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment

Applicant/Assignee: BOSTON SCIENTIFIC SCIMED, INC

Application No.: 09/997855   Filing Date: 29/Nov/2001

Abstract:

A mechanical dilatation and medicament delivery device for enlarging a flow passage of a vessel by dilating and delivering a therapeutic agent or medicament to an obstruction in the vessel. The present invention comprises a substantially cylindrically shaped expansion member and includes a means engaged to the expansion member for altering the distance between the proximal end and the distal end of the expansion member thereby transforming the expansion member between a diametrically contracted configuration to diametrically expanded configuration. A therapeutic agent or medicament is coated on either the expansion member, or incorporated into a substrate coated on the expansion member.

The present method comprises the steps of advancing the coated expansion member to the obstruction in a vessel and applying opposed forces on said expansion member in an axial direction to move the expansion member to an expanded configuration wherein the expansion member dilates the obstruction and the expansion member either passively or actively delivers a therapeutic agent or medicament to the obstruction.

Priority:

Inventor: SEGAL JEROME [US]; SCOTT NEAL [US]


Patent No.: US7491768B2  Issued: 17/Feb/2009

Title: Polymer resin formulation having anti-microbial or anti-coagulability and preparation method thereof

Applicant/Assignee:

Application No.: 10/519345   Filing Date: 23/Dec/2004

Abstract:

The present invention relates to an anti-microbial or anti-coagulating polymer resin and a method for preparing the same, and a medical appliance or instrument using the same, and more particularly to a method for preparing an anti-microbial or anti-coagulating medical polymer resin comprising the steps of simply mixing a polymer resin with at least one kind of pharmaceutically active material without using a solvent. The pharmaceutically active material is preferably an anti-microbial or anti-coagulant.

According to the present invention, an anti-microbial or anti-coagulating material that is safe to a human body is mixed with a polymer resin by simple addition in an environmentally favorable non-solvent method, thereby maintaining superior anti-microbial effects even after high temperature molding, minimizing a released amount of anti-microbial to increase anti-microbial effect durability, and solving a toxic problem in a body. Therefore, the present invention can be extensively applied for medical appliances/instruments for a human body.

Priority: KR20020035793 Applic. Date: 2002-06-25; WO2003KR01249 Applic. Date: 2003-06-25

Inventor: MOON WOONG-SIG [KR]; KIM JAE-CHUL [KR]; BYOUN YOUN-SEOP [KR]; CHUNG KYOO-HYUN [KR]; KANG HEUN-SOO [KR]; KONG KI-OH [KR]; HWANG JUNG-HWA [KR]


Patent No.: US7494504B2  Issued: 24/Feb/2009

Title: Methods and apparatus for regional and whole body temperature modification

Applicant/Assignee: RADIANT MEDICAL INC ZOLL CIRCULATION, INC

Application No.: 11/724075   Filing Date: 13/Mar/2007

Abstract:

Methods and apparatus for temperature modification of selected body regions including an induced state of local hypothermia of the brain region for neuroprotection. A heat exchange catheter is provided with heat transfer fins projecting or extending outward from the catheter which may be inserted into selected blood vessels or body regions to transfer heat with blood or fluid in the selected blood vessels or body regions. Another aspect of the invention further provides methods and apparatus for controlling the internal body temperature of a patient. By selectively heating or cooling a portion of the catheter lying within a blood vessel, heat may be transferred to or from blood flowing within the vessel to increase or decrease whole body temperature or the temperature of a target region.

Feed back from temperature sensors located within the patient's body allow for control of the heat transfer from the catheter to automatically control the temperature of the patient or of the target region within the patient. The apparatus may include a blood channeling sleeve that directs body fluid over a heat exchanger where the body fluid's temperature is altered, and then is discharged out the distal end of the sleeve to a desired location, for example, cooled blood to the brain for neuroprotection. The catheter may be used alone or in conjunction with other heat exchangers to cool one region of a patient's body while heating another.

Priority: US2003-626007 Applic. Date: 2003-07-24; US1998-138830 Applic. Date: 1998-08-24; US1996-584013 Applic. Date: 1996-01-08; US1994-324853 Applic. Date: 1994-10-18; US1993-015714 Applic. Date: 1993-02-09

Inventor: GINSBURG LEGAL REPRESENTATIVE [US]; MACHOLD TIMOTHY R [US]; DINEEN MICHAEL T [US]


Patent No.: US7494824B2  Issued: 24/Feb/2009

Title: Interactive system for presenting and eliminating substances

Applicant/Assignee: MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V., MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E. V., BERLIN

Application No.: 11/170666   Filing Date: 29/Jun/2005

Abstract:

An interactive system is provided with at least one active surface of plastic from monomers containing at least one structural element derived from a carbon dioxide (A), and at least one substance associated to a linker with at least one structural element (B) capable of establishing a hydrogen bond, and involving an interaction between the structural elements (A) and (B). The interactive system is suitable for presenting and eliminating substances in liquids.

Priority: DE19971015504 Applic. Date: 1997-04-14; US1999-417534 Applic. Date: 1999-10-14

Inventor: BUCHA ELKE [DE]; NOWAK GOETZ [DE]


Patent No.: US7500569B2  Issued: 10/Mar/2009

Title: Plasma on demand tube

Applicant/Assignee: BECTON, DICKINSON AND COMPANY

Application No.: 11/015949   Filing Date: 17/Dec/2004

Abstract:

A device for separating plasma from whole blood is provided having an evacuated primary collection chamber capable of fluid communication through a porous filter to an evacuated secondary collection chamber. An agglutinating agent is provided within the primary collection chamber so as to aggregate blood cells within a whole blood sample. The porous filter has a pore size which is small enough to capture the aggregated blood cells therein, yet large enough to permit plasma to transfer therethrough under pressures associated with conventional evacuated blood collection tubes. The primary and secondary collection chambers may be provided in separate containers or tubes, with transfer occurring therebetween through a transfer device including the porous filter therein.

Priority: US20030532509P Applic. Date: 2003-12-24

Inventor: MANOUSSAKIS DIMITRIOS [US]; LOSADA ROBERT J [US]


Patent No.: US7504497B2  Issued: 17/Mar/2009

Title: Orally bioavailable compounds and methods for inhibiting platelet aggregation

Applicant/Assignee: INSPIRE PHARMACEUTICALS, INC

Application No.: 11/595837   Filing Date: 09/Nov/2006

Abstract:

This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis or related disorders. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a non-nucleotide compound, preferably a P2Y12 receptor antagonist compound, wherein said amount is effective to inhibit platelet aggregation. The compounds useful for this invention include compounds of general Formulae III, IIIa, and IIIb, or salts, hydrates, and solvates thereof. The present invention also provides novel compounds of Formulae IIIa and IIIb, which are potent and have a good oral bioavailability.

Priority: WO2006US17781 Applic. Date: 2006-05-05; US2005-124619 Applic. Date: 2005-05-05; US2004-971766 Applic. Date: 2004-10-21; US20030513845P Applic. Date: 2003-10-21

Inventor: DOUGLASS III JAMES G [US]; WATSON PAUL S [US]; SAMUELSON CARL A [US]; CREAN CHRISTOPHER S [US]


Patent No.: US7507533B2  Issued: 24/Mar/2009

Title: Systems and methods of identifying biomarkers for subsequent screening and monitoring of diseases

Applicant/Assignee: VITRIMARK, INC

Application No.: 11/232597   Filing Date: 22/Sep/2005

Abstract:

A system for generating an image of ultrastructural biomarkers from a biological sample is provided. The system includes a grid onto which a sample to be imaged may be placed and a cryogenic reservoir into which the grid and sample may be immersed for vitrification of the sample. The system also includes a stage onto which the grid and sample may be situated for subsequent imaging in a high contrast imager to permit identification of ultrastructural biomarkers therein. A method for generating an image of ultrastructural biomarkers from a biological sample is also provided. The generated image of ultrastructural biomarkers may be used subsequently for screening and monitoring diseases, evaluating drug and therapeutic efficacy, and assessing risks associated with a drug or therapeutic candidate, among other things.

Priority: US20040612713P Applic. Date: 2004-09-24

Inventor: BOSE ARIJIT [US]; AZIZ NAZNEEN [US]


Patent No.: US7510540B2  Issued: 31/Mar/2009

Title: Autotransfusion device

Applicant/Assignee: SORIN GROUP ITALIA S.R.L

Application No.: 10/990341   Filing Date: 16/Nov/2004

Abstract:

An autotransfusion device having: a first line and a first pump, the first line being connected to the inlet of a blood centrifugation cell, and branches of the first line being (i) connected to a red blood cell container, (ii) provided with a coupling, and (iii) being suitable to be connected to the patient

a second line connected to the outlet of a blood centrifugation cell and two branches of the second line being provided with two couplings

and a third line and a second pump, the third line being connected to the first line in an intermediate position between the first pump and the blood centrifugation cell, and branches of the third line (i) being connected to a physiological solution container and (ii) being provided with a coupling.

Priority: IT2003MI02341 Applic. Date: 2003-11-28

Inventor: VALLUZZI MARGHERITA [IT]; SIMONINI GIAMPAOLO [IT]


Patent No.: US7517332B2  Issued: 14/Apr/2009

Title: Infusion device for medical fluids

Applicant/Assignee: GAMBRO LUNDIA AB

Application No.: 11/104447   Filing Date: 13/Apr/2005

Abstract:

An infusion device comprises a pusher for a plunger of a syringe containing a liquid to be infused. A load cell measures the push force. An encoder associated to a motor commanding the pusher measures the displacement of the pusher. A controller signals an alarm when the ratio between the variation of the push force and the displacement exceeds a predetermined threshold. The device, which serves for infusing an anticoagulant into an extracorporeal blood circuit in a dialysis apparatus, is able to signal an onset of an anomalous situation of lack of infusion in good time.

Priority: IT2004MO00085 Applic. Date: 2004-04-20; US20040522442P Applic. Date: 2004-10-01

Inventor: TONELLI CLAUDIO [IT]; LIGABUE ANDREA [IT]; CESTARI SILVANO [IT]


Patent No.: US7517342B2  Issued: 14/Apr/2009

Title: Polymer coated device for electrically medicated drug delivery

Applicant/Assignee: BOSTON SCIENTIFIC SCIMED, INC

Application No.: 10/425170   Filing Date: 29/Apr/2003

Abstract:

The present invention relates to a catheter with an expandable distal end for delivering one or more medicaments. The catheter is manufactured with materials of construction that allow the transfer of electrical energy from the proximal end of the catheter to the distal expandable end. The catheter also has a means for controlling or manipulating the expandable distal end to expand and contract into various configurations. The distal end of the catheter is processed by a specific method of manufacturing whereby the expandable distal end is coated with one or more layers of a hydrogel copolymer wherein at least one layer of which coating encapsulates one or more medicaments and zero or more charged carriers to facilitate the electrophoretic and electro-osmostic mobilities of the medicaments.

Priority:

Inventor: SCOTT NEAL [US]; SEGAL JEROME [US]; SHIH LIH-BIN [US]; BURKOTH TERRY L [US]


Patent No.: US7530995B2  Issued: 12/May/2009

Title: Device for reduction of pressure effects of cardiac tricuspid valve regurgitation

Applicant/Assignee: 3F THERAPEUTICS, INC

Application No.: 10/418677   Filing Date: 17/Apr/2003

Abstract:

A method of protecting an upper and a lower body of a patient from high venous pressures comprising: providing an elongate valve stent, wherein the stent comprises a first stent member with a first tissue valve secured to a first support structure being disposed at a first end of the stent and a second stent member with a second tissue valve secured to a second support structure being disposed at an opposite second end of the stent, wherein both support structures are collapsibly expandable, the second end being connected to the first end with at least one elongate connecting member

passing the elongate valve stent through a blood vessel with the first and second support structures in a collapsed position

and securing the first support structure to an inferior vena cava and the second support structure to a superior vena cava with both support structures in an expanded shape.

Priority:

Inventor: QUIJANO RODOLFO C [US]; MCCARTHY PATRICK M [US]


Patent No.: US7530996B2  Issued: 12/May/2009

Title: Surgical implant, method for the production and use thereof

Applicant/Assignee: AESCULAP AG & CO. KG

Application No.: 10/478128   Filing Date: 30/Apr/2004

Abstract:

A surgical implant is made from biocompatible fiber material as a woven textile fabric, in particular in the form of a vascular prosthesis, the woven fabric being so configured that its permeability to blood is so low that the blood impregnates the textile fabric upon implantation and seals it off by coagulating, but does not flow through it.

Priority: DE20011025712 Applic. Date: 2001-05-21; WO2002EP05544 Applic. Date: 2002-05-21

Inventor: BENTELE FRANZ [DE]; GOLDMANN HELMUT [DE]


Patent No.: US7531364B2  Issued: 12/May/2009

Title: Clinical method for the genetic screening of newborns using tandem mass spectrometry

Applicant/Assignee: PERKINELMER GENETICS, INC

Application No.: 11/225615   Filing Date: 13/Sep/2005

Abstract:

A method for screening newborns using electrospray tandem mass spectrometry. The method improves the current protocols that use tandem mass spectrometry by assuring accurate and consistent results at the clinical level through enhanced quality controls and quality assurance protocols as applied to the scan profiling and sample preparation of blood spots from newborns. Specific additives are used in precise concentrations of internal standards, employing detailed controls adapted to distinguish twenty metabolites, which are scanned and vigorously compared to known spectra results. Revealing peaks, metabolite concentration, and scan intensities in the quality assurance steps are then compared to a range of thresholds to determine whether or not the sample is contaminated, drug-ridden, diagnosable, or unacceptable.

All spectra results and quality assurance flags are organized in spreadsheet form and exported to a database where values are compiled and stored for daily output results and trend analysis. The method provides for high-throughput and quality results, having a consistent predictability for genetically testing newborns efficiently and accurately.

Priority: US2005-169158 Applic. Date: 2005-06-28; US2002-252115 Applic. Date: 2002-09-23; US1999-464132 Applic. Date: 1999-12-16; US1999-277119 Applic. Date: 1999-03-26; US19990117880P Applic. Date: 1999-01-30

Inventor: CHACE DONALD H [US]


Patent No.: US7534887B2  Issued: 19/May/2009

Title: Thiazoline derivative and use of the same

Applicant/Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Application No.: 10/574048   Filing Date: 12/May/2006

Abstract:

A thiazoline derivative represented by Formula (I): wherein R is a cyclic hydrocarbon group which may be substituted, or a heterocyclic group which may be substituted

X is a bond or a divalent chain hydrocarbon group which may be substituted

X' is a bond or -N(R5)-

Y is a divalent hydrocarbon group which may be substituted

Y' is a bond or -C(-O)-

ring A is a nitrogen-containing heterocycle which may be substituted

Z1 and Z3 are each independently a bond or a divalent chain hydrocarbon group which may be substituted

Z2 is a bond or -N(R6)-

and B is a group represented by the formula: which is useful as a therapeutic drug for thrombosis, is provided.

Priority: JP20030341430 Applic. Date: 2003-09-30; WO2004JP14685 Applic. Date: 2004-09-29

Inventor: KUBO KEIJI [JP]; KUROITA TAKANOBU [JP]; KAWAMURA MASAKI [JP]; SAKAMOTO HIROKI [JP]


Patent No.: US7550158B2  Issued: 23/Jun/2009

Title: Controlled release by extrusion of solid amorphous dispersions of drugs

Applicant/Assignee: PFIZER INC BEND RESEARCH, INC

Application No.: 10/799536   Filing Date: 11/Mar/2004

Abstract:

Controlled release dosage forms for low solubility drugs are disclosed wherein an amorphous solid dispersion of the drug is coated with a non-dissolving and non-eroding coating that controls the influx of water to the core so as to cause extrusion of a portion of the core, as well as a method of treating a disease or disorder comprising administering such dosage form to a person.

Priority: US2000-495061 Applic. Date: 2000-01-31; US19990119406P Applic. Date: 1999-02-10

Inventor: APPEL LEAH E [US]; CURATOLO WILLIAM J [US]; HERBIG SCOTT M [US]; NIGHTINGALE JAMES A S [US]; THOMBRE AVINASH G [US]


Patent No.: US7563810B2  Issued: 21/Jul/2009

Title: Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases

Applicant/Assignee: CELGENE CORPORATION

Application No.: 10/411656   Filing Date: 11/Apr/2003

Abstract:

Methods of treating, preventing and/or managing a myeloproliferative disease are disclosed. Specific methods encompass the administration of an immunomodulatory compound, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent, and/or the transplantation of blood or cells. Particular second active agents are capable of suppressing the overproduction of hematopoietic stem cells or ameliorating one or more of the symptoms of a myeloproliferative disease. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.

Priority: US20020424730P Applic. Date: 2002-11-06

Inventor: ZELDIS JEROME B [US]


Patent No.: US7566315B2  Issued: 28/Jul/2009

Title: Blood component collection apparatus and method

Applicant/Assignee: TERUMO KABUSHIKI KAISHA

Application No.: 11/453840   Filing Date: 16/Jun/2006

Abstract:

A blood component collection apparatus comprises a blood component collecting circuit which includes an anticoagulant line for feeding an anticoagulant and a line for collecting an initial flow of collected blood. In the blood component collection apparatus, air is intermediately present between the anticoagulant and the blood in the passage of a blood collection needle side line, after a priming operation is performed in which anticoagulant is supplied from the anticoagulant line toward the side of a centrifugal separator in the blood collection needle side line through a branch connector and after an initial flow collecting operation is performed in which the initial flow of blood is collected.

Priority: JP20050178316 Applic. Date: 2005-06-17

Inventor: HIRABUKI MAKOTO [JP]


Patent No.: US7569367B2  Issued: 04/Aug/2009

Title: Nucleic acid preparation from whole blood for use in diagnosis of transmissible spongiform encephalopathy

Applicant/Assignee: ROCHE DIAGNOSTICS OPERATIONS, INC

Application No.: 11/514776   Filing Date: 01/Sep/2006

Abstract:

The present invention deals with a method of preparing nucleic acids, particularly RNA, from a whole blood sample. The nucleic acids purified by the method of the invention are particularly suited for detection of nucleic acid marker molecules. Preferred are markers for the diagnosis of transmissible spongiform encephalopathy (TSE). Such diagnosis is based on the detection, by means of real-time PCR, of certain mRNAs of the TSE-infected organism. Said mRNAs specifically originate as splicing variants and are isolated from whole blood by the method of the invention.

Priority: EP20050019479 Applic. Date: 2005-09-07

Inventor: KNOLL MICHAEL [DE]; EBERLE WALTER [DE]; KIRSCHBAUM THOMAS [DE]


Patent No.: US7575936B2  Issued: 18/Aug/2009

Title: Method for making enhancing the reliability of the traceability of blood samples

Applicant/Assignee: BIOLOG

Application No.: 10/482408   Filing Date: 01/Apr/2004

Abstract:

Method for enhancing the reliability of the traceability of blood samples resulting from collection of whole blood in a mother blood bag using sampling kits, whose contents vary depending on the blood products needed and statutory regulations, and which are mainly composed of bags connected to each other by tubes and incorporating at least one filtration unit. Each bag includes an electronic chip capable of memorising and exchanging information with an electronic communication device. This abstract is not intended to define the invention disclosed in the specification, nor intended to limit the scope of the invention in any way.

Priority: FR20010009246 Applic. Date: 2001-07-12; WO2002FR02465 Applic. Date: 2002-07-12

Inventor: DE GAULLE ANTOINE [FR]; MONGRENIER JEAN-CLAUDE [FR]


Patent No.: US7579000B2  Issued: 25/Aug/2009

Title: Tissue factor targeted antibodies as anticoagulants

Applicant/Assignee: CPS COLOR EQUIPMENT S.P.A BAYER SCHERING PHARMA AG

Application No.: 10/512215   Filing Date: 12/Jan/2005

Abstract:

This invention relates to novel antibodies that bind with greater affinity to the factor VIIa/tissue factor (FVIIa/TF) complex than to tissue factor (TF) alone, do not compete for binding to TF with FVII and FX, an inhibit FX activation. The antibodies bind at the site of injury and prevent the initiation of thrombosis. The antibodies can be used to treat a variety of thrombotic conditions including but not limited to deep vein thrombosis, disseminated intravascular coagulation, and acute coronary syndrome.

Priority: US20020376566P Applic. Date: 2002-05-01; WO2003US13521 Applic. Date: 2003-04-30

Inventor: LIGHT DAVID [US]; MCLEAN KIRK [US]


Patent No.: US7592186B2  Issued: 22/Sep/2009

Title: Methods to measure immunosuppressive tacrolimus, sirolimus, and cyclosporin a complexes in a blood sample

Applicant/Assignee: ABBOTT LABORATORIES

Application No.: 11/398997   Filing Date: 06/Apr/2006

Abstract:

The present invention provides methods, diagnostic assays, and diagnostic kits based on said methods, to determine levels of immunosuppressive complexes containing immunosuppressive drugs tacrolimus, sirolimus and cyclosporine A separately and in combination, formed in the blood of a drug-treated patient or in a patient candidate to immunosuppressive drug therapy. These methods, assays and kits are especially useful when using automated systems.

Priority: US20050668714P Applic. Date: 2005-04-06

Inventor: DRENGLER SUSAN M [US]; BAUGHER BENNETT W [US]


Patent No.: US7597677B2  Issued: 06/Oct/2009

Title: Wearable ultrafiltration device

Applicant/Assignee: NATIONAL QUALITY CARE, INC

Application No.: 10/251937   Filing Date: 19/Sep/2002

Abstract:

An ultrafiltration device adapted to be worn on a portion of the body of a patient includes a blood inlet tube leading from a first blood vessel, a blood pump, an anticoagulant reservoir for infusing anticoagulants into the blood, a blood filter including a substrate through which the blood is circulated and filtered, a fluid bag for storing the excess fluid and a blood outlet tube leading to a second blood vessel.

Priority: US2001-085349 Applic. Date: 2001-11-16

Inventor: GURA VICTOR [US]; RAMBOD EDMOND [US]


Patent No.: US7598031B2  Issued: 06/Oct/2009

Title: Method for the detection of gene transcripts in blood and uses thereof

Applicant/Assignee: GENENEWS CORPORATION

Application No.: 10/268730   Filing Date: 09/Oct/2002

Abstract:

The present invention is directed to detection and measurement of gene transcripts in blood. Specifically provided is a RT-PCR analysis performed on a drop of blood for detecting, diagnosing and monitoring diseases using tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-associated genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen.

Priority: US2000-477148 Applic. Date: 2000-01-04; US19990115125P Applic. Date: 1999-01-06

Inventor: LIEW CHOONG-CHIN [CA]


Patent No.: US7603166B2  Issued: 13/Oct/2009

Title: Method and apparatus for detection of vulnerable atherosclerotic plaque

Applicant/Assignee: TEXAS HEART INSTITUTE BOARD OF REGENTS UNIVERSITY OF TEXAS SYSTEM

Application No.: 10/640570   Filing Date: 12/Aug/2003

Abstract:

Methods for the detection of inflammation associated with vulnerable atherosclerotic plaque to prevent heart attack and stroke are disclosed. The methods are also applicable to detection of infection, cancer, wounds or auto-immune disease in the body. Certain embodiments of the new methods provide a way of predicting the level of vulnerability of an atherosclerotic plaque to rupture or thrombus formation by assessing via fiber optic NIR spectrophotometry the status of two or more parameters associated with inflamed atherosclerotic plaque in a vessel of a living patient.

From these measurements such conditions as low pH, hypoxia, low glucose, oxidative stress or compounds abundant in vulnerable plaque such as oxidized LDL cholesterol and oxidized metabolites of NO, significant active macrophage population, thin plaque cap, as well as senescence and/or apoptosis of smooth muscle or endothelial cells are determined with the assistance of a suitably programmed microprocessor. By considering together the status of some or all of these conditions with respect to successive sites along a vessel wall, particular plaques which are at significant risk of rupturing or thrombosing can be distinguished from "normal" vessel wall and from "intermediate" and relatively stable or "lower risk" plaques.

Sites having more of the indicator conditions would be considered most in need of prompt intervention, and certain combinations of parameter levels would be suggestive of relatively stable plaque. Also disclosed is a multi-parameter catheter and analytical processing assembly for use in the methods.

Priority: US1998-188661 Applic. Date: 1998-11-09; US1996-717449 Applic. Date: 1996-09-20

Inventor: CASSCELLS III S WARD [US]; WILLERSON JAMES T [US]; NAGHAVI MORTEZA [US]; GUO BUJIN [US]


Patent No.: US7604626B2  Issued: 20/Oct/2009

Title: Multiple ratio fluid dispenser

Applicant/Assignee: ARTERIOCYTE MEDICAL SYSTEMS, INC

Application No.: 10/876147   Filing Date: 24/Jun/2004

Abstract:

A double syringe delivery system is disclosed for holding a pair of syringes in a manner so as to accommodate the simultaneous activation of the plunger of each syringe in order to effect simultaneous delivery of the contents of each syringe. The delivery system includes a delivery mechanism for delivering the contents of both syringes to a site of application. The delivery system further includes a support member that is positioned between the two syringe bodies. The elongated support member has resilient, C-shaped clamps on one end of the support member. The clamps are designed to be removably clamped onto the applicator so that the syringe barrels will be held together in a parallel manner. The elongated support member further comprises finger grips. A plunger connects the two syringe plungers so that they can also be simultaneously activated.

Priority: US2002-212430 Applic. Date: 2002-08-05; US20020388822P Applic. Date: 2002-06-14

Inventor: MCINTOSH KEVIN D [US]; ALBRECHT RICHARD M [US]


Patent No.: US7608258B2  Issued: 27/Oct/2009

Title: Method for treatment of tendinosis using platelet rich plasma

Applicant/Assignee:

Application No.: 11/085987   Filing Date: 22/Mar/2005

Abstract:

Methods and kits are disclosed to promote vascularization of tissue in mammals using an autologous platelet-rich plasma composition. The kit includes components for the preparation of platelet-rich plasma from the patient's blood and components for administration to an area in need of vascularization. The methods and kits are useful for the treatment of tendinosis, and in particular, lateral epicondylitis and plantar fasciitis.

Priority: US2004-941124 Applic. Date: 2004-09-15; US2003-412821 Applic. Date: 2003-04-11; US20050655668P Applic. Date: 2005-02-23; US20020372682P Applic. Date: 2002-04-13

Inventor: MISHRA ALLAN [US]


Patent No.: US7611830B2  Issued: 03/Nov/2009

Title: Device to lavage a blood vessel

Applicant/Assignee: THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERAN'S AFFAIRS

Application No.: 10/257176   Filing Date: 14/Jul/2003

Abstract:

The present invention provides for compositions and methods for the preservation of tissues and organs ex vivo and in situ. In addition, the present invention provides for kits that may be used in the preparation of the solutions of the present invention. The present invention also provides a device for perfusing tissues and organs with the solutions of the present invention.

Priority: US2000-546860 Applic. Date: 2000-04-10; WO2001US11834 Applic. Date: 2001-04-10

Inventor: THATTE HEMANT [US]; BISWAS KUNDA [US]; KHURI SHUKRI [US]; MICHEL THOMAS [US]


Patent No.: US7618652B2  Issued: 17/Nov/2009

Title: Glycosaminoglycan anticoagulants derived from fish

Applicant/Assignee: HEPMARIN AS

Application No.: 10/472381   Filing Date: 09/Apr/2004

Abstract:

The present invention provides anticoagulant piscine gill glucosaminoglycans, high affinity anticoagulant piscine glycosaminoglycans anticoagulant glycosaminoglycans extractable from salmon guts, skin, tail or gills and salts and derivatives thereof.

Priority: GB20010007385 Applic. Date: 2001-03-23; US20010278418P Applic. Date: 2001-03-26; WO2002GB01397 Applic. Date: 2002-03-22

Inventor: SKJERVOLD PER OLAV [NO]; OEDEGAARD OLE RASMUS [NO]; BROSSTAD FRANK [NO]; FLENGSRUD RAGNAR [NO]


Patent No.: US7625507B2  Issued: 01/Dec/2009

Title: Extrusion process for forming chemically stable drug multiparticulates

Applicant/Assignee: PFIZER INC

Application No.: 11/004165   Filing Date: 03/Dec/2004

Abstract:

Reduced levels of drug degradation in drug-containing multiparticulates are obtained by an extrusion/melt-congeal process.

Priority: US20030527315P Applic. Date: 2003-12-04

Inventor: RAY RODERICK J [US]; APPEL LEAH E [US]; NEWBOLD DAVID D [US]; FRIESEN DWAYNE T [US]; MCCRAY SCOTT B [US]; LYON DAVID K [US]; WEST JAMES B [US]; CREW MARSHALL D [US]; SHOCKEY JOSHUA R [US]


Patent No.: US7627359B2  Issued: 01/Dec/2009

Title: Quantitative contrast enhanced black-blood imaging using quadruple-inversion recovery

Applicant/Assignee: UNIVERSITY OF WASHINGTON

Application No.: 11/385201   Filing Date: 21/Mar/2006

Abstract:

A reduced field-of-view (FOV) imaging technique combines suppression of signals from outer volume and inflowing blood. Both outer volume and blood suppression are achieved using an SFQIR (Small-FOV Quadruple-inversion-Recovery) preparative pulse sequence including two double-inversion pulse pairs separated by appropriate delays. Within each pair, inversion pulses are successively applied to the imaged slice and the slab orthogonal to the imaging plane, with the thickness equal to the FOV size in the phase-encoding direction. Each double-inversion results in a reinversion of the magnetization in a central part of the FOV, while outer areas of the FOV and inflowing blood remain inverted. The SFQIR module was implemented for single-slice and multislice acquisition with a fast spin-echo readout sequence.

Timing parameters of the sequence corresponding to the maximal suppression efficiency can be found by minimizing variation of the normalized signal over the entire range of T1 occurring in tissues.

Priority: US2003-740354 Applic. Date: 2003-12-18; US20020435835P Applic. Date: 2002-12-19

Inventor: YARNYKH VASILY L [US]; YUAN CHUN [US]


Patent No.: US7632411B2  Issued: 15/Dec/2009

Title: Method for detecting filter clogging by using pressure information, apparatus for monitoring filter clogging and bed-side system

Applicant/Assignee: KONINKLIJKE PHILIPS ELECTRONICS N.V

Application No.: 10/545990   Filing Date: 18/Aug/2005

Abstract:

A method is provided for detecting filter clogging which are able to keep track of the filter clogging with precision and in detail. At least one pressure selected from the group consisting of a pressure Pa in a blood inflow portion (32a), a pressure Pv in a blood outflow portion (32b), a pressure Pf1 in a filtrate inflow portion (32c), and a pressure Pf2 in a filtrate outflow portion (32d) is measured continuously, then a variation (pressure waveform) of the pressure is analyzed, a clogging of a filter (32) is detected using the analyzed result. Thereby a clogging of a filter is detected early. As a result, it is possible to prevent from developing of the filter clogging by controlling a dosage amount of anti-coagulant properly and changing a flow rate of blood. The variation of the pressure wave may be analyzed by subjecting the variable to Fast Fourier Transform.

Priority: JP20030041731 Applic. Date: 2003-02-19; WO2004IB00415 Applic. Date: 2004-02-11

Inventor: KURODA YASUHIRO [JP]; KINOUCHI YOHSUKE [JP]; AKUTAGAWA MASATAKE [JP]; OKAHISA TOSHIYA [JP]; OHNISHI YOSHIAKI [JP]


Patent No.: US7637895B2  Issued: 29/Dec/2009

Title: System and device for medically treating an individual

Applicant/Assignee:

Application No.: 11/507876   Filing Date: 22/Aug/2006

Abstract:

A system for medically treating/vaccinating an individual comprising a first syringe, containing an anticoagulant material therein, for drawing a sample of blood from the individual. A centrifuge is provided for centrifuging the sample of blood contained within the first syringe to obtain a buffy coat. A second syringe comprising a second plunger and at least one microtubule member containing one of a treatment agent and a vaccine antigen. At least one open end formed within the at least one microtubule member for drawing a portion of the buffy coat therein and exposing the buffy coat to one of the treatment agent and vaccine antigen. A second needle capable of being attached onto the second syringe for introducing the exposed sample into the individual to effect treatment/vaccination thereof.

This system is capable of allowing a plurality of treatment agents and/or vaccine antigens to be simultaneously applied to an individual.

Priority:

Inventor: NALIN DAVID R [US]


Patent No.: USRE33924E  Issued: 12/May/1992

Title:

Applicant/Assignee:

Application No.: US 1990-627405   Filing Date: 14/Dec/1990

Abstract:

Priority: US1986-886196 Applic. Date: 1986-07-16

Inventor:


Patent No.: USRE36331E  Issued: 05/Oct/1999

Title: Use of L-carnitine and alkanoyl L-carnitines in the storage of blood for transfusions and stabilizing solutions containing them

Applicant/Assignee: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A

Application No.: 35028   Filing Date: 05/Mar/1998

Abstract:

Solutions which contain L-carnitine and alkanoyl L-carnitine are useful for stabilizing blood for transfusions.

Priority: IT1993RM00364 Applic. Date: 1993-06-02; US1994-253275 Applic. Date: 1994-06-02

Inventor: ARDUINI ARDUINO [IT]


Patent No.: USRE36370E  Issued: 02/Nov/1999

Title: Resorbable vascular wound dressings

Applicant/Assignee:

Application No.: 777360   Filing Date: 27/Dec/1996

Abstract:

The present invention is related to prostheses, their methods of manufacture and methods for repairing vascular lesions using such prostheses. Natural polymers such as collagen are processed and fabricated to form tubular resorbable vascular wound dressings with unique physico-chemical and mechanical properties for repairing selected vascular segments, and for delivering therapeutic agents at selected sites within vessels and at the anastomoses.

Priority: US1993-046895 Applic. Date: 1993-04-15; US1992-821384 Applic. Date: 1992-01-13

Inventor: LI SHU-TUNG [US]


Patent No.: USRE39321E1  Issued: 03/Oct/2006

Title: Supplemented and unsupplemented tissue sealants, methods of their production and use

Applicant/Assignee: THE AMERICAN NATIONAL RED CROSS

Application No.: 10/465853   Filing Date: 20/Jun/2003

Abstract:

This invention provides a fibrin sealant dressing, wherein said fibrin sealant may be supplemented with at least one composition selected from, for example, one or more regulatory compounds, antibody, antimicrobial compositions, analgesics, anticoagulants, antiproliferatives, antiinflammatory compounds, cytokines, cytotoxins, drugs, growth factors, interferons, hormones, lipids, demineralized bone or bone morphogenetic proteins, cartilage inducing factors, oligonucleotides polymers, polysaccharides, polypeptides, protease inhibitors, vasoconstrictors or vasodilators, vitamins, minerals, stabilizers and the like. Also disclosed are methods of preparing and/or using the unsupplemented or supplemented fibrin sealant dressing.

Priority: US1995-479034 Applic. Date: 1995-06-07; US1994-351006 Applic. Date: 1994-12-07; US1994-328552 Applic. Date: 1994-10-25; US1993-031164 Applic. Date: 1993-03-12; US1991-798919 Applic. Date: 1991-11-27; US1990-618419 Applic. Date: 1990-11-27

Inventor: MACPHEE MARTIN J [US]; DROHAN WILLIAM N [US]; LIAU GENE [US]; NUNEZ HERNAN [US]; BURGESS WILSON H [US]; HOLLINGER JEFFREY O [US]; MACIAG THOMAS [US]


Patent No.: USRE39451E1  Issued: 26/Dec/2006

Title: Double-lumen catheter

Applicant/Assignee: SPIRE BIOMEDICAL, INC

Application No.: 10/994218   Filing Date: 19/Nov/2004

Abstract:

A catheter is described. In one embodiment, the catheter includes: a shaft segment including a shaft segment uptake lumen and a shaft segment return lumen

and a distal end segment coupled to the shaft segment, the distal end segment including a distal end segment uptake lumen and a distal end segment return lumen, where the distal end segment central axis forms a non-zero angle with the shaft segment central axis when the catheter is in its unstressed configuration. In a second embodiment, the catheter includes: a shaft segment

and a distal end segment coupled to the shaft segment

where the uptake lumen distal end is terminated by a closed surface, further where the uptake lumen distal segment includes only one side hole. In a third embodiment, the catheter includes: an uptake lumen

and a return lumen

where at least a portion of the return lumen distal segment is helically coiled around the uptake lumen distal end.

Priority: US2001-877827 Applic. Date: 2001-06-08; US20000210294P Applic. Date: 2000-06-08

Inventor: KUHLE WILLIAM G [US]


Patent No.: USRE40669E1  Issued: 17/Mar/2009

Title: Blood pump

Applicant/Assignee:

Application No.: 11/156362   Filing Date: 17/Jun/2005

Abstract:

A pump especially designed for pumping blood comprises a bladder, the interior surface area and volume of which is changeable, i.e., it stretches and expands during the filling phase, and elastically contracts to its normal relaxed size during the ejection phase. The bladder has a fluid inlet and a fluid outlet. A device, such as a vacuum pump, alternately expands and contracts the interior surface area and volume of the bladder. Most of the interior surface area of the bladder expands and contracts in each cycle. One or more check valves or other means for causing substantially one-way fluid flow through the bladder are also provided. The pump of the invention decreases the likelihood of blood clots forming in the pump, decreases the risk of damage to blood cells, improves the pumping characteristics of the device, and decreases or eliminates the chance of foreign fluids passing into the blood stream should a tear or break occur in the bladder.

Priority: US2001-928386 Applic. Date: 2001-08-13

Inventor: PALMER ARTHUR [US]

...or search a US patent No (ex:
7666555) or a US patent
application (ex: 2003123456)
or a World (PCT) No (Ex:
2007666555)
Search for anything. Simply
type the words in the box..
US Patents Granted in 2010
US Patents Granted from 1980-1996
Clck to enlarge and view details
US PATENTS IN BLOOD ANTICLOT TECHNOLOGY GRANTED FROM 1997 TO 2009
This list includes patents granted in the United States. The list was retrieved by searching the claims section of all patent applications. Salient search terms included drugs, medications,
formulation and devices related to blood anticlotting; blood thinners, anticoagulants, protease enzymes, coumadin and thrombin drugs, thrombin inhibitors, heparin, warfarin and related
technologies. The document search strategy of Formula Scan™ includes proprietary direct and proximity data mining algorithms to retrieve and select highly relevant documents